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Protein nanocages have been directed toward a myriad of applications such as drug 
delivery and material science as well as model systems to study protein folding and self-
assembly. These pursuits, because they have conventionally been explored through often 
indirect techniques which typically are implemented in a protracted and high-resource 
intensive manner, have been limited by the inability to design rapidly novel and unique 
properties of these proteins or to discover conditions most ideal for their efficacy. This thesis 
describes experiments performed to explore protein nanocage applications and fundamental 
self-assembly in a traditional sense while providing a path for the broadening of these goals by 
developing a novel technique to explore the properties and conditions of nanocage assembly 
quickly and directly.  
Chapter 1 provides an introduction to protein quaternary structure and nanocage 
assembly with a focus on the ferritin family of proteins. Chapter 2 describes the attempt to 
apply protein nanocages to nanotechnology. Chapter 3 reports the application of x-ray 
crystallography to understand the role of sub-tertiary structure in the generation of protein 
nanocage quaternary structure. However, although this work advanced nanoscience and 
provided fundamental insight, it became evident that these strategies could be augmented 
through the development of a more rapid screening technique for protein cage assembly. 
Thus, Chapter 4 and Chapter 5 develop this technique with two different protein nanocages in 
vitro, while Chapter 6 further expands it to allow the high throughput screening of protein 
libraries in vivo. This method could help to expand and hasten our understanding of protein 
quaternary structure as well as to facilitate the development or enhancement of nanocage 
applications where tailored properties would be desired for the generation of size selective 













 The generation of complex structures through the assembly of simpler and smaller 
building blocks is ubiquitous to Nature. The resulting structures are determined by both the 
inherent properties of the building blocks and the assembly process itself1. The interactions 
between the subunits and restrictions imposed by requirements from the end-structure as it 
forms, can also come into play. The research projects documented in this thesis, while diverse, 
are conceptually united in that they arise from the desire to understand or to exploit the 
assembly of complex structure.  
An analogy to the assembly of complex structures is a comparison to a brick house. 
The size, shape and composition of the individual bricks can determine the resulting structure 
of the building. Understanding the fundamental properties of the bricks can lead to 
innovations in architecture, while new innovations can also be achieved by inventing bricks 
with enhanced properties. A house, while a hollow cubic arrangement of bricks, can also be a 
home which provides shelter and a unique environment from that experienced by the outside 
of the house.  
 While the analogy to a brick home is rather simplistic, it does exemplify the assembly 
of complexity from many smaller, less complex, building blocks. Examples from biology are 
much more complicated and less able to be completely understood and described. Multi-
cellular organisms, for example, and some single celled organisms under certain circumstances 
like with biofilms,2 are assembled from cells which in turn are assembled from systems 
generated by the interactions of bio-molecules. Although each of these levels of building 
blocks (organs and tissues, cellular niches, cells, metabolic and genetic systems, quaternary 
structure, molecules) are complex in their own right, only in combination can certain functions 
be realised. Often, the function of the collective is unexpected or non-obvious even by close 
understanding of the individual building blocks and only through their interaction, can the new 




 Interestingly, a similar emergence of new properties is the focus of research into 
nanomaterials3. Although chemistry has matured to the extent that it is possible to predict 
molecular properties, it is nearly impossible to anticipate the bulk properties when these 
molecules are assembled into materials. It is in the nanoscale, when a threshold of atoms or 
molecules are assembled, where bulk properties of a material start to emerge. Thus, 
nanoscaled materials are extremely sensitive to size and shape which both are related to the 
number of building blocks and how they are assembled. 
With the rise of nanotechnology, we are beginning to investigate and explore the 
complex assembly of building blocks however, in order to better exploit assembled complex 
systems, more fundamental understanding of the building blocks themselves and their process 
of assembly is required. 
1.2. Organised assembly through protein-protein interactions  
Constructing complex structures from the hierarchical assembly of simpler building 
blocks is fundamental to protein function.  Protein assembly (quaternary structure) is 
complicated in that it is often coupled to protein folding (tertiary structure)4, 5. Although some 
proteins require the assistance of chaperones to assist in assembly6, most quaternary structure 
can form spontaneously, underlining the fact that the information required for assembly is 
stored in the folded polypeptide sequence and the resulting projection of surface functionality. 
The ability to engineer amino acid polypeptides with programmed folding and functional 
assembly has been explored7 with some limited success (see section 1.8).  
Quaternary structure formation is fundamental to almost all cellular processes. The 
interactions between proteins has been shown to be important for cell signalling8, often 
further implicated in cancer9, and for essential functions such as DNA replication10. Quaternary 
structure also provides the creation of large protein assemblies. For example, one of the first 




assembly dynamics,12 and controls cell shape and movement. Similarly the activity of tubulin in 
forming flagella, regulating facilitating cytoskeleton dependent cell division is dependent on its 
assembly13.  
While many protein assembly processes are fundamental to life, they can also be 
detrimental. Amyloids fold into cross -strands that assemble into fibrils that eventually 
precipitate as insoluble plaques14. These large protein aggregates are the causes of several 
human diseases. For example, amyloid precursor protein, which is proteolysed into -amyloid, 
can aggregate in the brain and is believed to lead to Alzheimer’s disease15. In addition, prion 
proteins can also misfold and aggregate. Interestingly, these aggregates appear to catalyse the 
aggregation of non-aggregated prion protein with such mechanisms being involved in diseases 
such as Creutzfeldt–Jakob disease (CJD)16.  
Nature’s strategy to assemble large, complex protein structures often takes advantage 
of symmetry1. The synthetically least intensive way to generate complexity is to assemble 
simple building blocks into structures with high symmetry. Repeating subunits can be utilised 
and types of interactions between them can be minimised so that complex solutions to 
problems can be realised with a higher than expected evolutionary efficiency. Furthermore, 
these symmetric interactions are often focused at ‘hot spot’ areas and not spread along the 
length of the interaction17. This further complicates their characterisation and eventual design 
as it can often remain unclear where these areas are located without extensive investigations.  
1.3. Protein nanocages 
One of the most common families of highly symmetric assembled protein structures 
are the nanocages where monomers are assembled into symmetrical capsules with large, 
hollow central cavities. One type of protein nanocage are virus capsids. Virus assemblies range 
in size from the small protein capsids of Porcine circovirus (17 nm diameter)18, to the giant 




icosahedral symmetry, such as in cowpea chlorotic mottle virus20 and the adenoviruses21, or 
non-spherical with helix-type structures such as in tobacco etch virus22.  
Viruses are not the only examples of protein nanocages. Among these is the ferritin 
superfamily (see section 1.4) which help to buffer cellular iron. Heat shock proteins, which 
form large nanocages of a large variety of sizes (from 8 – 80 kDa)23, that not only protect the 
cell from stress, but also act as chaperones. Lumazine synthase assembles from 180 monomers 
into an icosahedral protein nanocage and is used by Aquifex aeolicus in the formation of 
riboflavin24. Another interesting nanocage, whose function is still poorly understood, is the 
vault protein. Measuring 34 nm across and 60 nm long, it is one of the largest non-viral protein 
complexes25, 26 (see Figure 1.1 for examples of protein nanocages).  
 
Figure 1.1 – Structures of protein nanocages and quaternary related structures. (Not to scale.) (a) 
Ferritin 24-mer (PDB:1BFR27), (b) Lumazine synthase 60-mer (PDB:1HQK28), (c) B19 parvovirus capsid 




Many applications exploiting protein nanocages rely on the fact that they have three 
distinctively different surfaces, the surfaces on the outside of the nanocage, on the inside of 
the hollow cavity, and the surfaces making up the protein-protein interfaces, that can be 
engineered and utilised to generate constructs with multiple functions7, 32 (Figure 1.2). The 
protein-protein interfacial surfaces can be modified to change the assembly properties and 
possibly even the overall structure of the assembled nanocage itself. The outer protein 
nanocage surface has been chemically or genetically modified to control cellular localisation33 
and stability. It has even been functionalised so that the protein nanocage can be applied to 
novel applications like for MRI contrast agents34. The inner cavity surface is usually optimised 
for the functions of the native nanocage, such as metal mineralisation or DNA delivery, but can 
be augmented for new functions. The ability to target and manipulate either one of all of these 
very different surfaces provides a high level of control for the expansion of nanocages for 
novel applications. 
 
Figure 1.2 – Schematic representation highlighting the three distinctly different surfaces that can be 
altered in protein nanocages. (left) the outer surface, (middle) the surface located between protein 
interfaces and (right) the inner surface35. 
1.4. Ferritins 
Ferritin proteins are well characterised and have been the subject of much nanocage 
research. They are also the focus of this thesis. The ferritin proteins form well-defined 




seen in all forms of life and are employed by the cell to help control cellular iron 
homeostasis36.  They generally are selectively permeable to iron ions which are mineralised 
and stored in the ferritin inner cavity.  Ferritins have been studies for many years, and the first 
crystal structure of a ferritin was obtained in 197537. Since then many more ferritin structures 
have been solved and their regulation and function have been well documented. Interestingly, 
although the ferritins share little sequence similarity, their tertiary structures are strikingly 
homologous38. This structural similarity is carried through to the quaternary structure with 
only a few distinct subfamilies.  
1.4.1. Maxi-ferritins  
Maxi-ferritins are assembled from twenty-four monomer subunits and form a 
nanocage with octahedral symmetry39 (Figure 1.3). The most commonly observed maxi-ferritin 
assembly intermediate, is a two-fold symmetric anti-parallel dimer. It is believed that 
nanocage formation occurs from the assembly of these subunits around three- and four-fold 
axis of symmetry40, 41. Maxi-ferritins assemble into a nanocage of octahedral symmetry with an 
exterior diameter normally around 12 nm and an interior diameter of 7 nm27. An exception to 
this rule is the ferritin from archaeon, Archaeoglobus fulgidus which assemblies into a 24-
meric nanocage but with tetrahedral symmetry42. 
 
Figure 1.3 – The structure of a typical maxi-ferritin, E.coli Bfr (PDB:1BFR27) highlighting (in dark grey) 
interactions around its symmetry axes. (left) two-fold symmetry axis, (middle) the three-fold symmetry 
axis and (right) the four fold symmetry axis which is unique to maxi-ferritins. The dimer highlighted at 




Maxi-ferritins can be organised into two subgroups, the ferritins (Ftn) and the 
bacterioferritins (Bfr). While ferritins are seen in all three kingdoms of life, bacterioferritins 
only exist bacteria and fungi43, 44. Interestingly, the mammalian ferritins natively assemble into 
heterooligomers and are formed by the combination of two heavy and light chain monomers45. 
Although, homooligomers can also assemble in vitro. Bfr, on the other hand, only forms 
homooligomers. The most striking difference between these two subgroups is that Bfr contains 
twelve heme groups each bound in the middle of the dimer subunit at the protein-protein 
interface44.  
Like all nanocages, an important feature of ferritins is that they have three surfaces 
available for functionalisation and engineering. The inner and outer surfaces have been 
examined and altered to perform new functions as discussed in section 1.5. The interfacial 
surfaces have been less studied. E. coli Bfr exists in solution as a combination between the 
nanocage and the dimer oligomerisation states. Our laboratory has investigated the role these 
surfaces play in controlling the distribution between these two species41, 46, 47. Through this 
work, we have developed proteins, with mutated protein-protein interfaces, that favour one 
oligomerisation state over the other. These proteins, will serve as the basis for control 
experiments employed in this thesis (Chapter 4).  
1.4.2 Mini-ferritins 
 A second ferritin subfamily is made up by the mini-ferritins. One type of mini-ferritin is 
the DNA binding protein from starved cells (Dps). This protein shows a similar tertiary 
structure to the other ferritin, but it differs considerably in its quaternary structure. Dps 
nanocages are made up of twelve monomers. These nanocages have tetrahedral symmetry 
and exterior and interior diameter of 9 nm and 4.5 nm respectively48. Similar to maxi-ferritins, 
Dps is thought to assemble through dimer two-fold symmetric intermediates. The assembled 




(Figure 1.4). In addition to the storage of iron, Dps has been shown to bind DNA, and this 
binding plays a role in it providing protection from cellular oxidative stress49. In addition, the 
Orner laboratory has also generated protein-protein interfacial mutants of the Dps nanocage 
that can affect assembly, which will be used as controls in this thesis50 (Chapter 6). 
 
Figure 1.4 - The structure of a typical mini-ferritin, E.coli Dps(PDB:1DPS51) highlighting (in dark grey) 
interactions around its symmetry axes. (left) two-fold symmetry axis (dimer), (middle) the Dps-like 
three-fold symmetry axis and (right) the ferritin-like three-fold symmetry axis. The dimer highlighted at 
the two-fold axis is thought to be the major assembly intermediate. 
1.4.3. Ferritins and their role in iron mineralisation and storage 
 The control of cellular iron homeostasis is complex. First, the membrane receptor 
transferrin binds iron and internalises it to the cell52. The soluble Fe2+ is then released from 
transferrin and stored in the ferritins. Ferritins oxidize Fe2+ to Fe3+ with H2O2 and store the iron 
as a ferrihydrite mineral inside the protein nanocage cavity53. Maxi-ferritins can in general hold 
up to 4500 iron atoms while mini-ferritins can only store 150054. Each subgroup also differs in 
how iron is mineralised. Within the Ftn subgroup, only the heavy chain monomers are 
catalytic, and the light chain monomers only play a structural role in assembly. However, each 
Bfr monomer has ferroxidase activity, but for Dps, dimerization is required to form an intact 




1.4.4. Ferritins and their roles in disease 
 Ferritins can be recognised and taken up into cells from serum through specific cell 
surface receptors55. This function has led to the belief that this nanocage could be used as a 
delivery agent for therapeutics, a topic which is further explored in Chapter 256. However, the 
process by which ferritin localises to serum is still poorly understood and could potentially play 
an important role in disease. Neuroferritinopathy, a condition tied to the aggregation of 
ferritin monomers into large fibres follows a marked increase in iron concentration throughout 
the nervous system57, 58 and patients present symptoms similar to Alzheimer’s59. The 
aggregates are favoured by nanocage destabilising mutations. This ability of ferritins to 
aggregate, could be a challenge to any attempt to use these nanocages for various applications 
(see Chapter 2). 
1.5 Nanocage functionalisation 
Protein nanocages have been the focus of much recent research and characterisation 
which is leading to their use in novel applications. Nanocage proteins, because of their defined 
size and shape, have been used as size-constrained reactors to afford nanoparticles with very 
narrow polydispersities. In addition, they provide the resulting encapsulated particles with 
enhanced solubility, protect the particles from aggregating, and enable the further 
manipulation of the particles through bioconjugate and fusion chemistries60, 61. To date, gold62, 
63, 64, 62, 65, silver66, copper67, cadmium68, palladium69 and platinum70 nanoparticles have been 
formed inside of ferritins, a topic which is further explored in Chapter 2. Gold nanoparticles in 
particular have now been shown to be useful as catalysts, in contrast enhancing optical 
sensors and for medical diagnosis71. Iron oxide nanoparticles have been formed inside the 
protein nanocage lumazine synthase72. Moreover, the formation of a tungsten core inside 
cowpea chlorotic mottle virus73 has also been achieved. While other nanocages have been 
used for nanoparticle formation, the well characterised structure and native mineralisation 




Nanocages are beginning to find other applications as well. For example they have 
been used to sequester toxic cargo to enhance cell survival74 have been part of contrast 
enhancing agents for MRI34, 75. Interest in protein nanocages as drug delivery agents is also 
developing76. However applied research such as this is often hampered by a lack of 
fundamental understanding of the chemical and physical properties of these proteins which 
are mainly dependent on the assembly process and the protein-protein interactions that 
strongly influence it. However most of the techniques to characterise these properties are 
either time-intensive, indirect, or not amenable to discovering protein nanocages with new 
properties via high throughput screening. Because the majority of this thesis (Chapters 4, 5, 
and 6) focuses on the development of a rapid and direct assay for protein nanocage assembly, 
we will discuss the methods that have been developed to detect protein-protein interactions 
in the next section. 
1.6. Methods for the detection of quaternary structure 
Protein-protein interactions are fundamental to multiple cellular processes8 and are 
playing a larger role in materials and bio-medical applications77. Thus, several techniques have 
been developed to detect and characterise interactions between proteins. These techniques 
have helped to establish the fundamental and disease-based roles of these interactions and 
where in the cell they take place. Several families of techniques have been established, some 
of which have single molecule resolution. 
1.6.1. Detection of protein-protein interactions with classical protein characterisation 
techniques 
 Techniques that were developed to characterise proteins can likewise be used to 
detect when that character changes, such as when two or more proteins assemble and 
interact. When proteins interact their overall size tends to increase and many methods can 




polyacrylamide gel electrophoresis (native PAGE) which separate proteins based on their size 
and dynamic light scattering (DLS) which can determine the size of large particles based on the 
light they scatter have been used to detect the change in size of a complex when protein-
protein interactions occur. These three techniques have been used extensively with 
nanocages, and we also employ them in the research described in this thesis40, 41, 46, 47. While 
these methods are very useful for monitoring quaternary structure, they almost always require 
purified proteins and are limited to low throughput in vitro analysis.  
 Techniques that characterise the thermodynamics of proteins can also be used to 
evaluate quaternary structure. Isothermal titration calorimetry (ITC) measures the release of 
energy during the exothermic interaction between two binding partners78. While most notably 
used for drug discovery, ITC can monitor the interactions between biomolecules via the 
titration of one to the other79. This technique can not only help calculate the binding affinity of 
the interacting pair but also their stoichiometry and thermodynamic parameters describing 
their association. Differential scanning calorimetry (DSC), monitors the change in specific heat 
capacity of a solution which can be characteristic if proteins are interacting80. Although not 
widely adopted, it has been used to monitor the interaction between ribonuclease A (RNase) S 
protein and the RNaseA S peptide81. Our laboratory has used DSC to characterise ferritin 
protein nanocages. Although useful, ITC and DSC like the above techniques, require purified 
proteins, often in large quantities, and are limited to low throughput in vitro screening.  
 Another technique that is more frequently used for protein characterisation but can be 
modified to examine protein-protein interactions is mass spectrometry (MS)82. This can be 
challenging because large proteins are not only large in mass but they are also can be unstable 
in the gas phase and under ionization conditions83. This technique has been used to map the 
Wnt signalling pathway84 as well as assessing protein interactions in cancer cells using affinity-




small amount of sample, and advances in proteomics have advanced MS to high throughput. 
However, these proteomics strategies often involve enrichment steps that have not yet been 
developed for protein nanocages85. With that said, well characterised or purified protein 
samples could benefit from mass spectrometry analysis. 
 Techniques employing surface plasmon resonance (SPR) detection have gained much 
attention due to the fact that kinetic binding information can often be obtained86. SPR works 
by passing a beam of light through a prism at a resonance angle toward a thin layer of gold or 
silver. Some of this light interacts with the electron cloud of the metal surface generating a 
plasmon. This plasmon creates a small electric field on both sides of the thin layer and any 
change in environment near this field, such as binding of a protein to an immobilised target, 
creates a measureable change in resonance angle dependent upon a change in refractive 
index. From SPR, the association and dissociation constants and therefore the binding constant 
can be obtained, as well as the stoichiometry of the interacting parties. SPR has been used to 
monitor the concentration of serum ferritins, through its interactions with an antibody87 as 
well as monitoring the interactions of p53 and p7388. However this method is still limited to 
relatively low throughput in vitro conditions, requiring purified proteins and it is unclear how it 
could be applied to the assembly of protein nanostructure. 
 While all of the above methods can help characterise protein-protein interactions they 
are all low throughput, often requiring large quantities of purified protein (with the exception 
of MS), and are limited to in vitro analysis. However, there are several techniques that have 
been focused more directly toward observing quaternary structure. 
1.6.2. Anti-body based techniques (ELISA and Immunoprecipitation) 
Antibodies can be raised against a large variety of biological and chemical targets and 
can be used to tag many molecules and structures inside cells89. This ability to be able to target 




of antibody targeting include Western blots developed by Towbin and co-workers which used 
antibodies to tag selective protein targets after their transfer to a nitrocellulose film90. This 
method was expanded upon to help purify proteins from cellular lysate samples. 
Immunoprecipitation requires the use of an antibody that has been raised against a particular 
protein target. Upon combining this antibody with a protein mixture, the antibody molecules 
can swarm the protein target, causing the target protein to precipitate from the solution due 
to the large molecular weight of the complex. Alternatively, the antibody can be fused to a 
purification tag and the target protein can be purified through a ‘pull down’ experiment. 
Quaternary structure can be analysed through co-immunoprecipitation. Similar to using 
affinity-purification mass spectrometry (see above), any protein that interacts to the target 
protein is co-purified with the target. Co-immunoprecipitation has been used to monitor the 
oligomersation of G protein coupled receptors91 and to map protein interaction networks in 
yeast92.  
In 1971, Perlman and co-workers published the first reported application of the 
enzyme-linked immunosorbent assay (ELISA) which linked several existing antibody 
technologies and many variations of the ELISA have since been developed93. One version of 
ELISA works by first immobilising a target protein or ligand to the surface of a well. Different 
wells are then washed with potential binding partners which all present an antibody binding 
epitope. Any protein that binds to the original target remains immobilised while all 
unsuccessful binders are washed away. An antibody is added that binds to the antibody 
binding epitope. A secondary antibody that was raised against the primary antibody is then 
added. This secondary antibody is fused to an enzyme, most commonly a peroxidase, which 
allows for the turnover of chromogenic substrate leading to a coloured observable response. 
Therefore, any protein that binds to the target can be identified through this colourmetric 
assay. Importantly the turnover of the enzyme allows an amplification of a signal from a 




antibody-peroxidase, or a fluorescent probe fusion.  Although ELISA often requires extended 
preparation times, the commercial availability of pre made plates has increased their utility94. 
ELISA’s have been extensively used to screen for the presence of infectious agents. A HIV assay 
relies on the detection of the HIV protein capsid using an antibody immobilised to a well95.  
 This technique provides advantages over several of the ones discussed above, as the 
throughput of ELISA is much larger. However, both this technique and immunoprecipitation 
can only be performed in vitro, although they do work in complex solutions like lysates. The 
requirement of large amounts of antibodies can cause them to be prohibitively expensive. In 
addition, they often also need extended and repetitive washing steps which all reduce the 
ability of these methods to be expanded to screen a large number of proteins quickly in the 
absence of robotics.  
1.6.3. Fluorescence Polarisation 
Fluorescence polarisation (FP)96 is a commonly used in vitro technique. In this method, 
polarised light is use to excite a molecular probe attached to one protein of a complex. The 
degree that the polarisation of the emitted light is lost is related to the tumbling rate of the 
molecule and hence its size. When the protein forms a large complex, the loss of polarisation is 
less. Thus, monitoring the change in polarisation can be used to detect the extent that 
interactions between the protein and other species occur. FP has been used to monitor the 
interactions between the RNase S protein and the RNase S peptide using a GFP reporter97 and 
to help screen small molecule inhibitors of the p53-DM2 protein complex98. While this 
technique is relatively simple, requiring only a single fluorophore, it too, is limited to in vitro 
conditions. 
Several of the methods described above, can provide detailed information and help to 
map the protein interactome through the analysis of protein-protein interactions in a low or 




thermodynamics can also be achieved through the analysis of two or more binding partners. 
However all of the methods described so far, are limited to in vitro conditions, which means 
that any information obtained is done so in an artificial environment. Methods that can detect 
protein-protein interactions both in vitro and in vivo would provide the highest utility for 
understanding the role protein oligomerization plays in biology. 
1.6.4. Split protein approach 
Richards in 1957 demonstrated that when the enzyme bovine pancreatic ribonuclease 
A (RNAase A) is digested with the protease subtalisin, it is cleaved into two parts, RNAase S 
protein and RNAase S peptide, that individually have no activity but when mixed and refolded 
correctly, retain catalytic function99. In a conceptually similar manner, several proteins can be 
split into different parts that retain their function only when reassembled (Figure 1.5). These 
systems can be exploited to monitor protein-protein interactions if each pair of the split 
protein are fused to each of the protein partners of interest. This can be achieved both in vitro 
and importantly, in vivo. 
1.6.4.1. Split Green fluorescent protein 
 Green fluorescent protein (GFP) and its derivatives are among the most highly used 
protein-based tools in biochemistry and cell biology 100, 101 and the development of GFP earned 
the Nobel Prize in 2008102, 103, 104. GFP is the β-barrelled protein responsible for the green 
fluorescence of the Aequorea victoria species of jellyfish. Additionally, it has been engineered 
for optimised stability, increased quantum yield105, 106, 107, 108 and to produce many different 
colours such as yellow (YFP)109, blue (BFP)110 and cyan (CFP)111.  
While originally used as a localisation tag or transcriptional reporter, GFP has also been 
engineered to detect protein-protein interactions. This has been achieved through “split”-GFP 
as a non-enzymatic analogy to RNAase A described above (see section 1.6.4.) 112, 113. Each half 




of interest that are thought to interact, with their interaction being confirmed by the recovery 
of fluorescence. Split GFP has also been used to improve the expression and purification of 
membrane proteins through comparison of active, soluble protein and inactive proteins 
observed in inclusion bodies114. Furthermore, split GFP can be used to localise protein 
interactions inside yeast cells115. Related to the research described in this thesis split GFP has 
been used to report on the assembled structure of the papillomavirus capsid116. 
1.6.4.2. Split Luciferase 
Firefly Luciferase converts luciferin to oxyluciferin which is bioluminescent 117. Similar 
to RNAase, when split, Luciferase loses its enzymatic activity, however, upon reassembly, this 
activity is restored. In split mode, Luciferase is a very common in vivo method to detect 
protein-protein interactions 118, 119. To date, split luciferase has been used for applications to 
monitor the formation of DnaE in mammalian cells120, and to study the interactions between 
insulin and transforming growth factor beta (TGF-β)121. 
 
Figure 1.5 – Cartoon representations of “split protein” approaches to protein-protein interaction 
detection. (top) Split GFP (rectangles) reporter showing the restoration of fluorescence once the 




GFP are fused. (bottom) Split luciferase reporter technology: When the proteins of interest interact 
(ovals), they bring together the two halves of the split luciferase (rectangles) which can then convert 
luciferin to bioluminescent oxyluciferin. 
Conceptually these techniques use the formation of protein quaternary structure to 
observe protein quaternary structure. While able to expand the detection of protein-protein 
interactions into cells, these methods require large protein fusions which can alter the native 
folding, expression, and interaction of the target proteins.  
1.6.5. Förster resonance energy transfer (FRET) 
Theodor Förster discovered that energy can be transferred in a non-radiative manner 
between two proximal fluorophores. This property is referred to as Förster resonance energy 
transfer (FRET)122. When one of the fluorophores is excited, energy from the excited state can 
be transferred to the second fluorophore, which is then emitted at a wavelength unique to this 
fluorophore. This can only happen when the fluorophores are close in space. When they are 
distal, only the first fluorophore emits. Because FRET can identify the close proximity of two 
fluorophores, it can be used to detect, protein-protein interactions if the FRET donor and 
acceptor are placed on each of the binding partners123, 124. FRET has been used extensively for 
the study of protein interactions both inside and outside of cells. GFP and its derivatives are 
frequently used for FRET assays125. FRET has been used to study the activity of G-protein 
coupled receptors126, the interaction of epidermal growth factor receptor with the Src 
homology 2 domain127, as well as activation of the Fas receptor128. 
1.6.6. Two-hybrid screening 
 Another technique that has been widely used and that shares similarities to split 
protein assays, is two-hybrid screening, which was originally described in yeast cells129 (hence 
“yeast two hybrid screening” or Y2H). This is one of the most widely used methods for the 
detection of protein-protein interactions inside of cells. This method works by using 




the other actives transcription. By splitting these domains onto two proteins that are thought 
to interact, a detection system can be created. The first protein which is attached to the DNA 
binding domain locates to the section of DNA responsible for gene activation. If the second 
protein is able to bind to the first, it does so, thus bringing the activation domain into close 
proximity with its partner and switching on gene expression (Figure 1.6). This can lead to either 
a coloured response (expression of a fluorescent protein) or even cell survival if grown in 
nutrient lacking media. 
 
Figure 1.6 – Cartoon representation of two hybrid screening. a) Expression of two proteins each from a 
different plasmid, each fused to a different part of a transcription factor. b) Binding of the DNA 
transcription factor domain (square) to the DNA strand, c) Protein partners interact, bring the activation 
domain (circle) into close proximity to the DNA, d) which switches on the transcription of the gene of 
interest. 
 One advantage of two hybrid screening is that by using advanced cloning techniques, 
this method can be expanded to not just detect the interactions between two protein 
partners, but to map entire interactomes. This method has to date been used to map protein 
interactions for yeast130, human cells131, E.coli132 and even Drosophila133. This ability to create 
libraries over large numbers of protein targets makes two hybrid screening a power tool for 
both fundamental science and for drug development. It could also be employed to screen 




throughput manner. However, a high false positive rate is often observed providing some 
limitations or at least the need for robust secondary screens. 
1.6.7. Fluorescein arsenical hairpin binder (FlAsH) and its conceptual origins in GFP. 
GFP, as described, above is an invaluable tool in either its split form, when used for 
FRET, or for simple protein localisation experiments, but it is far from ideal. For example, the 
large size of GFP can lead to changes in the function or transport of the protein to which it is 
fused134, 135. To bypass these problems, Tsien and co-workers designed small chemical probes 
that can function as a GFP alternative for protein labelling. “Fluorescein arsenical hairpin 
binder” (FlAsH) and its alternative “resorufin arsenical hairpin binder” (ReAsH), were 
developed by positioning two arsenic atoms on the fluorophores fluorescein or resorufin. 
When the arsenic atoms are ligated to ethanedithiol (EDT), the molecules are weakly 
fluorescent89, 136, 137. When the EDT ligands are displaced by four sulfur atoms originating from 
cysteine residues positioned in an ideal geometry, the observable fluorescence intensity for 
these reagents greatly increases most likely due to a change in rotational properties about the 
carbon-arsenic bond (Figure 1.7)138. A short peptide including the four cysteines can be 
attached to any protein in analogy to GFP fusions, and, because the presences of four 
cysteines with this spacing are extremely rare, it provides orthogonality to the rest of the 
proteome. The ideal presentation of the four cysteines was initially thought to be a single face 
of a α-helix, but further optimisation resulted in the hairpin peptide CCPGCC139, 140, 141, 142. A 
family of arsenical hairpin binders has since been produced which not only vary in colour but in 
binding conformation as well,89, 143 and this family of probes has been applied to protein 





Figure 1.7 – The fluorescent activation of FlAsH-EDT2. (left) Non fluorescent form of FlAsH bound to two 
EDT ligands, (right) Fluorescence is activated once these ligands are displaced by four sulfur atoms 
presented by four cysteine residues in an appropriate geometry. 
 
FlAsH technology and the peptide sequence CCPGCC has been used to great effect but 
initially could be used to detect only single species. In response to this limitation, FlAsH was 
expanded for protein-protein detection applications. Tsien and co-workers eventually 
discovered peptide sequences that has even higher affinities for FlAsH/ReAsH than CCPGCC, 
and even found sequences that were more selective for one fluorophore over the other142. 
These sequences were used in a subsequent investigation to study the interactions between β-
arrestin2 and its cell surface receptor PTH, by labelling each of the proteins with a different 
biarsenical fluorescent probe by using the peptide sequences with specificity for either FlAsH 
or ReAsH, and monitoring FRET once they interacted148. Cross-linked analogues of FlAsH-EDT2 
have been used by Schultz and co-workers to probe for protein-protein interactions inside cells 
149. By expressing two proteins in cells that each contain the ideal binding sequence, an 
interaction can be detected via addition of the cross-linked analogue. This provides an 
interesting method for the detection of protein-protein interactions.  
An alternative approach was developed by Schepartz and co-workers, following on 




that, while distal in sequence, are proximal in space150. They demonstrated that bipartite 
cysteine pairs could be positioned across a protein-protein interface so long as the two sets of 
cysteines can collectively form a FlAsH-EDT2 binding site138, 150, 151. The deconstruction of the 
ideal binding site into cysteine residues placed appropriately in space has allowed for the 
detection of interacting proteins using very small disruptions to the protein primary sequence 
and, as FlAsH-EDT2 is cell permeable, it has been used to study the interactions of proteins in 
vivo in a structural context that is very near to native. Thus, the potential of such a tag, which 
can be easily appended to a protein and does not require complex post-translational 
modifications or large protein fusions, in concert with a small, cell-permeable fluorophore, 
cannot be understated. This technique will be the basis of our screen to assess the assembly of 
protein nanocages in vitro under different conditions, as described in Chapter 4 and 5, and will 
be scaled up to high throughput screens of protein libraries in vivo, as chronicled in Chapter 6.  
1.6.7.2. Development of FlAsH-EDT2 binding sites based on idealised geometry analysis  
 While termini do provide easy and useful locations for the formation of a binding site, 
it does limit the number of designs that can be formed, preventing this technology from being 
expanded to proteins that do not exhibit solvent accessible termini or protein ensembles 
without proximal termini. An investigation in 2009 by Goodman et al152, evaluated the ability 
to expand FlAsH-EDT2 technology to other types of secondary structures including 
unstructured strands, loops, beta sheets and a combination of the above, with an emphasis on 
moving the design process away from termini locations (Figure 1.8a)138. The proteins p53 and 
EmGFP were engineered to incorporate cysteines in various positions but on the principle of 
obeying geometry rules as stated by Shaikh et al153, who analysed the bond angles of different 
arsenic dithiolates. As FlAsH-EDT2 contains two sets of arsenic dithiolate bonding motifs, this 
investigation provides useful insights into the necessary geometric requirements for the 
relative positioning of the sulfur atoms, derived from the cysteine residues, to allow FlAsH 




guide FLAsH-EDT2 binding site design development. Work performed on p53 and EmGFP 
showed that binding sites could be achieved on both β-sheets and loops. By taking into 
account the distance between the two arsenic atoms on FlAsH, an ideal geometric limitation, 
in the form of a rhombus of 4 – 5 Å on one side and 6 – 8 Å on the other, was established. An 
interesting note is that this strategy is similar to the original FlAsH-EDT2 binding site, along the 
length of an α-helix as initially described by Tsien and co-workers136, before the wide spread 
adoption of the peptide CCPGCC140 and its analogues. However the expansion of this technique 
to incorporate not just multiple secondary structures but also multiple proteins across protein-
protein interfaces would provide the highest utility of this technique for the protein nanocage 
field. 
 
Figure 1.8 – a) Cartoon showing the advances by Schepartz and co-workers in establishing new FlAsH-
EDT2 binding sites (β-strands and loops) and the resulting rhombus shaped binding sites (red dots – 
cysteine residues). b) Proposed rhombus binding site geometric requirements based on arsenic 
dithiolate geometries. 
  The geometric design strategy described above was used to great effect by Scheck et 
al154, when trying to unravel the conformational changes during epidermal growth factor 
receptor (EGFR) signal transduction through a membrane155. This study showed the power of 




cell biological question. A similar strategy is adopted in part of the research described in 
Chapter 5 of this thesis. 
1.6.7.3. FlAsH technology in living cells 
To have the highest utility, any protein-protein interaction detection assay must be 
able to to work in vitro and in vivo. FlAsH-EDT2 has been highly employed in mammalian cells89, 
156, 137, 140, 157 since its inception, as well as yeast cells158 however its uses have been limited in 
bacterial cells159. Some studies have been undertaken to expand its utility into other cell types. 
Work performed by Enninga et al, followed the bacterial secretion of IpaB and IpaC as they 
came into contact with mammalian cells, via FlAsH-EDT2 labelling160, 161. This study established 
methods to label proteins with cysteine rich tags inside bacterial cells and examine the effect 
of FlAsH-EDT2. It was found that even high concentrations of FlAsH-EDT2 (20 µM) had little 
effect on the vitality of the cell. This investigation showed that simple diffusion was enough to 
label proteins inside bacteria. Another study by Ignatova et al144, labelled bacterial proteins 
and monitored the stability between their folded and unfolded states in bacterial cells. Their 
labelling technique required the short incubation of the cells with lysozyme in order to 
permeabilize the cells. Using this method to internalise FlAsH-EDT2, membrane protein 
structure was investigated162, 163. The cellular stability of the MtrC was establishing using a 
combination of FlAsH-EDT2 intercellular labelling and a cell-impermeable analogue, CrAsH)164. 
Although there are some published methods for the use of FlAsH-EDT2 in bacterial cells, 
further work would be needed to optimise their use for an in vivo nanocage detection library 
assay. This was developed in the research described in Chapter 6. 
1.7. Approaches for the engineering of novel protein-protein interactions  
One strain of the research described in this thesis (Chapters 3 and 6) is to develop new 
protein nanocages with new properties and are thus conceptually synthetic in nature. As 




These methods have uses as wide as assessing protein binding to a partner, or in mapping an 
interactome. Tools like these to understand natural phenomena are invaluable to the scientific 
community and can aid knowledge of how proteins fulfil their function as well as in diagnosing 
diseases when their functions go awry. However, the ability to assess protein-protein 
interactions can also be used for non-natural protein applications. 
The field of synthetic biology aims to create novel alternatives to what already exists in 
Nature, thus enveloping multiple fields of research under a broad umbrella. This breadth is 
best demonstrated through examples. One example of this is the engineering of enzymes to 
provide new catalysts for the chemical industry165. Another example is determining whether it 
is possible to create folded proteins from a smaller set of amino acids, as described by Hilvert 
and co-workers166. A third example described by Venter and co-workers167 showed that an 
organism can be successfully encoded by a completely synthetic genome. A fourth example is 
Gellman and co-workers’168 development of extended backbone amino acids to generate 
polyamides that robustly fold into novel tertiary structure.  
A large area of synthetic biology research is to engineer proteins with new function. 
However, this research is slowed due to the very limited knowledge about how secondary 
structure leads to tertiary structure and then on to quaternary structure. High resolution 
crystal and NMR structures, while incredibly useful, provide only a static picture and little 
insight into mechanisms of folding or assembly. These are still difficult to predict, leaving the 
de novo design of protein structure as mostly unattainable.  
1.7.1. Rational design and computational approaches to the engineering of protein-protein 
interactions 
Research to analyse the propensity of amino acids to form certain secondary 
structures and the resulting development of secondary structure prediction software, were the 




workers showed that by using these tools, a 4-helix bundle, not dissimilar to that observed in 
ferritin monomers, could be formed from completely designed, synthetic peptides169, 170. This 
synthetic 4-helix bundle was later used by Dutton and co-workers who modified the bundle so 
that it was able to incorporate a heme group. This new design was able to act as a rudimentary 
version of myoglobin for oxygen storage, impressive because it was constructed of only a 
simple peptide folding sequence171, 172. This design demonstrated that not only can protein 
tertiary structure be predicted and designed, but that this simple design can be used as a 
scaffold for grafting similar functions to those seen in nature without the need for the more 
complex structure of Nature-derived proteins. 
Woolfson and co-workers established design rules to expand the bundle from 4-helices 
to 6. Using semi-empirical methods, Woolfson and co-workers modified the peptide structure 
to extend the hydrophobic region that originally made up the core of the 4-helix bundle, to 
reposition the ‘knob in hole’ interactions to the edges of the bundle. This combination of 
changes resulted in a designed peptide sequence which could assemble into a novel 6-helix 
bundle with a central pore173. Woolfson and co-workers have expanded this technique to 
create arrays of peptides by controlling the hydrophobicity of different faces of the α-helix. 
This allowed for the construction of large nanostructures made up of hundreds of individual 
peptides174, marking an introduction into large artificial nanostructure design.  
While semi-empirical design has expanded the synthetic toolbox of protein folds, the 
number of designs that can be examined is limited. Using computational approaches, which 
would screen all possible conformations and are not subjected to the constraints of wet 
laboratory experiments, relevant designs can be virtually screened to fit set criteria.  
Computational design has been used to engineer enzymatic function. Baker and co-
workers used high powered computing technology to screen libraries of protein folds that 




transition state during enzymatic catalysts. By virtually combining designed cavities with 
protein folds that had no native enzymatic function, enzymes that catalyse retro-aldol175 and 
Kemp elimination reactions were generated176. By screening native protein folds with the 
computational approach, a protein was discovered that could bind to hemaglutinin with 
nanomolar affinity177 highlighting the ability of this method to generate novel protein-protein 
interactions.  
Recently, Baker’s approach has been applied to the design of proteins that assemble 
into nanocages.178 Building blocks were derived from proteins that natively provided the 
appropriate symmetries for the generation of key axes in the assembled nanocage. Two 
protein designs were found that could assemble with either tetrahedral or octahedral 
symmetries, similar to the mini- and maxi-ferritins described above. These reports 
emphatically demonstrated how far the design of quaternary structure has come, however, 
most of this research required the expression and characterisation of a large number of 
proteins to find those that actually conformed to the conformational design. This fact 
underlines an incongruity between computational designs and reality. Clearly, these need to 
be refined and a deeper understanding needs to be achieved to direct the refinement. 
These computational approaches to screen “virtual libraries” of protein nanocages 
often require extensive computing power and can be met with a high error rates thus requiring 
extensive traditional ‘wet lab’ characterisation of the expressed and purified proteins in vitro. 
An alternative approach to computational screens is using “actual libraries” of protein mutants 
and a direct detection assay screen. This approach is conceptually similar to computational 
screens as they both aim to create a large library of different designs which are individually 
analysed for a specific attribute, such as nanocage formation. Because the screen of library 
members is basically a high throughput characterisation assay, it should limit the number of 




technique. In addition, it could be imagined that a high throughput assay to directly assess 
nanocage formation could be coupled to the computational approach and help cull down the 
number of designs requiring full characterisation.  
1.8. Cloning techniques for the generation of protein libraries  
Chapter 6 of this thesis details the development of a high throughput assay to screen 
protein nanocage libraries. As part of that research, we were required to generate the libraries 
themselves. We therefore considered the several methods that have been developed to create 
large mutant protein libraries. 
1.8.1. Error prone PCR and DNA shuffling: Generation of diversity across entire genes or 
plasmids 
 A number of techniques exist to create diversity in proteins by generating diversity in 
the DNA that encodes them. One method to generate diversity is through error prone PCR 
where the PCR buffer conditions are manipulated and a low fidelity enzyme Taq polymerase is 
used, This results in the mis-incorporation of bases into the PCR product179. Mutations in the 
polymerase180, changing the concentration of MgCl2 and MnCl2181 or unequal use of the four 
dNTP’s affect the mutation rate and allow a high level of control182, 183, 184. This technique is 
somewhat imprecise in that it generates diversity in random locations between the PCR 
primers, but it has since been used to great effect for directed evolution where mutagenesis in 
implemented between screening steps.  
Error prone PCR was used by Arnold and co-workers to enhance the stability and 
function of the enzyme sublitisin E, greatly increasing its efficiency and survivability in high 
concentrations of dimethylformamide185, 186. This method has been used for other enzymes187 
and was even employed to evolve enzymes to accept and turnover new substrates. Random 
libraries of Cytochrome P450 monooxygenase were created and screened to select for the 




performing multiple rounds of mutation with selection cycles in between, the enzyme mutants 
were directed towards this new function188, 189. Error prone PCR has also been used for 
directed evolution of a protein container to sequester HIV protease74. Together, these and 
similar studies demonstrated that, with clever screen design, protein function can be altered 
toward new and novel applications without loss in protein stability, loss of solubility and 
without the need for extensive screening out of false positives as seen in “virtual screening”.  
 DNA shuffling can provide either a complementary or alternative method to error 
prone PCR190. One limitation of error prone PCR is that even successful mutations appear only 
a minimal number of times. Hence, combinations of beneficial mutations are rare. DNA 
shuffling, which involves the random digestion of a gene library, followed by the random 
reassembly of overlapping fragments through PCR. Repeated rounds of digestion and error 
prone PCR can shuffle up the mutations combinatorially. The resulting libraries can then be 
used in directed evolution screens 107.  
While both of these techniques are very useful for the creation of mutant libraries, 
there is little control over what position mutations occur. They can occur between the 
amplification primers and hence the points of diversification are inaccurately placed. This fact 
restricts the structural precision of a diversification strategy raising the possibility that a 
legitimate “hit” library member will have “success” through an undesired mechanism. This 
could be especially problematic if the screening step indirectly assesses a desired property (ie a 
survivability screen to find enzymes with a beta barrel fold). In addition, many of the library 
members may have limited activity due to protein misfolding thus wasting diversity. These 
artefacts can be compounded if error prone PCR is used to amplify the whole plasmid; copy 
number, origin sites and protein expression levels could be altered thereby lending non-




control of the placement of mutations give greater control of the diversity elements in the 
protein, and more useful diversity space is explored. 
1.8.2. Transfer PCR (TPCR) and saturation mutagenesis: Diversity at specific positions 
 Error prone PCR is a frequently used method for the generation of mutant protein 
libraries; however it is limited by being unselective in its placement of mutations. A novel 
technique takes a similar strategy to site directed mutagenesis and has been used for the 
creation of large mutant libraries is transfer PCR (TPCR)191, 192. This method originally described 
by Peleg and co-workers, allows for the rapid incorporation of several site directed mutations 
on a single gene in a one pot reaction. It uses several forward primers containing the desired 
mutations and only one reverse primer. The PCR is split into two parts, where first the primers 
generate super primers of different lengths along the gene including a collection with the 
desired mutations. The second stage incorporates these super primers back into the plasmid 
(Figure 1.9). While Peleg and co-workers used TPCR to create a single mutant with multiple 
mutations, it is straightforward to understand how a library could be generated if the mutated 
codons were randomised. Therefore, precise positions can be randomised, multiple positions 
can be randomised, and randomised positions can be coupled together on a single primer. A 
consequence of this is that it is possible to limit the area for the random incorporation of 
amino acids to certain structural regions of the protein, such as at enzyme active sites, at 







Figure 1.9 – Schematised explanation of the two step transfer PCR (TPCR) protocol that was used to 
generate protein nanocage libraries in Chapter 6. (Left) Circular plasmid containing the gene of interest 
with the locations of multiple forward primers containing different sites of random mutation (grey dots) 
and a single reverse primer. (Middle) The first step of the TPCR reaction creates multiple sized “super 
primers” that contain at least one, of the mutations. (Right) The second step of TPCR incorporates the 
“super primers” into the gene of interest in the plasmid. 
Since its inception, TPCR has been used to add restriction sites for fast cloning 
methods193, create mutant kinases194, and explore the binding landscapes of protein 
interactions195. Shifman and co-workers using ORBIT196 computational screening, a method 
similar to Baker’s (see above) increased the binding affinity between two proteins that only 
originally weakly interacted197. The predicted hits for characterisation were generated by TPCR.  
However, Shifman and co-worker’s paper, only envisioned the use of TPCR for the creation of 
large random mutant libraries and this was not the aim of the original study.  
A technique that shares several similarities to TPCR, is saturation mutagenesis198, 199. 
This method selects only a few residues for site directed mutagenesis with degenerate codon 
primers allowing for complete saturation of all possibilities onto those particular sites. This 
method has been used to alter the accessibility of substrates for the enzyme transketolase200, 
201, 202 as well as enhancing its stereoselectivity203.  
 TPCR provides advantages to error prone PCR by limiting the positions that are 
randomised. This increases the useable diversity in the library and reduces the occurrence of 
mutations at spurious positions that can affect have artefact generating consequences. 
However, it should be noted that the chance of finding a mutation that can provide a desired 




protein folding is lacking, it might be these ‘unexpected’ results that could lead to the largest 
breakthroughs.  We will discuss our use of TPCR in Chapter 6 to create libraries of a protein 
with crippled nanocage forming ability. We will develop a high throuhgput screen of these 
libraries to find novel proteins with recovered oligomerization. 
1.9. Goals of this investigation 
In the research chronicled in this thesis, we aim to contribute to the fundamental 
understanding of the role protein-protein interactions play in the assembly of ferritin 
nanocage proteins, to the exploitation of these proteins in nanotechnology, and to the 
development of new tools to advance this field. We begin by exploring the application of 
ferritins to the generation of gold nanoparticles formation and to targeted delivery (Chapter 
2). These and other applications will be enhanced by beginning to establish an understanding 
of symmetry axis formation and of the importance played by extra-bundle helicies to the 
assembly of ferritin nanocages through crystallography (Chapter 3). Furthermore we will 
develop a direct assay for ferritin nanocage formation, based on FlAsH technology that will 
allow the rapid screening of multiple conditions to optimise the nanoparticle generating 
reactions (Chapters 4 and 5). Finally, we will further develop this assay for screening, in live 
cells, libraries of ferritins with randomised protein-protein interfaces to enhance protein 
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2.1.1. Aims of this investigation 
 
Designing and creating new tools to answer scientific questions or to solve engineering 
problems in new ways is limited by the technology currently available. Nature, over the course 
of evolution has converged on processes and tools to complete a wide range of tasks 
sometimes in a more effective or efficient manner than what is possible with man-made 
processes. Therefore one strategy to enable science could be to learn and adopt methods from 
Nature and adapt them to fulfill current needs.  
This research described in this chapter aims to expand the utility of protein nanocages 
which, as discussed in Chapter 1, have already been applied to a number of applications. 
Previously, The Orner laboratory demonstrated that wild type nanocages, without any 
modifications to their primary sequence, could be used to create monodispersed protein 
encapsulated gold nanoparticles1. While this work pushed forward the boundaries of protein 
nanoparticle research, this method had not been expanded outside of the single protein 
example. Work described in this chapter aims to broaden this method to a larger repertoire of 
nanocages. If successful, it would demonstrate the breath and robustness of the technique. If 
not successful, it would hopefully shed light on and provide hints on overcoming some of the 
pitfalls and challenges with applying these proteins to the production of nanomaterials. 
 The second aim of this investigation was to perform early stage explorations into the 
potential of using nanocages for biomedical applications. It has been proposed that hollow 
protein nanocages possess the potential for drug delivery applications. In addition, a long term 




both technologies, it would be useful to direct these proteins to specific regions of the body 
most likely through the use of fusions to tissue-specific ligands. However, as an initial step to 
these ends, an understanding of the native preference of protein nanocages for the various 
bodily tissues must first be established, and this is the second aim of this project.  
2.1.2. Ferritin nanocage proteins: Horse spleen ferritin (HsFn), Bacterioferritin (Bfr) and DNA 
binding protein from starved cells (Dps) 
 
As discussed in Chapter 1, the ferritin superfamily provides excellent models for the 
study of quaternary structure due to the relativity simple fold of their monomers. Most 
ferritins assemble into nano-scaled, spherical nanocage structures which play a role in 
maintaining cellular iron homeostasis2, 3. The three ferritins described below are the main 
proteins studied and utilized in this thesis. 
In mammalian cells, ferritins are heterooligomers assembled from both a light (L) and 
heavy (H) chain, where the light chain is used as a structural scaffold and the heavy chain 
contains a ferroxidase catalytic centre where iron is oxidized from Fe2+ to Fe3+. Most 
mammalian ferritin is localized inside the cell, however, some is excreted to the serum, and 
serum ferritin levels can be used to approximate iron concentration of the body4, 5. Mammalian 
ferritin monomers fold into a four-helix bundle, like all ferritins, and have a short, C-terminal 
helix (E-helix) positioned perpendicular to the main body of the bundle. Twenty-four of these 
monomers assemble into an octahedral maxi-ferritin nanocage6. A widely studied mammalian 
ferritin, and one of the earliest examples to be isolated and characterised, is horse spleen 
ferritin (HsFn, see Appendix 2.1 for full sequence)7, 8. Although this protein assembles in the 
cell from a mixture of L- and H-chain monomers each can form a homomeric nanocage alone. 
Although the L-chain nanocage is non-catalytic, it is highly stable9. The highly stable and readily 




Ferritins from bacteria, in contrast to mammalian ferritins, form homomeric 
nanocages. Bacteria have maxi-ferritins that assemble into heme- and non-heme-containing 
nanocages. This thesis will primarily use a heme-containing ferritin, or bacterioferritin, from E. 
coli (Bfr, see Appendix 2.1 for full sequence) 11, 12. The Bfr monomer folds into a four-helix 
bundle with a C-terminal fifth, E-helix, running 78 0 to the main bundle axis. The E-helix points 
into the nanocage at the four-fold symmetry axis. Each monomer contains one ferroxidase 
active site13, 14, 15, and once assembled into a 12 nm octahedral nanocage, the resulting 9 nm 
inner cavity can store up to 4500 mineralized iron atoms. Analysis of Bfr with size exclusion 
chromatography (SEC) shows that it exists in solution as a mixture of nanocage and a dimer 
oligomerization states, and it is believed that the nanocage assembles through the association 
of two-fold symmetric dimers.  
The mini-ferritin, DNA binding protein from starved cells (Dps, see Appendix 2.1 for 
sequence) is another ferritin present in E.coli16, 17, 18. This protein assembles from twelve 
identical monomers into a 9 nm nanocage with tetrahedral symmetry and a 4.5 nm internal 
cavity. The Dps monomer folds into a four helix bundle with remarkable similarity to the 
tertiary fold of the Bfr monomer, however, Dps has a short additional helix (BC-helix) between 
the B- and C-helices and lacks the E-helix of Bfr. The BC-helix is located on the outside of the 
assembled nanocage at the two-fold symmetry axis and BC-helices from two monomers form 
part of the dimer protein-protein interface19. Unlike Bfr, Dps is a single oligomerization state in 
solution and although the dimer species is not observable, is it believed that, like Bfr, Dps also 
assembles from dimer subunits. While this nanocage is also capable of storing mineralized iron, 
the protein is only expressed as a response to oxidative stress. Interestingly, Dps has been 
shown to bind DNA nonspecifically and help protect it from reactive oxygen species20, 21, 22. 
2.1.3. Formation of inorganic nanoparticles inside ferritins 
The size and shape of an inorganic nanoparticle greatly affects its properties and, thus, 




Nanocage proteins, because of their defined size and shape, have been used as size-
constrained reactors to afford nanoparticles with very narrow polydispersities. In addition, 
they provide the resulting encapsulated particles with enhanced solubility in biological media, 
protection from aggregation, and enable the further manipulation or purification of the 
particles through bioconjugate and fusion chemistries. Ferritins, as discussed above and in 
Chapter 1, are examples of well-defined nanocages and have been used for nanoparticle 
research. A wide range of nanoscaled materials have been generated inside ferritins. 
Palladium23 and cadmium selenide24 particles have been created by exploiting ferritin affinity 
for metal cations, and gold particles have been generated through reagent photo-activation in 
the presence of the mineralized iron core25. However, these methodologies have been shown 
to be non-specific in that nanoparticles can form both inside and outside of the nanocage. 
Dmochowski and co-workers26 described conditions that resulted in polydisperse gold 
nanostructures forming on the outside of the ferritin nanocage and were only able to achieve 
particle formation inside though engineering the protein to remove metal binding residues 
such as cysteine or histidine on the outside and to position additional copies of these residues 
inside of the nanocage27. They also produced ferritin encapsulated gold nanoparticles by 
assembling ferritin subunits around pre-generated particles28. Naik and co-workers grew silver 
nanoparticle selectivity inside ferritins by fusing a silver binding peptide to the terminus which 
is located at the inner cavity of the ferritin29.  
These latter methods, while successful, have the drawback that protein engineering is 
required to elicit specificity inside the ferritin nanocage. A method with the most utility would 
be one that can generate nanoparticles in the inner cavity of any nanocage without any 
engineering required. The Orner laboratory has developed a method to create gold 
nanoparticles inside unmodified horse spleen light chain ferritins with the intention that it 
would be general for any protein nanocage1. This method initially used the HsFn L-chain 




oligomerization state in solution. The first step in the synthetic strategy involves the slow 
diffusion of gold ions into the ferritin cavity. Because the diffusion is slow, the protein solution 
can be rapidly desalted to remove gold external to the nanocage. Then the trapped gold is 
reduced with a fast-reducing agent, trapping it as a nanocluster inside the nanocage. More 
gold feedstock is added and a weaker reducing agent is then added to allow the nanocluster to 
grow slowly into a nanoparticle the size of the inner cavity. This method generated ferritin 
encapsulated gold nanoparticles with narrow polydispersities with little damage to the protein 
(Figure 2.1).  
 
Figure 2.1 – Schematic of the two-step reduction process to create monodisperse gold nanoparticles 
inside HsFn. (a) Incubation of HAuCl4 with the protein, followed by desalting of the protein sample to 
remove any external gold atoms. The remaining gold is located inside the ferritin nanocage which is 
reduced into a nanocluster using the first reducing agent, NaBH4. (b) Addition of extra HAuCl4 and the 
second reducing agent, ascorbic acid, to grow the nanocluster into a nanoparticle. (c) The formation of 
monodisperse gold nanoparticles inside of HsFn. This figure is adapted from figures in Fan et al (2010)1. 
This method is simple in its execution and could be a powerful tool for the generation 
of protein-encapsulated nanoparticles and monodisperse nanoparticles (Figure 2.2), however, 
to date, while a similar method has been used with copper,30 the generality of the approach 




increase this methods utility to the scientific community, it should be optimised for nanocages 
of different sizes and made up of different proteins. This chapter will describe attempts to 
achieve these goals. 
 
Figure 2.2 – Mono-dispersed gold nanoparticles generated and encapsulated inside HsFn protein 
nanocages. (top) SEC analysis showing the co-elution of protein nanocages (black) and nanoparticles 
(red). (bottom) Negative stained TEM analysis of HsFn encapsulated gold nanoparticles, showing the 
protein nanocages as pale rings and the gold nanoparticles electron rich black circles. Encapsulated 
nanoparticles have white rings surrounding the black circles. (a – b) before sucrose gradient purification, 
(c – f) after sucrose gradient purification, selecting for nanoparticles. This figure is adapted from figures 
in Fan et al (2010)1 and its supporting information.  
2.1.4. Functionalisation of nanocages for in vivo visualization of localisation 
 A key attribute of protein nanocages that makes them useful for many application is 
their multiple surface character; they have an external and internal surface, that often can be 
modified independently from each other10. Thus their characteristics, and resulting functions, 
can be expanded in sometimes orthogonal ways.  
To date, this feature of ferritins has allowed them to fulfil a range of in vivo tasks in 
both medical imaging and therapy. Ferritins encapsulating ferromagnetic iron oxide 
nanoparticles have been used as magnetic resonance imaging (MRI) contrasting agents31. 




protein (GFP) and the cancer targeting peptide RGD, to create a tumour cell targeting MRI and 
fluorescent imaging probe32 similar to work reported using a multifunctional liposome33. 
 The inner cavities of ferritins have also been used for radiolabelling. Radioactive Cu64 
was non selectivity loaded into the inner cavity of a protein nanocage which had the cancer 
cell targeting peptide RGD fused to its surface, with its uptake monitored over time34. Similarly, 
a RGD fusion human H chain ferritin containing a ferromagnetic iron oxide nanoparticle was 
used to monitor the targeting of cancer cells35, inflammation and angiogenesis36. 
 The above examples demonstrate the potential of ferritins for medical imaging; 
however they all require filling the nanocage with the imaging agent. This can be a drawback, 
especially with the realisation that a labelled ferritin could have in concert multiple functions 
of imaging, delivery, and direction. Therefore we thought that a better strategy would be to 
attach the label to the outside of the nanocage so that the inside would be preserved for 
eventual delivery and transport applications. This chapter will describe a first step toward the 
development of this technology where we will establish the labelling and imaging and 






2.2. Results and discussions 
2.2.1. Generation of gold nanoparticles inside Bfr and Dps 
  Our laboratory has extensive experience working with the protein nanocages Bfr and 
Dps. This experience and the fact that one is a maxi-ferritin and the other is a mini-ferritin led 
us to choose them as initial model systems to expand our method for generating encapsulated 
gold nanoparticles of different sizes. In addition, it should be recalled that the ferritin that was 
previously used was HsFn L-chain which has no catalytic activity. Both Bfr and Dps, however, 
are catalytic and can bind metal. Furthermore, Bfr contains multiple oligomerization states. 37, 
38 We thought these attributes of the two proteins would present a challenge to test the 
robustness of our methodology.  
 Our analytical techniques were similar to those that were used previously in the first 
generation of this synthetic method. Size exclusion chromatography (SEC) was used as the 
primary analytical tool. First, SEC can detect the presence of the protein (280 nm), and through 
separation, identify the size and number of species present (aggregate, nanocage, dimer, 
monomer, etc). Second surface plasmon resonance (SPR) can be used to detect the 
nanoparticles (530 nm). Overlaying the SEC traces from the two channels can show which state 
of protein the gold is associated. The secondary analytical tool was transmission electron 
microscopy (TEM) to determine morphology of gold structures and the state of the protein. 
First, standard elution volumes of intact Bfr and Dps needed to be established.  
The proteins Bfr and Dps were expressed, purified and characterised (see Appendix 2.2 
and 2.3 for SDS-PAGE and CD respectively). SEC analysis of Bfr showed, consistent with the 
literature, that two species are present37. Both the 24-mer nanocage (elution volume 11 ml) 
and a dimer species (elution volume 15.5 ml) are observed, while for Dps only a single 12-mer 
nanocage species (elution volume13 ml) exists in solution (Figure 2.3). These elution profiles 





Figure 2.3 – Size exclusion chromatograms of purified Bfr (left) and Dps (right). These chromatograms 
are standards that were used to assess the survival of the proteins under nanoparticle generation 
conditions. The chromatograms were normalised to their highest intensity. The data is the average of 
three runs (0.5 ml injection of 1 mg/ml protein(280 nm), using running buffer, 50 mM Tris.HCl, 50 mM 
NaCl, pH 7.8, at a flow rate of 0.5 ml/min.  
 We initially employed the unoptimised HsFn conditions using Bfr and Dps. However, 
SEC showed only large protein aggregates for both proteins with co-eluting SPR peaks (Figure 
2.4) and no peaks from surviving nanocages or dimers were observed. This surprising result 
immediately highlighted the difference in behaviour between HsFn and the bacterial ferritins. 
A small aggregate peak can be observed when HsFn is subjected to these conditions, however 
it is much smaller than with Bfr and Dps and nanocage is the major peak1.  Because of this 
initial failure, the components of the conditions were optimised. 
Figure 2.4 – Initial gold nanoparticle genesis conditions cause protein aggregation. Size exclusion 
chromatograms of purified Bfr (left) and Dps (right) after being subjected to nanoparticle generation 
conditions. The chromatograms normalised to their highest intensity. 280 nm (black) and 530 nm (red). 
Nanoparticle experiment from trial 1, used 1 ml of 1mg/ml protein in phosphate buffer ( 50 mM 
Na2HPO4, 50 mM NaCl, pH 7) incubated with 22.6 µl of 0.1 M HAuCl4 for 3 hrs, at room temp. 20 µl of 0.1 
M NaBH4 was then added and was incubated for 3 hrs, at room temp followed by desalting. An 
additional 10 µl of 0.1 M HAuCl4 and 30 µl of 0.1 M ascorbic acid was added and incubated, overnight at 
room temp. All reagent solutions are in H2O. After concentration, 0.5 ml of the remaining sample was 




2.2.1.1. Optimisation of nanoparticle generation conditions for protein stability 
 A number of changes were made in the initial conditions with the hope of trying to 
eliminate protein aggregation. There are several areas for optimisation (Figure 2.5), including 
the reagents, the reagent concentrations, volumes and buffering conditions. Each condition 
that was attempted was analysed with SEC for the presence of nanocages or protein 
aggregates. If nanocage peaks were observed the sample was further characterised with TEM 
(all conditions that were attempted are listed in Appendix 2.7). 
 
Figure 2.5 – Schematic representation of the experimental procedure to create gold nanoparticles inside 
of HsFn as previously reported1 highlighting areas of possible optimisation (black dashed boxes). HAuCl4 
is first added to the protein sample, which is subsequently desalted and reduced with the addition of 
the first reducing agent. More HAuCl4 is added and further reduced with the addition of the second 
reducing agent. All concentrations and volumes of the reagents are the added quantities and not the 
final. All the possible areas of optimisation are highlighted (black dashed boxes), including the 
concentration, volume and buffering condition of each reagent, plus the reagents themselves, as well as 
the protein buffer and desalting running buffer.  
 The first two conditions that were screened involved attempts to prevent aggregation. 
In the first set of conditions (Trial 1), the same method as previously published1 was attempted 
at 4 °C however this resulted in protein aggregation as was seen above. In a second set of 
conditions (Trial 2) a detergent (0.1% tween20) was included, but again, only large protein 
aggregates were observed. Although potentially a quick fix, stopping the aggregation of the Bfr 




 Next we tried to determine if aggregation was caused by any specific reagent that was 
used for the generation of the nanoparticles. First the role of the first reducing agent, NaBH4, 
in forming aggregates was examined. In the next group of conditions, the concentration of 
NaBH4 was decreased from 0.1 M to 0.01 M (Trial 3) and 0.001 M (Trial 4). Again, only a large 
protein aggregate peak was observed. Next, the HAuCl4 concentration was decreased from 0.1 
M to 0.05 M HAuCl4 (Trial 5), however, again, both proteins aggregated. Taken together, these 
trials suggested that at least one, if not all, of these reagents were not compatible with Bfr and 
Dps. 
 In the initial conditions, the reagents were dissolved in water before addition to the 
buffered protein solution. The gold source in our method is chloroauric acid (HAuCl4). The pH 
of the 0.1 M HAuCl4 solution in water is 1.2. We considered that the addition of a strongly 
acidic solution to the protein sample, although buffered, could cause a sudden or permanent 
drop in pH which could lead to protein aggregation. Potentially, by buffering the HAuCl4 
solution to a neutral pH, protein aggregation could be avoided. However, it was realised that 
changing the pH could affect the reduction potential of the reductant. Therefore a mini-screen 
was performed where the ability to reduce HAuCl4 was determined in a number of conditions 
in the absence of protein.   
For the screen, reagents dissolved in various buffers were assessed for their ability to 
cause a solution of HAuCl4 to turn red in twenty-four hours, indicating reduction of HAuCl4 (see 
Appendix 2.5). An assay like this was ideal because of its simple and rapid detectability and the 
small volumes that were used. The reductant, NaBH4 was assessed at different concentrations 
in H2O (unbuffered), sodium phosphate buffer (pH 7) and Tris buffer (pH 7.8) Phosphate 
buffered reductant, especially at lower concentrations, only poorly reduced gold whereas the 
reagent was successful in both Tris and in H2O across all concentrations. Because of its 




Using Tris buffered solutions (pH 7.8) optimisation of HAuCl4 was again attempted in 
the presence of the proteins. However, for conditions using buffered HAuCl4 at both 0.1 M 
(Trial 6) and 0.05 M (Trial 7), again, only aggregation for both Bfr and Dps was observed.  
 All the optimisations of the method thus far only analysed the product at the end of 
the process. Thus, it was thought that to better understand the cause of the aggregation it 
would be better to check protein stability after the addition of each reagent. Two different 
concentrations of the Tris buffered HAuCl4 solution (0.1 M and 0.05 M Trials 8 and 9 
respectively) were added to the Bfr and Dps solutions. After a three hour incubation period, 
they were analysed by SEC. The resulting chromatograms indicated the presence of nanocages 
and dimers and very little aggregates for both proteins. This result clearly demonstrated that 
the buffered gold solution was not responsible for protein aggregation. A similar experiment 
was performed using NaBH4 (0.1 M and 0.01 M Trial 10 and 11 respectively) however, after 
three hours of incubation, only protein aggregates were observed for Bfr. Chromatograms of 
the Dps solution, however, showed both nanocages and aggregates.  
 As a goal of this research is to find conditions that can be generally applied to any 
protein nanocage, it was important that we used reagents that permitted the survivability of 
both Bfr and Dps. An alternative reducing agent to NaBH4 is NaCNBH3. Due to the electron 
withdrawing properties of the cyanide group, NaCNBH3 is less reactive than NaBH4. This drop 
in reactivity could provide milder conditions that would be general for both Bfr and Dps. 
Therefore, NaCNBH3 was screened for its ability to reduce gold in buffered and unbuffered 
conditions (see Appendix 2.6). The Tris buffer conditions were superior. 
 Analysis of the survivability of Bfr and Dps were conducted using NaCNBH3 as the first 
reducing agent. The concentration of NaCNBH3 was examined at 0.1 M (Trials 12, 14 and 15) 
and 0.01 M (Trial 13) as well as a change in volume, using a 20 µl addition (Trials 12 and 13) a 




nanocages could be seen for both Bfr and Dps. This highlights the success in using NaCNBH3 as 
the first reducing agent to combat protein aggregation. Taking these data into account, a new 
experiment was preformed which buffered both the gold solutions and the new first reducing 
agent NaCNBH4 (Trial 16). The SEC data showed a continual signal across a wide elution volume 
for both Dps and Bfr when monitoring at 280 nm, but with no clear nanocage peak. While an 
SPR signal peak could be observed, this did not elute at the volume expected for nanocages 
(Figure 2.6).  
Figure 2.6 – Semi optimised gold nanoparticle genesis conditions buffering both the gold source and first 
reducing agent in Tris buffer (50 mM Tris, pH 7.8.). Size exclusion chromatograms of purified Bfr (left) 
and Dps (right) after being subjected to nanoparticle generation conditions. The chromatograms 
normalised to their highest intensity. 280 nm (black) and 530 nm (red). Nanoparticle experiment from 
trial 16, used 1 ml of 1mg/ml protein in Tris buffer (50 mM Tris.HCl, 50 mM NaCl, pH 7) incubated with 
20 µl of 0.1 M HAuCl4 buffered in Tris (50 mM Tris.HCl, pH7.8) for 3 hrs, at room temp. 20 µl of 0.1 M 
NaCNBH3 buffered in Tris (50 mM Tris.HCl, pH7.8) was then added and was incubated for 3 hrs, at room 
temp followed by desalting. An additional 10 µl of 0.1 M HAuCl4 buffered in Tris (50 mM Tris.HCl, pH7.8) 
and 30 µl of 0.1 M ascorbic acid was added and incubated, overnight at room temp. After concentration, 
0.5 ml of the remaining sample was injected. Each sample was run once. 
 The lack of well-defined nanocage peaks in figure 2.6, made it unclear if the nanocages 
where aggregated or not. Samples were taken from the elution volume corresponding to the 
nanocages of both Bfr and Dps and analysed with TEM. Micrographs from TEM did not show 
the presence of any intact nanocages but did show nanoparticles with pale rings around them 
(Figure 2.7). These nanoparticles were of a fairly regular size and could be surrounded by 
folded nanocages. However the lack of empty but intact nanocages led us to believe that these 
nanoparticles were covered with protein aggregates. The similar size of the observed 




to isolate them. Only conditions that allowed for the observance of both empty and filled 
white rings (nanocages) would be seen as optimal and proof of nanocage survival.  
 
Figure 2.7 – Transmission electron microscopy of semi optimised nanoparticle genesis condition from 
the SEC elution volume corresponding to the Bfr and Dps nanocages seen in figure 2.4. Nanoparticle 
experiment from trial 16, used 1 ml of 1mg/ml protein in Tris buffer (50 mM Tris.HCl, 50 mM NaCl, pH 7) 
incubated with 20 µl of 0.1 M HAuCl4 buffered in Tris (50 mM Tris.HCl, pH7.8) for 3 hrs, at room temp. 20 
µl of 0.1 M NaCNBH3 buffered in Tris (50 mM Tris.HCl, pH7.8) was then added and was incubated for 3 
hrs, at room temp followed by desalting. An additional 10 µl of 0.1 M HAuCl4 buffered in Tris (50 mM 
Tris.HCl, pH7.8) and 30 µl of 0.1 M ascorbic acid was added and incubated, overnight at room temp. 
After concentration, 0.5 ml of the remaining sample purified via SEC and this sample was subject to TEM 
using 1% uranyl acetate as a negative stain. 
 Buffering the reagents and the use of a weaker reducing agent did seem to have an 
effect on the species observed under SEC. With the change in pH seemingly being resolved 
through reagent buffering, further trails analysed the concentration and volume of the gold 
source and the first reducing agent. The concentration of the HAuCl4 was dropped to 0.01 M 




protein aggregation, small volumes were added multiple times (5 x 20 µl additions ten minutes 
apart) while keeping the first reducing agent the same as above (20 µl addition of 0.1 M 
NaCNBH3) (Trial 17).  Smaller volumes of HAuCl4 solution were trialled including 100 µl of 0.05 
M (Trial 18) and 20 µ of 0.1 M (Trial 19) while keeping the first reducing agent the same as 
above (20 µl addition of 0.1 M NaCNBH3). This condition was repeated but with an increased 
volume of first reducing agent (100 µl of 0.1 M NaCNBH3) with both a 5 x 20 µl of 0.05 M 
HAuCl4 solution addition (Trial 20) and a 100 µl of 0.05 M HAuCl4 solution addition (Trial 21). 
However, under all conditions, SEC analysis showed a continual signal across a wide elution 
volume similar to figure 2.6.  
The only reagent which has so far not been examined was the second reducing agent, 
ascorbic acid. As the name suggests, this too is acidic and could be playing a role in the 
aggregation of the proteins. Initially this reagent was overlook as it is found in cells and 
therefore should be biocompatible. All further trials were conducted with all reagents buffered 
in Tris (50 mM Tris.HCl, pH 7.8). Experiments were performed where the concentration and 
volume of the first (100 µl of 0.1 M NaCNBH3 in 50 mM Tris.HCl, pH 7.8 buffer) and second (50 
µl of 0.1 M ascorbic acid in 50 mM Tris.HCl, pH 7.8 buffer) reducing agents were kept constant, 
but the concentration and volume of the HAuCl4 solution from both additions was varied. For 
the first HAuCl4 addition 5 x 20 µl (Trial 22) 5 x 40 µl (Trial 23) and 1 x 100 µl (Trial 24) of gold at 
0.05 M was added with 10 µl of 0.1 M gold added in the second addition for all three trials. 
Further optimisation repeated the last three trials but using 100 µl of 0.05 M HAuCl4 for the 
second additions while varying the first gold addition to 5 x 20 µl (Trial 25) 5 x 40 µl (Trial 26) 
and 1 x 100 µl (Trial 27) of at 0.05 M HAuCl4. 
SEC analysis showed the presence of not just a UV 280 nm signal across the nanocage 
elution volume but a well-defined peak corresponding relatively well with the nanocages of 




Well defined peaks were seen for both proteins, at the expected nanocage elution volume, 
with corresponding SPR signals. This co-elution suggested the presence of intact protein 
nanocages either attached to size selective nanoparticles or with nanoparticles encapsulated 
within them. The presence of only a small aggregation peak from Bfr and Dps suggests that this 
new mild condition is optimal for nanocage survival.  
 
Figure 2.8 – Further optimised gold nanoparticle genesis conditions buffering all reagents in Tris buffer 
(50 mM Tris, pH 7.8.). Size exclusion chromatograms of purified Bfr (left) and Dps (right) after being 
subjected to nanoparticle generation conditions, protein 280 nm (black) and SPR 530 nm (red). 
Nanoparticle experiment from trial 27, used 1 ml of 1mg/ml protein in Tris buffer (50 mM Tris.HCl, 50 
mM NaCl, pH 7) incubated with 100 µl of 0.05 M HAuCl4 buffered in Tris (50 mM Tris.HCl, pH7.8) for 3 
hrs, at room temp. 100 µl of 0.1 M NaCNBH3 buffered in Tris (50 mM Tris.HCl, pH7.8) was then added 
and was incubated for 3 hrs, at room temp followed by desalting. An additional 100 µl of 0.05 M HAuCl4 
buffered in Tris (50 mM Tris.HCl, pH7.8) and 50 µl of 0.1 M ascorbic acid buffered in Tris (50 mM 
Tris.HCl, pH7.8) was added and incubated, overnight at room temp. After concentration, 0.5 ml of the 
remaining sample was injected. Each sample was run once. 
 
 To assess whether or not intact nanocages are present, a sample from the elution 
volumes corresponding for nanocages were collected and examined via TEM (Figure 2.9). The 
presence of empty nanocages was very evident for Bfr showing that this method does not 
completely lead to protein aggregation. Nanoparticles were also observed, but with two 
distinct sizes. The larger sized nanoparticles that show the presence of a white protein ring 
around them are the size expected for the internal cavity of Bfr. However, the smaller size 
which appear more frequently, tend to also have pale rings, or protein shells around them and 




change to a weaker reducing agent. However the presence of intact nanocages, suggests that 
the pale rings seen around the nanoparticles are nanocages and not protein aggregates. 
Although this is promising, there are clearly nanoparticles that are present outside of the 
nanocages. The Dps TEM images present a different picture. No intact nanocages can be 
observed even although a clear peak in the SEC (Figure 2.8) at the correct elution volume for 
Dps can be seen. Nanoparticles of two sizes are again observed. A larger nanoparticle, which is 
too large to be from the internal cavity of Dps and a smaller particle whose size is similar to 
that of the cavity, were seen. Further TEM analysis with a higher intensity electron beam could 
be useful to ascertain the presence of intact Dps nanocages. 
 
Figure 2.9 – Transmission electron microscopy of further optimised nanoparticle genesis condition from 
the SEC elution volume corresponding to the Bfr and Dps nanocages seen in figure 2.8. (left) Bfr, 
highlighting both empty but intact nanocages (blue arrow), and nanoparticles with pale rings of a size 
similar to the Bfr inner cavity (red arrow). (right) Dps, highlighting nanoparticles with pale rings of the 
size constant with the Dps inner cavity (red arrow). Nanoparticle experiment from trial 27, used 1 ml of 
1mg/ml protein in Tris buffer (50 mM Tris.HCl, 50 mM NaCl, pH 7) incubated with 100 µl of 0.05 M 
HAuCl4 buffered in Tris (50 mM Tris.HCl, pH7.8) for 3 hrs, at room temp. 100 µl of 0.1 M NaCNBH3 
buffered in Tris (50 mM Tris.HCl, pH7.8) was then added and was incubated for 3 hrs, at room temp 
followed by desalting. An additional 100 µl of 0.05 M HAuCl4 buffered in Tris (50 mM Tris.HCl, pH7.8) 
and 50 µl of 0.1 M ascorbic acid buffered in Tris (50 mM Tris.HCl, pH7.8) was added and incubated, 
overnight at room temp. After concentration, 0.5 ml of the remaining sample purified via SEC and this 





 While SEC analysis of this semi-optimised condition from trial 27, showed the presence 
of nanocages, which for Bfr was verified through TEM, work is still needed to explore further 
conditions that improve on this initial data for Bfr and for Dps. 
Due to time constraints, further optimisation was only conceived. By the presence of 
small nanoparticles that did not fill the cavity, it is apparent that the growth of the 
nanoparticle is insufficient. Therefore further conditions could be analysed that enhance this 
stage. Incubation times, the volume and concentrations of both the first and second reducing 
agents could be increased as well as the amount of gold added during the second reduction 
step. A range of other reducing agents could also be examined for their potential to reduce 
gold in a manner that does not aggregate the proteins. However, the examination of so many 
alterable conditions using this current system is time and resource expensive. If a quicker 
method can be obtained that can screen for protein stability in the presence of different 
reagents at varying concentrations, nanoparticle formation could be optimised faster. This 
screen is further discussed in Chapters 4 and 5 and used to examine nanoparticle formation 
conditions in Chapter 5.  
2.2.2. Radioactive labelling of a apo-ferritin for in vivo localisation in mice 
Protein nanocages are potential candidates for a range of applications (see Chapter 1). 
One such usage would be in targeted drug delivery. Through modification of the protein 
sequence or through fusions, protein nanocages can be made to target areas of the body, thus, 
in combination with its cargo, be used as a targeted delivery agents. In order to fully 
appreciate the ability of ferritin nanocages for such applications, some fundamental questions 
first need to be asked. Among these are “How to determine the targeting?” and “Where do 
ferritin have a background targeting preference?” We set out to answer these questions in this 
chapter. We designed a strategy to radiolabel the readily available and highly stable HsFn L-




monitored with single-photon emission computed tomography and X-ray computed 
tomography (SPECT/CT) over the course of several days. The data obtained from this 
investigation would form a foundation for targeted drug delivery using ferritins.  
2.2.2.1 Conjugation of CHX-A’-DTPA ligand to horse spleen ferritin and radiolabelling with 
111In 
 Light chain horse spleen ferritin is a highly stable, readily available and non-
catalytically active protein nanocage. It was chosen as a robust model system for this 
investigation. The ligand N-[(R)-2-Amino-3-(p-isothiocyanato-phenyl) propyl]-trans-(S,S)- 
cyclohexane-1,2-diamine-N,N,N’,N”,N”-pentaacetic acid (CHX-A’-DTPA, Macrocyclics) (Figure 
2.10) has been used often by our collaborator's laboratory, and was chosen for this 
investigation due to their expertise and its high binding affinity to 111Indium. Isothiocyanate 
groups are able to react with the amine group of lysine side chains. HsFn L-chain has nine 
lysine residues (K59, K68, K84, K98, K105, K140, K143, K144 and K173). While several are either 
buried (K59, K140, K143 and K144) or inside the potentially ligand inaccessible cavity (K68 and 
K173), some are surface exposed and accessible (K84, K98 and K105) (PDB:2W0O, see 
Appendix 2.1 for full sequence). These residues are expected to be the targets for conjugation 
to the CHX-A’-DTPA ligand.  
 
Figure 2.10 – Chemical structure of N-[(R)-2-Amino-3-(p-isothiocyanato-phenyl) propyl]-trans-(S,S)- 




 CHX-A’-DTPA was conjugated to horse spleen ferritin through a simple overnight 
incubation and then characterised by the ability of the resulting complex to bind to radioactive 
111In. HPLC with dual protein (280 nm) and radiation monitoring can be used to generate co-
elution profiles to identify protein species associated with radioactivity. HPLC, using a size 
exclusion chromatography column, of HsFn alone was run as a standard (Figure 2.11). The 280 
nm channel shows a single peak at 8 ml and with no associated radiation.  
 
Figure 2.11 – Analysis of the radioactivity of the unconjugated HsFn protein nanocage. Size exclusion 
chromatography column used in conjunction with HPLC. Protein monitored at 280 nm (10 μl of 5 mg/ml 
protein sample in 0.1 M ammonium acetate) run at 1 ml/min (running buffer – 0.1 M Na2HPO4, 0.001 M 
EDTA, pH 7.5). Sample was run once. a) HPLC of sample through size exclusion column, b) radioactivty. 
 As ferritins are known to bind metal ions, it was important to determine whether HsFn 
can bind 111In. If binding or trapping did occur, then this could show false positives for the 
successful incorporation of CHX-A’-DTPA, but, ferritin would most likely have a much lower 
affinity for 111In than CHX-A’-DTPA allowing for its undesirable release during in vivo analysis. 




The protein channel showed a similar profile to the standard (Figure 2.9). It should be noted 
that the buffer used in this analysis contains ethylenediaminetetraacetic acid (EDTA) which 
sequesters 111In. The resulting complex elutes from this column at 13 ml. The radioactive 
channel of the protein interjection only showed this peak. Importantly, no radiation co-eluted 
with the ferritin suggesting that it does not bind 111In when it is not conjugated to CHX-A’-
DTPA.  
 
Figure 2.12 – Analysis of the radioactivity from a unconjugated HsFn protein nanocage after 30 min 
incubation with 111In. Size exclusion chromatography column used in conjunction with HPLC. Protein 
monitored at 280 nm (10 μl of 5 mg/ml in 0.1 M ammonium acetate, pH 6, mixed with 5 μl of 111In with 
128 Mbq of activity) run at 1 ml/min (running buffer – 0.1 M Na2HPO4, 0.001 M EDTA, pH 7.5). Sample 
was run once. a) HPLC of sample through size exclusion column, b) radioactivty. 
 With the controls established, the CHX-A’-DTPA-ferritin complex was subjected to the 
same HPLC analysis after incubation with 111In (Figure 2.13). The HsFn nanocage peak was 
evident in the protein channel, indicating that the majority of the protein survives the 
conjugation. Importantly, this peak co-elutes with the radioactivity, demonstrating that the 




the complex in hand we were prepared to use it to monitor the position of exogenous ferritins 
inside of a complex organism through in vivo radioactive monitoring techniques (SPECT/CT). 
 
Figure 2.13 – Analysis of the radioactivity of the protein nanocage HsFn after being conjugated to CHX-
A’-DTPA and incubated for 30 min with 111In. Size exclusion chromatography column used in conjunction 
with HPLC. Protein monitored at 280 nm (10 μl of 5 mg/ml in 0.1 M ammonium acetate, pH 6, mixed 
with 5 μl of 111In with 128 Mbq of activity) run at 1 ml/min (running buffer – 0.1 M Na2HPO4, 0.001 M 
EDTA, pH 7.5). Sample was run once. a) HPLC of sample through size exclusion column, b) radioactivty. 
 2.2.2.3. In vivo localisation of exogenous ferritin in mice 
 The CHX-A’-DTPA-ferritin complex was radioactively labelled with 111In, injected in the 
tail vein of three mice and a SPECT/CT scan was performed at 0, 3, 24 and 48 hours post 
injection (Figure 2.14 and Figure 2.15). For the 0 and 3 hour post injection images, a large 
radioactive response was detected in the liver, intestine and bladder, corresponding to normal 
routes of expulsion from the body. After 24 hours, the liver was still highly active but the 
majority of the mice had much lower responses. Interestingly two additional pairs of ‘hot 
spots’ were seen with much higher activity than the surrounding tissue (Figure 2.12 areas 1 




systems would be expected to be active, the hot spots were intriguing as they might suggest 
some specific targeting by ferritin even without any appended targeting functionality 
 
Figure 2.14 – Two-dimensional SPECT image for a mouse injected with 111In CHX-A’-DTPA-ferritin 
complex after 0, 3, 24 and 48 hours. Each injection contained 0.1 mg of protein incubated with 25 μl of 
111In with 193 Mbq of activity for 30 min, then made up to 100 μl with saline. Each syringe contained 16 
Mbq of activity after preparation, with 0.1047 g (105.4 μl), 0.1024 g (102.4 μl), and 0.1078 g (103.8 μl) 
being injected into the tail vein of mouse 1, 2 and 3. 
 The combined SPECT reconstruction and the CT scan can be used to direct dissection 
as a first step toward identifying these hotspots (Figure 2.14). The mice were culled and their 
organs harvested and a mass that corresponded to the shape and location of area 1 from 
figure 2.12 was collected and its identity was suggested to be that of dorsal lymph nodes. The 
second area, labelled as 2 in figure 2.14, was not identified and no organ in that location 
corresponding to that shape could be harvested from the mice. Its location as seen from 3D 
reconstructions suggests it could be located between the joints in the hip bone, but this could 








Figure 2.15 – SPECT/CT reconstruction of a mouse injected with 111In CHX-A’-DTPA-ferritin complex after 
(a) 0 hours, (b) 3 hours, (c) 24 hours and (d) 48 hours. Each injection contained 0.1 mg of protein 
incubated with 25 μl of 111In with 193 Mbq of activity for 30 min, then made up to 100 μl with saline. 
Each syringe contained 16 Mbq of activity after preparation, with 0.1047 g (105.4 μl), 0.1024 g (102.4 
μl), and 0.1078 g (103.8 μl) being injected into the tail vein of mouse 1, 2 and 3. Bladder was not 
removed during image reconstruction. 
 The dissected organs were analysed and their activities were determined with respect 
to their weights (Figure 2.16). As expected from the SPECT reconstructions, the liver showed 
high activity as did the spleen. Area 1 from Figure 2.14, shows very high activity for its size and 
has clearly been labelled strongly by the CHX-A’-DTPA-ferritin complex. There also is slight 





Figure 2.16 – Comparison of radioactivity based on weight to the control (see Appendix 2.8) of organs 
harvested from the mice after 48 hours post injection of the 111In labelled CHX-A’-DTPA-ferritin complex. 
‘Hot spot’ is area 1 from Figure 2.12. Data is averaged from the organs of three mice.  
 Further controls are required to ensure that this native targetting is not due to just the 
ligand, but is infact a product of the ferritin. However, if that data presented here is found to 
be due to the ferritin and not the ligand, then this inital data could suggest that even without 
targeting functionality added, HsFn could target a number of locations within a mouse. 
Labelling of the spleen might suggest a natural uptake mechanism to this iron rich organ for 
iron binding proteins. The low but significant binding to bone and the highly selective labelling 
to two ‘hot spot’ areas, warrants further investigation. Even if these areas are not bio-
medically interesting targets, this data can be used as a first step to characterizing a drug 


































































































 Our laboratories previously published method for the formation of mono-dispersed 
gold nanoparticles inside of light chain horse spleen ferritin was expanded to two other 
ferritins with the aim of showing the versatility and breath of this technique. These ferritins, 
differing in size and symmetry, and both from bacteria behaved differently than HsFn in the 
nanoparticle generating conditions with both proteins completely aggregating. The conditions 
were explored more deeply and the problem was determined to be a combination of pH and 
the strong reducing agent used in the first reduction step. Through a combination of using a 
weaker reducing agent, and buffering all solutions, the survival of both proteins was enhanced. 
However, under these conditions optimised for protein stability, the formation of 
nanoparticles was less than optimal, with different particle sizes observed for both Bfr and 
Dps. This may be a consequence of lowering the strength of the first reducing agent. While this 
work is a step forward in generalizing our method toward other protein nanocages, especially 
those less robust than HsFn, this technique must still be further optimised to reliably produce 
protein nanocage encapsulated gold nanoparticles.  
 This investigation did highlight some challenges to working with nanocages. Applying 
them to various nanotechnologies can sometimes be hindered if their fundamental physical 
and chemical properties are not fully understood or characterised. A step in this direction is 
addressed in Chapter 3. Furthermore, although several new conditions were assayed for their 
potential to not only form nanoparticles but also to maintain the structural integrity of the 
proteins, this process was slow and relied upon traditional low throughput techniques such as 
SEC. If a method could be found that allows for the rapid assessment of protein quaternary 
structure without relying on slow characterisation techniques, the throughput could be 
expanded, and many more conditions and reagents could be screened in a much more rapid 




methodology, it could also be used as a tool to better understand the fundamentals of 
quaternary structure of nanocages, which ultimately would aid in their utilisation. The 
development of such a method is explored in Chapters 4 and 5, and its utilisation for 
engineering more robust protein nanocages is discussed in Chapter 6. An important take-home 
lesson from our work with the nanoparticles is that HsFn is clearly much more robust than Bfr 
and Dps. As the long term aim of the project described in this chapter is to explore ways to 
exploit ferritin nanocages for novel applications, it became apparent, that using a highly stable 
ferritin would provide the most optimal route. Thus, for the second half of this chapter, where 
we applied ferritins to imaging, we employed HsFn.  
Another envisioned application of protein nanocages is as delivery and transport 
vessels. It is imagined that the cavities could be loaded with cargo, be it small molecule drugs, 
genomic material or even nanoparticles, and the “package” would be targeted to certain 
tissues within the body. However, before targeting studies can take place, initial research into 
the suitability of ferritins for these applications must be determined. Therefore we sought to 
establish the background targeting of ferritins in living mice. We conjugated HsFn to a 
radioactive reporter to allow visualisation of the ferritin in living mice using SPECT/CT. The 
conjugation was successful most likely due to the robust nature of this particular ferritin and 
readily visualized particular organs in the mouse. We did see accumulation in the liver, spleen 
and two “hot spots” one of which may be the dorsal lymph nodes. This alone could suggest its 
use as a targeting agent, or this data could be used as background for applications with more 
specific targeting. Taken together, these data indicate that HsFn could be a suitable tool for 







2.4.1. Generation of ferritin encapsulated nanoparticles  
2.4.1.1. Protein production and purification 
Vectors (pET-32b) containing the genes coding for wild type Bfr and Dps (see Sequence 
Appendix 2 for full sequences) were electroporated into BL21 E.coli cells and plated on LB 
plates (50 μl/ml of carbenicillin). Selected colonies were then grown in LB (5 ml, 37 °C, 
overnight) as pre-culture which was later added to LB (500 ml) and grown (37 °C) until an 
O.D600 of 0.6. Protein expression was then induced by the addition of IPTG (final concentration 
of 400 mM) and the cultures were further incubated (3 h, 30 °C). The cells were isolated by 
centrifugation (10,000 rpm, 20 min at 4 °C). The cell pellet was resuspended with lysis buffer 
(50 mM NaH2PO4, 300 mM NaCl, 40 mM Imidazole, pH 8) and sonicated (15 min, pulsed 10 s 
off then on, with a Sonics vibra cell sonicator). The protein solutions were clarified by 
centrifugation (10,000 rpm, 20 min at 4 °C) and then filtered (Pall, 0.2 μm).  
The protein was purified via affinity chromatography via the His6 tag with a GE 5 ml 
Histrap FF Column using wash buffer (30 mM NaH2PO4, 300 mM NaCl, 40 mM Imidazole, pH 
7.6). The proteins of interest were eluted from the Histrap using elution buffer (30 mM 
NaHPO4, 300 mM NaCl, 500 mM Imidazole, pH 7.6) and then digested. Enterokinase digestion 
(NEB 2 μg/ml) was performed to cleave off the peptide tag from the protein of interest 
followed by a second Histrap (GE, Histrap FF, 5 ml, (wash buffer-40 mM Imidazole, 50 mM 
NaH2PO4, 300 mM NaCl, pH 7.4), (elution buffer-500 mM Imidazole, 50 mM NaH2PO4, 300 mM 
NaCl, pH 7.4)) to remove the tag from solution. The protein solutions were further purified by 
size exclusion chromatography (GE Hiload 16/60 Superdex with running buffer (50 mM 





2.4.1.2. Iron removal from pure protein 
The purified proteins underwent dialysis into ‘apo buffer’ (1% thioglycolic acid, 1% 2’2’ 
bipyridine, pH 4.5) for 24 hours to remove any iron39. This buffer was then changed to a Tris 
buffer (50 mM Tris.HCl, 50 mM NaCl, pH 7.8) and left for a further 24 hours. After dialysis the 
protein sample was adjusted to 1 mg/ml ready for nanoparticle experiments.  
2.4.1.3. Initial conditions for the formation of nanoparticles inside unmodified apo-ferritins1 
For control experiments, purchased apo-horse spleen ferritin light chain (HsFn, Sigma, 
5 mg/ml stock) was purified via SEC (1 ml, running buffer 50 mM Tris, 50 NaCl, pH 7.8, GE 
Superdex 200 10/300 GL) then diluted for nanoparticle experiments (1 mg/ml). 
The initial method for the creation of nanoparticles as previously described required 
the addition of a first gold source (22.6 μl of a 0.1 M HAuCl4 solution in water) to 1 ml of a 1 
mg/ml protein sample. This solution was incubated (3 h, room temp). The sample was then 
desalted using a GE 5 ml HiTrap desalting column and Tris buffer (50 mM Tris, 50 mM NaCl, pH 
7.8) to remove any un-encapsulated gold. The protein was collected (1 ml) and the first 
reducing agent was added (20 μl of 0.1 M NaBH4 solution in water) and the resulting solution 
was incubated (3 h, room temp) while shaking. After initial reduction, a second gold source 
was added (10 μl of a 0.1 M HAuCl4 solution in water) followed by a second reducing agent (30 
μl of a 0.1 M Ascorbic acid solution in water) followed by incubation (overnight, room temp). 
Samples were centrifuged (10 min, 10,000 rpm) before characterisation. 
 All alterations to the above method including changes to the concentration, volume 





2.4.1.4. Screening of buffer conditions for the reduction of gold without protein 
 To analyse the best buffering conditions for the reduction of gold a medium 
throughput screen was envisioned. To a stock buffer (1 ml of either dH2O unbuffered; or 50 
mM Tris.HCl, 50 mM NaCl, pH 7.8; or 50 mM Na2HPO4, 50 mM NaCl, pH 7) gold solution was 
added (20 µl in either dH2O unbuffered; or 50 mM Tris.HCl, 50 mM NaCl, pH 7.8; or 50 mM 
Na2HPO4, 50 mM NaCl, pH 7), shaken, followed by the introduction of a reducing agent (20 µl 
in either dH2O unbuffered; or 50 mM Tris.HCl, 50 mM NaCl, pH 7.8; or 50 mM Na2HPO4, 50 mM 
NaCl, pH 7). This was incubated (overnight, room temperature) and its colour analysed. 
2.4.1.5. Modified method for the formation of nanoparticles inside unmodified apo-ferritins 
 This is the most successful method to date for the formation of nanoparticles inside 
both Dps and Bfr, while causing the least damage to the protein nanocages. To 1 mg of 1 
mg/ml protein sample the first gold source was added (100 µl of 0.05 mM HAuCl4 in Tris buffer 
(50 mM Tris.HCl, pH 7.8)) and the solution was incubated (2 h, rom temp). This sample was 
desalted using a GE 5 ml HiTrap desalting column and Tris buffer (50 mM Tris, 50 mM NaCl, pH 
7.8) to remove any un-encapsulated gold. The protein peak was collected (1 ml) and the first 
reducing agent was added (100 μl of 0.1 M NaCNBH3 in Tris buffer (50 mM Tris.HCl, pH 7.8)) 
and the solution was incubated (3 h, room temp) while shaking. After incubation, a second 
gold source was added (100 µl of 0.05 mM HAuCl4 in Tris buffer (50 mM Tris.HCl, pH 7.8)), as 
well as a second reducing agent (50 µl of 0.1 mM ascorbic acid in Tris buffer (50 mM Tris.HCl, 
pH 7.8)) and this was incubated (overnight, at room temperature) before characterisation. 
2.4.1.6. Surveying of nanoparticle formation via Size exclusion chromatography (SEC) 
All samples were analysed for both protein stability (280 nm) and nanoparticle 
formation (520 nm) via SEC. The samples (0.5 mg/ml) in Tris buffer (50 mM Tris.HCl, 50 mM 




ml/min.  The column was calibrated using six proteins as standards (GE Biosystems Calibration 
Kit). 
2.4.1.7. Surveying of nanoparticle formation via Transmission electron microscopy (TEM) 
TEM was performed on Jeol JEM-1400, operating at 100keV, electron microscope set 
at 200 KeV. Proteins were immobilized on Formvar/carbon coated 3.05 mm copper grids 
(TAAB) and negatively stained with 1% Uranyl acetate using 0.05 mg/ml protein 
concentrations.  
2.4.1.8. Circular Dichroism Spectroscopy (CD) 
All proteins were purified into phosphate buffer (50 mM Na2HPO4, 50 mM NaCl, pH 7). 
This experiment was performed on JASCO J-810 spectropolarimeter from 250 nm to 200 nm 
with a protein concentration of 0.2 mg/ml with a path length of 0.5 mm. Thermal melts were 
performed on all purified proteins (0.2 mg/ml in phosphate buffer, 50 mM Na2HPO4, 50 mM 
NaCl, pH 7) in a range of 4 to 100 °C40, 41 (see Appendix 2.3). 
2.4.2. Imaging the localization of the 111In-CHX-A’-DTPA-Ferritin complex 
2.4.2.1. Conjugation of CHX-A’-DTPA to Horse spleen ferritin (HsFn) 
 Purchased apo-horse spleen ferritin light chain (HsFn, Sigma, 5 mg/ml stock) was 
purified via SEC (1 ml, running buffer 50 mM Tris, 50 NaCl, pH 7.8, GE Superdex 200 10/300 
GL). This protein sample was concentrated (using a 100 kDa cut off ultrafiltration tube 
(Millipore)) followed by the addition of EDTA (50 µl of 0.01 M EDTA solution, incubated for 30 
min) to ensure that this sample is free from any metal contaminates, and then buffer 
exchanged (0.1 M HEPES buffer pH 8.9) via several washing steps to remove all EDTA. This 
solution was diluted (1 ml of 4 mg/ml protein) to which the ligand CHX-A’-DTPA (3.4 mg, 
Macrocyclics) was added followed by agitated incubation (overnight at room temperature). 




ultrafiltration tube (Millipore) into 0.1 M ammonium acetate, pH 6, free from metal 
contaminates). The number of washing steps depended on the noise seen in HPLC, for this 
experiment the sample was washed 12 times. The final sample had a concentration of 3.4 
mg/ml and a volume of 1 ml which was a 68% recovery. 
2.4.2.2. Radioactive labelling of CHX-A’-DTPA-Ferritin complex and HPLC characterisation  
 HPLC with an inline radio nucleotide detector was used to verify the state of the 
protein after the reaction and whether or not the bio-conjugation worked and the sample can 
now bind to the radioactive isotope. 
 To the ferritin sample (10 μl of 3.4 mg/ml in 0.1 M ammonium acetate, pH 6) the 
radioactive isotope was added (5 μl of 111In with 128 Mbq of activity, Coridien, Petten) and the 
resulting solution was incubated (30 min at room temperature). This sample was injected into 
a Bio-sep-SEC-S2000 HPLC column (10 μl of sample, 1 ml/min, running buffer – 0.1 M Na2HPO4, 
0.001 M EDTA, pH 7.5) and analysed for the presence of protein (280 nm) and radioactivity.  
2.4.2.3. In vivo SPECT imaging 
 For in vivo experiments, three mice were used (Balb/C, female, 8-12 weeks old). In 
total, four injections were prepared, three for the mice, one as a control (each sample 
contained 0.1 mg of protein, 25 μl of 111In with 193 Mbq of activity. This was diluted to 100 μl 
with saline). Each syringe contained 16 Mbq of activity after preparation, with 0.1047 g (105.4 
μl), 0.1024 g (102.4 μl), and 0.1078 g (103.8 μl) being injected into the tail vein of mouse 1, 2 
and 3 respectively. The last syringe underwent serial dilutions to act as a control (see Appendix 
2.8). Each mouse was examined using a Bioscan nanoSPECT/CT scanner (Mediso, Budapest) 
(after 0 h, 3 h, 24 h and 48 h) under isofluorane anaesthesia and respiration monitoring. After 
scanning, the mice were culled and their organs harvested and analysed with a gamma counter 
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NOTE: Parts of this chapter were undertaken in collaboration with Dr. Ralf Jauch (Genome 
Institute of Singapore, A*STAR, Singapore). All crystal plates were set up and the crystal 
structure was solved by Tom Cornell, the PhD candidate, and Dr. Jauch provided advice, 
expertise and arranged data collection at the Brookhaven National Synchrotron Light. 
3.1. Introduction 
Protein nanocages can be a source of adaptable tools and are rapidly being developed 
to fulfill a range of applications (see Chapter 1). However, protein folding and assembly, which 
are fundamental to the structure and stability of these proteins, are not fully understood and 
as was seen in Chapter 2, a lack of understanding of these fundamentals can hamper their 
development. This field often requires complex and time- and resource-intensive 
characterisation when establishing any application. 
Expanding our understanding of the principles required for self-assembly and protein 
folding could enhance our ability to exploit protein nanocages and could aid in their 
development. While many methods already exist to assess and study proteins with complex 
quaternary structure (see Chapter 1), these methods are often indirect and individually often 
only provide limited knowledge. A technique with atomic level resolution could provide a wider 
and more detailed level of understanding of the entire assembled structure of a protein. This 
information could then be used to aid the development of novel tools such as nanoparticle 
formation reactors (see Chapter 2), due to the increased understanding of the structural 
fundamentals behind assembly. By targeting this approach toward hybrids of proteins that 
separately have different assembly characteristics, a fuller understanding of why they are 
different and how to control these differences could be discovered. 
3.1.1. Aims of this investigation  
 As part of a project to understand the role subdomains of mini- and maxi-ferritins 
played in their assembly, our laboratory previously generated a number of hybrid proteins 
where the subdomains were swapped.1 One of these, Dps+E, which was made up of Dps, a 




with a size intermediate between its two parents but maintains the Dps-like stoichiometry of 
twelve monomers. The aim of the research described in this chapter was to obtain the crystal 
structure of Dps+E and to determine why this protein assembles into an oligomer with a 
unique size and if the symmetry constraints of Dps, which has tetrahedral symmetry and no 4-
fold axis, override those of the E-helix which is located at the 4-fold axis of symmetry in the 
octahedral Bfr.  
3.1.2. The role of helical subdomains in mini- and maxi-ferritins, and the genesis of Dps+E 
 
The bacterial ferritin nanocage proteins, Bacterioferritin (Bfr) and DNA binding protein 
from starved cells (Dps) have been extensively explored by our laboratory 2, 3, 4, 5, 6 (see 
Chapters 1 and 2). The monomers of Bfr and Dps, while having very different amino acid 
sequences, share a strikingly similar, four helix-bundle tertiary structure (Figure 3.1). This is 
surprising as the quaternary structures of these proteins are very different; the maxiferritin Bfr 
assembles into a 24-mer with octahedral symmetry and the miniferritin Dps is a 12-mer with 
tetrahedral symmetry. While the monomers of Bfr and Dps can be superimposed with few 
immediately obvious differences, the quaternary structures cannot.  
 
Figure 3.1 – Structural alignment of the monomer crystal structures of Bfr (grey, PDB:1BFR7) and Dps 
(blue, PDB:1DPS8) demonstrating the similarity of their four-helix bundle tertiary folds. Image generated 
with Chimera9. 
One of the differences between the tertiary structures of the two proteins is the 




terminus, running 78° with respect to the bundle axis7. This “E-helix” is at the heart of the four-
fold axis of the assembled nanocage. A four-fold axis is distinctive to octahedral symmetry and 
therefore it is thought that the E-helix could potentially be the driving force for the adoption of 
the assembled structure. Dps lacks the E-helix but instead has an additional helix, the “BC-
helix”, on the loop in between the second and third helices of the bundle8. The Dps nanocage 
has tetrahedral geometry which has no four-fold axis but two distinct types of three-fold axes 
and a two-fold axis, across which the BC-helix is positioned.  
A previous study undertaken in the Orner laboratory attempted to unravel the roles of 
these two helixes by creating a set of mutants that incorporated all combinations of these 
helixes on the core four-helix bundles of both Dps and Bfr1. The sizes of the resulting 
nanocages were scrutinized using size exclusion chromatography (SEC), transmission electron 
microscopy (TEM) and dynamic light scattering (DLS). Through the course of this study, it was 
determined that the E-helix plays a larger role in assembly than does the BC-helix. In addition, 
several of the mutants showed no nanocage formation at all, while others displayed sizes that 
were no different from their parent protein. However, a protein consisting of Dps with the BC-
helix and the E-helix from Bfr, “Dps+E”, cleanly assembled into a nanocage larger than Dps, but 
smaller than Bfr (Figure 3.2). Sedimentation equilibrium confirmed that Dps+E, consistent to 





Figure 3.2 – The role of helical subdomains in mini- and maxi-ferritin assembly. (left) Schematic 
representation of the Dps and Bfr monomers emphasizing the four helix bundles (circles) and the BC- 
and E- helices (ovals). Chimera were created by deleting, adding, and swapping the BC- and E- helices 
between Dps and Bfr. (middle top) Hydrodynamic diameter measured by DLS. Dps+E is on the right. 
(right top) SEC analysis of Bfr derivatives, and (bottom right) Dps derivatives. Dps+E is the trace in green. 
(bottom middle) Quantitative analysis of SEC data. This figure is from Orner and co-workers (2009)1. 
 
Although it had been established that Dps+E was larger than Dps but smaller than Bfr 
and was made up of twelve monomers like Dps, it was unclear how this actually manifested in 
the structure of Dps+E. Based on this data, we had two initial questions. First, because the E-
helix in Bfr is positioned at the four-fold axis of symmetry in octahedral Bfr, but Dps is 
tetrahedral, without any four-fold symmetry, we were curious if the a four-fold or three-fold 
symmetric quaternary structure would prevail. In other words, would the structural preference 
of Dps or the Bfr E-helix win? The second question involved an older paper from the ferritin 
literature10. This paper speculated that the E-helix, which is normally pointing into the protein 
nanocage cavity in octahedral maxi-ferritins, could “flop” in and “flip” out of the nanocage in a 
dynamic manner. We therefore were curious whether Dps+E could be frozen in a “flipped out” 
state. (Figure 3.3). The best way to obtain answers to these questions is to obtain the crystal 
structure of Dps+E. A crystal structure should be able to definitively answer these questions 




have been altered from those in Bfr or Dps. In addition the crystal structure could provide 
insight into the structural energetics of nanocage structures and this insight could help to 
engineer similar assemblies in the future. 
 
Figure 3.3 – Schematic representation of the possible presentation of the E-helix residues from Bfr 
(rectangle) in the hybrid protein Dps+E (assembled circle). Establishing the position of these residues is 




3.2. Results and discussions 
3.2.1. Cloning, expression and purification of Dps+E 
 The gene encoding Dps+E was transferred to an expression plasmid (pET-46, Novagen) 
that provides a fusion with a small His6 tag on the N-terminus, thus avoiding extended 
purification methods requiring the removal of large purification tags with protease digestion as 
were used in Chapter 2. In addition, this new purification protocol bypassed problems with 
fragmentation of Dps+E initially observed in proteolytic conditions (see Appendix 3.3 for SDS-
PAGE). Expression and purification and characterisation of the protein confirmed that it was 
intact and assembled as a 12-mer (see Appendices 3.2, 3.3, 3.4, 3.5 and 3.6 for the full amino 
acid sequence, SDS PAGE, TEM, mass spec and SEC). In addition, SEC analysis of this protein 
with the His6 tag resulted in a similar elution profile to that previously reported (Figure 3.2) 
further confirming that its unique conformation was robust.  
3.2.2. Crystallisation of Dps+E 
Although there are many existing ferritin crystal structures in the protein data bank 
(PDB), their crystallisation conditions are highly varied. Therefore, the screening for 
crystallisation preceded without focusing on previously used conditions. Using this purified 
protein, high throughput screens were initially constructed using the JCSG+, Classic (Qiagen) 
and Morpheus (Molecular dynamics) suites to find first generation crystallisation conditions. 
The most promising conditions contained polyethylene glycol (PEG) which lead us to optimise 
the conditions with screens using the PEG I and PEG II (Qiagen) suites. These results were the 
basis of further optimisation (see Appendix 3.7 for full range of conditions screened). It should 
be noted that the high throughput screens were set up robotically using the sitting drop 





Figure 3.4 – Preliminary crystallization conditions of Dps+E obtained through screening. (top left) 16% 
PEG3350, 0.2 M magnesium chloride, 0.1M Tris.HCl pH 8.6 (top right) 16% PEG3350, 0.2 M magnesium 
formate, 0.1M Tris.HCl pH 8.6 (bottom left) 18% PEG3350, 0.1 M trisodium citrate, 0.1M Tris.HCl pH 8.6 
(bottom right) 12% PEG6000, 0.2 M lithium sulfate, 0.1M Tris.HCl pH 8.6. All conditions in this figure 
used a protein concentration of 15 mg/ml. 
 The majority of conditions that produced crystals contained PEG 3350 and magnesium 
chloride. However, when inspected for preliminary diffraction patterns, none of the crystals 
grown in the presence of magnesium chloride diffracted. But Diffraction data however, was 
obtained from crystals grown in the presence of lithium sulfate. Therefore these conditions 





Figure 3.5 – Optimised crystallization conditions for Dps+E (top left) 16% PEG1000, 0.1 M lithium 
sulfate, 0.1 M sodium acetate trihydrate pH 4. (top right) 18% PEG1000, 0.2 M lithium sulfate, 0.1M 
sodium acetate trihydrate pH 4.2. (bottom left) 20% PEG1000, 0.3 M lithium sulfate, 0.1 M Sodium 
acetate trihydrate pH 4.2. (bottom right) 18% PEG1000, 0.1 M lithium sulfate, 0.1 M sodium acetate 
trihydrate pH 4.8. All conditions in this figure used a protein concentration of 15 mg/ml. 
 
 Several of these crystals were sent to the Brookhaven National Synchrotron Light 
Source for analysis. Crystals grown in 18% PEG1000, 0.2 M lithium sulfate, 100 mM sodium 
acetate trihydrate, pH 4.2 provided the highest resolution diffraction data. 
Initial attempts to solve the crystal structure of Dps+E were successful and resulted in a 
2.0 Å structure of assembled Dps+E. A polyalanine model of the 1DPS crystal structure 
monomer (obtained with Chainsaw11 software) was used for molecular replacement analysis 
with Phaser12 software. As it was already determined through sedimentation equilibrium that 
Dps+E was made up of twelve monomers, molecular replacement was performed using twelve 




Coot13 and Refmac14 and validated with Phenix15, which provided the refined crystal structure 




aValues for the highest resolution shell in parentheses. 
Method – Vapour diffusion, hanging drop 
pH – 4.2 
 Temperature – 292.0 K 
 Method – 18% PEG 1000, 0.1 M sodium acetate trihydrate, 0.2 
M Lithium sulfate 
 
  
Space group P 21 21 21 
Cell dimensions    
 
A = 103.14 Å 
 
B = 104.72Å 
 
C = 207.76Å 
 
α = 90.0 ⁰ 
 
 
β = 90.0 ⁰ 
 
 




Resolution (Å) 50.00 – 2.00 (2.07-2.00)  
Rmerge (%) 6.9 (51.7) 
Completeness (%) 93.5 (98.5) 
I/σI    
Redundancy 27.8 (4.4) 
Refinement 12.8 (11.9) 
 Resolution (Å) 46.8 – 1.99 
 No. Reflections used 135612 
 Rwork/Rfree (%) 19.1/23.8 
 
  
No. Atoms   
  Protein 16696 
  Water 1865 
  Cl- 2 
Non hydrogen atoms 16696 
 
  
Mean isotropic B value 24.433 
 R.M.S deviations from 
ideal 
  
  Bond lengths (Å) 0.012 
  Bond angles (◦) 1.494 






  Favoured 98.3 
  Additionally allowed 17 
  Disallowed 0 
 
  
R-Factor (All) 0.1895  
R-Factor (Observed) 0.1895 
R-work 0.1868 
R-free 0.2408 




Table 3.1 – Data collection and refinement statistics for the crystal structure of Dps+E 
3.2.3. Analysis of the Dps+E crystal structure 
Initial inspection of the Dps+E crystal structure showed that it assembles into a very 
similar tetrahedral symmetric protein nanocage to that of the parent protein, Dps (Figure 3.6). 
The global Route Mean Square Deviation (RMSD) for the overlaid monomers with identical 
sequences was 0.185 Å demonstrating strong similarity (for individual amino acid RMSD 
comparisons see Appendix 3.8). Thus, one question posed at the outset of this project is 
definitively answered. The symmetry requirements of the parent protein, Dps, overcome those 
of the residues from the Bfr E-helix. The hybrid protein, Dps+E clearly assembles into a protein 
nanocage that is tetrahedral and not octahedral, and the residues from the E-helix are 





Figure 3.6 – Comparison of the crystal structures for wild type Dps (PDB:1DPS, grey) and for Dps+E 
obtained in research described in this chapter (red). Comparison of monomers (top) and assembled 
nanocages (bottom). Highlighted region (black dashed box) shows the position of the C-terminus for 
both structures. Note that the electron density for all the residues from the Bfr E-helix is poor, although 
it is clear that they are flipped out of the nanocage, the exact structure of this entire domain is 
undetermined. Image created with Chimera9 with overlay generated with the ‘match’ function. 
The second question this research posed can also be definitively answered, however 
not in as satisfying way. Unfortunately, our crystal structure of Dps+E had only limited electron 
density in the C-terminal domain made up of the residues from the Bfr E-helix. Although 
several residues from the fusion could be modeled, the structure of the entire domain is 
undetermined, however, enough data could be obtained to confirm that these residues are 
pointing external to the assembled protein and, thus, this domain is “flipped out” of the 
nanocage (Figure 3.7). Taken together, these results explain how the Dps+E nanocage can be 
made up of only twelve monomers, as confirmed by sedimentation equilibrium, but appear 
larger than Dps and smaller than Bfr in SEC and DLS; the E-domains fused to the C-terminus of 






Figure 3.7 – Electron density map with constructed structure for the protein Dps+E highlighting the 
fourth amino of the fused E-helix domain of Bfr. Note the fall off in electron density beyond this residue. 
Image was generated with Coot software13. 
While the aims set out in this project, (to obtain the DPS+E crystal structure, confirm 
the overall symmetry, determine the position of the E-domains with respect to the nanocage, 
and understand why the protein is larger in size than Dps) were all fulfilled, it was disappointing 
to not be able to observe the entire E-domain. With these termini projecting away from the 
nanocage on the three-fold axes of symmetry, it was thought that they might have engineering 
uses as “handles” for applications like drug delivery or supra-assembled materials. Therefore 
we intend to pursue high resolution electron microscopy studies to understand the relative 






The hybrid ferritin protein Dps+E, which had previously been shown to be a 12-mer but 
larger in size than the miniferritin Dps, was crystalized and its high resolution crystal structure 
was obtained. Examination of this crystal structure showed that the tetrahedral symmetry of 
Dps, was retained in the assembled Dps+E protein nanocage and that the addition of the E-
domain from octahedral Bfr was not enough to change the symmetry. Moreover, it was 
determined that the E-domain was forced into a “flipped out” state where it projects away 
from the nanocage. However, as the electron density at this domain was poorly defined, the 
entire structure of the domain could not be fully determined. It is presumed that the 
projection of twelve copies of this domain away from the nanocage is the reason the protein 
was determined to be larger in size than Dps. 
While answering fundamental questions, a unique high resolution protein nanocage 
structure was established. However, obtaining a crystal structure is time and resource 
intensive, and it gives little information about the thermodynamics and mechanism of 
assembly. Additionally it is also not immediately clear how the information provided by this 
structure could dramatically aid in the design of other novel quaternary structures or help to 
overcome the limitations in protein nanocage stability at different conditions as was 
experienced in the project described in Chapter 2. Clearly it is necessary to develop new 
techniques that are complementary to existing ones, both to study the fundamentals of 
quaternary structure and to help engineer new structures in a rapid and dynamic manner. The 





3.4.1. Cloning, protein purification and characterisation 
3.4.1.1. Construction of the DPS+E plasmid 
The Dps+E gene was prepared for ligation to the plasmid by first extending the ends to 
include LIC nucleotide sequences. This was done in a mixture containing reaction buffer 
(Fermentas, 5 μl of 10xPfu buffer), dNTP mix (Fermentas, 2 μl of a solution containing dATP, 
dTTP, dGTP, and dCTP at 2 mM each), forward oligonucleotide primer (400 ng, Suprenom, 
Singapore, see Appendix 3.1), reverse oligonucleotide primer (400 ng, Suprenom, Singapore, 
see Appendix 3.1 for primers used), the dsDNA template of Dps+E (100 ng) and Pfu polymerase 
(Fermentas, 2 μl of 2.5 U/μl) and made up to a total volume of 50 μl with deionised water. The 
PCR conditions involved an initial step at 95 °C for 30 s, followed by 30 cycles of amplification 
(95 °C for 30 s, 55 °C for 45 s and 72 °C for 1 min) followed by incubation (72 °C for 7 min). The 
resulting PCR product was isolated by gel excision from a 1% agarose gel. The gene was then 
treated with T4 polymerase in order to create the required complementary overhangs. This 
was done in a reaction mixture containing NEB reaction buffer 2 (NEB, 2 μl of 10x buffer), dATP 
(NEB, 2 μl of 25 mM), DTT (Sigma, 1 μl of 100 mM), BSA (NEB, 0.2 μl of 100x buffer), Dps+E 
extended gene (0.3 pmol) and T4 DNA polymerase (NEB, 0.6 μl of 5 U/μl) and made up to a 
total volume of 20 μl with deionised water. This reaction was incubated (30 min at 22 °C) 
followed by heat inactivation (75 °C for 20 min). The insert was annealed to plasmid pET-46 
(Novagen) by adding insert (1 μl) to the plasmid (0.5 μl) and incubating the solution (30 min, 
room temp). A solution of EDTA (1 μl of 100 mM) was then added and the mixture was further 
incubated (30 min). This solution (2.5 μl) was then electroporated into electrocompetent 
Novablue E.coli cells. The resulting colonies were assessed by colony PCR using a reaction 
mixture containing Taq reaction buffer (Fermentas, 2.5 μl of 10x buffer), MgCl2 (Fermentas, 




dCTP at 2 mM each), T7 promoter primer (150 ng, Suprenom, Singapore), T7 terminator primer 
(150 ng, Suprenom, Singapore), Taq DNA polymerase (Fermentas, 0.25 μl of 5 U/μl), colony 
suspension (10 μl of a 50 μl total colony suspension in deionised water) and 5 μl of deionised 
water. The PCR conditions involved an initial step of 95 °C for 10 min, followed by 30 cycles of, 
95 °C for 30 s, 59 °C for 30 s and 72 °C for 30 s, followed by 72 °C for 7 min. All samples were 
visualised using a 1% agarose to confirm band size. Any colonies showing the correct band size 
in the colony PCR were grown then isolated using miniprep (Invitrogen) and sequenced (see 
Sequence Appendix 3 for full gene sequence and Appendix 3.1 for primers used). 
3.4.1.2. Protein production and purification 
The vector containing the correct Dps+E gene was electroporated into BL21 E.coli cells 
and plated. A colony was taken and placed into LB and incubated (5 ml, 37 °C, overnight) to 
generate a pre-culture. These cells were then grown in LB (500ml inoculated with 50 μl/ml of 
carbenicillin, 37 °C). Protein expression was then induced at an OD600 0.6 by the addition of 
IPTG (400 mM) and incubated for an additional 3 hours at 20 °C. The cells were isolated by 
centrifugation (10,000 rpm, 20 min at 4 °C). The cell pellet was resuspended with lysis buffer 
(50 mM NaH2PO4, 300 mM NaCl, 40 mM Imidazole, pH 8) and sonicated (15 min, with 10 s off 
and on pulses, Sonics vibra cell sonicator). The protein solution was clarified by centrifugation 
(10,000 rpm, 20 min at 4 °C) and then filtered (Pall, 0.2 μm). His-tagged proteins were isolated 
from cell lysates via His trap chromatography. The filtered lysate was injected onto a GE 5ml 
Histrap FF Column using wash buffer (30 mM NaH2PO4, 300 mM NaCl, 40 mM Imidazole, pH 
7.6) at 1 ml/min. The protein of interest was eluted from the His trap using elution buffer (30 
mM NaHPO4, 300 mM NaCl, 500 mM Imidazole, pH 7.6). The partially purified protein sample 
was bound to a GE HiTrap Q HP ion exchange column using IEX binding buffer (50 mM Tris.HCl, 
10 mM NaCl, pH 7.6) at 2 ml/min. An elution gradient using IEX elution buffer (50 mM Tris.HCl, 
500 mM NaCl, pH 7.6) was established with the protein of interest eluting between 26-30% 




Hiload16/60 Superdex 200pg 120 ml size exclusion column (5 ml injection, running buffer - 50 
mM NaH2PO4, 50 mM NaCl, pH 7.0) at 1 ml/min. The extent of protein purification was 
assessed through SDS-PAGE (see Appendix 3.3 for SDS-PAGE). 
3.4.2. Crystallisation conditions 
3.4.2.1. Crystallisation 
Purified Dps+E protein underwent buffer exchange and was concentrated (15 mg/ml, 
10 mM NaCl, 10 mM HEPES, pH 7) for crystal screening. Initial high throughput screens were 
set up using robotics in 96 well plates with a sitting drop technique (JCSG+ (Qiagen), Classic 
suite (Qiagen), Morpheus suite (molecular dynamics), PEG suite I (Qiagen) and PEG suite II 
(Qiagen)). Further crystal screening took place in 15 well plates using the hanging drop 
technique (see Appendix 3.7 for all crystal screening conditions). The crystal that gave the 
diffraction pattern that was solved was grown using 0.2 M Lithium sulfate, 18% PEG 1000, pH 
4.2. Crystals grew after 3 - 4 days at 19 °C. 
3.4.2.2. Data collection, processing and structure solution 
A 1.99 Å data set was obtained from the National Synchrotron Light source (NSLS) at 
Brookhaven. The data was integrated, scaled and merged using HKL200016. PHASER12 (CCPi4) 
was used for molecular replacement experiments, using 12 copies of a poly-alanine monomer 
of wild type Dps from E.coli (1DPS). This structure has around an 85% similarity with the 
expected new structure. PARROT was used to improve the phases from the molecular 
replacement. The model was built manually in COOT13 using 2Fo-Fo and Fo-Fc maps. The 
refinement was done using REFMAC514 from CCP4i applying NCS restraints and a weighting 
term of 0.2. Translation/Liberation/Screw (TLS) refinement was conducted towards the final 
steps of the refinement17. Each monomer of the protein nanocage was assigned its own TLS 




3.4.2.3. Calculation of RMSD 
 The coordinates for the crystal structures of both wild type Dps (PDB:1DPS8) and 
Dps+E were aligned using Chimera software9 with the Matchmaker tool, which uses a 
Needleman-Wunsch alignment algorithm. This tool focuses on aligning alpha carbon atoms 
after sequence alignments have been performed. From this overlay, least square fitting is used 
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Direct detection of maxi-ferritin 






NOTE: Parts of this chapter were taken from published work with the candidate as first author 
(see appendix – Published Work 1)1. 
4.1. Introduction  
The exploitation of protein nanocages for novel applications such as encapsulated 
nanoparticle genesis can be impeded by inherent challenges in working with these proteins. It 
was seen in Chapter 2 that one of these difficulties is protein instability. Furthermore, these 
complex protein assemblies can be difficult to purify, although our laboratory has extensive 
experience in this regard2, 3, 4, 5. Adding to the challenges, these proteins, upon purification, 
require extensive biophysical characterisation to determine their assembly state, but the 
techniques that are commonly employed for this characterisation are often not directly related 
to nanocage formation.  
The time it takes to overcome these challenges can delay innovation in this field. In 
addition, the lack of understanding into the fundamentals of how protein quaternary structure 
forms, and why it fails under different conditions inhibits the ability to troubleshoot and 
resolve problems. Protein crystallography (see Chapter 3) can provide some degree of insight 
into what residues are involved in protein-protein interactions and can even be used to 
estimate binding thermodynamics, but it is low throughput and requires conditions that are 
very dissimilar from those used for the generation of nanoparticles. In addition crystallography 
provides little information into the mechanisms of folding, unfolding, assembly, disassembly or 
amorphous aggregation. Furthermore, because it is a fundamental technique by nature, even 
if it did provide explanations as to why a particular protein is problematic to a particular 
application, it would provide no direct solutions to the problem.  
The development of a tool for the rapid and direct detection of specific protein 
nanocage oligomerization states would have great utility in this field by helping to overcome 
some of the protein-specific problems that challenge the field. It could provide information on 




production of nanoparticles. If it were rapid enough it might shed light on the dynamics and 
mechanisms of assembly. Moreover, if this technique were applicable to living cells, it could be 
expanded to a high throughput protein library screen to detect protein nanocages with novel 
properties using a “one clone/one bacterium” cell sorting strategy.  
Such an assay must be robust on multiple levels. It must be able to identify both the 
protein of interest over any background proteins and a specific oligomerization state of the 
protein of interest over any other oligomerization states. Additionally, it should implement a 
flexible design so as to be exportable to mutants of a specific protein nanocage or other 
protein nanocage systems in general. Moreover, it should be able to scrutinize a range of 
conditions for the evaluation of protein quaternary structure in different environments. 
Finally, it should behave well in complex solutions, a criterion which would allow the bypass of 
the need to purify and fully characterise the proteins and thus permit a substantial increase in 
throughput. 
4.1.1. Aims of this investigation 
 
Many high resolution protein nanocage structures are available (PDB: 2Y3Q, 1BFR, 
1BCF), and although these structures have paved the way for rational engineering and design 
of protein nanocages with application-bespoke properties, rational design can be time-
consuming and resource intensive due to the necessity of iteratively purifying each mutant 
followed by extensive biophysical characterisation with techniques that are often not directly 
related to nanocage formation. The investigation described in this chapter aims to develop a 
novel method for the direct detection of nanocage oligomerization with specificity of the 
nanocage over other states. This technique could be used to rapidly ascertain the 
oligomerization state of various nanocage proteins or to screen protein nanocage stability in 




the screening of libraries of mutant proteins for their ability to form more stable nanocage 
structures.  
4.1.2. Bacterioferritin properties to be exploited for the assembly assay 
As described in chapter 2, E. coli Bacterioferritin (Bfr) is a maxi-ferritin which buffers 
cellular iron by storing it as a mineral inside the hollow cavity of the assembled state6, 7, 8. Bfr 
assembles from twenty-four identical monomers into an octahedral nanocage with two-, 
three- and four-fold symmetric protein-protein interfaces9. The Bfr protein nanocage is a 
useful starting point in any new investigation as it is extremely well characterised and has been 
extensively employed in many laboratories including the Orner laboratory2, 3, 10. Previous 
studies on the self-assembly of Bfr and ferritins in general have shown that monomers rarely 
persist in solution on their own unless severely mutated, and, for most ferritins, the dimer is 
the most prevalent intermediate observed2, 3. Bfr exists in vitro as a mixture of the nanocage 
form and the anti-parallel dimer in a near equal ratio resulting in a unique challenge for a 
detection technique that can be specific for a single oligomerization state4. In the Bfr dimer, 
the termini diverge whereas in the nanocage form they converge, it is thought that this could 
direct the placement of the cysteine pairs in the design of a FlAsH binding site that is specific 
for the nanocage state. The fact that Bfr forms a mixture of states can help in the development 
of this technique for the determination of the specificity of early generation designs.  
4.1.2.1. Control proteins: Mutations that influence the ratio of oligomerization states of Bfr 
The development of a technique to detect a specific oligomerization state of Bfr will 
require control proteins that have altered nanocage to dimer ratios. To date there is no rapid 
and direct method for determining the oligomerization states of nanocages other than 
expressing, purifying and characterizing them with mostly low throughput biophysical 
techniques such as size exclusion chromatography (SEC), dynamic light scattering (DLS) and 




manipulate the oligomerization state of ferritins. Our laboratory has investigated the 
quaternary structure of Bfr by disrupting the interaction network through alanine scanning11 to 
discover ‘hot spot’ residues along key protein-protein interactions 3, 12, 13. Additionally we have 
used computational approaches to more efficiently pack the protein-protein interfaces by 
filling water pockets with bulky hydrophobic residues4, 10. Through these studies, we have 
discovered a number of mutants with distinct ratios of nanocage to dimer. Some of these 
mutants that are relevant to the study described in this chapter are N23F, which exists as 70% 
nanocage, D118F, which favours the nanocage to such an extent that almost no dimer is 
observable. These works demonstrate that Bfr is well studied, and when combined with the 
availability of the well-characterised mutants to act as controls, can provide a rich system to 
act as a proof of concept for the development of the FlAsH-based technique. 
4.1.3. FlAsH technology for the detection of protein-protein interactions 
 
As described in Chapter 1 there are many existing techniques that can be used for the 
detection of protein-protein interactions which is the goal of this investigation. However these 
techniques are not without theirs flaws, often requiring the fusion and creation of large 
protein constructs which can inhibit native properties and can limit expansion and throughput 
of any developed screen. 
A new probe called, fluorescein arsenic hairpin binder (FlAsH, Figure 4.1 –A), described 
by Tsien and co-workers only fluoresces once it is bound to four correctly spaced sulfur atoms 
presented on cysteine amino acids along the face of a α-helix (Figure 4.1- B)15. FlAsH 
technology works by only requiring the addition or alteration of four amino acids to cysteines 
and can bypass problems seen with larger fusions. Development of FlAsH technology showed 
that binding to the hexapeptide sequence CCPGCC increased observed fluorescence signal 
(Figure 4.1 – C)16. FlAsH had being used to monitor several protein attributes such as location17 




protein-protein interactions using this small cell permeable probe. They showed that the 
hexapeptide sequence could be split into two bipartite spilt cysteine tags that still allowed for 
FlAsH binding sites either when placed on termini of the same protein that appear close in 
space (Figure 4.1 – D) or on two interacting peptides (Figure 4.1 – E)19. This technique, known 
as bipartite tetracysteine display, could provide a better approach for the detection of protein-
protein interactions seen on nanocages as it only needs the addition of four amino acids, and 
allows for greater control via the external addition of the probe.  
By designing cysteine rich FlAsH-EDT2 binding sites at interfaces that only appear upon 
nanocage formation, it is hoped that a rapid and direct assay for self-assembly can be found 
(Figure 4.1 – F). A system that can identify specific oligomerization states with increased 
throughput and with respect to states in cell lysates or in vivo, would greatly advance research 
on protein nanocages and protein self-assembly in general. 
 
 
Figure 4.1 – Conceptual evolution of FlAsH binding site design. (A) Structure and schematic of FlAsH-
EDT2. (B) Initial presentation of four cysteines on one face of a α-helix. (C) Optimized hairpin peptide. (D) 
Bipartite cysteine display with the two cysteine pairs placed proximal on each termini of the same 
protein. (E) Bipartite cysteine display with cysteine pairs straddling a protein-protein interface between 





4.2. Results and discussion 
4.2.1. Design of Bfr controls and optimisation of experimental parameters 
 To evaluate our reagents and initial experimental set up it was necessary to establish 
robust positive and negative Bfr controls. A positive control was constructed by placing the 
ideal FlAsH-EDT2 binding site, the peptide CCPGCC (see above), onto the N-terminus of Bfr 
(BfrCCPGCC-N-term) while the wild-type protein acted as a negative control (BfrWT). The 
positive control is oligomerization state independent, as every monomer with this sequence 
should be able to bind to FlAsH-EDT2 no matter the assembly state whereas the negative 
control has no binding site.  
Initial optimisation of conditions was performed in bacterial lysates so as to not only 
speed the process by removing the need to purify proteins, but also to bring the system one 
step closer to examining self-assembly in in vivo conditions. Both of the controls described 
above, were analysed using a fluorimeter for lysate samples with different concentrations of 
FlAsH-EDT2 incubated for two hours (Figure 4.2). As expected, the signal from the positive 
control increased significantly as FlAsH-EDT2 concentrations were increased, while the negative 
control remained low, demonstrating that the controls, reagents and instrumentation behaved 
as expected and that a dose dependent signal could be achieved in lysate conditions for 
BfrCCPGCC-N-term. While there was a clear significant difference between BfrCCPGCC-N-term 
and BfrWT across different FlAsH-EDT2 concentrations, the widest window was at the highest 





Figure 4.2 – Dose dependent normalised fluorescent signal from both a positive (left - BfrCCPGCC-N-
term, red dots represent cysteines, bound signal) and negative (right – BfrWT, background or free 
fluorophore signal) control at different FlAsH-EDT2 concentrations in bacterial lysates resuspended in 
FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8). The only reagent used for this 
experiment was FlAsH-EDT2 (1 µM). Total protein concentration: 1 mg/ml. Values are average of six 
replicates from three different protein expressions. Error bars are S.D. 
 A number of optimised conditions for working with FlAsH-EDT2 have been published. 
These conditions include additives meant to ensure all cysteine residues are fully reduced. 
Among these are tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT) and 2-
mercaptoethanol (2-ME)20. 2-ME has also been credited with acting as a shuttling agent to 
increase the binding kinetics of the probe15. In addition the bi-dentate ligand 1, 2-ethanedithiol 
(EDT) which quenches FLAsH when bound has also been used as an optimisation additive. The 
buffer additive ethylenediaminetetraacetic acid (EDTA) acts not only to control ion 
concentration but could also be especially useful in acting as a protease inhibitor in lysate 
experiments.  
To further optimise these conditions for our initial experiments, several combinations 
of additives were examined to determine their effect on the fluorescence of FlAsH-EDT2 in the 
presence of bacterial lysates containing the over expressed positive control, BfrCCPGCC-N-




between bound and free fluorophore is observed when only FlAsH-EDT2 is present, this 
difference is greatly improved with the introduction of additives. The presence of a reducing 
agent (either TCEP or 2-ME) provided the largest increase in fluorescent signal, suggesting the 
importance of fully reducing thiols, presumably those associated with cysteines in the binding 
site. It has been suggested that a high EDT concentration ensures that the arsenic atoms on 
FlAsH retain bound EDT ligands, and thus quenching the fluorescence, until it is exchanged 
with two cysteine residues. Therefore it is thought that EDT helps to maintain a low 
background. In our hands, the addition of EDT caused a small increase in signal but with that 
followed a small increase in background. The highest fluorescence in the presence of protein 
with respect to buffer control was observed with addition of all three additives, TCEP, 2-ME 
and EDT. The combined effect of two reducing agents, one of which could also act as a 
shuttling agent, and with the bi-dentate ligand EDT, were the optimal conditions to provide the 
highest positive signal while maintaining a low background.  
 
Figure 4.3 – Effect of additives on the fluorescence intensity of FlAsH-EDT2 bound to BfrCCPGCC-N-term 
in lysates with respect to buffer control. Reagent concentrations: TCEP – 3.5 mM, EDT – 1 mM, 2-ME – 1 
mM, FlAsH-EDT2 – 1 µM. Total protein concentration: 1 mg/ml in FlAsH buffer, (100 mM Tris.HCl, 100 
mM NaCl, 1 mM EDTA, pH 7.8) with two hours incubation at room temperature with reagents. Each 




 From this experiment, the optimal conditions for a 1 mg/ml protein sample were 
found to be, 1 µM FlAsH-EDT2, 3.5 mM TCEP, 1 mM EDT 1 mM 2-ME in buffer containing 100 
mM Tris.HCl, 100 mM NaCl, 1 mM EDTA at pH 7.8. The additives were added to the protein 
solution and the solution was incubated for two hours to allow for thorough reduction to 
occur. The probe was then added and the sample was incubated a further two hours before 
determining the signal. With controls and conditions set, bipartite designs were designed and 
analysed. 
4.2.2. Design and analysis of bipartite and tetrapartite FlAsH binding sites in Bfr  
To achieve the aims of the research described in this chapter, it was necessary to 
design a binding site for FlAsH-EDT2 that forms when the ferritin nanocage is assembled, and 
does not result in the generation of fluorescence upon the formation of other oligomerization 
states. As stated above, this requirement is especially challenging with Bfr which forms a 
mixture of dimers and nanocages in solution. Therefore, we need to be sure that we are not 
only designing binding sites for FlAsH-EDT2 to detect nanocage formation, but also designing 
nanocage specific binding sites that do not form upon formation of the dimer.  
Another concern that poses a complication for most protein-protein interface 
engineering studies, but has some distinct aspects for this protein nanocage work, is that an 
improperly designed binding site might actually disrupt assembly. Therefore we sought a 
conservative approach in our designs so as to have as little disruption as possible to the 
secondary, tertiary or quaternary structure. It is thought that the dimer intermediate is similar 
to the pair of proteins positioned at the two-fold symmetry axis in the nanocage state4. This 
dimer is anti-parallel in that the N- and C-termini of the two proteins diverge. However, in the 
nanocage, the termini converge at the other symmetry axes. Thus, our strategy focused on 
placing the partial binding sites at the terminus of the monomers. It was thought that a) upon 
assembly the termini would converge and generate a cysteine-rich FlAsH-EDT2 binding site that 




would have the least effect on assembly while allowing a degree of flexibility to achieve the 
optimal projection of cysteines. In the nanocage state, the N-terminus of Bfr points toward a 
three-fold symmetry axis and is projected outside the nanocage while the C-terminus, is at the 
end of the E-helix which projects inside of the nanocage at the four-fold axis (Figure 4.4) 
Therefore, our initial designs focused on placing partial binding sites at these termini. 
 
Figure 4.4 – Oligomers of Bfr abstracted from the crystal structure of the nanocage assembly state 
(PDB:1BFR) emphasizing the two-, three- and four-fold symmetry axes with termini highlighted in red 
(N-termini at three-fold, C-termini at four-fold and both at two-fold). Images created with Chimera21. 
Multiple designs were generated to increase the likelihood of establishing a successful 
construct. The first set of designs placed pairs of cysteines at the C-terminus (BfrCC-C-term), 
the N-terminus (BfrCC-N-term), and both (BfrCC-N/C-term) (Figure 4.5). Because we were 
curious about the effect of placing a binding site inside the nanocage and because we 
suspected this nuance might be potentially be consequential for the development of this 




assembly, an additional positive control was designed by fusing CCPGCC to the C-terminus of 
Bfr (BfrCCPGCC-C-term). 
 
Figure 4.5 – Bipartite Bfr designs for nanocage-dependent FlAsH binding sites. (top left) Bfr crystal 
structure (PDB: 1BFR) emphasising the four-fold axis of symmetry. (top right) Schematic representing 
four monomers (elongated) and the E-helix (circle) followed by a side-on view of two of the proteins. 
(bottom) Engineered monomers viewed side-on with the N-terminus on left and C-terminus on right at 
the bottom of the E-helix. Red circles indicate cysteine residues. The negative control (BfrWT) has no 
appended cysteines whereas the two positive controls (BfrCCPGCC-N-term and BfrCCPGCC-C-term) 
display full binding sites on the monomers.  
As an additional design strategy, single cysteine mutations near the Bfr C-terminus 
were generated to achieve ‘tetrapartite’ based binding sites upon nanocage formation. As 
tetrapartite cysteine display was unprecedented, six designs were created along the length of 
the C-terminal domain containing the E-helix (Figure 4.6). Bfr is ideal for exploration of 
tetrapartite display because of its four-fold symmetry and that cysteines can be arranged in 
close proximity at semi rigid locations. Two designs take advantage of the fact that one face of 
the two turn E-helix faces the other monomers, therefore positions at i (BfrN148C) and i+3 
(BfrQ151C) of the helix were mutated to cysteines. A third design placed a cysteine at the end 




extended the C-terminus of Bfr with one cysteine (BfrExt-C) and with a GlyCys dipeptide 
(BfrExt-GC). It should be noted that these last two proteins could serve as deletion controls for 
the BfrCC-C-term bipartite design (above). As the C-terminus domain points inside the 
nanocage, the accessibility to FlAsH-EDT2 was a concern. A possible solution was to mutate the 
methionine residue that caps the top of the E-helix to a less bulky alanine in one of the 
designs, thus generating a double mutant (BfrM147A,N148C). 
 
Figure 4.6 – Tetrapartite Bfr designs for nanocage-dependent FlAsH binding sites. (top left) Schematic of 
Bfr monomer as defined in Figure 4.7. (bottom left) Crystal structure of Bfr (PDB: 1BFR) highlighting the 
mutated positions. (right) Schematics of designed proteins emphasizing the relative position of mutated 
residues. (red – cysteine, light grey – glycine, black - alanine). 
4.2.2.1. Analysis of bipartite and tetrapartite Bfr designs in lysates  
The bipartite Bfr designs (see above), were initially screened in lysates with optimised 
conditions (see above) (Figure 4.7). As expected and consistent with the optimisation 
experiments the positive control, BfrCCPGCC-N-term, which does not require nanocage 
formation for the generation of a FlAsH-EDT2 binding site, displayed a high fluorescence signal 




These control proteins were used to normalise the fluorescence signal for the other designs. 
The second positive control, BfrCCPGCC-C-term, gave a strong fluorescence although lower 
than BfrCCPGCC-N-term. Interestingly, the N-terminal hexapeptide fusion disrupts nanocage 
formation whereas BfrCCPGCC-C-term forms a substantial amount of nanocage (Figure 4.16). 
In BfrCCPGCC-C-term the binding sites were inside of the nanocage. Taken together, these data 
suggest that there is a slight inhibition of FlAsH-EDT2 uptake into the nanocage under these 
conditions possibility due to the need for the probe to diffuse into the nanocage or due to the 
need for some nanocage-centered dynamic event (for example, partial disassembly or partial 
unfolding while assembled etc).  
The bipartite designs which showed the highest signals both had cysteine pairs on the 
C-terminus, with fluorescence around 25% and 20% of the BfrCCPGCC-N-term positive control 
(BfrCC-N/C-term and BfrCC-C-term respectively) (it should be noted that this response is 
modest compared to the designs discussed in Chapter 5.). The design containing an N-terminal 
pair of cysteines, BfrCC-N-term resulted in a protein that had no detectable FlAsH-EDT2 signal. 
This is not completely unexpected because the crystal structure (Figure 4.4) suggests that the 
distance between the N-termini of the monomers may be too large (roughly 30 Å) to form a 
single binding site. As this result suggests that high numbers of additional cysteines in the 
lysates does not lead to a significant increase in background signal and that the correct 
geometry is important for FlAsH-EDT2 fluorescence, this mutant may prove to be a more 
relevant negative control protein than the wild type. Taken together, these data eliminates the 





Figure 4.7 - FlAsH fluorescence of Bfr bipartite designs (see figure 4.5 for schematic explanation) in 
lysates. The data is normalised to the positive and negative controls. All designs set to 1 mg/ml total 
protein concentration, in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 1 µM 
FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME, Average of three protein expressions each repeated twice. 
Error bars are S.D. 
 
The tetrapartite designs were evaluated as described above, using BfrCCPGCC-N-term 
and BfrWT as positive and negative controls respectively (Figure 4.8). Interestingly, the two 
designs, BfrExt-C and BfrExt-GC, which are the single cysteine versions of BfrCC-C-term, 
showed almost no signal as tetrapartite designs. Negligible signal was observed for BfrN148C 
with little change seen when the methionine was removed, BfrN147A,N148C. The highest 
signals recorded, around 10% of positive control, were from BfrQ151C and BfrE157C. While 





Figure 4.8 - FlAsH fluorescence of Bfr tetrapartite designs (see figure 4.6 for schematic explanation) in 
lysates. The data is normalised to the positive and negative controls. All designs set to 1 mg/ml total 
protein concentration, in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 1 µM 
FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME, Average of three protein expressions each repeated twice. 
Error bars are S.D. 
 
While this initial data suggests the possibility that several designs are acting as FlAsH-
EDT2 binding sites, it is important to verify that these binding sites are indeed dependent on 
the self-assembly of the nanocage.  
4.2.2.2. Effect of denaturation on Bfr designs in lysate conditions 
To determine whether the designed binding sites are self-assembly dependent, the 
mutants were reanalysed in lysates under denaturing conditions. High concentrations of 
guanidine.HCl (6 M) were added to each sample in order to remove any quaternary, tertiary 
and secondary structure (Figure 4.9). Any loss in signal could be attributed to the loss of FlAsH-
EDT2 binding sites. The positive control under denaturing conditions, BfrCCPGCC-N-term, 
demonstrated a high signal, and BfrWT had very little signal similar to non-denatured 
conditions. This is expected because BfrCCPGCC-N-term can bind to FlAsH regardless nanocage 
assembly. Interestingly the other positive control, BfrCCPGCC-N-term, showed an observable 
increase in signal upon denaturation. This result lends further support to the hypothesis that 




denaturation, the site is more accessible. The bipartite designs showing the highest lysate 
signals were reexamined in denaturing conditions. Both BfrCC-N/C-term and BfrCC-C-term 
showed high loss of signal (80 and 90% respectively) as would be expected if the FlAsH binding 
and fluorescent signal were assembly dependent.  
 
Figure 4.9 – The assembly dependence of FlAsH fluorescence for Bfr bipartite designs (see figure 4.5 for 
schematic explanation) in lysates under denaturing conditions. The data is normalised to the change in 
fluorescence of the positive and negative controls. All designs set to 1 mg/ml total protein 
concentration, in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 1 µM FlAsH, 
3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME and 6 M guanidine·HCl (GuHCl), Data shows the average change 
from three protein expressions each repeated twice.  
 
The tetrapartite designs which showed the highest lysate signal were also reanalysed 
under denaturing conditions (Figure 4.10), and in a similar fashion to the bipartite designs, 
tetrapartite BfrQ151C and BfrE157C designs showed significant loss of signal (80 and 100% 
respectively).  
These data taken together suggest that the designs BfrCC-N/C-term, BfrCC-C-term, BfrQ151C 
and BfrE157C provide a binding site in a geometry that can bind FlAsH-EDT2 and that this 





Figure 4.10 - The assembly dependence of FlAsH fluorescence for Bfr tetrapartite (see figure 4.6 for 
schematic explanation) designs in lysates in denaturing conditions. The data is normalised to the change 
in fluorescence of the positive and negative controls. All designs set to 1 mg/ml total protein 
concentration, in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 1 µM FlAsH, 
3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME and 6 M guanidine·HCl (GuHCl), Data shows the average change 
from three protein expressions each repeated twice.  
4.2.2.3. Detecting stabilising mutations in Bfr 
 A long term aim of this project is to screen Bfr mutant libraries to discover proteins 
with enhanced abilities to assemble. Therefore an assay strategy should be robust enough to 
detect changes in the Bfr oligomerization state ratio. Work conducted by the Orner laboratory 
to establish rational methods to stabilise Bfr resulted in mutants that favour the nanocage 
form over the dimer to various degrees (see above). The Bfr mutants, N23F4 and D118F10 
increased the nanocage populations to roughly 70% and 100% respectively as observed 
through size exclusion chromatography analysis. Introduction of these mutations into Bfr with 
designed FlAsH-EDT2 binding sites would provide a test of whether it is possible to utilise our 
technique to discover stabilising mutations in the future. 
The mutations N23F and D118F were placed onto the best bipartite designs, BfrCC-N/C-term 




BfrCC-C-termD118F), and analysed in lysates (Figure 4.11). As anticipated, the N23F mutation, 
which causes wild type Bfr to shift from 50% nanocage to 70%, resulted in an increase in signal 
in both bipartite backgrounds. The D118F, which pushes wild type entirely to nanocage results 
in an even more dramatic increase. These data, establish a correlation between the expected 
concentration of nanocages present in solution and the fluorescent readout paving the way for 
using this strategy to discover protein cages with enhanced stability. Moreover, these 
experiments suggest the potential for not only a qualitative assay for the detection of 
nanocages, but perhaps one that is quantitative. 
 
Figure 4.11 – Detecting stabilising mutations with Bfr bipartite designs (see figure 4.5 for schematic 
explanation) in lysates. The data is normalised to positive and negative controls. All designs set to 1 
mg/ml total protein concentration, in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) 
with 1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. Data from three protein expressions each 
repeated twice. Error bars are S.D. 
The stabilising mutants were also introduced onto the tetrapartite designs, BfrQ151C 
(BfrQ151C,N23F and BfrQ151C,D118F) and Bfr157C (BfrE157C,N23F and BfrE157C,D118F), and 
analysed (Figure 4.12). For these designs, the results were less emphatic and somewhat 




very little difference compared to its non-stabilised counterpart, and no detectable signal was 
observed for the other proteins. The dissimilarity between the bipartite and tetrapartite data 
could be an indication of the unsuitability of tetrapartite designs for rapid screening of Bfr 
libraries. Their lower lysate signals compared to bipartite designs, also suggest that tetrapartite 
designs might have a large enough signal to noise ratio window through which to see subtle 
differences in stability. 
 
 
Figure 4.12 - Detecting stabilising mutations with Bfr tetrapartite (see figure 4.6 for schematic 
explanation) in lysates. The data is normalised to positive and negative controls. All designs set to 1 
mg/ml total protein concentration, in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) 
with 1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. Data from three protein expressions each 
repeated twice. Error bars are S.D. 
 
The data above suggests that some of the designed systems can a) bind FlAsH b) bind 
FlAsH in an oligomerization dependent manner and c) be used to distinguish more stable 
nanocages. However, these experiments were all performed in lysates. While operating in this 
mode strongly demonstrates its strength in permitting the rapid screening of a number of 




direct observation of the nanocage state limits the definitive conclusions that can be drawn. 
Therefore we set out to determine the oligomerization state of these proteins.  
4.2.2.4. Native polyacrylamide gel electrophoreses (PAGE) analysis of Bfr bi- and tetrapartite 
designs 
 
It is clear that purified protein samples are required to further interrogate the success 
of these Bfr designs, as it is essential to determine what oligomerization states are formed by 
each design as well as providing additional solid proof as to which oligomerization state is 
responsible for the fluorescent signal. However, expression and purification is a time 
consuming process and restricts the number of designs that can be assessed. One technique 
that could bridge the lysate and purified protein work is native PAGE. By running lysate 
samples of the designs and controls on native gels, the nanocage, dimer and other 
intermediate species can be separated and observed. Not only would this confirm the 
presence of nanocages but, if run in the presence of FlAsH-EDT2, the gel could be visualized by 
fluorescence to determine the oligomer responsible for the fluorescent signals obtained in 
lysates. 
 Lysate samples for the Bfr controls and bipartite designs were analysed via native 
PAGE with purified BfrWT acting as a marker to identify both the nanocage and dimer species 
(Figure 4.13). Although the resulting data is interesting and can lend insight for the further 
characterisation of this technique there are some caveats with this data. First, the dimer or 
possibly some other Bfr intermediate, is clearly running with the gel front as seen when 
analysing purified Bfr. This, along with data from the dye only lane, which exhibits a strong 
fluorescence response also at the gel front prevents the ability to clearly identify what species 
is responsible for fluorescence. This lower sized band, be it a Bfr intermediate or a small 
molecule is more responsible for the large fluorescence intensity seen in this gel compared to 




identification  of the species responsible for this intensity.  While contradictory, the data 
suggests that a gradient native gel would be ideal for the separation of the dimer and the 
nanocage, the nanocage is readily observable under these conditions. The second caveat is 
that the nanocage bands exhibit extremely modest fluorescence compared to that arising from 
the lower co-moving band. Furthermore, in a number of cases, a very large fluorescence band 
is evident that has no corresponding coomassie band at this point. 
 
Figure 4.13 – Native PAGE (8%) analysis with both coomassie blue stain (left) and fluorescence (right) 
visualisation of the same gel, for Bfr bipartite protein designs and controls (see figure 4.5 for schematic 
explanation). To each well was added 20 µl of overexpressed protein lysate sample set to 1 mg/ml in 
FLAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) containing 1µM FlAsH-EDT2, 3.5 mM 
TCEP, 1 mM EDT and 1 mM 2-ME with purified BfrWT being used as a standard (first lane in each gel). 
Fluorescence visualisation took place using a 488 ± 20 nm excitation filter and a 526 ± 10 nm emission 
filters. 
Another immediate observation from the native gel is that any design with an 
extension on the N-terminus (BfrCCPGCC-N-term, BfrCC-N-term and BfrCC-N/C-term) showed 
a complete absence of nanocage bands which suggests that bulky substitution at the N-
terminus is detrimental to assembly. Also this electrophoresis data contradicts the initial 
steady state fluorescence data for BfrCC-N/C-term which demonstrated a high signal that was 
oligomerization dependent (see above). 
Designs containing extensions only at the C-terminus (BfrCCPGCC-C-term, and BfrCC-C-
term) showed the presence of nanocages. The presence of nanocages in the BfrCCPGCC-C-
term sample supports the hypothesis that the reduced signal arising from this protein 




EDT2 (above). BfrCC-C-term exhibited a strong band corresponding to the presence of 
nanocage. However the fluorescence imaged gel, shows only a very small corresponding band.  
 This analysis was repeated for the stabilised mutants BfrCC-N/C-termN23F, BfrCC-N/C-
termD118F, BfrCC-C-termN23F and BfrCC-C-termD118F in lysate samples (Figure 4.14). For all 
mutants, a fluorescent, albeit faint, nanocage band was evident. Inconsistent with our previous 
data (above), however, is that the D118F mutant seems to have less nanocages than the N23F 
mutant observed through its smaller band size. Under native PAGE scrutiny, the design BfrCC-
N/C-term exhibited no nanocage band. Results from its stabilised mutants showed the 
presence of nanocages which corresponded to a faint fluorescent band suggesting the ability 
of the stabilised mutants to overcome the effects of an extension on the N-terminus.  
 
Figure 4.14 – Native PAGE (8%) analysis with both coomassie blue stain (left) and scanned for 
fluorescence off the same gel (right), for Bfr bipartite protein designs with stabilising mutation N23F and 
D118F(see figure 4.5 for schematic explanation). To each well was added 20 µl of overexpressed protein 
lysate sample set to 1 mg/ml in FLAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) 
containing 1µM FlAsH-EDT2, 3.5 mM TCEP, 1 mM EDT and 1 mM 2-ME with purified BfrWT being used as 
a standard (first lane in each gel). Fluorescence visualisation took place using a 488 ± 20 nm excitation 
filter and a 526 ± 10 nm emission filter. 
 Although the use of native gels was proving problematic, for thoroughness they were 
used to analyse the Bfr tetrapartite designs (Figure 4.15). Only minor bands corresponding to 
the nanocage oligomer were observed for BfrN148C, BfrM147A,N148C and BfrQ151C further 




presence of nanocage bands that could correspond to bands that are fluorescent in the FlAsH 
gel. Curiously, the coomassie stained gels for Bfr157C and BfrExt-C exhibited a large band of 
size intermediate between nanocage and dimer. 
 
Figure 4.15 – Native PAGE (8%) analysis with both coomassie blue stain (left) and scanned for 
fluorescence from the same gel (right), for Bfr tetrapartite protein designs and controls (see figure 4.6 
for schematic explanation). To each well was added 20 µl of overexpressed protein lysate sample set to 
1 mg/ml in FLAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) containing 1µM FlAsH-
EDT2, 3.5 mM TCEP, 1 mM EDT and 1 mM 2-ME with purified BfrWT being used as a standard (first lane 
in each gel). Fluorescence visualisation took place using a 488 ± 20 nm excitation filter and a 526 ± 10 
nm emission filter. 
While native PAGE, due to the ability to run multiple proteins in parallel, is a relatively 
rapid method for the observation of Bfr nanocages in lysate samples clearly the technique was 
producing data that was inconsistent with previous experiments. While it is possible that the 
issues could be solved through optimisation of conditions, full characterisation of purified 
proteins was seen as a more precise option. It was also felt that for future understanding of 
the technology it would be best to understand the pitfalls of this technique it was best to start 
eliminating the multiple variables associated with lysates.  
4.2.2.5. Characterisation of purified Bfr bipartite designs 
All controls were expressed and purified along with the two bipartite designs: BfrCC-
N/C-term, was used to understand why a protein that isn’t forming nanocages (see gel data 
above) can exhibit such a high fluorescence, and BfrCC-C-term, which so far, was the best Bfr 




could form nanocage oligomers and exhibited high fluorescence intensity in lysates were also 
expressed and purified. BfrCC-N-term and all tetrapartite designs were not generated due to 
low signal or lack of observable nanocages on the gels.  
The proteins described above were purified and fully characterised (See appendix 4.5, 
4.6, 4.7, 4.8 and 4.9 for SDS-PAGE, mass spectrometry, CD and TEM and Figure 4.16 for SEC; 
the experimental details are presented in this chapter below). BfrCCPGCC-N-term and BfrCC-
N/C-term exhibited no nanocage-like oligomers in SEC as expected from the native gel; 
however, nanocages were observed with TEM. Contradictory results like this are not unknown; 
we have seen effects with ferritin mutants that form only dimer in solution but can assemble 
into nanocages in the “forcing”, dried conditions of TEM3. Consistent with native gels, 
BfrCCPGCC-C-term showed the presence of nanocages in both SEC and TEM as did BfrWT and 
BfrCC-C-term along with the stabilised proteins, BfrCC-C-termN23F and BfrCC-C-termD118F. 
While BfrCC-C-termN23F did not show a significant increase in the nanocage population over 






Figure 4.16 - Size exclusion chromatograms of purified Bfr derivatives monitored at absorbance of 280 
nm (protein) normalised to their highest intensity. Results for the UV are averages of three runs (0.5 ml 
injection of 1 mg/ml protein). 
With their quaternary structures confirmed, the purified proteins were evaluated for 
FlAsH binding and fluorescence (Figure 4.17). While the positive and negative controls, as well 
as BfrCC-C-term and BfrCC-C-termD118F behaved in a similar manner to lysate experiments 




some other species in the lysate sample, BfrCC-N/C-term and BfrCC-C-termN23F did not. In 
this case, BfrCC-C-termN23F displayed a decreased fluorescence response compared to the 
background protein. However, this is consistent with the lack of increase in nanocage 
population observed in the SEC (see figure 4.16). More surprising, BfrCC-N/C-term generated a 
signal comparable to the positive control, BfrCCPGCC-N-term. This is surprising as not only 
does this design not form any nanocages as evidenced by the SEC, this signal is much higher, 
compared to controls, to that seen in lysates. 
 
Figure 4.17 - FlAsH fluorescence of purified Bfr bipartite designs (see figure 4.5 for schematic 
explanation). The data is normalised to the positive and negative controls. All designs set to 1 mg/ml 
total protein concentration, in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 1 
µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. Error bars are S.D. Each purified protein repeated six 
times. 
4.2.2.6. Identification of specific oligomerization states responsible for fluorescence: size 
exclusion chromatography monitored with a fluorescent plate reader (SEC-FPR) 
 
An aim of the research described in this chapter is to create FlAsH-EDT2 binding sites in 
Bfr that can only form when the nanocage assembles. The data obtained so far, especially 
those of the potential false positive BfrCC-N/C-term, highlights that this might be more 
challenging than first thought. A method to directly detect which oligomer is binding and 




designs and to verify whether or not BfrCC-C-term is acting as a nanocage detector and why 
BfrCC-N/C-term has such a high signal without forming nanocages. 
A possible method, in analogy to fluorescence-imaged native gels (above), to directly 
detect which oligomerization state of the protein is responsible for the observed fluorescent 
signals, could be achieved by combining SEC with the fluorescence assay. By collecting small 
volume fractions and reading them with a fluorescence plate reader (SEC-FPR), an overlay with 
the 280 nm absorbance and fluorescence intensity, and thus a correlation between oligomer 
state and FlAsH signal, could be generated.  
Using this technique, the positive control, BfrCCPGCC-N-term, exhibited a large 
fluorescence response co-eluting with the dimer as expected. (Figure 4.18 - a) The negative 
control, BfrWT, had little, although detectable, correlation of fluorescence with the nanocage 
or dimer peaks (Figure 4.18 – b). It should be noted that both proteins formed a small, rapidly 
eluting population. It is assumed that this state is nonspecific aggregate. This population has a 
small amount of detectable fluorescence and, although it is a small population, this could be a 
concern later on. Another concern is the observation that, in these experimental conditions, 
the proteins exhibited more oligomerization states than they did in the conditions used for 
purification (see Fig. 4.16). This effect is mostly likely due to the redox exchange buffer used to 
optimise FlAsH binding in combination with the disulfide kinetics associated with Bfr assembly. 
This effect was much less evident with the miniferritin, Dps which was developed in parallel 
(see Chapter 5). Because of the more direct success of Dps and the desire to expand it into high 





Figure 4.18 – Identification of specific oligomerization states responsible for fluorescence—controls (see 
figure 4.5 for schematic explanation, a – positive control BfrCCPGCC-N-term, b – negative control 
BfrWT). Size exclusion chromatograms monitored at absorbance of 280 nm (protein) and fluorescence 
samples taken every 200 µl and analysed using a 510 ± 5 nm excitation and a 530 ± 5 nm emission filter 
set. Each run contained 0.5 ml of 1 mg/ml purified protein in FlAsH buffer (100 mM Tris.HCl, 100 mM 
NaCl, 1 mM EDTA, pH 7.8) with 0.4 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. Each protein was 
repeated three times with data above showing the average of all three runs. Data normalised using the 
highest gained fluorescent signal as 100% for both sample and the lowest of each as 0%. Error bars are 
S.D.  
  
The SEC-FPR technique was expanded to the other bipartite designs and controls 
(Figure 4.19). Most of the proteins showed a strong signal co-eluting with a peak that 
corresponds to protein aggregates. Worryingly, all C-terminal extensions, BfrCCPGCC-C-term, 
BfrCC-C-term, and the corresponding stabilised mutants, showed the presence of nanocage 
peaks without co-eluting fluorescent signal. Furthermore, strong signals were obtained from 
peaks corresponding to the dimer. Taken together, these data suggest that proteins with poorly 
designed or ill-placed FlAsH-EDT2 binding sites or proteins with oligomerization kinetics on the 
order of FlAsH exchange could result in spurious responses from nonspecific aggregation, 
artifactual oligomerization or other false negative/positive generating mechanisms. Many 
valuable lessons were learned from working with this system however the miniferritin, Dps 
came progressed with more straightforward data (see Chapters 5 and 6). Although initial 
experiments and controls appeared positive for Bfr, further characterisation proved intractable. 
The application of bipartite tetracysteine display for a nanocage oligomerization assay to Bfr 





Figure 4.19 - Identification of specific oligomerization states responsible for fluorescence—designs (see 
figure 4.5 for schematic explanation, a – BfrCCPGCC-C-term, b – BfrCC-C-term, c – BfrCC-N/C-term, d – 
BfrCC-C-termN23F and e – BfrCC-C-termD118F). Size exclusion chromatograms monitored at 
absorbance of 280 nm (protein) and fluorescence samples taken every 200 µl and analysed using a 510 ± 
5 nm excitation and a 530 ± 5 nm emission filter set. Each run contained 0.5 ml of 1 mg/ml purified 
protein in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 0.4 µM FlAsH, 3.5 mM 
TCEP, 1 mM EDT, 1 mM 2-ME. Each protein was repeated three times with data above showing the 
average of all three runs. Each design was normalised individually using the highest and lowest 
fluorescent signals as 100% and 0% respectively. Error bars are S.D.  
4.2.3. A potential new direction: Detection of Bfr assembly through binding site 
inaccessibility  
 Although some of the reasons for the failure of the Bfr designs remain unclear, the 
data above, while emphasizing the importance of rigorous control experiments, establishing 
useful characterisation methods, and beginning to define the scope of the technology, lends 
some additional fundamental insight. The results taken together suggest that the efficiency of 
the C-terminus to bind FlAsH-EDT2 is restricted due to its position inside the protein nanocage. 
Although this fact could, in some regard, be a limitation, it was realized that it could also be 




BfrCCPGCC-C-term exhibits a decreased fluorescence signal under both lysate (Figure 
4.7) and purified conditions (Figure 4.17) compared to BfrCCPGCC-N-term. Denaturing 
BfrCCPGCC-C-term (Figure 4.9) recovers the signal. It is thought that this effect is due to slower 
FlAsH-EDT2 penetration kinetics. Providing a complete binding site that is inaccessible to FlAsH-
EDT2 only in the assembled, nanocage state could be the basis for a method to detect 
nanocage formation and thus decreased signal would correlate to increased assembly. 
Because all proteins would have a complete, four cysteine binding motif, problems associated 
with bipartite and tetrapartite design could be bypassed. 
To test this concept, the stabilising mutants N23F and D118F were placed into the 
control BfrCCPGCC-C-term, which has a complete binding site for each monomer (BfrCCPGCC-
C-termN23F and BfrCCPGCC-C-termD118F) (Figure 4.20). Because BfrCCPGCC-N-term exists in 
solution as a dimer (Figure 4.16) and is therefore freely accessible to FlAsH-EDT2, this protein 
could act as a positive signal/negative assembly control. BfrCCPGCC-C-term, would serve as 
the negative signal/positive assembly control. A more stabilising mutant would generate less 
signal than both of these controls but have a great percentage increase in signal upon 
denaturation. 
 
Figure 4.20 – Detection of Bfr assembly through binding site inaccessibility. (Bottom) Schematic 
demonstrating how the change in accessibility of full, four cysteine binding sites can be decreased upon 
nanocage assembly if the binding sites are positioned inside the cage. (Top) designs of controls and 




 It was realized that the signal response window is narrow and the number of binding 
sites is increased, so for this system to be successful, further optimisation of the protein and 
probe stoichiometry is essential. In addition, so as to be more accurate in controlling the 
number of binding sites, we only worked with purified proteins. To that end, the proteins 
BfrCCPGCC-N-term, BfrCCPGCC-C-term, BfrCCPGCC-C-termN23F, BfrCCPGCC-C-termD118F 
and BfrWT were expressed, purified and characterised (see Appendices 4.5, 4.6, 4.7, 4.8, 4.9 
and 4.10 for mass spectrometry, SDS-PAGE, TEM and SEC and section 4.4 of this chapter for 
experimental procedures).  
 As expected, BfrCCPGCC-C-termN23F and BfrCCPGCC-C-termD118F showed nanocage 
character in both SEC and TEM with an increase in nanocage population compared to 
BfrCCPGCC-C-term. These proteins were assayed for their fluorescence intensity with a 1:1 or 
a 2:1 probe to protein molar ratio (Figure 4.21). For both ratios, the trend in signal was as 
expected from the least stable nanocage, BfrCCPGCC-C-term, generating the highest signal and 
the other proteins having decreased signal correlated to their relative stabilities with the 1:1 
ratio providing the largest range in fluorescence (Fig. 4.21a and 4.21c) However, less expected 
were the results from the denaturation control where it was thought that upon denaturation, 
all the binding sites would be freely accessible to the probe and the signals would match that 
of BfrCCPGCC-N-term. This was clearly not the case where the stabilised mutations exhibit 
nearly undetectable changes in fluorescence upon denaturation. (Fig. 4.21 b and 4.21d) In fact, 
the control protein BfrCCPGCC-N-term, did not reach full signal upon denaturation at the 2:1 
probe to protein ratio suggesting that something was clearly wrong with these conditions. 
Further conditions were analysed using different concentrations of proteins and fluorophore, 
with similar trends observed (see appendix 4.11). At the moment it remains unclear what is 
going on with this experiment and further optimisation is required. As these experiments were 






Figure 4.21 – Fluorescence analysis to detect Bfr assembly through binding site inaccessibility. (a and c) 
normalized fluorescence of purified proteins (b and d) recovery of fluorescence through denaturation. (a 
and b) 1:1 molar ratio of fluorophore to monomer (c and d) 2:1 ratio of fluorophore to monomer. The 
data is normalised to positive and negative controls. All designs set to 0.1 mg/ml total protein 
concentration, in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with, 3.5 mM TCEP, 
1 mM EDT, 1 mM 2-ME and varying concentrations of FlAsH-EDT2. Denatured experiments contained 6 






A method to rapidly and directly determine the self-assembly of bacterioferritin using 
bipartite tetracysteine display and encapsulated full binding sites was developed and analysed. 
All designs were constructed around the rule that any binding site could bind the probe FlAsH 
and fluoresce only upon nanocage assembly formation and not with any other oligomerization 
state. Selective fluorescence signals from both bipartite and tetrapartite designs were 
observed in lysate conditions suggesting the flexibility and robustness of these designs. These 
signals could be switched off upon protein denaturation suggesting that they are 
oligomerization dependent. Furthermore, by applying mutations that have been previously 
shown to stabilise nanocage formation, the FlAsH signal was greatly enhanced. Further 
analysis, using native PAGE and SEC with purified proteins was performed to confirm the 
oligomerization state responsible for observed fluorescent signals. A new technique was 
developed that combined size exclusion chromatography with a fluorescence plate assay. 
However, when examined, none of the designed proteins exhibited any fluorescent signal 
associated with the protein nanocage and showed multiple oligomerization states. Fluorescent 
signals from the designs instead resulted from either dimer intermediates or protein 
aggregates. As an alternative strategy, a second method relying on the shielding of the full 
FlAsH binding site inside the assembled nanocage was developed. While purified protein 
fluorescence signals showed trends similar to those expected, there was little change observed 
upon denaturation suggesting a lack of correlation between oligomerization state and 
fluorescent signal. 
It is unknown what caused the failure of the bipartite and tetrapartite designs. One 
possibility could be related to the fact that many more peaks in the SEC under FlAsH binding 
conditions than when the protein was initially purified. This suggests that complex, disulfide 
exchange to generate transient but non-native oligomerization may be occurring. Clearly more 




designs showed dimers that appeared to fluoresce in these conditions. It is possible that either 
the oligomerization state is misassigned in the SEC or that these dimers are not native dimers 
because it is unclear how our designs would permit fluorescence when the dimers are 
antiparallel, two-fold symmetric with divergent termini observed in the crystal structure.  
As we learned that the buffer conditions may be important to the success of this 
technique, it is thought that the kinetics of both binding and assembly should also be a focus of 
future optimisation. The majority of Bfr designs on the C-terminus placed the binding sites 
inside the nanocage. For the incubation times used in our standard conditions, positioning the 
binding sites inside the nanocage resulted in restricted access by FlAsH. However, while 
attempting to exploit this setback into a new strategy of probing assembly by purposely 
restricting access to full binding sites, problems where encountered in our denaturation 
controls. To work as designed, all binding sites should be exposed and able to bind FlAsH-EDT2 
resulting in an increased signal upon denaturation. However, little change in fluorescence was 
observed. Incomplete denaturation could be the cause although this is unlikely due to the high 
concentrations of denaturant (6 M GuHCl) and extended denaturation time (6 hours). A more 
probable explanation again may lie with non-native oligomerization further emphasizing the 
importance of buffer and protein/probe stoichiometry optimisation. 
From these experiments it was learned that placing binding sites at exposed termini 
can generate FlAsH binding sites that are oligomerization dependent and that this technique 
can be robust in complex lysates. The characterisation methods and designed rules established 
here can be easily ported to other designs and the robustness in lysates points the way toward 




4.4. Methods and Materials 
4.4.1. Cloning of Bfr designs and controls 
4.4.1.1. Transfer of Bfr gene to pET-22b plasmid for lysate analysis with extensions to N-
terminus for BfrCCPGCC-N-term, BfrCC-N-term and BfrWT designs 
 
The BfrWT gene was amplified with primers providing restriction sites and the required 
alterations on the N-terminus2. The PCR reaction (50 μl total volume) was a solution of reaction 
buffer (Fermentas, 5 μl of 10xPfu buffer), dNTP mix (Fermentas, 2 μl of a solution containing 
dATP, dTTP, dGTP, and dCTP at 2 mM each), forward and reverse primers (400 ng each, 
Suprenom, Singapore, see Appendix 4.1), template (100 ng) and Pfu polymerase (Fermentas, 2 
μl of 2.5 U/μl) which was subjected to an initial melting step at 95 °C for 30 s, followed by 30 
cycles of amplification (95 °C for 30 s, 55 °C for 45 s and 72 °C for 1 min) followed by 72 °C for 7 
min. The resulting PCR product was isolated by gel purification (Promega). The PCR product 
(300 ng) was digested (Tango buffer, Fermentas, 10 μl of 2x buffer), Nde1 (Fermentas, 1.5 μl of 
20 U/μl), Xho1 (Fermentas, 1.5 μl of 20 U/μl), 50 μl total volume, 37 °C, 3 hours). The plasmid 
pET-22b (Novagen) was treated in the same way, followed by ligation of the insert with T4 
ligase buffer (Fermentas, 2 μl, 10x buffer), digested insert (30 ng), digested plasmid (80 ng), T4 
ligase (Fermentas, 0.2 µL of 20 U/µl), 20 μl total volume (37 °C, 2 hours). The constructs (2 μl) 
were transformed (Novablue, Novagen) and the resulting colonies were assessed by colony 
PCR (a solution of buffer (2.5 μl of 10x), MgCl2 (Fermentas, 1.75 μl of 25 mM) dNTP mix 
(Fermentas, 2 μl of a solution containing dATP, dTTP, dGTP, and dCTP at 2 mM each), T7 
promoter and terminator primers (150 ng each, Suprenom, Singapore), Taq DNA polymerase 
(Fermentas, 0.25 μl of 5 U/μl), colony suspension (10 μl of a 50 μl total colony suspension in 
deionised water) and deionised water (5 μl), was subjected to an initial melting step (95 °C for 
10 min) followed by 30 cycles of amplification, ((95 °C for 30 s, 59 °C for 30 s and 72 °C for 30 s) 




subjected to miniprep (Invitrogen) and the resulting purified plasmids were sequenced (see 
Sequence Appendix 4 for sequence results and Appendix 4.1 for primers used).  
4.4.1.2. Construction of BfrCCGPCC-C-term, BfrCC-C-term, BfrCC-N/C-term, BfrExt-C, BfrExt-
GC, BfrCC-C-termN23F and BfrCC-C-termD118F via site directed mutagenesis for screening in 
lysates 
 
The constructs for BfrCCPGCC-N-term, BfrCC-N-term and BfrWT in pET-22b were used 
as templates for site directed mutagenesis (Quikchange, Stratagene) to introduce mutations at 
the C-terminus. The reaction mixture containing Pfu turbo buffer (Fermentas, 2 μl of 10x), 
dNTP mix (Fermentas, 2 μl of a solution containing dATP, dTTP, dGTP, and dCTP at 2 mM each), 
forward and reverse primers (125 ng each, Suprenom, Singapore, see appendix 4.1), the dsDNA 
template (100 ng) and Pfu turbo polymerase (Fermentas, 1 μl of 2.5 U/μl) in a total volume of 
25 μl was subjected to melting (95 °C for 5 min), followed by 20 cycles of amplification (95 °C 
for 1 min, 55 °C for 1 min and 68 °C for 6 min) followed by 70 °C for 10 min. The reaction was 
then digested with Dpn1 (NEB buffer 4 (1 μl of 10x), amplification product (5 μl), deionized 
water (3.5 μl), Dpn1 (NEB, 0.6 μl of 10 U/μl), 37 °C, 2h). The resulting solution was desalted 
(Promega, PCR cleanup kit) and transformed. The resulting colonies subjected to miniprep 
(Invitrogen) and sequenced (see Sequence Appendix 4 for sequence results and Appendix 4.1 
for primers used). 
4.4.1.3. Expression plasmid transfer of Bfr designs to allow for analysis with purified proteins 
In order to express the proteins for isolation and purification, the genes were placed 
into a vector that provides affinity tags. The constructs were amplified from the mutated pET-
22b plasmid with primers providing ligation independent cloning (LIC) sites. The PCR solution 
(Pfu reaction buffer (Fermentas, 5 μl of 10x), dNTP mix (Fermentas, 2 μl of a solution 
containing dATP, dTTP, dGTP, and dCTP at 2 mM each), forward and reverse primers (400 ng 
each, Suprenom, Singapore, see Appendix 4.1), reverse oligonucleotide primer Suprenom, 




total volume) was subjected to an initial melting step (95 °C for 30 s), followed by 30 cycles of 
amplification (95 °C for 30 s, 55 °C for 45 s and 72 °C for 1 min) followed by 72 °C for 7 min. The 
resulting PCR product was isolated by gel purification (Promega). The PCR product was then 
treated with T4 polymerase in order to create the required complementary overhangs (NEB 
buffer 2, 2 μl of 10x buffer), dATP (NEB, 2 μl of 25 mM), DTT (Sigma, 1 μl of 100 mM), BSA (NEB, 
0.2 μl of 100x), PCR product (0.3 pmol) and T4 DNA polymerase (NEB, 0.6 μl of 10 U/μl) in a 
total volume of 20 μl 30 min, 22 °C). The insert was annealed to open plasmid pET-32b 
(Novagen) (1 μl of the T4 Pol product, 0.5μl of plasmid solution (50 ng/μl)) by incubating (room 
temperature, 30 min) followed by a second incubation (room temperature, 30 min) with EDTA 
(1 μl of 100 mM). The constructs (2.5 μl) were transformed (Novablue, Novagen) and the 
resulting colonies were assessed by colony PCR (a solution of buffer (2.5 μl of 10x), MgCl2 
(Fermentas, 1.75 μl of 25 mM) dNTP mix (Fermentas, 2 μl of a solution containing dATP, dTTP, 
dGTP, and dCTP at 2 mM each), T7 promoter and terminator primers (150 ng each, Suprenom, 
Singapore), Taq DNA polymerase (Fermentas, 0.25 μl of 5 U/μl), colony suspension (10 μl of a 
50 μl total colony suspension in deionised water) and deionised water (5 μl), was subjected to 
an initial melting step (95 °C for 10 min) followed by amplification 30 cycles of (95 °C for 30 s, 
59 °C for 30 s and 72 °C for 30 s) followed by 72 °C for 7 min). Clones demonstrating a PCR 
product of the predicted size were subjected to miniprep (Invitrogen) and the resulting purified 
plasmid was sequenced. For BfrCC-C-term, BfrCC-N/C-term and the stabilized mutants N23F 
and D118F, site directed mutagenesis was performed as described above using specific primers 
for the required mutations (see Sequence Appendix 4 for sequencing results and Appendix 4.1 
for primers used). 
4.4.1.4. Construction of Bfr designs with restricted full binding sites, BfrCCPGCC-N-term, 





Site directed mutagenesis was performed on the BfrCCPGCC-C-term design in pET-32b 
with the primers necessary for N32F and D118F mutations as described in 4.4.1.2. (see 
sequence Appendix 4 for sequence results and Appendix 4.1 for primers used)4, 10. 
4.4.2. FlAsH analysis in lysates 
The pET-22b expression vectors containing Bfr variants were transformed into BL21 
E.coli cells and plated on LB plates (50 μl/ml of carbenicillin). Selected colonies then were 
grown in LB (3 ml with 50 μl/ml of carbenicillin, 37 °C, overnight) as a pre-culture which was 
then added to LB (100 ml) and grown (37 °C) until an O.D600 of 0.6. Protein expression was then 
induced by the addition of IPTG (400 mM) and the culture was further incubated (3 h, 30 °C 
with the exception of CC-C-termN23F and CC-C-termD118F (20 °C, overnight). The cells were 
isolated by centrifugation (10,000 rpm, 20 min at 4 °C). The cell pellet was resuspended in 
Flash buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) and sonicated (Sonics vibra 
cell sonicator, 60% amplitude, pulsed 5 s on 5 s off for 15 min). The protein solution was 
clarified by centrifugation (10,000 rpm, 20 min, 4 °C) and then filtered (Pall, 0.2 μm). The 
protein concentration was determined (BCA, Novagen) and the cell lysate was diluted to 1 
mg/ml. with FlAsH buffer. To assure that all the 1 mg/ml samples had similar amounts of the 
desired protein, each was analyzed by SDS PAGE (see appendix 4.2, 4.3 and 4.4). For each 
sample, (200 μl, 1 mg/ml) in FlAsH buffer TCEP (Sigma, final concentration of 3.5 mM), EDT 
(Sigma, final concentration of 1 mM) and 2-ME (Sigma, final concentration of 1 mM) were 
added and the solution was incubated (room temperature, 2 h) followed by the addition of 
FlAsH-EDT2 (Invitrogen, final concentration of 1 μM) followed by a further incubation (20 °C, 2 
h) in the dark. Each lysate sample was examined (Varian Cary Eclipse spectrofluorimeter, Ex 510 
nm, Em 530 nm, Ex and Em slits 5 nm, for 1 min in kinetic mode in a quartz fluorescence 
cuvette) at least six times in total with at least three separate protein expressions assessed 
twice. For the denaturing experiments each sample was also incubated with a final 




4.4.3. FlAsH analysis with purified proteins  
The pET-32b vectors containing the Bfr variants were transformed into BL21 E.coli cells 
and plated on LB plates (50 μl/ml of carbenicillin). Selected colonies were then grown in LB (5 
ml, 37 °C, overnight) as a pre-culture which was added to LB (500 ml) and grown (37 °C) until 
an O.D600 of 0.6. Protein expression was then induced by the addition of IPTG (final 
concentration of 400 mM) and the cultures were further incubated (3 h, 30 °C). The cells were 
isolated by centrifugation (10,000 rpm, 20 min, 4 °C). The cell pellet was resuspended in lysis 
buffer (50 mM NaH2PO4, 300 mM NaCl, 40 mM Imidazole, pH 8) and sonicated (Sonics vibra 
cell sonicator, 60% amplitude pulsed 5 s on, 5 s off for 15 min). The protein solution was 
clarified by centrifugation (10,000 rpm, 20 min at 4 °C in an Eppendorf 5810 centrifuge) and 
then filtered (Pall, 0.2 μm). The protein was purified via affinity (GE, Histrap FF, 5 ml, (wash 
buffer-40 mM Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4), (elution buffer-500 mM 
Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4)). Enteriokinase digestion (NEB 2 μg/ml) was 
performed to cleave off the peptide tag from the protein of interest followed by a second 
Histrap (GE, Histrap FF, 5 ml, (wash buffer-40 mM Imidazole, 50 mM NaH2PO4, 300 mM NaCl, 
pH 7.4), (elution buffer-500 mM Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4)) to remove 
the tag from solution. The protein solution was further purified by size exclusion 
chromatography (GE Hiload 16/60 Superdex). The degree of purification was assessed with SDS 
PAGE (see appendix 4.5), SEC (see figure 4.18), TEM, CD and mass spec (appendix 4.6, 4.7, 4.8, 
4.9 and 4.10). FlAsH analysis was performed as described above for lysate proteins, with each 
sample being repeated 8 times with a set concentration of 1 mg/ml. Bfr encapsulated designs 
were analysed with different concentrations of both fluorophore and protein as indicated in 




4.4.4. Protein characterisation 
4.4.4.1. Size exclusion chromatography (SEC) and SEC-FPR 
The samples (0.5 mg/ml) in GFC buffer (50 mM Na2HPO4, 100 mM NaCl, pH 7) was 
injected (0.5 ml) on to the column (GE Superdex 200 10/300 GL) at 0.5 ml/min and each was 
repeated 3 times. The column was calibrated using six proteins as standards (GE Biosystems 
Calibration Kit). 
 For fluorescent monitoring, samples were prepared by adding to pure protein (0.5 ml 
of 1 mg/ml) in FlAsH buffer, TCEP (Sigma, final concentration of 3.5 mM), EDT (Sigma, final 
concentration of 1 mM) and 2-ME (Sigma, final concentration of 1 mM) and incubated (2 h, 
room temperature). FlAsH-EDT2 dye was added and incubated in the dark (Invitrogen, final 
concentration of 0.4 μM, 2 h, room temperature). This sample was desalted (GE, HiTrap 5 ml 
Desalting column) before injection onto a SEC column (GE Superdex 200 10/300 GL). Samples 
were taken every 200 μl during the elution and placed into a black Corning 96 well plate. This 
plate was examined in a PerkinElmer Envision 2101 multilabel plate reader (Ex filter 485 nm 
bandwidth 14 nm, Em filter 535 nm bandwidth 25 nm). Each purified protein was analysed 
three times with each plate re-read three times.  
4.4.4.2. Native gel fluorescence analysis 
Native gels were performed (4% stacking gel, 8% resolving gel, 20 min 80 volts, 
followed by 1 h 130 volts at 4 °C) on all samples subjected to FlAsH analysis (total protein 
concentration of 1 mg/ml in 200 µl total volume with 1 µM FlAsH-EDT2). Each gel was scanned 
with a fluorescent gel reader (Typhoon Trio Variable mode imager Ex 488 nm, Em 526 nm) and 
then stained with coomassie brilliant blue. Gel pictures were analyzed using ImageJ23. 
4.4.4.3. Transmission Electron Microscopy (TEM) 
TEM was performed on a FEI, Tecnai G2 20, electron microscope set at 200 KeV. Purified 




were immobilized on Formvar/carbon coated 3.05 mm copper grids (TAAB) and negatively 
stained with 1% Uranyl acetate. Micrographs were analyzed using ImageJ23 (see Appendix 4.9). 
4.4.4.4. Circular Dichroism Spectroscopy (CD) 
All proteins were purified and made to 0.2 mg/ml in phosphate buffer (50 mM 
Na2HPO4, 50 mM NaCl, pH 7) performed on a JASCO J-810 spectropolarimeter from 250 nm to 
200 nm with a path length of 0.5 mm. Thermal melts were performed from 5 to 100 °C 24, 25 
(see Appendix 4.7). 
4.4.4.5. Mass Spectrometry 
Purified proteins (0.05 mg/ml) were desalted into dH2O (GE, Hitrap 5ml Desalting 
column) and analysed on a Bruker MaXis mass spectrometer after the addition of 1% Formic 
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Chapter 5  
 
Direct detection of mini-ferritin 








NOTE: Parts of this chapter were taken from published work with the candidate as first author 
(see appendix – Published Work 2)1. 
5.1. Introduction  
 The complexity of creating a specific protein nanocage self-assembly detection 
strategy using FlAsH-EDT2 technology, was emphasized by the initial attempts with the maxi-
ferritin Bfr (see Chapter 4). Although fluorescence signals were obtained for several bipartite 
and tetrapartite designs and these were shown to be oligomerization dependent, the data did 
not hold up to rigorous scrutiny, and, in the conditions explored, we observed signal 
associated with protein aggregates and dimers. However, control proteins and tools were 
established (for example SEC-FPR) that could complement prolonged biophysical 
characterisation. It was therefore thought, that it was worth determining whether a similar 
strategy would be more successful with a different protein nanocage. 
5.1.1. Aims of this investigation 
With lessons learned from Chapter 4, an altered approach was taken using a different 
protein nanocage. This nanocage needed to be less complex than Bfr but still be a multimeric, 
highly symmetric protein nanocage. A protein nanocage that natively assembles into a single 
species, should be easier to work with and be less prone to the complexities seen with Bfr. We 
had also learned that placing the FlAsH binding sites on the outside of the nanocage might 
avoid additional complications. The goals of the research described in this chapter remain the 
same as in Chapter 4: Develop the ability to analyse multiple conditions or mutants of a 
protein nanocage for the stability of its quaternary structure stability with the long term aim of 
transferring this technique from in vitro to in vivo where protein nanocage libraries could be 
screened using cell sorting. Perhaps by using a target protein with more tractable properties, 
we can more directly establish basic and fundamental guidelines to help develop a nanocage-





5.1.2. New model system for a protein self-assembly assay: Favourable aspects of Dps  
As discussed in Chapter 2, the E.coli DNA-binding protein from starved cells (Dps), is a 
mini-ferritin with a 9 nm outer diameter that assembles from twelve identical monomers and 
stores cellular iron through mineralisation inside its hollow cavity. Each monomer folds into a 
four helix bundle with an additional helix in the loop between the second and third helix of the 
bundle (the “BC helix”)2, 3. Dps self-assembles into a nanocage with tetrahedral symmetry, 
possessing six identical two-fold symmetry axes, most likely the dimer intermediate, and four 
each of two distinct three-fold axes. During Dps self-assembly, monomers rarely persist and as 
for most ferritins, a two-fold symmetric dimer is believed to be the most prevalent 
intermediate4. This dimer is thought to be the fundamental building block for nanocage 
formation, however, unlike Bfr, the dimer species in Dps represents a nearly undetectable 
fraction of the total protein population when analysed with SEC3. However, like Bfr, these 
dimer intermediates are presumed to be anti-parallel, meaning that the termini of one 
monomer projects away from those of the other monomer; only with increased 
oligomerization to the fully formed nanocage state do the termini converge.  
Similar to Chapter 4, the aim of the project described in this chapter is to create a 
method to detect nanocage formation with specificity over all other assembly intermediates. 
Dps was selected for this work, as this mini-ferritin, not unlike Bfr, assembles around 
symmetric protein-protein interfaces, some of which are nanocage- and not dimer-specific. 
The low level of dimer in native Dps also might make is more tractable model system than Bfr. 
In addition both termini of Dps are located on the outside compared to the complicating 
inward projection of the Bfr C-terminus (see Chapter 4). Therefore it was thought that Dps 






Figure 5.1 – A self-assembly assay for Dps protein nanocage self-assembly should generate signal in a 
nanocage specific manner. In an ideal assay, the fluorescent probe, FlAsH should bind and fluoresce, 
only in the presence of the nanocage oligomerization state and not the anti-parallel dimer. Designed 
binding sites for FlAsH should thus only form upon nanocage formation. 
5.1.3. FlAsH binding site design strategies applied to Dps 
 One strategy to design binding sites in Dps is to focus on the termini in analogy to what 
was done in Chapter 4 with Bfr. A potential advantage to Dps is that both the N- and C-
terminal ends are located outside of the nanocage. The most accessible convergence for FlAsH 
binding site design is formed by the C-terminus which is located at a three-fold axis of 
symmetry. The N-terminus comprises of a long unstructured flexible loop (residues 1-21) with 
only the last few amino acids observable in most crystal structures (PDB:1DPS, 1L8H and 
1JRE)2. The unstructured nature of this loop could prove useful, as mutations located here 
would not interfere with secondary structure, lowering the risk of disrupting nanocage 
assembly. However, it is unclear where the end of this terminus is located and whether or not 
it converges with other termini upon nanocage formation. Thus the N-terminus was deemed 
less ideal than the C-terminus for binding site design.   
Along with designs focused on the convergence of Dps termini, other strategies were 
employed. The designs using the termini as set out in Chapter 4 relied on the idea that 
concentrating cysteines in space would lead to a FlAsH binding site. No real concern was given 
to stoichiometry and geometry. Therefore, more precise designs were conceived. Schepartz 
and co-workers have established geometric design rules for optimal FlAsH-EDT2 binding5, 6 with 





geometrically optimised binding site approach was used to aid in unravelling the mechanism of 
Epidermal growth factor receptor (EGFR) transmembrane signalling7. We therefore had this 





5.2. Results and discussions 
5.2.1. Dps designs 
Two philosophies were pursued in designing FlAsH binding sites for Dps. In one, the 
interaction between one dimer subunit and other dimers in the assembled nanocage acted as 
a starting point. In the other, the goal was to generate binding sites by converging cysteines in 
space upon nanocage assembly through N- and/or C-terminal fusions. The fundamentals of 
this latter philosophy was discussed and employed in Chapter 4. To pursue the former 
philosophy, all dimer-dimer interactions that form in the Dps nanocage were surveyed for their 
potential to be exploited for FlAsH binding sites. High potential interfaces were determined by 
three rules: 1) Mutatable residues at the interfaces must be close in space (<8 Å), 2) Mutatable 
residues cannot be in between the same dimer unit, 3) Mutatable residues must be 
predominantly on the outside of the nanocage. These rules, formed from lessons learned in 
Chapter 4 and derived from the desire to have an accessible binding site that would not form 
independently of the nanocage oligomerization state. The size constraints on the distance 
between amino acids followed the principles set out by Schepartz and co-workers by designing 
binding sites based on the geometry of FlAsH itself5. These rules were kept intentionally 
flexible and do not exclude the termini-focused designs. Because we had the luxury of being 
able to assess the designs in lysates, we could explore a wider range of designs and scrutinize 
these two philosophies in parallel. It should be mentioned however that an additional lesson 
learned in Chapter 4 with the need for full characterisation with rigorous controls for any 
design that proved promising in the lysate screens.  
5.2.2. Design and assessment of FlAsH binding sites across Dps dimer-dimer interfaces 
 There are a number of considerations that must be made in designing binding sites 
across dimer-dimer interfaces in Dps. The Dps nanocage has tetrahedral symmetry, thus, 





dimer-dimer interfaces, while not located directly at symmetry axes are reliant on this 
symmetry nonetheless. Therefore there are a limited number of unique dimer-dimer 
interactions, but they are repeated multiple times in the assembled nanocage. In addition, the 
location of native cysteines must also be considered. Dps has a single cysteine close to the C-
terminus of the monomer, well away from a dimer-dimer interface (see Appendix 5.2). While 
the single native cysteine will not impede this investigation, consideration must be taken when 
employing this approach with other proteins.  
Dps was analysed to identify the major type of dimer-dimer interaction (Figure 5.2). 
This, the ‘T-interaction’, is formed between a dimer and a second dimer which resembles a 
“cap stone” on top of the first. Deeper analysis of this interface using the criteria defined 
above leads to only one area of potential interest (positions in red, Figure 5.2). This area is 
made up of the unstructured N-terminal tail from one monomer in one dimer and parts of 
both the C- and D-helix from a monomer in the other dimer. Thus, two complementary 
locations on opposing monomers were provided for possible mutations to cysteines to create 
a FlAsH binding site. These residues obey most of our design rules: each residue is located on a 
monomer that belongs to a different dimer and each unit is close in space. Through further 
examination of the crystal structure at this region, it is evident that some of the residues on 
the C-helix are buried and therefore inaccessible. The remaining residues are on the N-
terminal tail (R18, N19, D20) and the D helix (D123, A126, N130). These six residues were the 






Figure 5.2 – Structural analysis of Dps dimer-dimer interfaces. (bottom left) Crystal structure (PDB:1DPS) 
showing a Dps ferritin nanocage viewed down a two-fold axes between monomers forming an anti-
parallel dimer. (top) expansion of the T-interaction highlighting residues (red) that obey the design rules 
(see text). Protein figures made with Chimera8. 
It was unclear which four of these six residues were optimal; therefore, we decided to 
try all possible combinations. It should also be pointed out that because Dps is a highly 
symmetric homooligomer, each monomer is involved in two of these interactions at two 
different positions—once in the D-helix and the other near the N-terminal tail. Therefore, four 
cysteine mutations must be incorporated into each monomer to form the binding site in the 
assembled nanocage. Mutants were formed and examined (DpsR18C-N19C-A126C-N130C, 
DpsN19C-D20C-A126C-N130C, DpsR18C-N19C-D123C-A126C, DpsR18C-D20C-D123C-A126C, 
DpsN19C-D20C-D123C-A126C, DpsR18C-D20C-A126C-N130C, Figure 5.3) with some 
combinations omitted as they created binding sites too large for ideal FlAsH-EDT2 geometry as 






Figure 5.3 – Location and description of designed binding sites across Dps T-interfaces. (left) Dps T-
interface with N-terminal tail R18, N19 and D20 and D-helix D123, A126, N130 amino acids highlighted 
(red). (Right) schematic of Dps T-interface expanded to show which amino acids (in red) were mutated 
into cysteines (red balls) from their native amino acid (grey) in each design (top left: DpsR18C-N19C-
A126C-N130C. Top right: DpsN19C-D20C-A126C-N130C. Middle left: DpsR18C-N19C-D123C-A126C. 
Middle right: DpsR18C-D20C-D123C-A126C. Bottom left: DpsN19C-D20C-D123C-A126C. Bottom right: 
DpsR18C-D20C-A126C-N130C.)  
 Using wild type Dps with no additional cysteines as a negative control (Dps), and a 
well-characterised Bfr positive control from Chapter 4 (BfrCCPGCC-N-term), the designs were 
analysed in lysate conditions for their ability to bind to FLAsH-EDT2. As in Chapter 4, lysate 
conditions were deemed an advantageous starting point as the proteins require no purification 
leading to their faster development, the speed provides the ability to assess more designs, and 
the complex conditions provide insight into how such designs might behave in vivo. While 
most of the designs showed low signal in these conditions, DpsR18C-N19C-D123C-A126C 






Figure 5.4 - FlAsH fluorescence of mutants with designed binding sites across Dps T-interfaces (see 
Figure 5.3 for schematic explanation) in lysates. The data is normalised to the positive and negative 
controls. All designs are 1 mg/ml in total protein concentration, in FlAsH buffer (100 mM Tris.HCl, 100 
mM NaCl, 1 mM EDTA, pH 7.8) with 1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. Signals are 
average of three separate protein expressions each repeated twice. Error bars are S.D. 
Only one out of six designs showed significant fluorescence intensity above negative 
control, perhaps pointing to poor overall site geometry for FlAsH binding or to disruption of 
protein-protein interactions. This most promising design was denatured with the addition of 6 
M guanidine·HCl to assess the effect of quaternary structure on the FlAsH signal following our 
procedure established in Chapter 4 (see Figure 5.5 A). The fluorescent signal decreased by 
nearly 100% suggesting that the fluorescent signal is dependent upon structured protein.  
 To confirm that the observed fluorescent signal observed in lysate experiments was 
arising from Dps nanocage assembly and not another species within the lysate sample, 
DpsR18C-N19C-D123C-A126C was purified and further characterised (see Appendix 5.4 for 
SDS-PAGE and Figure 5.5 for SEC). Unfortunately, during the purification process it became 





analysis suggested DpsR18C-N19C-D123C-A126C had formed a much larger, possibly 
aggregated state. The aggregation of the protein, taken together with data from Chapter 4, 
begins to describe a narrative where possibly FlAsH-EDT2 itself, the reducing conditions used, 
or the engineering of protein-protein interfaces leads to protein instabilities. 
 
Figure 5.5 – (A) Assembly dependence of FlAsH fluorescence for the most successful mutant with a 
designed binding site across the Dps T-interface, DpsR18C-N19C-D123C-A126C (see Figure 5.3 for 
schematic explanation) in lysates. The data is presented as the percent change in fluorescence of the 
signal normalized to the positive and negative controls. All designs are 1 mg/ml in total protein 
concentration in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 1 µM FlAsH, 3.5 
mM TCEP, 1 mM EDT, 1 mM 2-ME and 6 M guanidine·HCl (GuHCl). Signals are average of three separate 
protein expressions each repeated twice. (B) SEC of purified protein (0.5 mg/ml), DpsR18C-N19C-D123C-
A126C. This data is the average of three repeats. 
 The philosophy of creating more precise FlAsH binding sites across a Dps protein-
protein interface seems to result in similar problems to those observed with the terminus-
focused Bfr designs described in Chapter 4. These problems could have been associated with 
redox conditions in the buffer as was suspected in Chapter 4 or with a non-ideal FlAsH binding 
site. Schepartz and co-workers determined that an ideal FlAsH binding site is a parallelogram 
with sides of 4-5 A and 6.8 A9. Analysis of the position of the four cysteines in DpsR18C-N19C-
D123C-A126C suggested that they are close to the ideal geometry, although far from 
symmetric. (Figure 5.6) (It should be noted that this analysis did not perform any energy 
minimizations to determine the lowest energy conformers.) However, this does not account 
for the disruption of nanocage assembly. A third explanation may lie within the underlying 





Chapter 4, we suggested that designing a binding site across a protein-protein interface may 
cause a disruption of a key interaction. It is possible that the mutation across the T-interface 
destroyed key protein-protein interfaces which resulted in a disruption of the nanocage. 
Therefore, we decided to pursue a terminus-focused approach. 
 
Figure 5.6 – Analysis of Dps T-interfaces (see Figure 5.3 for schematic explanation) FlAsH binding site 
geometry. (top) Optimal FlAsH binding site determined by Schepartz and coworkers, (bottom) distances 
between the cysteine sulfur atoms from each design determined from a crystal structure. The design 
(DpsR18C-N19C-D123C-A126C) that was the study of this investigation is highlighted (black dashed box). 
Crystal structure modifications made using Acceryl software10 to place cysteines into the correct 
position for geometry analysis.  
5.2.3. Design and assessment of FlAsH binding sites at Dps termini 
 While extending flexible termini to contain bipartite cysteine pairs (as seen in Chapter 
4) provides a less precise design than engineering binding sites across a protein-protein 
interface, it could bypass any problems associated with protein-protein interaction disruption. 
The N-terminus of Dps is long (21 amino acids) and unstructured to the extent that the crystal 





C-terminus however is more ordered. Therefore one possible strategy would be to design 
binding sites at the C-terminus of Dps that exploit the divergence of monomer termini in the 
antiparallel dimer, but which converge during nanocage formation. Thus, terminally appended 
cysteines could provide a sulfur rich area for a FlAsH binding site that only forms upon 
nanocage assembly and not in a dimer intermediate.  
Designs were created by placing cysteine pairs at the Dps C-terminus (Figure 5.7). A 
series of mutants were generated to optimise the binding site. These designs differ in how the 
two cysteines are displayed by the monomer either based on linker length (DpsCC, DpsGCC, 
DpsGGCC, DpsGGGCC) or conformation (DpsPAGCC). It was thought that different 
conformational presentations might be necessary because of the lack of flexibility at the Dps C-
terminus. Extending the C-terminus to display the peptide sequence CCPGCC which includes all 
four cysteines of an ideal binding site on a single monomer, resulted in a Dps positive control 
(DpsCCPGCC) which would require neither folding nor assembly to generate a FlAsH signal. 







Figure 5.7 – Dps crystal structure (PDB: 1DPS) emphasizing a dimer subunit and divergent presentation 
of the C-termini along with schematics representing proteins used in this study. The negative control 
(Dps) has no appended C-terminal cysteines whereas the monomer of the positive control (DpsCCPGCC) 
displays a full binding site. The other proteins present a pair of cysteines with a variety of flexible and 
constrained linkers. Cysteine (red), glycine (light grey), alanine (dark grey), proline (black). 
An oligomerization state assay with the most utility would be able to evaluate multiple 
samples rapidly. Therefore, instead of initially working with purified proteins, cellular lysates 
were used (as in Chapter 4 and above). In addition, the use of complex solutions allowed for 
the optimisation of this assay for selectivity. However, these samples were initially screened 
with a plate reader instead of a steady state fluorimeter as was used in Chapter 4. This plate 
reader exhibited far higher sensitivity than the steady state fluorimeter which permitted a 
decrease in both the fluorophore and protein concentrations (FlAsH-EDT2 - 0.1 µM, protein - 
0.1 mg/ml). Under these conditions, (Figure 5.8) the positive control, DpsCCPGCC, generated 
robust fluorescence with added FlAsH, and the negative control (Dps) gave nearly 
undetectable signal. Of the bipartite designs, DpsCC and DpsGCC had a very weak response 





35% of the positive control suggesting that a longer linker is ideal and one that is more rigid 
may be optimal. 
 
Figure 5.8 - FlAsH fluorescence of designs with bipartite FlAsH binding sites at the Dps C-terminus (see 
Figure 5.7 for schematic explanation) in lysates. The data is normalised to the positive and negative 
controls. All designs are 0.1 mg/ml total protein concentration, in FlAsH buffer (100 mM Tris.HCl, 100 
mM NaCl, 1 mM EDTA, pH 7.8) with 0.1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. The 
fluorescence is the average of three protein expressions each repeated twice. Error bars are S.D. * Two-
tailed P-values = 0.4804. ** Two-tailed P-values = 0.020050. *** Two-tailed P-values = 0.0001. 
To confirm that FlAsH-EDT2 binding was indeed dependent on nanocage formation, the 
samples were reanalysed in denaturation conditions (Figure 5.9). This experiment was 
normalised differently to the other denaturing experiments in Chapter 4 and above. In this case 
we used an un-denatured positive control normalised to 0% change, to show the effect of 
denaturant on the controls. As expected the negative control, Dps, exhibited no change in 
fluorescence upon denaturation. The positive control, DpsCCPGCC, was also expected to have 
no change; however, it did generate a small, but significant loss which may be attributed to 
restricted access to the tetracysteine tag similar to that seen in Chapter 4. This alteration in 
experimental methodology was due to a better understanding of working with FlAsH because 
of the extended work performed in Chapter 4. As expected, the bipartite designs displayed a 
large loss in fluorescence upon denaturation with DpsGGGCC and DpsPAGCC exhibiting nearly 






Figure 5.9 - The assembly dependence of FlAsH fluorescence for designs with bipartite FlAsH binding 
sites at the Dps C-terminus (see Figure 5.7 for schematic explanation) in lysates under denaturing 
conditions. The data is the change in the signal normalised to the positive and negative controls. All 
designs are 0.1 mg/ml in total protein concentration in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 
mM EDTA, pH 7.8) with 0.1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME and 6 M guanidine·HCl 
(GuHCl). Data is the average of three separate protein expressions each repeated twice. 
To verify these results, the leading proteins were expressed, purified and fully 
characterised (see Appendices 5.4, 5.5, 5.6, 5.7, 5.8, 5.10 and 5.5 for SDS-PAGE, mass 
spectrometry, TEM and CD and Figure 5.10 for SEC) where all proteins exhibited nanocage 
character in both TEM and SEC with the largest population being the nanocage oligomerization 
state.  
 
Figure 5.10 - Size exclusion chromatograms of purified designs with bipartite FlAsH binding sites at the 
Dps C-terminus monitored at 280 nm absorbance (protein) normalised to their highest intensity. Results 





These proteins were subjected to the binding and subsequent denaturation 
experiments (Figures 5.11 and 5.12). The controls behaved as expected with the exception of 
the positive control that, consistent with the data in lysates (Figure 5.9) lost a small amount of 
signal upon denaturation. The bipartite designs, DpsGGGCC and DpsPAGCC, displayed strong, 
oligomerization dependent, binding to FlAsH with the latter protein generating ~60% of 
control.  
 
Figure 5.11 - FlAsH fluorescence of purified designs with bipartite FlAsH binding sites at the Dps C-
terminus (see Figure 5.7 for schematic explanation). The data is normalised to the positive and negative 
controls. All designs are 0.1 mg/ml protein, in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, 
pH 7.8) with 0.1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME, averaged from 8 replicates. Error bars 
are S.D. *** Two-tailed P-values = 0.0001. 
 
 
Figure 5.12 – The assembly dependence of FlAsH fluorescence for purified designs with bipartite FlAsH 
binding sites at the Dps C-terminus (see Figure 5.7 for schematic explanation) in denaturing conditions. 
The data is the change in the signal normalised to positive and negative controls. All proteins are 0.1 
mg/ml protein concentration, in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 
0.1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME and 6 M guanidine·HCl (GuHCl). Data is the average 





The steady state fluorescence experiments, coupled with denaturation, suggest that 
split cysteine bipartite technology with the Dps C-terminus-focused designs was successful. The 
strong signals seen in lysate and purified samples that greatly decrease when denatured, as 
well as the presence of nanocage structures in both SEC and TEM, provide initial indication that 
these designs could be good candidates for a broader system to follow protein nanocage 
assembly. However, our experience has shown us that they need to be more rigorously 
characterised. 
5.2.4. Identification of fluorescent oligomerization state for designs with bipartite FlAsH binding 
sites at the Dps C-terminus via SEC-FPR 
 
The oligomerization of the designs with bipartite FlAsH binding sites at the Dps C-
terminus is much more defined in favour of the nanocage state than our other design 
strategies (above and Chapter 4). Very little dimer and undefined aggregate was evident. 
However, it is essential to determine which species is responsible for fluorescence. Therefore 
SEC-FPR which combines the SEC absorbance detector with a fluorescence plate reader, was 
employed (Figure 5.13). If the binding sites were successfully designed to appear only during 
the formation of the nanocage, then the fluorescent peaks should correspond to only that 
state. The negative control, wild type Dps, generated a single peak from the nanocage and 
nearly undetectable dimer when monitored at 280 nm (Figure 5.13b) as expected. Also as 
expected, no nonspecific interactions were observed in the FlAsH channel. The positive 
control, DpsCCPGCC, generated only a nanocage and a small dimer peak, both of which were 
positive in the fluorescence channel, again as expected (Figure 5.13a). The proteins with the 
bipartite, C-terminal fusions, DpsPAGCC and DpsGGGCC, both showed a nanocage and a small 
dimer peak in the 280 nm channel, however, fluorescence only elutes with the nanocage, 
suggesting that FlAsH is specific for the nanocage (Figures 5.13c and d). It should be noted that 
DpsPAGCC did aggregate slightly in these conditions, but the fact that the aggregate peak also 





of Bfr. As a further analysis of specificity, the same technique was used to assess clarified 
lysates for DpsPAGCC and DpsGGGCC (Figures 5.13e and f). Again, fluorescence elutes at a 
volume consistent with the nanocage state. Taken together these data strongly suggest that 
not only are the designed binding sites forming upon oligomerization, they form specifically 
only upon nanocage formation. 
 
Figure 5.13 - Identification of fluorescent oligomerization state for designs with bipartite FlAsH binding 
sites at the Dps C-terminus via SEC-FPR (see Figure 5.7 for schematic explanation). Size exclusion 
chromatograms were monitored at absorbance 280 nm (protein). Fluorescence samples were taken 
every 200 µl and analysed using a 510 ± 5 nm excitation and a 530 ± 5 nm emission filter set. Each run 
injected 0.5 ml of 0.5 mg/ml purified protein or total protein (lysate samples) in FlAsH buffer (100 mM 
Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 0.4 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. 
The data is the average of three runs per protein. Data is normalised using the highest fluorescence 
signal from the positive control as 100% for all samples and the lowest of each as 0%. Error bars are S.D.  
5.2.5. Medium throughput screen of nanocage stability conditions using DpsPAGCC  
With the design of a bipartite FlAsH binding site at the Dps C-terminus proven to be 
robust, we set out to fulfill one of our more advanced goals to utilise DpsPAGCC in an assay 
with higher throughput. As a proof of principle, we expanded the assay to a 96-well plate 





Both pH and denaturant were screened simultaneously (Figures 5.14 and 5.15). As expected, 
there was little significant change in fluorescent signals from the controls DpsCCPGCC for any 
condition although it should be noted that these provide an indication of the pH dependence 
of FlAsH binding in these buffer conditions. For DpsPAGCC, a wide range of signals was 
observed across the window of conditions. Most interestingly, the protein seemed most stable 
below pH 7.0. This is somewhat surprising considering that most published accounts of 
research on this protein describe experiments performed at pH 7.85, 11. Thus it was affirming 
that even this simple proof of principle experiment could make a contribution to the field. 
More broadly, it emphasizes the utility of a rapid, direct, and less reagent intensive assay for 
protein nanocage formation. It not only underlines the strength of our approach, but this 
increased throughput can lead to useful experiments (with potentially unexpected results) that 







Figure 5.14 – Medium throughput screening of buffer conditions for protein nanocage stability in a 96-
well format. Normalised fluorescence data for pH vs GuHCl for designs with bipartite FlAsH binding sites 
at the Dps C-terminus (see Figure 5.7 for schematic explanation). This data is presented more clearly in 
Figure 5.15. Data normalised to the controls with the average response from DpsCCPGCC being 100% 
and the average response of Dps being 0%. All designs were 0.1 mg/ml total protein concentration in 
FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 0.1 µM FlAsH, 3.5 mM TCEP, 1 






Figure 5.15 - Medium throughput screening of buffer conditions for protein nanocage stability in 96-well 
format. Normalised fluorescence intensity for DpsPAGCC as a function of both pH and Gu.HCl. This data 
is a visualization of the data presented in Figure 5.14. Fluorescence intensity is grey-scaled so that black 
is most intense and white is least. The protein is 0.1 mg/ml in 0.1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 
mM 2-ME. The data is the average of 3 replicates.  
 To explore the scope of this technology, we were curious to determine whether it is 
possible to disassemble the Dps nanocage without denaturing it. Along with useful knowledge 
that may aid future research with these proteins, it may also point towards the mechanism of 
assembly. Moreover, it could lend insight into how to disassemble and reassemble these 
proteins with the intention of loading them with “cargo” for eventual delivery applications as 
discussed in Chapter 2. Therefore, a similar 96-well plate denaturation experiment was 
performed with DpsPAGCC at pH 7.8 as described above (Figure 5.16) and this data was 
overlaid with a CD denaturation experiment (Figure 5.17). Circular dichroism monitors 
secondary structure whereas our technique is specific for the nanocage quaternary structure. 
The quaternary structure assay (Figure 5.17) performed as expected with the controls having 







Figure 5.16 – Monitoring disassembly of DpsPAGCC in the 96-well format. Fluorescence intensity is grey-
scaled so that black is most intense and white is least. Data normalised to controls. This data was used 
to create the plot in Figure 5.17. All proteins are 0.1 mg/ml in FlAsH buffer (100 mM Tris.HCl, 100 mM 
NaCl, 1 mM EDTA, pH 7.8) with 0.1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. Data is averaged 
from 3 replicates. Error bars are S.D.  
 The secondary structure of DpsPAGCC was monitored with respect to guanidine by its 
ability to differentially absorb 222 nm (a major absorbance for the alpha helix secondary 
structure) plane polarized light (Figure 5.17 and Appendix 5.9 for CD scans). The protein loses 
the majority of its secondary structure after the addition of 2.2 M guanidine·HCl. The 
difference between the concentration required to disassemble the protein and to totally 
denature it could present a window where the disassembled-but-folded nanocage is stable. 







Figure 5.17 – Determination of stability window for disassembled-but-folded protein nanocage. Overlay 
of DpsPAGCC FlAsH fluorescence (510 ± 5 nm excitation and a 530 ± 5 nm emission filter set, red line) 
and loss of protein secondary structure, as monitored by CD (222 nm black line), with respect to 
guanidine·HCl concentration. Fluorescence data is plotted from data presented in Figure 5.16 from 3 
repeats, error bars not shown. Fluorescence experiment is 0.1 mg/ml total protein concentration, in 
FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 0.1 µM FlAsH, 3.5 mM TCEP, 1 
mM EDT, 1 mM 2-ME, averaged from 3 replicates. Circular dichorism is 0.1 mg/ml protein concentration 
in FlAsH buffer with taken from a single scan of each condition. Fluorescence fitting made using 
Kaleidagraph (Synergy) calculated to 1.39 M Gu·HCl and CD fitting made also using Kaleidagraph 
(Synergy) calculated to 2.15 M Gu·HCl. 
5.2.6. Medium throughput screen of nanocage stability in nanoparticle genesis conditions  
 Our technique, in addition to helping to explore protein biochemistry and biophysics, 
could aid in the manipulation and engineering of proteins for novel applications. An issue that 
arose when trying to expand hybrid nanoparticle synthesis technology to bacterial ferritins 
(see Chapter 2) was protein stability and the extended time it took to determine whether the 
proteins had survived the multi-step process. The slow characterisation time lead to a 
reduction in the number of experiments that could be attempted. Therefore we set out to 
determine whether it is possible to apply the medium throughput assay for nanocage stability 
to the screening of conditions that would be typical for the production of gold nanoparticles12 





Different concentrations of reagents for the generation of gold nanoparticles inside 
ferritins (HAuCl4, NaBH4, NaCNBH3, trisodium citrate, ascorbic acid) were screened individually 
in buffer or water for their ability to disrupt DpsPAGCC assembly (Figure 5.18). Sodium 
cyanoborohydride and trisodium citrate showed stable protein nanocages across the range of 
concentrations in buffer. Interestingly, in water, citrate while having very little concentration 
dependence showed increased stability over protein alone. Furthermore, cyanoborohydride 
caused a steady decline in assembly with respect to concentration. These results might be an 
extension of the pH trend seen in the experiment presented in Figure 5.15 where more acidic 
conditions were more stable than basic ones although it should be noted that ascorbic acid 
induced strong destabilisation in unbuffered conditions. The protein assembled state is quite 
sensitive to chloroauric acid solution, but buffered conditions can extend the stability into a 
rather flexible window, which confirms the trend seen in Chapter 2. Curiously, sodium 
borohydride, which appears to be more stabilizing at low concentrations in water over that of 
buffered conditions however, at higher concentrations, the stability falls off rapidly in both 
water and buffer. The comparison between sodium borohydride and sodium 
cyanoborohydride is striking and suggests that it was a good choice to switch to sodium 
cyanoborohydride in Chapter 2.  
This example further demonstrates the practical utility of our method. It permits the 
rapid analysis of reagents and their usable concentration ranges. While only limited reagents 
were used in this study, it could easily be extended to examine other reagents or reagent 
combinations in a rapid and parallel manner. The straightforward “enabling” aspect of this 
technique is underlined when reflecting, perhaps painfully; at least to the author of this thesis, 





Figure 5.18 – Medium throughput screen of DpsPAGCC stability to nanoparticle genesis reagents (top 
left) chloroauric acid (top right) sodium cyanoborohydride (middle left) sodium borohydride (middle 
right) trisodium citrate (bottom left) ascorbic acid. (Bottom right) 96 well plate format with greyscale 
corresponding to fluorescence intensity. The data is normalised to DpsPAGCC in buffer with no added 
reagents. Each reagent was analysed both as a solution in water (light grey) and in Flash buffer (dark 
grey). Proteins were 0.1 mg/ml in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) 
with 0.1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. All data is averaged from 3 replicates. Error 






In summary, the goal of developing a method for the direct detection of protein 
nanocage assembly was refocused onto the mini-ferritin Dps, and in this case, the goal was 
achieved. With lessons learned from Chapter 4, design rules were applied including a 
requirement for any binding site to be on the exterior of the nanocage, and two specific 
philosophies were pursued. One philosophy involved designs spanning key protein-protein 
interfaces. Mutations straddling the T-interface were positioned on the D-helix and the N-
terminal loop of Dps. Although these designs fulfilled the design rules and geometric 
requirements for FlAsH binding, and some exhibited denaturation-dependent fluorescence 
signals in lysates, no folded protein was observed.  
A second philosophy was pursued similar to that used in Chapter 4 where cysteine 
pairs were fused to the C-terminus of Dps monomers. Multiple designs were explored that 
differed in the linker length and conformational presentation of the cysteine pair. The longest 
and most rigid of these designs showed initial fluorescent signals in lysates that diminished 
upon denaturation. Moreover, this trend was repeated in purified proteins, and nanocage 
architectures were observed in both SEC and TEM. Furthermore, SEC-FPR demonstrated that 
the fluorescence signal co-eluted only with the nanocage confirming the ability for this assay 
to selectivity detect nanocage formation over other oligomerization states. With this design, 
the assay was expanded to a medium throughput screen, to discover the ideal conditions for 
Dps nanocage stability as well as to investigate destabilising conditions when attempting to 
form encapsulated nanoparticles.  
While this chapter describes a large step forward the goal of developing a rapid and 
direct strategy to assess protein nanocage formation in complex solutions, a question is raised 
as to why this strategy was successful for the Dps model system but not for Bfr, especially 





origins of this should be thoroughly scrutinized if this technology is to be expanded to other 
nanocages. While the thermal and chemical denaturation stabilities for these proteins do not 
differ greatly, behavioural differences could arise from differences in structural energetics3, 13. 
Bfr was initially chosen as a model system due to the fact that it forms mixtures of nanocage 
and dimer in solution; the thought being that having two states, and mutants that provide 
different ratios of these states, would be an advantage towards assessing oligomerization state 
selectivity and thus higher stringency in assay development. Because this was later seen as an 
unnecessary complication, Dps was chosen for the second attempt due to the fact that the 
dimer is much less prevalent. Although the FlAsH methodology has been successful for Dps, 
and could also be used for other nanocages, the issues experienced with Bfr could limit its 
applications to other proteins. However, the characterisation methods in Chapters 4 and 5 
provide rigorously controlled approaches for the detection of successful designs over non-
successful ones. Thus, our success, while perhaps limited in scope is still a step forward for 
both split tetracysteine technology, showing that is can work in large complex multimeric 
proteins, as well as protein-protein interaction research, presenting a new method that could 
be used to aid future investigations in this area. 
 While the success of this method could help in speeding and providing direct 
information into assembly in vitro, this method is still limited to a medium throughput. To use 
it to greatly aid nanocage and quaternary structure research, further expansion of the 






5.4.1. Cloning of Dps designs 
5.4.1.1. Cloning of all Dps designs for screening in protein lysates (Dps, DpsCC, DpsGCC, 
DpsGGCC, DpsGGGCC, DpsPAGCC, DpsCCPGCC, DpsR18C-N19C-A126C-N130C, DpsN19C-
D20C-A126C-N130C, DpsR18C-N19C-D123C-A126C, DpsR18C-D20C-D123C-A126C, DpsN19C-
D20C-D123C-A126C, DpsR18C-D20C-A126C-N130C) 
 
  The WT Dps gene4 was amplified with primers providing restriction sites. The PCR 
reaction (50 µl total volume) was a solution of reaction buffer (Fermentas, 5 µl of 10xPfu 
buffer), dNTP mix (Fermentas, 2 µl of a solution containing dATP, dTTP, dGTP, and dCTP 2 mM 
each), forward and reverse primers (400 ng each, Suprenom, Singapore, see Appendix 5.1 for 
primers), template (100 ng) and Pfu polymerase (Fermentas, 2 µl of 2.5 U/ µl) which was 
subjected to an initial melting step at 95 °C for 30 s, followed by 30 cycles of amplification (95 
°C for 30 s, 55 °C for 45 s and 72 °C for 1 min) followed by 72 °C for 7 min. The resulting PCR 
product was isolated by gel purification (Promega). The PCR product (300 ng) was digested 
(Tango buffer, Fermentas, 10 µl of 2x buffer), Nde1 (Fermentas, 1.5 µl of 20 U/ µl), Xho1 
(Fermentas, 1.5 µl of 20 U/ µl), 50 µl total volume, 37 °C, 3 hours). The plasmid pET-22b 
(Novagen) was treated in the same way, followed by ligation of the insert with T4 ligase buffer 
(Fermentas, 2 µl, 10x buffer), digested insert (30 ng), digested plasmid (80 ng), T4 ligase 
(Fermentas, 0.2 µL of 20 U/µl), 20 µl total volume (37 °C, 2 hours). The constructs (2 µl) were 
transformed (Novablue, Novagen) and the resulting colonies were assessed by colony PCR, a 
solution of Gotaq buffer (Promega, 5 µl of 5x), dNTP mix (Promega, 2 µl of a solution 
containing dATP, dTTP, dGTP, and dCTP at 2 mM each), T7 promoter and terminator primers 
(150 ng each, Eurofins MWG), Gotaq DNA polymerase (Fermentas, 0.25 µl of 5 U/ µl), colony 
suspension (10 µl of a 50 µl total colony suspension in deionised water) and deionised water (5 
μl), was subjected to an initial melting step (95 °C for 10 min) followed by 30 cycles of 





Clones demonstrating a PCR product of the predicted size were subjected to miniprep 
(Invitrogen) and the resulting purified plasmids were sequenced (see Sequence Appendix 5 for 
sequences and Appendix 5.1 for primers used).  
 Using the newly constructed Dps in pET-22b as a template, site directed mutagenesis 
was performed to create all other designs (Quikchange, Stratagene). The reaction mixture 
containing Pfu buffer (Promega, 2 µl of 10x), dNTP mix (Promega, 2 µl of a solution containing 
dATP, dTTP, dGTP, and dCTP at 2 mM each), forward and reverse primers (125 ng each, 
Suprenom, Singapore, see Appendix 5.1 for primers used), the dsDNA template (Dps pET-22b, 
100 ng) and Pfu polymerase (Promega, 1 µl of 3 U/ µl) in a total volume of 25 µl was subjected 
to melting (95 °C for 5 min), followed by 20 cycles of amplification (95 °C for 1 min, 55 °C for 1 
min and 68 °C for 6 min) followed by 70 °C for 10 min. The reaction was then digested with 
Dpn1 (NEB buffer 4 (1 µl of 10x), amplification product (5 µl), deionized water (3.5 µl), Dpn1 
(NEB, 0.7 µl of 10 U/ µl), 37 °C, 2h). The resulting solution was transformed (XL-1 blue, 
Novagen) and the subsequent colonies subjected to miniprep (Promega, Wizard plus SV) and 
sequenced (see Sequence Appendix 5 for sequences and Appendix 5.1 for primers used).  
5.4.1.2. Cloning of all designs for screening as purified proteins (Dps, DpsCCPGCC, DpsGGGCC 
and DpsPAGCC) 
 
  In order to express the proteins for isolation and purification, the genes were placed 
into a vector that provided affinity tags. The constructs were amplified from the mutated pET-
22b plasmid with primers providing ligation independent cloning (LIC) sites. The PCR solution 
Pfu reaction buffer (Promega, 5 µl of 10x), dNTP mix (Fermentas, 2 µl of a solution containing 
dATP, dTTP, dGTP, and dCTP at 2 mM each), forward and reverse primers (400 ng each, 
Integrated DNA technologies, see Appendix 5.1 for primers used), the template (100 ng) and 
Pfu polymerase (Promega, 2 µl of 2.5 U/ µl) in 50 μl total volume was subjected to an initial 





s and 72 °C for 1 min) followed by 72 °C for 7 min. The resulting PCR product was isolated by 
gel purification (Qiagen). The PCR product was then treated with T4 polymerase in order to 
create the required complementary overhangs (NEB buffer 2, 2 µl of 10x buffer), dATP (NEB, 2 
µl of 25 mM), DTT (Sigma, 1 µl of 100 mM), BSA (NEB, 0.2 µl of 100x), PCR product (0.3 pmol) 
and T4 DNA polymerase (NEB, 0.6 µl of 10 U/µl) in a total volume of 20 µl, 30 min, 22 °C). The 
vector, pET-32b (Novagen) was treated in the same way. The insert was annealed to open 
plasmid (1 µl of the T4 Pol product, 0.5 µl of plasmid solution (50 ng/µl) by incubating (room 
temperature, 30 min) followed by a second incubation (room temperature, 30 min) with an 
addition of EDTA (1 µl of 100 mM). The constructs (2.5 µl) were transformed (XL-1 Blue, 
Novagen) and the resulting colonies were assessed by colony PCR. A solution of Gotaq reaction 
buffer (5 µl of 5x), dNTP mix (Promega, 2 µl of a solution containing dATP, dTTP, dGTP, and 
dCTP at 2 mM each), T7 promoter and terminator primers (150 ng each, Eurofins MWG), 
Gotaq DNA polymerase (Promega, 0.25 µl of 5 U/ µl), colony suspension (10 µl of a 50 µl total 
colony suspension in deionised water) and deionised water (5 μl), was subjected to an initial 
melting step (95 °C for 10 min) followed by amplification 30 cycles (95 °C for 30 s, 59 °C for 30 s 
and 72 °C for 30 s followed by 72 °C for 7 min). Clones demonstrating a PCR product of the 
predicted size were subjected to miniprep (Promega) and the resulting purified plasmid was 
sequenced (see Sequence Appendix 5 for sequences and Appendix 5.1 for primers used).  
5.4.2. FlAsH Binding in Lysates.  
T-interface Dps designs were analysed for their ability to bind to FlAsH in lysates as 
described in 4.4.2. 
The pET-22b expression vectors containing Dps designs with varying C-terminal linkers, 
were transformed into Rosetta E.coli cells (Novagen) and plated on LB agar plates (50 μl/ml of 
carbenicillin and 34 μl/ml chloramphenicol). Selected colonies then were grown in LB (1 ml 
with 50 μl/ml of carbenicillin, 37 °C, overnight) as a pre-culture which was then added to LB 





addition of IPTG (50 µl of a 1 M stock) and the culture was further incubated (3 h, 30 °C). The 
cells were isolated by centrifugation (4,000 rpm, 15 min at 4 °C). The cell pellet was 
resuspended in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) and 
sonicated (Misonix, Ultrasonic cell disruptor, pulsed 5 s on 5 s off for 5 min). The protein 
solution was clarified by centrifugation (15,000 rpm, 45 min, 4 °C) and then filtered (Sartorius, 
0.2 μm).  
The protein concentration was determined (BCA, Novagen) and the cell lysate was 
diluted to 1 mg/ml with FlAsH buffer. To insure that all the 1 mg/ml samples had similar 
amounts of the desired protein, each was analysed by SDS PAGE (see appendix 5.3). Each 
fluorescence experiment contained protein lysate (200 μl, 0.1 mg/ml) in FlAsH buffer, TCEP 
(Sigma, final concentration of 3.5 mM), EDT (Sigma, final concentration of 1 mM) and 2-ME 
(Sigma, final concentration of 1 mM) were added and the solution was incubated (room 
temperature, 2 h) followed by the addition of FlAsH-EDT2 (Invitrogen, final concentration of 0.1 
μM) followed by a further incubation (room temperature, 2 h) in the dark. Each lysate sample 
was analysed in a black Corning 96 well plate in a PerkinElmer Envision 2101 multilabel plate 
reader, with each design being expressed three times and each expression being examined in 6 
different wells and re-read twice (Ex filter 485 nm bandwidth 14 nm, Em filter 535 nm 
bandwidth 25 nm). For the denatured experiments, the above was repeated but with the 
addition of 6 M guanidine·HCl and incubated for 2 hours prior to the addition of TCEP, EDT and 
2-ME, with protein concentration remaining the same as in previous un-denatured 
experiments. 
5.4.3. FlAsH Binding with Purified Proteins.  
The pET-32b vectors containing the Dps variants were transformed into Rosetta E.coli 
cells (Novagen) and plated on LB agar plates (50 μl/ml of carbenicillin and 34 μl/ml of 
chloramphenicol). Selected colonies were then grown in LB (5 ml, 37 °C, overnight) as a pre-





expression was then induced by the addition of IPTG (250 µl of a 1 M stock) and the cultures 
were further incubated (3 h, 30 °C). The cells were isolated by centrifugation (4,000 rpm, 20 
min, 4 °C). The cell pellet was resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 40 
mM Imidazole, 1 mM EDTA, pH 8). Cellytic (10x, Sigma) was added and the solution was 
incubated (20 min, on ice) and then sonicated (Misonix, ultrasonic cell distruptor, pulsed 5 s on, 
5 s off for 5 min). The protein solution was clarified by centrifugation (15,000 rpm, 45 min at 4 
°C) and then filtered (Sartorius, 0.2 μm). The protein was purified via affinity purification (GE, 
Histrap FF, 5 ml, (wash buffer-40 mM Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4), 
(elution buffer-500 mM Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4)). Enteriokinase 
digestion (NEB 2 μg/ml) was performed to cleave off the peptide tag from the protein of 
interest followed by a second Histrap (GE, Histrap HP, 5 ml, (wash buffer-50 mM NaH2PO4, 300 
mM NaCl, pH 7.4), (elution buffer-500 mM Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4)) 
to remove the tag from solution. The protein solution was further purified by size exclusion 
chromatography (GE Hiload 16/60 Superdex, running buffer- FlAsH buffer (100 mM Tris.HCl, 
100 mM NaCl, 1 mM EDTA, pH 7.8).  
Each purified protein was analysed by incubating the protein (200 μl of 0.1 mg/ml) in 
FlAsH buffer with TCEP (Sigma, final concentration of 3.5 mM), EDT (Sigma, final concentration 
of 1 mM) and 2-ME (Sigma, final concentration of 1 mM) and left to incubate (2 h, room 
temperature) followed by the addition of FlAsH-EDT2 (Invitrogen, final concentration of 0.1 μM, 
2 h, room temperature in the dark). Each sample was prepared directly into a black Corning 96 
well plate which was examined in a PerkinElmer Envision 2101 multilabel plate reader (Ex filter 
485 nm bandwidth 14 nm, Em filter 535 nm bandwidth 25 nm). Each pure protein was 
examined six times and reread three times. For the denaturant experiment, each protein was 
analysed as described above but with the addition of 6 M guanidine·HCl, while keeping the 
protein concentration the same and was incubated for 2 hours prior to the addition of TCEP, 2-





5.4.4. Medium throughput pH Vs GuHCl analysis 
Each purified protein was analysed by incubating the protein (200 μl of 0.1 mg/ml) in a 
buffer at the relevant pH (pH 6-7, 100 mM Citrate-phosphate. pH 7.5-8.5 100 mM Tris.HCl) and 
with the correct concentration of GuHCl, with TCEP (Sigma, final concentration of 3.5 mM), EDT 
(Sigma, final concentration of 1 mM) and 2-ME (Sigma, final concentration of 1 mM) and 
incubated (2 h, room temperature) followed by the addition of FlAsH-EDT2 (Invitrogen, final 
concentration of 0.1 μM, 2 h, room temperature). Each sample was prepared directly in a black 
Corning 96 well plate which was scanned in a PerkinElmer Envision 2101 multilabel plate 
reader (Ex filter 485 nm bandwidth 14 nm, Em filter 535 nm bandwidth 25 nm). Each protein 
was prepared three times separately and each plate was reread three times. 
5.4.5. Medium throughput analysis of nanoparticle genesis reagents 
DpsPAGCC was expressed and purified as described above and analysed by incubating 
the protein (200 μl of 0.1 mg/ml) in the presence of the reagent of choice. Each reagent 
(Chloroauric acid, Sodium borohydride, sodium Cyanoborohydride, Trisodium citrate and 
Ascorbic acid) was solubilised in both water, with no change to the pH, and flash buffer which 
was changed to pH 7.8. Varying final concentrations of each reagent was added to each well 
(0.01 M, 0.05 M, 0.1 M, 0.2 M, 0.5 M and 1 M) and left to incubate for an hour. To this, TCEP 
(Sigma, final concentration of 3.5 mM), EDT (Sigma, final concentration of 1 mM) and 2-ME 
(Sigma, final concentration of 1 mM) was added and incubated (2 h, room temperature) 
followed by the addition of FlAsH-EDT2 (Invitrogen, final concentration of 0.1 μM, 2 h, room 
temperature). Each sample was prepared directly in a black Corning 96 well plate which was 
scanned in a PerkinElmer Envision 2101 multilabel plate reader (Ex filter 485 nm bandwidth 14 
nm, Em filter 535 nm bandwidth 25 nm). Each protein was prepared three times separately 





5.4.6. Protein characterisation 
5.4.6.1. Analytical Size Exclusion Chromatography (SEC) and combined with fluorescence 
detection 
  The samples (0.5 ml of 1 mg/ml) in FlAsH buffer (100 mM Tris-HCl, 100 mM NaCl, 1 
mM EDTA, pH 7.8) were injected onto the column (GE Superdex 200 10/300 GL) at 0.5 ml/min 
with each protein repeated 3 times. The column was calibrated using six proteins as standards 
(GE Biosystems Calibration Kit).  
For fluorescent monitoring, samples were prepared by adding to pure protein (0.5 ml 
of 1 mg/ml) in FlAsH buffer, TCEP (Sigma, final concentration of 3.5 mM), EDT (Sigma, final 
concentration of 1 mM) and 2-ME (Sigma, final concentration of 1 mM) and incubated (2 h, 
room temperature). FlAsH-EDT2 fluorophore was added and incubated in the dark (Invitrogen, 
final concentration of 0.4 μM, 2 h, room temperature). This sample was desalted (GE, HiTrap 5 
ml desalting column, running buffer - FlAsH buffer (100 mM Tris, 100 mM NaCl, 1 mM EDTA, pH 
7.8)) before injection onto a SEC column (GE Superdex 200 10/300 GL, running buffer - FlAsH 
buffer (100 mM Tris, 100 mM NaCl, 1 mM EDTA, pH 7.8)). Elution volumes of 200 μl were 
collected during the run and placed into a black Corning 96 well plate. This plate was examined 
in a PerkinElmer Envision 2101 multilabel plate reader (Ex filter 485 nm bandwidth 14 nm, Em 
filter 535 nm bandwidth 25 nm). Each purified protein was examined three times with each 
plate reread three times.  
5.4.6.2. Transmission Electron Microscopy (TEM) 
TEM was performed on a FEI, Tecnai G2 20, electron microscope set at 200 KeV. 
Proteins set to a concentration of 0.01 mg/ml in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 
1 mM EDTA, pH 7.8) were immobilized on Formvar/carbon coated 3.05 mm copper grids (TAAB) 
and negatively stained with 1% Uranyl acetate. 12 Micrographs were analysed using ImageJ14 





5.4.6.3. Circular Dichroism Spectroscopy (CD) 
 The purified proteins were inspected in FlAsH buffer (100 mM Tris, 100 mM NaCl, 1 
mM EDTA, pH 7.8). This experiment was performed on an Applied Photophysics LTD Chirascan 
spectrometer in a range of 200 nm to 260 nm with a protein concentration of 0.2 mg/ml with a 
path length of 0.5 mm. Thermal melts were performed on all purified proteins (0.2 mg/ml in 
FlAsH buffer) in a range of 4 to 85 °C 15, 16 (see Appendix 5.5, 5.6 and 5.7). 
5.4.6.4. Electrospray Mass Spectrometry 
 Purified proteins were desalted into H2O (GE, Hitrap 5ml desalting column) and set to 
a total protein concentration of 0.05 mg/ml and analysed on a Bruker MaXis mass 
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6.1. Introduction  
 The development of a Dps protein nanocage self-assembly detector, which was used to 
assay quaternary stability in conditions needed for gold nanoparticle formation in a medium 
throughput manner (Chapter 5), was a significant step forward in nanocage research. This 
technique was used to quickly allow for the detection of nanocages without the need for 
protein purification. The potential applications of such a technology could be for nanoparticle 
formation as previously mentioned but also to speed up research to engineer protein 
interfaces and map key or ‘hot spot’ residues. The major limitation of this technique is that it is 
currently limited to in vitro, limiting the number of proteins or conditions that can be examined 
at any one time. 
 This assay could be used for other techniques rather than just for characterisation after 
a mutant design has been cloned and expressed. In fact, such a technology which can detect 
one state or species over another could be adapted to screen and separate a mixture of 
mutants based on which state they belong to. By examining the alterations that could push 
proteins from one state to another, data can be gathered about the structural attributes or 
residues that are needed for protein-protein interactions, helping to resolve the reasons for 
quaternary structure formation. Not only could fundamental data be obtained unravelling how 
proteins interact, but potentially the ability to separate different states, could allow for the 
development of new and novel engineered traits, such as newly engineered interactions or 
functions. However, to successfully gather enough data or screen enough engineered 
conditions; any approach must be taken into a high throughput manner. The easiest way to 
perform this is to use cells that contain overexpressed proteins which bind to or exhibit the 
property that allows for their separation. This way, with a ‘one cell/one clone’ format, entire 
cells can be separated and their contents analysed to reveal the genetic differences that have 
allowed for their selection and separation. This can then allow for the collection of mass data 





6.1.1. Aims of this investigation 
 While a method for the direct detection of the self-assembly of the Dps nanocage was 
reported in Chapter 5, this method was limited to in vitro conditions and although this assay 
worked in cellular like lysate environments, the throughput of this approach was still limited. 
The aim of this investigation is to move that assay into in vivo, for use in bacterial cells with 
over expressed proteins. Methods such as microscopy and flow cytometry were employed to 
see the extent of fluorescence in cells, but also the efficiency of the labelling process. A further 
goal of this investigation was to see if this assay could be used in a high throughput manner to 
screen libraries of mutants to see if specific nanocage characteristics could be selected over 
others. 
6.1.2. Dps as a model system for screening libraries for protein cage stability 
It was decided that Dps would act as the proof of concept system for the expansion of 
our technique to the screening of protein libraries for nanocage stability in living cells. 
Chapters 4 and 5 described our efforts in developing the method in vitro for Bfr and Dps, 
respectively, with the latter protein exhibiting behaviour much more amenable to our 
conditions. In addition, extensive research in our laboratory on Dps provides insight and 
controls for the development of the technique in vivo. For example, we used alanine scanning 
mutagenesis to identity ‘hot spot’ residues along the interfaces of Dps which provided us with 
Dps mutants that exhibit a range of nanocage to dimer intermediate ratios in contrast to wild-
type which forms nanocages predominantly 1,2. One mutant that is used chapter, is a Dps 
double mutant (R83A and R133A) that assembles cleanly into 100% dimers. These arginine’s 
are located near the ‘Dps like’ three-fold axis of symmetry at the interface between two 
monomers and form an extended hydrogen network with three aspartic acid residues. 
Disruption of this network results in disassembly of the nanocage state (Figure 6.1). Thus, 
along with the wild-type protein as a control for 100% presentation of nanocage, this project 





described above, along with double aspartate and double tryptophan, which should inhibit 
nanocage formation by coulombic and steric repulsion respectively, were all developed in this 
regard (see sections 6.2.1.1 and 6.2.1.3.). 
 
 
Figure 6.1 – Protein crystal structure for Dps (PDB:1DPS) showing the location of the mutants R83 and 
R133 (red) at a monomer-monomer protein-protein interface near the Dps-like three-fold axis of 
symmetry. Double mutation of these residues to alanine results in Dps that cleanly forms dimer. 
Proteins with double mutations at these positions will be the basis of library screens described in this 
chapter. Figure made using Chimera software3. 
6.1.3. FlAsH technology with living cells 
 Expansion of our method in vivo would likely require re-optimisation of conditions 
from those discussed in Chapters 4 and 54 therefore the details of the procedure were 
reassessed. Since its early development, FlAsH-EDT2 has been used for monitoring proteins 
inside cells, and multiple conditions have been employed5, 6, 7. As discussed in Chapter 1, most 
cellular work performed with FlAsH-EDT2 was performed in mammalian cells. This can provide 
us with useful information into the requirements and limitations of FlAsH, however, it is 
intended that E. coli is used throughout this investigation. Only a small body of work has 
involved the use of FlAsH technology in bacterial cells. Most notably, Van Nhieu and co-





of FlAsH on the viability of the cell8. This, along with other work9, 10, 11 described in Chapter 1, 
provides a foundation from which to expand the Dps nanocage detection assay into living 
bacterial cells. 
6.1.4. Generation of protein nanocage libraries  
 The design, generation and characterisation of individual mutants is slow and labour-
intensive, thus limiting the number of designs that can be explored. The development of in 
vivo conditions, which is an aim of the research described in this chapter permits direct 
detection of the oligomerization state of the protein inside of the cell bypassing the necessity 
of purification. The second aim of this research is to develop a high throughput screen of 
protein libraries to discover proteins with enhanced nanocage forming ability. Fluorescently 
activated cell sorting (FACS) allows for the fluorescent analysis of individual cells followed by 
their collection. In principle, this would provide us with a method to screen libraries. We could 
express single protein clones of a library in single bacteria, label these clones with FlAsH, and 
then use FACS to identify and isolate individual living bacteria that are most fluorescent and 
presumably are expressing the most nanocage-prone library member. Because we would be 
screening living cells, we would also be able to amplify after screening and run the evolved 
library back through additional rounds of screening. We could also imagine performing 
mutagenesis between screening rounds to enhance diversity. Because each clone is expressed 
inside a bacterium which encodes its sequence, a simple “identification tag” is intrinsically 
provided, and simple DNA sequencing could be used to “deconvolute” hits. It could be 
imagined that high-content sequencing strategies could be used to follow the evolution of the 
library over multiple rounds in the future.  
 The “one clone/one bacterium” (OCOB) FACS screening technique is flexible enough to 
be coupled to various methods for diversity generation. As described in Chapter 1, several 





along the length of a gene12, the entire plasmid13, or at selective sites14. These methods can be 
used to create diverse libraries of designs often in one pot molecular biology reactions. One 
method, transfer polymerase chain reaction15 (TPCR, see Chapter 1), is harnessed in this 
chapter to generate a library of Dps mutants. The TPCR technique allows us to diversify specific 
residues in key protein-protein interactions semi-rationally. This method was chosen because 
it introduces mutations selectively to positions separated along the primary sequence, and 
cloning success can be easily followed by agarose gel. 
 The strategy pursued in this chapter will be to first expand our protein nanocage 
stability fluorescence assay into living bacteria by further optimising conditions using well-
characterised control proteins. When it is characterised, semi-rationally designed Dps mutant 
libraries will be generated and screened to identify proteins that assemble into more stable 
nanocages. It is thought that these resultant mutants could form a foundation of bypassing 
problems experienced in Chapter 2 along with a multitude of other applications, possibly some 





6.2. Results and discussions 
6.2.1. Expansion of Dps oligomerization assay to in vivo conditions 
6.2.1.1 Generation of single constructs in pET-46 Ek/LIC to provide nanocage forming 
proteins both in vivo and that can also be easily purified  
 
 Throughout Chapters 4 and 5, two different plasmids were used. One plasmid, pET-
22b, was employed for expression of the target proteins without any fusions to enhance 
purification or stability and the second, pET-32b, provided expressed proteins fused to three 
tags at the N-terminus (Trx-tag, S-tag and His6). While the tags of pET-32b are necessary to 
purify the proteins, these large fusions can interfere with nanocage assembly. Thus, this 
plasmid also provides an Enteriokinase protease (Ek) site to remove the tags after purification. 
While this does not hinder any in vitro assays that take place post digestion, it hinders 
experiments in lysate conditions or in vivo with this plasmid and necessitated pET-22b for the 
lysate experiments. This strategy, while effective, was inefficient. It was thought that a method 
allowing us to directly express, isolate, and characterise in vitro a “hit” clone after performing 
the FlAsH/FACS/OCOB screening without requiring re-cloning would be more ideal.  
To do this, we opted to express the proteins from a single plasmid, pET-46 Ek/LIC, that 
provides only a short, Ek-cleavable, His6 purification tag at the N-terminus, which, due to its 
small size should not interfere with nanocage assembly. This strategy would permit in vivo 
selection followed by in vitro characterisation without the time consuming re-cloning process. 
It should be noted that this approach may prove non-general to other protein systems because 
a) the N-terminus of Dps is projected outside the nanocage and thus a small fusion at this 
position is not expected to greatly affect a protein-protein interaction b) the designed FlAsH 





Thus, the genes for all designs and controls described in this Chapter were cloned into 
pET-46 Ek/LIC (Figure 6.2). These included the positive control, DpsCCPGCC, negative control, 
Dps, and most promising design, DpsPAGCC, from Chapter 5. In addition, expected dimer 
forming mutants, Dps(AA)PAGCC, Dps(DD)PAGCC and Dps(WW)PAGCC, (see section 6.2.1.3. 
for details) were cloned as additional controls. The TPCR library was generated on the 
Dps(AA)PAGCC pET-46 Ek/LIC control as a background sequence. Screening of the library 
resulted in the mutants Dps(AA)PAGCCQ86V,L87F,N130F, Dps(AA)PAGCCN130Y and 
Dps(AA)PAGCCN130L,D141D,D142W,D143G, that were isolated and characterised in vitro (see section 
6.2.2.3. for details) (Figure 6.2). It should be noted that when the proteins were isolated for in 
vitro analysis, the His6 purification tag was not removed so as to result in more rapid and 
higher yielding purification. Therefore to ensure these slightly altered variants still assembled 
correctly and bound to FlAsH as previously determined, the control proteins were expressed, 
purified and fully characterised (see below and Appendices 6.2 and 6.3 for SDS-PAGE and Mass 






Figure 6.2 – Proteins used in the research described in this chapter. (left column) Dps crystal structure 
(PDB: 1DPS) and all nanocage forming designs and controls as described and characterised in Chapter 5: 
the positive control (DpsCCPGCC) with full tetracysteine FlAsH binding site, the most promising bipartite 
design (DpsPAGCC) and the negative control with no additional cysteines (Dps). (middle column) Control 
proteins designed to have crippled assembly properties (See section 6.2.1.3 for details). Each contains 
mutations at R83 and R133, including double alanine, Dps(AA)PAGCC, double aspartic acid, 
Dps(DD)PAGCC, and double tryptophan, Dps(WW)PAGCC. (right column) Mutants with recovered 
assembly properties obtained from FlAsH/FACS screening of an OCOB library based on Dps(AA)PAGCC 
(See section 6.2.2.3. for details). Cysteine (red), glycine (light grey), alanine (dark grey), proline (black). 
For crippled assembly controls; alanine (A), aspartic acid (D), tryptophan (W). 
The three proteins characterised in Chapter 5 (DpsCCPGCC, DpsPAGCC, Dps) showed 
nanocage like architectures in both SEC (Figure 6.3) and TEM (See Appendix 6.4) and the 
purified proteins demonstrated fluorescence intensities with FlAsH similar to those previously 





Dps(DD)PAGCC, and Dps(WW)PAGCC and 6.2.2.3 for discussion of library design, sorting and 
characterisation). 
 
Figure 6.3 – Size exclusion chromatograms of purified Dps derivatives expressed in pET-46 Ek/LIC. (top 
left) positive control DpsCCPGCC, (middle left) most promising bipartite design DpsPAGCC, (bottom left) 
negative control Dps. (top right) DpsPAGCC with cage-crippling mutations R83A and R133A 
(Dps(AA)PAGCC), (middle right) DpsPAGCC with cage-crippling mutations R83D and R133D 
(Dps(DD)PAGCC), (bottom right) DpsPAGCC design with cage-crippling mutations R83W and R133W 
(Dps(WW)PAGCC). Traces are averages of three runs, normalised to the highest intensities for each (0.5 
ml injection of 0.5 mg/ml protein). For explanation of cage-crippled mutants see Section 6.2.1.3. See 






Figure 6.4 - FlAsH fluorescence of purified Dps derivatives expressed in pET-46 Ek/LIC. The data is 
normalised to the positive and negative controls. All proteins are 0.1 mg/ml in FlAsH buffer (100 mM 
Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 0.1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. 
Data is averaged from 8 replicates. Error bars are S.D* Two-tailed P-values = 0.0001. ** Two-tailed P-
values = 0.0023. See Figure 6.2 for explanation of schematics. 
These data verified that expressing these proteins with the small His6 tag from the new 
plasmid had little impact on either nanocage assembly or FlAsH binding in vitro. The next step, 
therefore, was to analyse the ability of FlAsH to bind selectivity to these control proteins in 
living E. coli. 
6.2.1.2. Dps nanocage assembly evaluated in vivo with fluorescence microscopy. 
 To gain an initial indication of whether or not FlAsH-EDT2 can be used to selectivity 
label our designed proteins in living bacterial cells, individual bacterium were assessed with 
fluorescence microscopy. Nhieu and co-workers9 analysed the toxicity of FlAsH-EDT2 on gram 
negative bacteria and found little effect in concentration ranges up to 20 µM. They were also 
able to FlAsH label intracellular proteins tagged with CCPGCC by incubating the cells in a 
solution containing high concentrations of reducing agent (TCEP)8. However, Gierasch and co-
workers showed that intracellular proteins in E. coli could also be labelled by first treating the 
cells with lysozyme to permeabilize the bacteria. With both of these conditions in mind, we 





dithiol EDT (2 mM). As the cytosol of the bacterium is already in a reduced condition, it was 
deemed unnecessary to add either of the reducing agents seen in Chapter 5 (TCEP or 2-ME). 
The Dps controls (DpsCCPGCC and Dps) were exposed to these conditions and analysed with 
fluorescence microscopy (Figure 6.5). As expected micrographs of bacteria expressing 
DpsCCPGCC showed a strong fluorescence response whereas control cells expressing Dps 
exhibited almost no detectable fluorescence in identical conditions. Taken together these data 
suggest that there is low background signal, that FlAsH-EDT2 can successfully penetrate these 







Figure 6.5 – Analysis of intracellular FlAsH labelling of overexpressed Dps protein controls in E.coli with 
epi-fluorescence microscopy. (top) Positive control cells expressing DpsCCPGCC, (bottom) negative 
control cells expressing Dps (left to right) DIC image (100x magnification, 20 ms exposure), green 
channel (50 ms exposure, filter sets Ex – 490 ±20 nm, Em – 525 ±36 nm), overlaid image. Two 
micrographs of each are included to demonstrate reproducibility. After 1.5 hours of protein expression, 
the cells were treated with 20 µM FlAsH-EDT2 in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM 
EDTA, pH7.8) with 2 mM EDT. Images generated with ImageJ16. Gain was not changed between images 
of the controls. 
 With controls firmly validated, cells expressing DpsPAGCC was subjected to identical 
microscopic analysis (Figure 6.6). These cells were clearly fluorescent however with intensities 





demonstrates that bipartite tetracysteine display can be used in bacterial cells for the 
detection of nanocage self-assembly. 
 It should be noted, however, that several of the cells in the micrographs of both the 
DpsCCPGCC and DpsPAGCC expressing cells had very little associated fluorescence. There 
could be a number of explanations for this result, including selective protein expression, 
contamination, cell death, or differentiation. Although this may suggest a limitation with 
microscopy for the determination of how many of the cells are labelled and to what extent, 
other methods, such as flow cytometry could complement this technique by providing more 
quantitative data. 
 
Figure 6.6 - Analysis of intracellular FlAsH labelling of overexpressed DpsPAGCC in E.coli with epi-
fluorescence microscopy. (left to right) DIC image (100x magnification, 20 ms exposure), green channel 
(50 ms exposure, filter sets Ex – 490 ±20 nm, Em – 525 ±36 nm), overlaid image. Two micrographs of 
each are included to demonstrate reproducibility. After 1.5 hours of protein expression, the cells were 
treated with 20 µM FlAsH-EDT2 in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH7.8) 
with 2 mM EDT. Images generated with ImageJ 16. These images were collected in identical conditions, 
on the same day and with the same microscope as those in Figure 6.5, with no change in gain. 
 Before flow cytometry was attempted, and to provide additional controls for the 





impact it has on bacteria viability because the high throughput screening of OCOB libraries 
with FACS requires that the bacteria survive the process. To investigate this, a bacterial 
dead/live screen was envisioned using two additional fluorophores. Hoechst 33342, which 
fluoresces upon DNA binding, was used to identify all (living and dead) bacterial cells and 
propidium iodide (PI), which can only penetrate cells with disrupted membranes, identified 
dead cells. While this is not precisely a dead/live screen, this method can identify all cells, 
which is a useful tool when removing background signals from flow cytometry, and separately 
identify dead cells which can then be removed leaving only the live cells (Hoescht+, PI-). In 
addition the number of PI-positive cells would indicate the extent to which the cells are being 
killed. One consideration for the selection of these probes, is spectral overlap (Table 6.1). This 
combination of fluorophores should allow for a three channel excitation system using the blue, 
green and red channels with little overlap. 
Fluorophore Excitation maxima (nm) Emission maxima (nm) Channel Detection role 
Hoechst 33342 350 461 Blue Bacterial cells 
FlAsH-EDT2 508 528 Green Nanocages 
Propidium Iodide 535 617 Red Dead cells 
Table 6.1– Excitation and emission maxima for all fluorophores used in the research described by this 
chapter (Invitrogen). 
To confirm that each fluorophore can be observed in our conditions with these cells, 
the microscopy method described above was repeated with all three probes (Figure 6.7) and 
the three proteins. The response from the green channel showed a similar trend to that seen 
above when just using a single fluorophore. A response was seen in both the blue and red 
channels, with most of the cells being Hoechst positive and only a limited number of cells were 
PI positive, meaning that the majority of cells survived this process and were alive. Moreover, 
the presence of a response from all three probes showed that this system could work to not 
only identify whether a nanocage is formed but also whether or not the cell is alive. With this 
method characterised in cells using microscopy, it was important to analyse the level of 













Figure 6.7 - Analysis of intracellular labelling of the three fluorophore system for bacteria expressing Dps 
protein controls and designs with epi-fluorescence microscopy. (top) cells expressing positive control 
DpsCCPGCC, (middle) negative control Dps, (bottom) bipartite design DpsPAGCC. (left to right of top 
row) DIC image (100x magnification, 20 ms exposure), blue channel (2 s exposure, filter sets Ex – 402 ± 
15 nm, Em – 455 ± 50 nm), red channel (20 ms exposure, filter sets Ex – 555 ± 25 nm, Em – 605 ± 52 
nm). (left to right bottom row) green channel (50 ms exposure, filter sets Ex – 490 ± 20 nm, Em – 525 ± 
36 nm) and overlaid image. After 1.5 hours of protein expression, the cells were treated with 20 µM 
FlAsH-EDT2 in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH7.8) with 2 mM EDT. After a 
further 1.5 hours, 0.1 µM Hoechst 33342 and 0.03 µM PI were added. Images generated with ImageJ 16.  
6.2.1.3. Dps nanocage assembly evaluated in vivo with flow cytometry 
 Flow cytometry measures the fluorescence intensity of each cell in multiple channels. 
While the Hoechst and PI fluorophores could be used to select cells that are alive during this 
investigation, and aspect which is important if these cells were to be sorted and collected, the 
FlAsH-EDT2 probe assesses the ability of any proteins to self-assemble into nanocages. First, 
however, it was necessary to confirm that the cells can be selected and that dead ones can be 
screened out. This was accomplished by applying the two fluorophore, dead/alive screen that 
was described above to flow cytometry (Figure 6.8).  
To determine the ability of cytometry to identify the live and dead populations, cells 
expressing the positive control protein DpsCCPGCC, was treated with either PI, Hoechst 33342, 





the entire population when Hoechst 33342 is added indicating that this dye is able to identify 
all cell populations, however, only a small shoulder appears in the red channel when PI is 
administered, indicating a small population of dead cells. This population becomes the 
majority when the cells are killed by heat treatment as would be expected confirming that the 
shoulder in the red channel of un-heat treated cells is, in fact, due to dead cells. The fact that 
the population of dead cells when they are not heat treated is small, indicates that the 
conditions we are using for FlAsH-EDT2 labelling are non-lethal. 
 
Figure 6.8 – Dead/live analysis using flow cytometry with cells expressing the Dps positive control 
DpsCCPGCC. (left top and bottom) Fluorescence in red and blue channels of population of bacteria 
expressing DpsCCPGCC with no added PI or Hoechst 33342. (middle top) Fluorescence in blue channel in 
the presence of Hoechst 33342. (middle bottom) Fluorescence in the red channel in the presence of PI, 
(right bottom) Fluorescence in the red channel in the presence of PI after cells were killed by heating at 
60 0C for 5 minutes. After 1.5 hours of protein expression, samples changed into FlAsH buffer (100 mM 
Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH7.8) with 2 mM EDT. After a further 1.5 hours, 0.1 µM Hoechst 
33342 and/or 0.03 µM PI were added if indicated. Blue channel: Ex laser - 375 nm, Em filter- 450 ±20 
nm. Red channel: Ex laser – 488 nm, Em filter – 670 ±20 nm. Data normalised through software (FlowJo, 





Before discussing how this was applied to assessing nanocage formation, a note about 
how the data will be handled is appropriate. (Figure 6.9) Bacteria probed with all three 
fluorophores will first be analysed in the blue channel and Hoechst-positive events will be 
gated before analysis in the red channel. Of these, PI-positive (i.e. dead cells) will be noted and 
PI-negative events will be gated out for analysis in the green channel. The Hoechst-positive, PI-
negative, FlAsH-positive events would be gated out and collected if performing cell sorting 
(Figure 6.9).  
 
Figure 6.9 – Schematic representation of data treatment in flow cytometry analysis of bacteria probed 
with Hoechst 33342, PI and FlAsH. (top left) First the blue channel is analysed and the Hoechst+ cells 
gated (red dashed box). This population is analysed in the red channel (top right) and the live, PI -, cells 
(green dashed box) are gated away from the PI+, dead cells. (bottom) The live population is then further 
interrogated in the green channel for binding to FlAsH to identify the FlAsH+ cells that express proteins 
that can self-assemble into nanocages.  
The flow cytometry analysis using the method described above demonstrated that 
baseline separation was evident between the positive, DpsCCPGCC, and negative controls, 
Dps, (Figure 6.10a) indicating a sufficient window to identify clones expressing proteins of 
varying nanocage stabilities. Satisfyingly consistent with the microscopy and lysate data (above 
and Chapter 5), the cells expressing DpsPAGCC displayed a distribution that was intermediate 





identify proteins that assemble into nanocages (Figure 6.10b). While this data is extremely 
promising, if this strategy is to be used to screen OCOB libraries, it needs to be able to 
distinguish clones that express bipartite designs that have different levels of stability. To test 
this, we used Dps mutants that are crippled in their ability to form the nanocage 
oligomerization state. 
 
Figure 6.10 – Flow cytometry to assess the oligomerization state of Dps derivatives. (A) Fluorescent 
events for populations of cells expressing negative control, Dps (light grey), and positive control, 
DpsCCPGCC (black), (B) comparison of clones expressing Dps controls to those expressing DpsPAGCC 
(red). (C) Comparison of clone expressing DpsPAGCC (red) to to one that expresses the cage crippled 
control, Dps(AA)PAGCC (blue). D) Comparison of cage crippled controls Dps(AA)PAGCC (blue), 
Dps(DD)PAGCC (brown) and Dps(WW)PAGCC (green). After 1.5 hours of protein expression, the cells 
were treated with 20 µM FlAsH-EDT2 in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, 
pH7.8) with 2 mM EDT. After a further 1.5 hours, 0.1 µM Hoechst 33342 and 0.03 µM PI were added if 
indicated. Blue channel: Ex laser - 375 nm, Em filter- 450 ±20 nm. Red channel: Ex laser – 488 nm, Em 
filter – 670 ±20 nm. Data normalised through software (FlowJo, Tree star) using 100,000 cells. 
Because an early goal for developing a FlAsH/FACS OCOB high throughput screen 





determine if it was possible to distinguish proteins with different nanocage stabilities and to 
optimise the relative difference between their oligomerization-dependent signals. Previously, 
our laboratory performed alanine shaving mutagenesis on the wild-type protein Dps to identify 
residues important for nanocage assembly17. Several positions were found that lowered the 
melting temperature of Dps as well as alter the ratio between nanocage and dimer. A double 
mutant, Dps(R83A, R133A) involving residues located near the Dps-like three-fold axis of 
symmetry (Figure 6.1), formed 100% dimer. We thought this double mutant could be the basis 
of the next step of development. These mutations were placed onto the bipartite Dps design 
resulting in Dps(AA)PAGCC which was expected to assemble into 100% dimer. This protein was 
cloned, expressed, purified, and characterised (see Appendices 6.2 and 6.3 for SDS-PAGE and 
mass spectrometry respectively). As expected, this protein showed no nanocage-like 
structures in either SEC (Figure 6.3) or during the forcing conditions of TEM (see Appendix 6.4). 
In addition, it exhibited little fluorescence signal in the in vitro FlAsH assay (Figure 6.4) 
compared to DpsPAGCC. Dps(AA)PAGCC was further characterised with flow cytometry 
(Figure 6.10c). Cells expressing Dps(AA)PAGCC and treated with FlAsH exhibited an average 
fluorescence intensity lower than that of DpsPAGCC but higher than Dps. This decrease in 
signal compared to DpsPAGCC was promising; however, the fact that it was higher than the 
negative control, Dps, was somewhat unexpected because very little nanocage state was 
observed in vitro. It is possible that this signal is caused by a population of nanocages inside 
the bacteria where high concentrations of proteins are “pushing” the nanocage together from 
dimer intermediates. Alternatively, protein aggregates could be responsible for the higher than 
expected signal, however, very little aggregation was observed in the SEC and during 
purification. Therefore, further investigation of Dps(AA)PAGCC was undertaken in lysates with 
high total protein concentrations to try to replicate cellular conditions.   
 To determine if the higher than expected signal for Dps(AA)PAGCC in vivo was due to 





scanned (Figure 6.11). While a significant change in signal is observed at different protein 
levels, it is not concentration dependent. The lack of a clear trend highlights some of the 
difficulties when working with lysate samples especially at high protein concentrations. 
Another approach to explore this issue was to create mutants that are even more crippled in 
their ability to form the nanocage oligomerization state.  
 
Figure 6.11 – FlAsH fluorescence of Dps(AA)PAGCC, which is crippled in its ability to form nanocage, and 
controls high totally protein concentrations in lysates. The data is normalised to the 5 mg/ml positive 
and negative control response. All designs examined in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 
mM EDTA, pH 7.8) with 0.1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. Lysate data from a single 
expression examined 12 times. Error bars are S.D. (see Figure 6.2 for explanation of schematics.) 
The double mutation from arginine to alanine (R83A, R133A) has been shown to 
prevent nanocage formation by removing important interactions; however the small size and 
the neutrality of alanine might not prevent formation of the nanocage state under “forcing” 
conditions. Therefore it was envisioned that other mutants could be created that might 
prevent the nanocage from reforming through negative design. The two positions R83 and 
R133 were both mutated to aspartic acids (D) and tryptophan’s (W) (Dps(DD)PAGCC and 
Dps(WW)PAGCC) with the rationale being that a charge inversion and increase in size should 
further cripple nanocage formation. These new control proteins were expressed, purified and 





For both proteins, no nanocage structures were observed in either SEC (Figure 6.3) or under 
the forcing conditions of TEM (see Appendix 6.4) and their in vitro fluorescence was lower than 
that exhibited by DpsPAGCC (Figure 6.4). The in vitro fluorescence signals for all three crippled 
nanocage controls displayed signals that were statistically higher than Dps although they had 
all been shown to form no nanocages. Consistent with this, when these controls were analysed 
via flow cytometry, populations were observed that were intermediate between negative 
control (Dps) and DpsPAGCC, results that were comparable to that observed for 
Dps(AA)PAGCC (Figure 6.10d). This similarity between all three dimer forming mutants in both 
purified and flow cytometry conditions adds confidence that the signal initially observed for 
Dps(AA)PAGCC that was higher than the Dps control in flow cytometry is not due to the 
formation of the protein nanocage state under cellular conditions, but perhaps caused by an 
increased background activity of FlAsH-EDT2 in the presence of large numbers of cysteine rich 
proteins.  
The in vivo conditions described above include the use of EDT to reduce background 
signal. While a difference between DpsPAGCC and Dps(AA)PAGCC is significant, maximizing 
this difference is desirable so as to more efficiently separate clones with different nanocage 
stabilities during eventual library screening. Therefore a range of reducing conditions were 
screened using flow cytometry to optimise the cytometric differentiation of the DpsPAGCC and 
the crippled nanocage clones (Figure 6.12 and Figure 6.13). We explored EDT concentrations 
and the use of TCEP which has been reported as an alternative reducant in cellular FlAsH 
conditions8.  
Increasing EDT concentration has little effect on the average fluorescence difference 
between bacteria expressing DpsPAGCC and Dps(AA)PAGCC, but as expected, it did slightly 
decrease the overall signal for both (Figure 6.13). In the presence of the reducing agent TCEP, 





expressing DpsPAGCC, however, a second species overlapping with those expressing DpsPAGCC 
was observed (Figure 6.12). It is unclear what is the origin of these two populations is but it is 
clear that these conditions should be avoided. Therefore, it was decided that the best 
conditions involved 2 mM EDT and no TCEP. Although the close separation of these clones was 
a concern for a library screen, it was thought that it could be overcome by performing multiple 
rounds of selection. 
 
Figure 6.12 – Optimisation of reducing conditions (TCEP) for flow cytometry with cage-forming and 
cage-crippled clones. The green channel fluorescence intensity of DpsPAGCC (top) and Dps(AA)PAGCC 
(bottom) was monitored in the presence of different concentrations of TCEP. After 1.5 hours of protein 
expression, the cells were treated with 20 µM FlAsH-EDT2 in FlAsH buffer (100 mM Tris.HCl, 100 mM 
NaCl, 1 mM EDTA, pH7.8) with 2 mM EDT. After a further 1.5 hours, 0.1 µM Hoechst 33342 and 0.03 µM 
PI were added if indicated. Blue channel: Ex laser - 375 nm, Em filter- 450 ±20 nm. Red channel: Ex laser 







Figure 6.13 - Optimization of reducing conditions (EDT) for flow cytometry with cage-forming and cage-
crippled clones. The green channel fluorescence intensity of DpsPAGCC (top) and Dps(AA)PAGCC 
(bottom) was monitored in the presence of different concentrations of EDT. After 1.5 hours of protein 
expression, the cells were treated with 20 µM FlAsH-EDT2 in FlAsH buffer (100 mM Tris.HCl, 100 mM 
NaCl, 1 mM EDTA, pH7.8) with 2 mM EDT. After a further 1.5 hours, 0.1 µM Hoechst 33342 and 0.03 µM 
PI were added if indicated. Blue channel: Ex laser - 375 nm, Em filter- 450 ±20 nm. Red channel: Ex laser 
– 488 nm, Em filter – 670 ±20 nm. Data normalised through software (FlowJo, Tree star) using 100,000 
cells. 
  To summarize this section, a method to detect nanocage oligomerization states of 
proteins over expressed inside living E. coli was created. The method was characterised and 
verified by both flow cytometry and microscopy with large differences observed between the 
positive and negative controls. High fluorescence signal was observed for cells expressing the 
bipartite tetracysteine design, DpsPAGCC, and when mutations were added to disrupt 
nanocage formation, the fluorescence signal decreased as expected. This decrease in signal 
therefore permits not only the detection of self-assembly in vivo, expanding this technology 
even further, but also the ability to use cell sorting to separate bacteria expressing different 
levels of assembled and non-assembled proteins from each other. This will be the basis of a 





6.2.2. Development of a FlAsH/FACS, OCOB high throughput screen to recover nanocage 
formation from nanocage-crippled clones 
 
 Extending protein nanocage bipartite tetracysteine display technology from in vitro to 
in vivo monitored with flow cytometry permits the advancement to high throughput screening 
using cell sorting. The plate based, medium throughput in vitro screening described in Chapter 
5 can help advance biophysical analysis, and optimise conditions for nanoparticle formation 
and protein stability. However, this technique has been limited to only one protein design at a 
time. A complementary approach therefore is required to discover new proteins with 
enhanced properties. Traditionally this has been done through rational design and mutagenesis 
of key residues followed by purification and characterisation. As stated previously, this process 
can be time-consuming which limits the number of designs that can be assessed. A 
consequence of this, is that only a narrow slice of “design space” can be explored, thus 
encouraging safe and conservative designs, at the expense of the risky and bold, and making 
the discovery of unexpected solutions to design requirements improbable. An alternative 
approach is to use high throughput screening so as to explore a much greater number of 
designs. Because purification and characterisation is often rate limiting, performing the screen 
inside living cells would be ideal. To further facilitate this endeavor, one clone/one bacterium 
(OCOB) libraries would link phenotype to genotype, providing a straight forward way to tag and 
identify hit clones. These libraries would be coupled to a screen dependent on FlAsH 
fluorescence monitored and separated by FACS. While this has been shown to be a viable 
strategy (see above), the last remaining hurdle is the design and production of the libraries 
themselves.  
6.2.2.1. Library design: Dps(AA)PAGCC with a randomized protein-protein interface for the 
recovery of assembly 
 
 As a first generation proof that the concept of FlAsH/FACS assay for screening OBOC 





Dps(AA)PAGCC, which is crippled in its ability to assemble into nanocages, as a background 
which we subjected to random mutagenesis to create a library. The aim of the research 
described in this section is to discover library members with recovered assembly properties. 
Along with establishing this technique for other, more ambitious applications, any mutants 
discovered in this way could shed light on the fundamentals of protein-protein interactions and 
quaternary structure and complement the computational interface repacking strategies that 
have been recently applied to protein nanocages18.  
Our strategy focused on the repacking of the protein-protein interface near the Dps-
like three-fold axis of symmetry where the two residues R83 and R133 are located. Mutation of 
these two residues to alanine in Dps(AA)PAGCC causes a disruption in nanocage assemble. 
Positions for randomization at this interface were selected rationally by examining what amino 
acids interacted directly with the interfacial network made up by the R83 and R133 residues 
(Figure 6.14). Because of the symmetry of the homomeric protein, the impact of even a single 
mutation would be maximized at the three-fold interface. Residues N19, D20, V21, D141, 
D142, D143, S152, R153 and D156 were identified as being part of the key interfacial network 
(see Appendix 6.5). These residues reside at three distinct positions on the tertiary structure of 
the Dps monomer. The first set of residues, N19, D20 and V21, are located on the semi-
unstructured N-terminal tail leading to the A-helix. The second set of residues, D141, D142 and 
D143 are at the N-terminus of the D-helix. Third, S152, R153 and D156 are also on the D-helix 
but across the interface from D141, D142, and D143 of another monomer. Further inspection 
of the Dps crystal structure showed that Q86, L87 and N130, while not involved directly in the 
interaction network, were positioned proximally in space to the network residues making 
them also candidates for randomization. Q86 and L87 are at the end of the C-terminal end of 
the B helix and N130 is positioned along the C-helix. Taken together, these represent a large 






Figure 6.14 – Positions of randomization for libraries of Dps(AA)PAGCC in a screen to recover nanocage 
formation. Crystal structure is of WT Dps (PDB:1DPS) showing a protein-protein interface at the three-
fold, Dps-like symmetry axis. Residues that were mutated to alanine, R83 and R133, to crippled 
nanocage formation are highlighted in red. The positions that were randomized in this chapter to 
generate Dps(AA)PAGCC libraries are highlighted in blue. The randomized residues are organized in sets 
based on primers used in the TPCR generation of the libraries. 
6.2.2.2. Generation of Dps(AA)PAGCC library with TPCR  
 With the locations for randomization set, a method had to be employed to introduce 
diversity at these positions in an efficient manner. There are several methods for the creation 
of protein libraries including error prone PCR19, the use of mutator strains (XL1-red) and DNA 
shuffling20 (see Chapter 1). Most of these methods do not allow for the precise structural 
control of where points of diversity are introduced, limiting them for surgical analysis of 
specific protein-protein interfaces.  
Transfer PCR (TPCR, see Chapter 1 and Figure 1.9) was chosen as a diversification 





reaction with multiple primers15. Primers were designed with two different sizes: Five longer 
forward primers (F1, F2, F3, F4, F5) (long) that had higher melting temperatures and shorter 
primers (short) that had lower melting temperatures (see Appendix 6.1 for primer sequences). 
Codons that corresponded to the residues selected for randomization were replaced with NNS 
codons, where ”N” can be any natural base and “S” is restricted to C or G. This codon set limits 
the expression of two stop codons, and one of the codons for cysteine while including codons 
encoding all natural amino acids. Stop codons are avoided so as to limit truncations and 
cysteines were avoided to prevent artifactual FlAsH binding. It should be noted that remaining 
stop codons can be prevented by the use of stop suppressor bacteria strains, but that was not 
used for this library.  
When the TPCR technique was first reported, it was very sensitive to primer 
concentration, and required extensive optimisation of conditions15. This was indeed found to 
be true in our hands. (see Appendix 6.6 and 6.7 for agarose gels and reaction conditions 
respectively). We optimized the concentration of both long and short primers in test PCRs 
which were analyzed by agarose gels. We found 6 nM of each of the long primers provided the 
highest yield of amplified plasmid, however, when this product was transformed and clones 
were sequenced, little incorporation of either the F1 or F5 primers was observed. Therefore 
new conditions used higher concentrations (10 nM) of these primers while keeping the rest at 
6 nM. This led to an increase in plasmid amplification and, after sequencing, incorporation of 






    
 
F1  F2 F3 F4 F5 
Dps(AA)PAGCC  
 sequence 
83 133 19 20 21 86 87 130 141 142 143 152 153 156 
A A N D V Q L N D D D S R D 





1 A A N D V Q L N D D D S R D 
2 A A N D V Y V N D D D S R D 
3 A A N D V Q M T D D D S R D 
4 A A N D V Q L N D D D S R D 
5 A A N D V Q L N D D D S R D 
6 A A N D V Q L S D D D S R D 
7 A A N D V Q L S D D D S R D 
8 A A N D V R A S D D D S R D 
9 A A N D V E V N T L C S R D 
10 A A N D V F L Y E * D S R D 
11 A A N D V Y * S D D D S R D 
12 A A N D V G G R A G T S R D 
13 A A N D V Q L L D D D Y V A 
14 A A N D V Q L N Q L P S R D 
15 A A N D V Q L N M A A S R D 
16 A A N D V Q L Y D D D S R D 
17 A A N D V Q L N K K V S R D 
18 A A N D V Q L N D D D S R D 
19 A A N D V Q L R D D D S R D 
20 A A N D V Q L D D D D S R D 
 
          
 Table 6.2 – Generation of Dps(AA)PAGCC library with TPCR. Sequences of twenty clones from the native 
TPCR library of Dps(AA)PAGCC with twelve sites of diversity. The degenerate residues are organized 
based on forward primer from which they were derived in the TPCR. Changes from Dps(AA)PAGCC are 
highlighted. *=stop. Note that a suppressor strain was not used. Grey highlighting denotes where 
mutations to the Dps(AA)PAGCC sequence are observed. 
 Twenty clones were sequenced to get an idea of the diversity explored in the library. 
(Table 6.2) It should be noted that statistically speaking, twenty clones provides no way near a 
significant sample of the library. However, it does provide some indication of primer 
incorporation, and any gross prescreening convergences of sequence could be identified. The 
sequencing data shows clones that have incorporated four of the five primers and some clones 
have multiple incorporations. However, F1 had no incorporation and F5 only appeared in one 
clone. Moreover, few clones had more than two or three primers incorporated. 
 A diverse set of amino acids were presented by the clones, however, some of the 
primers seem to be restricted in the residues encoded. Primer F3, for example, encodes a large 





allowed by the NNS codon set (see above). These would be expected to generate truncated 
proteins. 
After cloning, fifteen separate optimized transformations resulted in a predicted 
library size of 63,000 clones (4,200 transfectants per transformation). However, with twelve 
position of mutagenesis, this library has a potential of diversity of 4x1015 clones and clearly the 
actual library diversity is very far from this. Further optimization of the cloning is required to 
remove the background wild-type sequence and to increase the incorporation of the F1 and F5 
primers. Although, complete library diversity was not achieved, 63,000 is still a large number 
and the library diversity was deemed large enough to attempt screening. It was felt that even if 
clones with no new properties were discovered, at the very least, potential pitfalls with the 
screen could be identified by pushing forward.   
6.2.2.3. FlAsH/FACS screen of a Dps(AA)PAGCC OCOB library with a randomized protein-
protein interface for the recovery of assembly 
 
 The library was screened by FACS using the three fluorophore system described above 
(Figure 6.9). It was sorted four times where the top 1% of most fluorescent clones were 
collected and amplified before the next round of sorting (Figure 6.15). The average FlAsH 
fluorescence of the native library was less than that for bacteria expressing Dps(AA)PAGCC, 
however this intensity increased after the first two rounds of screening. Surprisingly the 
fluorescence of the library after the third round was lower than that for the second round 
however this may be a consequence of the fact that the clones after the second round were 
not sorted the next day like in the other rounds but instead was kept alive for two days by 
diluting parts of this sample into fresh LB before being sorted. This decrease in fluorescence 
intensity could be attributed to a change in the state of the cells. However, the sample after 
the third round was again sorted for the fourth and final time. Although the general increase in 





concern. The clones after the fourth sort were plated and twenty of the resultant colonies 
were sequenced (Table 6.4). 
 
Figure 6.15 – FlAsH/FACS screen of a Dps(AA)PAGCC OCOB library with a randomized protein-protein 
interface for the recovery of assembly (A) Comparison of the clones expressing the naïve protein library 
before any selection rounds (yellow) and those expressing the cage-crippled mutant, Dps(AA)PAGCC 
(blue), (B) Comparison of clones expressing the native protein library before any selection rounds 
(yellow), after one round of selection (light grey) and after two rounds (grey). (C) Comparison of clones 
expressing the library after two rounds of selection (grey) and after three rounds (dark grey). Note that 
the later sample was amplified for two days instead of the usual one day before the round of selection., 
(D) Comparison of clones expressing the library after three rounds of selection (dark grey) and those 
expressing the nanocage-crippled mutant, Dps(AA)PAGCC (blue). After 1.5 hours of protein expression, 
the cells were treated with 20 µM FlAsH-EDT2 in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM 
EDTA, pH7.8) with 2 mM EDT. After a further 1.5 hours, 0.1 µM Hoechst 33342 and 0.03 µM PI were 
added if indicated. Blue channel: Ex laser - 375 nm, Em filter- 450 ±20 nm. Red channel: Ex laser – 488 
nm, Em filter – 670 ±20 nm. Data normalised through software (FlowJo, Tree star). During a round of 
selection, the top 1% were collected and amplified for either 12 hours (rounds 1,2,3) or 48 hours (round 
4) before being subjected to the next round. 
 
  Sequencing of the twenty clones after four rounds of FlAsH/FACS seemed to 





sequenced of the native library and the mature library precludes anything but superficial 
analysis of changes in the library composition or the absence of any specific clones. However, 
we hope that after more thorough optimisation to increase diversity, deep sequencing 






    F1  F2 F3 F4 F5 
Dps(AA)PAGCC 
 sequence 
83 133 19 20 21 86 87 130 141 142 143 152 153 156 
A A N D V Q L N D D D S R D 
 
          
 
1 # A A N D V V F F D D D S R D 
2 # A A N D V R G * D D D S R D 
3 A A N D V Q L V D D D S R D 
4 # A A N D V Q L Y D D D S R D 
5 A A N D V Q L V D D D S R D 
6 Deletion         
 7 A A N D V * Q N D D D R E I 
8 A A N D V Q L Y D D D S R D 
9 A A N D V Q L Y D D D S R D 
10 A A N D V Q L Y D D D S R D 
11 A A N D V Q L Y D D D S R D 
12 A A N D V Q L P D D D S R D 
13 A A N D V Q L N D D D S R D 
14 A A * T M Q L S D D D S R D 
15 # A A N D V Q L L D W G S R D 
16 A A N D V Q L Y D D D S R D 
17 A A N D V Q L P D D D S R D 
18 A A N D V Q L N D D D S R D 
19 A A N D V Q L L D D D S R D 
20 A A N D V Q L P D D D S R D 
 
          
 
Table 6.4 – Sequencing results of clones after FlAsH/FACS screen. Sequences of twenty clones from the 
screened library after four rounds of selection. The degenerate residues are organized based on forward 
primers from which they were derived in the TPCR. Changes from Dps(AA)PAGCC are highlighted. 
*=stop. Note that a suppressor strain was not used. #=sequences that were taken for purification and 






6.2.2.4. Characterisation of Dps(AA)PAGCC mutants obtained from FlAsH/FACS high 
throughput screen 
 
 Of the twenty sequences cloned from the library after four rounds of selection (Table 
6.4), the most commonly observed mutant was Dps(AA)PAGCCN130Y which was present in six of 
the sequenced clones. Although initial analysis of the native library (see Table 6.2) suggested 
that the TPCR method favoured incorporation of the F3 primer, the matured library exhibited 
an enhanced percentage of sequences with mutations at position 130, suggesting that this is a 
good site from which to stabilise nanocage formation. Therefore, it was decided to carry this 
protein on to the characterisation step. Only two sequences were observed with mutations 
arising from more than one included TPCR primer and no stop codon: 
Dps(AA)PAGCCQ86V,L87F,N130F and Dps(AA)PAGCCN130L,D141D,D142W,D143G. These two proteins were 
also carried to the next step. One of the most striking aspects of the sequences of these 
twenty clones is the high percentage containing stop codons, which would not be a concern if 
using suppressor strains. Therefore Dps(AA)PAGCCQ86V,L87G,N130Stop was also carried through to 
confirm that it was indeed producing a truncated protein. These four proteins were expressed, 
purified, and characterised (see Appendices 6.2 and 6.3 for SDS-PAGE and mass spectrometry 
respectively). It was confirmed by mass spectrometry that Dps(AA)PAGCCQ86V,L87G,N130Stop was 
indeed truncated. Why we seem to be selecting for truncated proteins is currently unknown. It 
should be emphasized that the truncated proteins are not expressing the PAGCC and therefore 
should not have a FlAsH binding site even if assembled. 
 The three full-length proteins were assayed for their FlAsH-dependent, in vitro 
fluorescence as described in Chapters 4 and 5 (Figure 6.16). While their signals were 
significantly larger than the crippled nanocage mutant Dps(AA)PAGCC, they were not a high as 







Figure 6.16 - FlAsH fluorescence of purified proteins from FlAsH/FACS screening (see Figure 6.2 for 
explanation of schematics). All proteins are 0.1 mg/ml as purified proteins, in FlAsH buffer (100 mM 
Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with 0.1 µM FlAsH, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME. * 
Two-tailed P-values = 0.0001. The data is normalised to DpsPAGCC and Dps(AA)PAGCC. The data is 
averaged from 8 replicates. Error bars are S.D. 
Each protein was further characterized with SEC and TEM. (Figure 6.17 for SEC and see 
appendix 6.4 for TEM) For the control Dps(AA)PAGCC, neither TEM or SEC showed any 
nanocage-like structures. All three proteins obtained from the screen to recover nanocage-
assembly showed nanocage structures in TEM suggesting that the screen was successful. This 
was further emphasized by the presence of nanocage peaks in the SEC for all three proteins. In 
the SEC, Dps(AA)PAGCCQ86V,L87F,N130F and Dps(AA)PAGCCN130L,D141D,D142W,D143G, showed a larger 
ratio of nanocage than Dps(AA)PAGCCN130Y, however the dimer species was still the dominant 
population for all three. Interestingly, an intermediate species seems to exist, generating a 
peak between the nanocage and dimer. Although this is speculative, this result raises the 
possiblity that we are stablizing an intermediate that isn’t nanocage but that also has a similar 
three-fold interface. This should not be a complete surprise because, in retrospect, the screen 
as designed is screening for the formation of a three-fold symmetry axis and not explicitly the 
nanocage. Although the implications of this have not been fully realized, this might be an 






Figure 6.17 – Size exclusion chromatograms of purified proteins from FlAsH/FACS cage recovery 
screening. Traces are averages of three runs, normalised to the highest intensities for each (0.5 ml 
injection of 0.5 mg/ml protein). For explanation of cage-crippled mutants see Section 6.2.1.3. See Figure 
6.2 for explanation of schematics. 
 To further confirm the recovered nanocage forming ability of these proteins, they 
were further characterised by dynamic light scattering (DLS) (Figure 6.18). All three crippled 
nanocage controls, (Dps(AA)PAGCC, Dps(DD)PAGCC and Dps(WW)PAGCC) exhibited a small 
hydrodynamic diameter while all nanocage forming controls, DpsCCPGCC, DpsPAGCC and Dps 
assembled into larger structures. Further confirming that the screen was successful, all three 
mutants from the nanocage recovery screen, Dps(AA)PAGCCQ86V, L87F, N130F, Dps(AA)PAGCCN130L, 
D141D, D142W, D143G, and Dps(AA)PAGCCN130Y, exhibited hydrodynamic diameters on par with the 






Figure 6.18– Dynamic light scattering analysis of purified proteins from FlAsH/FACS cage recovery 
screen. Each protein was 0.2 mg/ml in FLAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 
7.8). Data is the average of three replicates. Error bars are S. D. See Figure 6.2 for explanation of 
schematics. 
 Taken together, the DLS, SEC and TEM data, point to the conclusion that 
Dps(AA)PAGCCQ86V, L87F, N130F, Dps(AA)PAGCCN130L, D141D, D142W, D143G, and Dps(AA)PAGCCN130Y can 
all assemble into the nanocage oligomerization state and that the mutations, discovered by 
our high throughput screen can recover assembly even in the presence of the nanocage 
crippling mutations R83A and R133A. These three mutants represent 40% of the sequences 
obtained from the twenty sequenced clones from the mature library suggesting that this 
technology, even at an unoptimized, proof-of-concept stage, can discover new nanocages with 
novel assembly properties. Although nanocages were observable the ratio of nanocage to 
dimer was not recovered to the distribution observed for DpsPAGCC.  
Along with nanocage stability, the secondary structure and thermal stability of the 
proteins isolated from the screen was also investigated. This data (see Appendices 6.8, 6.9 and 
6.10) demonstrated that the proteins cooperatively denature indicating that they are well 
folded, however, the melting points and isotherm shapes are distinct. DpsPAGCC exhibits a 
single melting transition (67 0C) while Dps(AA)PAGCC displays two transitions (43 0C and 73 0C) 





the screens had similar bimodal isotherm shape to that of their parent with a low temperature 
transition near 43 0C. The lack of ability of the mature library mutants to overcome the change 
in thermal stability caused by the assembly crippling mutations could be indicative of the extra 
intermediates observed in SEC (Figure 6.17). 
It should be noted that this screen was decidedly focused on discovering proteins with 
the enhanced ability to assemble into nanocages. It was not designed to discover proteins with 
enhanced thermal stability of secondary structure. When working with these and similar 
protein nanocages17, 21, 1, we have found that these two properties, assembly and thermal 
stability, while surely coupled in some ways, are not always congruent. So it should not come 
as a complete surprise that thermal stability does not always scale with assembly.  
The appearance of a possible assembly intermediate is interesting. Although much 
more characterisation is required, its presence may suggest a non-native mechanism to 
assembly. This also is not surprising because, the design rules of the library, retained the R83A, 
R133A mutation, and randomised the rest of the interface. It stands to reason that any 
nanocage forming clones would be required to converge on a solution to assembly that is an 
alternative one to the wild-type protein.  
While we have been successful in designing a high throughput screen to recover 
nanocage assembly in a nanocage-crippled protein, clearly there is much room for 
enhancement. One of the clear weaknesses is the poor coverage of library diversity. The TPCR 
strategy needs further optimization to ensure robust incorporation of all five primers. In 
addition a simple way to expand diversity would be to increase the number of transformations 
from fifteen to one-hundred. While this is somewhat crude, it would increase the number of 
diverse clones from 63,000 to nearly 630,00 and could easily be accomplished in an afternoon 
without any additional optimisation. Furthermore, a mutagenesis step between screenings 





nanocage formation with thermal stability would be to perform expression or FlAsH treatment 
(30 °C and 25 °C respectively) at higher temperatures, although it should be noted that protein 
expression, cell metabolism, etc would all be affected. Finally, as we think that we are may be 
seeing new intermediates that have nanocage-like symmetry (see the discussion about the SEC 
data above), perhaps employing alternative FlAsH binding sites or even multiple types in 






6.3. Conclusions  
 In summary, the research described in this chapter expanded the in vitro FlAsH-based 
assay for the direct detection of Dps assembly described in Chapter 5 into living bacteria and a 
high throughput screen using one clone/one bacterium libraries sorted with FACS. As far as we 
know, this is the first example of a high throughput screen for protein nanocage engineering 
and the first application of a FlAsH-based OC/OB screen using FACS.  
This in vivo method was confirmed with both fluorescence microscopy and flow 
cytometry. Clones expressing negative and positive control proteins demonstrated very low 
and very high fluorescence respectively and cells expressing the protein with the bipartite 
FlAsH binding site developed in Chapter 5 (DpsPAGCC) exhibited intermediate fluorescence. 
The technique was more deeply explored using controls that were known to have crippled 
assembly properties and cells expressing proteins with these mutations applied to DpsPAGCC 
were observed to have less fluorescence. 
 The in vivo assay to determine when a protein does or does not self-assemble into a 
nanocage was then developed into part of a high throughput screen to recover assembly from 
a nanocage-crippled background by protein-protein interface repacking. A cloning method was 
developed to introduce random mutations at twelve specific locations in the Dps structure 
which were located at the same interface near the nanocage-crippling mutations. The resulting 
library was transformed into cells in a one clone/one bacterium manner allowing each cell to 
express a different clone and providing the sequencing tag to identify the clone. The bacteria 
with the strongest FlAsH fluorescence were collected with FACS. After four rounds of selection, 
twenty clones were sequenced. Of these, three mutant proteins were purified and 
characterised with SEC, TEM, DLS, and CD. All three mutants could assemble into nanocage 
structures despite containing the mutations that were assembly crippling in the parent 





discover protein nanocages with enhanced assembly properties applied to protein-protein 
interface repacking. We think that this high throughput technique could be used to discover 
better FlAsH binding sites (i.e. to enhance the technique itself), to understand more deeply the 
role of protein-protein interactions in nanocage assembly, complimenting computational 
strategies (as discussed in Chapter 1), and to identify protein nanocages with novel properties 







6.4. Methods and Materials 
6.4.1. Cloning 
6.4.1.1. Transfer of genes developed in previous chapters to pET-46 (DpsCCPGCC, DpsPAGCC 
and Dps) 
 The plasmids containing the genes coding for DpsCCPGCC, Dps and DpsPAGCC were 
transferred to pET-46 via amplification with primers that provided ligation independent cloning 
(LIC) sites4. The PCR solution (Pfu reaction buffer (Promega, 5 μl of 10x), dNTP mix (Promega, 2 
μl of a solution containing dATP, dTTP, dGTP, and dCTP at 2 mM each), forward and reverse 
primers (400 ng each, IDT, Germany), template (100 ng) and Pfu polymerase (Promega, 2 μl of 
2.5 U/μl) in 50 μl total volume) was subjected to an initial melting step (95 °C for 30 s), 
followed by 30 cycles of amplification (95 °C for 30 s, 58 °C for 45 s and 72 °C for 1 min) 
followed by 72 °C for 7 min. The resulting PCR product was isolated by gel purification 
(Promega). The PCR product was then treated with T4 polymerase in order to create the 
required complementary overhangs (NEB buffer 2, 2 μl of 10x buffer), dATP (NEB, 2 μl of 25 
mM), BSA (NEB, 0.2 μl of 100x), PCR product (0.3 pmol) and T4 DNA polymerase (NEB, 0.6 μl of 
10 U/μl) in a total volume of 20 μl 30 min, 22 °C). The insert was annealed to open plasmid 
pET-46 (Novagen) (1 μl of the T4 Pol product, 0.5μl of plasmid solution (50 ng/μl)) by 
incubating (room temperature, 30 min) followed by a second incubation (room temperature, 
30 min) with EDTA (1 μl of 100 mM). The constructs (2.5 μl) were transformed (Xl-1 blue, 
Novagen) and the resulting colonies were assessed by colony PCR, a solution of Gotaq buffer 
(Promega, 5 µl of 5x), dNTP mix (Promega, 2 µl of a solution containing dATP, dTTP, dGTP, and 
dCTP at 2 mM each), T7 promoter and terminator primers (150 ng each, Eurofins MWG), taq 
DNA polymerase (Promega, 0.25 µl of 5 U/ µl), colony suspension (10 µl of a 50 µl total colony 
suspension in deionised water) and deionised water (total volume of 25 μl), was subjected to 
an initial melting step (95 °C for 10 min) followed by 30 cycles of amplification, ((95 °C for 30 s, 





product of the predicted size were subjected to miniprep (Sigma) and the resulting purified 
plasmids were sequenced (see Sequencing Appendix 6.1 for sequencing results and Appendix 
6.1 primers).  
6.1.1.2. Introduction of mutations for nanocage-crippled mutants Dps(AA)PAGCC, 
Dps(DD)PAGCC and Dps(WW)PAGCC 
 
 Using DpsPAGCC in pET-46 as a template (see section 6.1.1.1), site directed 
mutagenesis was performed to create controls that only exist in the dimer oligomerization 
state. The reaction mixture containing Pfu buffer (Promega, 2 µl of 10x), dNTP mix (Promega, 2 
µl of a solution containing dATP, dTTP, dGTP, and dCTP at 2 mM each), forward and reverse 
primers (125 ng each, IDT, Germany), DMSO (1% V/V), the dsDNA template (pET-46 designs, 
100 ng) and Pfu polymerase (Promega, 1 µl of 3 U/µl) in a total volume of 25 µl was subjected 
to melting (95 °C for 5 min), followed by 20 cycles of amplification (95 °C for 1 min, 65 °C for 1 
min and 72 °C for 6 min) followed by 72 °C for 10 min. The reaction was then digested with 
Dpn1 (NEB buffer 4 (1 µl of 10x), amplification product (5 µl), deionized water (3.5 µl), Dpn1 
(NEB, 0.7 µl of 10 U/µl), 37 °C, 2h). The resulting solution was transformed (XL-1 blue, 
Novagen) and the subsequent colonies subjected to miniprep (Sigma) and sequenced (see 
Sequencing Appendix 6 for sequencing results and Appendix 6.1 primers). 
6.1.1.3. TPCR library generation 
 The TPCR library used Dps(AA)PAGCC in pET-46 as a template and included 5 forward 
primers, with randomized residues, and 1 reverse. The PCR reaction contained a total volume 
of 50 µl including, Pfu reaction buffer (Promega, 5 µl of 10), dNTP mix (Promega, 2 µl of a 
solution containing dATP, dTTP, dGTP, and dCTP at 2 mM each), forward and reverse primers (8 
nM of F1 and F5, 6 nM of F2, F3, F4 and R1, IDT, Germany) dsDNA template (20 ng), DMSO (2% 
V/V), Pfu polymerase (promega, 1 µl of 3 U/µl) and deionised H2O (to a total of 50 µl) which 





(95 °C for 30 s, 58 °C for 1 min, raising 0.3 °C every cycle and 72 °C for 6 min) followed by 72 °C 
for 10 min. The product of this reaction was then digested with Dpn1 in a reaction mixture 
containing buffer (NEB buffer 4 (2 µl of 10x), amplification product (17 µl), Dpn1 (NEB, 1 µl of 
10 U/µl), 37 °C, 1.5 h). The solution was desalted (Promega, PCR clean up wizard) before any 
transformations (see Sequencing Appendix 6 for sequencing results and Appendix 6.1 primers). 
6.4.2. In vivo analysis 
6.4.2.1. Live cell fluorescence microscopy 
 E.coli containing Dps variants in the vector pET-46, were grown from frozen stocks in 
LB (5 ml, 37 0C, overnight) with 1% being added to fresh LB (5 ml) and grown (37 °C) until an 
O.D600 of 0.6. Protein expression was then induced by the addition of IPTG (2.5 µl of a 1 M 
stock) and the cultures were further incubated (1.5 h, 30 °C). From this culture, 100 µl was 
taken and centrifuged (4000 rpm, 30 s) and resuspended ((20 µl of FlAsH buffer (100 mM 
Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with EDT (final concentration of 2 mM)) to which 
FLAsH-EDT2 was added (Invitrogen, 0.2 µl of 2 mM stock) followed by further incubation (25 °C, 
1.5 h). This solution was first pelleting with centrifugation (4000 rpm, 30 s) then washed twice 
(using 20 µl of FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with EDT 
(final concentration of 2 mM)) followed by a final re-suspension (100 µl, FlAsH buffer (100 mM 
Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) and kept at 4 °C). To this solution, the 
fluorophores needed to screen for bacterial survival were added (Invitrogen, Hoechst 33342, 1 
µl of a 5 mg/ml stock and Propidium iodide, 2 µl of a 1 mg/ml stock). To a polylysine slide, 5 µl 
of the cells was added with a cover slip placed on top and left at 4 °C. Images were taken using 
a wide field Nikon Eclipse Ti-E Inverted microscope at 100x magnification (Filter sets, Hoechst 
33342 Ex - 402 ±15 nm, Em - 455 ±50 nm. FlAsH Ex – 490 ±20 nm, Em – 525 ±36 nm. Propidium 






6.4.2.2. Flow cytometry analysis 
 E.coli containing Dps variants in the vector pET-46, were grown from frozen stocks in 
LB (5 ml, 37 °C, overnight) with 1% being added to fresh LB (5 ml) and grown (37 °C) until an 
O.D600 of 0.6. Protein expression was then induced by the addition of IPTG (2.5 µl of a 1 M 
stock) and the cultures were further incubated (1.5 h, 30 °C). From this culture, 100 µl was 
taken and centrifuged (4000 rpm, 30 s) and resuspended ((20 µl of FlAsH buffer (100 mM 
Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with EDT (final concentration of 2 mM)) to which 
FLAsH-EDT2 was added (Invitrogen, 0.2 µl of 2 mM stock) followed by further incubation (25 °C, 
1.5 h). This solution first pelleting with centrifugation (4000 rpm, 30 s) and then washed twice 
((using 20 µl of FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) with EDT 
(final concentration of 2 mM)) and then resuspended (1 ml, FlAsH buffer (100 mM Tris.HCl, 100 
mM NaCl, 1 mM EDTA, pH 7.8) and kept at 4 °C). To this solution, the fluorophores needed to 
screen for bacterial survival were added (Invitrogen, Hoechst 33342, 1 µl of a 5 mg/ml stock 
and PI, 2 µl of a 1 mg/ml stock). This solution was filtered (DB, flow cytometry tube) and run on 
a DB Fortessa (Hoechst 33342 Ex laser - 375 nm, Em filter - 450 ±20 nm. FlAsH Ex laser – 488 
nm, Em filter – 530 ±30 nm. Propidium iodide Ex laser – 488 nm, Em filter – 670 ±20 nm) with 
data being analysed on FACSDiva and FlowJo (Tree star) software. Gating was first applied to 
the Hoechst+ response to collect all bacterial cells. This population was further gated to collect 
all PI- (alive) cells, which was lastly analysed for FlAsH fluorescence.  
6.4.2.3. FlAsH/FACS of one clone/one bacterium libraries 
 The desalted constructs (8 µl) were electroporated (XL-1 Blue, Novagen) and 
recovered using SOC medium and left to incubate (overnight, 37 °C) and inoculated 
(carbenicillin, 1 µl of a 50 mg/ml stock per 1 ml of SOC). The plasmids were collected via 
miniprep (Sigma) and re-electroporated (8 µl (Rosetta, Novagen)) using SOC medium to 





50 mg/ml stock per 1 ml of SOC). This process was repeated 15 times to create the library 
described here. 
 The bacteria was pelleted via centrifugation (3500 rpm, 10 min) the SOC media was 
removed and fresh LB was added and inoculated (carbenicillin, 1 µl of a 50 mg/ml stock per 1 
ml of LB) and left to incubate (1 h, 37 °C) followed by the induction of protein expression (IPTG, 
0.5 µl of 1 M stock for each 1 ml of LB, 30 °C, 1.5 h). For the first round, 4 x 1 ml samples were 
taken and centrifuged (4000 rpm, 1 min) and resuspended ((100 µl of FlAsH buffer (100 mM 
Tris.HCL, 100 mM NaCl, 1 mM EDTA, pH 7.8) with EDT (final concentration of 2 mM)) and 
FLAsH-EDT2 was added (Invitrogen, 1 µl of 2 mM stock) followed by further incubation (25 °C, 
1.5 h). This solution first pelleted with centrifugation (4000 rpm, 30 s) and washed twice 
((using 100 µl of FlAsH buffer (100 mM Tris.HCL, 100 mM NaCl, 1 mM EDTA, pH 7.8) with EDT 
(final concentration of 2 mM)) and then re-suspension (1 ml, FlAsH buffer (100 mM Tris.HCL, 
100 mM NaCl, 1 mM EDTA, pH 7.8) and kept at 4 °C). To this solution, the fluorophores need to 
screen for bacterial survival were added (Invitrogen, Hoechst 33342, 1 µl of a 5 mg/ml stock 
and PI, 2 µl of a 1 mg/ml stock). This solution was filtered (DB, flow cytometry tube) and run on 
a DB Aria III (Hoechst 33342 Ex laser - 375 nm, Em filter - 450 ±20 nm. FlAsH Ex laser – 488 nm, 
Em filter – 530 ±30 nm. Propidium iodide Ex laser – 488 nm, Em filter – 670 ±20 nm) with data 
being analysed on FACSDiva and FlowJo (Tree star) software. Gating was first applied to the 
Hoechst+ response to collect all bacterial cells. This population was further gated to collect all 
PI- (alive) cells, which was lastly analysed for FlAsH fluorescence with the highest intensity cells 
being collected. The collected cells were placed into inoculated LB (total of 10 ml, with 10 µl of 
carbenicillin 1 M stock) and left to incubate (overnight, 37 °C). The process described above 
was repeated for each round of sorting. After the final sort, the solution was plated on LB agar 
plates (50 μl/ml of carbenicillin and 34 μl/ml of chloramphenicol) with resulting colonies 





6.4.3. Protein characterisation 
6.4.3.1. In vitro protein FlAsH analysis 
The pET-46 vectors containing the Dps variants were transformed into Rosetta E. coli 
cells (Novagen) and plated on LB agar plates (50 μl/ml of carbenicillin and 34 μl/ml of 
chloramphenicol). Selected colonies were then grown in LB (9 ml, 37 °C, overnight) as a pre-
culture which was added to LB (900 ml) and grown (37 °C) until an O.D600 of 0.6. Protein 
expression was then induced by the addition of IPTG (400 µl of a 1 M stock) and the cultures 
were further incubated (3 h, 30 °C). The cells were isolated by centrifugation (4,000 rpm, 20 
min, 4 °C). The cell pellet was resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 40 
mM Imidazole, 1 mM EDTA, pH 8) and sonicated (Misonix, ultrasonic cell distruptor, pulsed 5 s 
on, 5 s off for 5 min). The protein solution was clarified by centrifugation (15,000 rpm, 45 min 
at 4 °C) and then filtered (Sartorius, 0.2 μm). The protein was purified via affinity purification 
(GE, Histrap FF, 5 ml, (wash buffer-40 mM Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4), 
(elution buffer-500 mM Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4)). Digestion to 
remove the short His6 tag was not performed on any pET-46 variants. The protein solution was 
further purified by size exclusion chromatography (GE Hiload 16/60 Superdex, running buffer- 
FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8).  
In vitro analysis of all Dps variants were performed as described in 5.4.3. in the Corning 
black 96 well plate format. 
6.4.3.1. Analytical Size Exclusion Chromatography (SEC)  
The samples (0.5 ml of 1 mg/ml) in FlAsH buffer (100 mM Tris-HCl, 100 mM NaCl, 1 
mM EDTA, pH 7.8) were injected onto the column (GE Superdex 200 increase) at 1 ml/min with 
each protein repeated 3 times. The column was calibrated using six proteins as standards (GE 





6.4.3.2. Transmission Electron Microscopy (TEM) 
TEM was performed as described in 5.4.6.2. (See Appendix 6.4)16. 
6.4.3.3. Mass Spectrometry 
  Mass spectrometry data was obtained as described in 4.4.4.5. (See Appendix 6.3). 
6.4.3.4. Circular Dichorism (CD) 
 Circular Dichorism data was obtained as described in 5.4.6.3. (See Appendix 6.8, 6.9 
and 6.10)22. 
6.4.3.5. Dynamic light scattering (DLS) 
 Purified proteins were diluted to a concentration of 0.2 mg/ml in FlAsH buffer (100 
mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) and analysed in a 1 cm path length cuvette on 
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Summary, final conclusions, 






 Protein nanocages can act as model systems to understand the roles of protein 
folding, protein-protein interactions and symmetry, in assembling protein quaternary 
structures and nanoarchitectures. Understanding these fundamentals can help realise the 
numerous applications that have been proposed to exploit the unique properties of protein 
nanocages among which are their nanoscale, hollow architecture, water solubility, self-
assembly and genomic encodability. This thesis chronicles a body of work which explored the 
fundamentals of protein nanocage structure (Chapter 3), made inroads toward directing 
protein nanocages toward nanotechnological applications (Chapter 2) and developed 
technologies to enable both applied and fundamental protein nanocage research in the future 
(Chapters 4, 5 and 6).  
Chapter 2 explored methods to apply the ferritin nanocages Bfr, Dps and HsFn to the 
burgeoning field of nanotechnology. The first half of the chapter described attempts to expand 
our technique to produce protein nanocage encapsulated nanoparticles. Our laboratory had 
previously devised a double reduction technique to generate gold nanoparticles inside HsFn. 
The goal of the research described in the first half of Chapter 2 was to apply this technique to 
Bfr and Dps. Although, protein aggregation thwarted direct application of the original 
procedure, optimisation was performed with moderate success. In the future, more work 
needs to be done to further optimise the conditions for these proteins and to determine if 
lessons learned through this exercise can be carried through to other protein nanocages. In 
general, the challenges experienced in this project underlined how even application-based 
science could be aided by fundamental research. They also emphasized the potential utility of 
developing a methodology for screening multiple particle generation conditions in a rapid 
manner for their tendency to destabilise protein nanocages. A methodology that does this was 
achieved in Chapter 5. The second half of Chapter 2 set out to establish initial protocols and 
controls for the eventual application of protein nanocages to delivery and imaging. If protein 





important to establish if they have any background targeting preference when not ligated to a 
tissue- or cell-type specific ligand. Therefore we labelled HsFn, which was demonstrated to be 
a uniquely stable ferritin in the first half of Chapter 2, with 111In and probed its localisation in 
mice with SPECT/CT. The imaging was highly successful, establishing a baseline for future 
specific targeting and perhaps suggesting some degree of innate specificity to dorsal lymph 
nodes and spleen. 
The research described in Chapter 3 answered fundamental questions concerning the 
self-assembly of protein nanocages. Previously our laboratory demonstrated that if a C-
terminal helical domain (the E-helix) from Bfr, a maxi-ferritin, were fused to the mini-ferritin 
Dps, a 12-meric protein, Dps+E, a size intermediate between Bfr and Dps was generated. 
Chapter 3 describes a crystallography project to determine if the E-domain is flipped inside or 
outside the nanocage and if the resulting protein adopted the tetrahedral symmetry of Dps or 
the octahedral symmetry of Bfr. We successfully obtained the crystal structure and 
determined that Dps+E is tetrahedral and the E-domain is flipped out of the nanocage. 
Unfortunately, aside from a few residues, the electron density along the E-domain is weak, 
preventing us from fully characterising its structure. A future direction of the project is to 
perform high resolution electron microscopy and determine the structure of Dps+E with the 
help of tomographic analysis of the micrographs. In addition, we think that the E-domain 
projected from the nanocage could have future applications as a handle, either for appending 
directing ligands for delivery applications or to help supra-assemble protein-based materials. 
Chapters 4, 5 and 6 describe the development of a new tool which should enable both 
fundamental research into protein nanocages and protein nanocage applications. With the 
challenges associated with protein aggregation during the nanoparticle studies described in 
Chapter 2 and the general frustration our laboratory has experienced with the slow progress of 





nanocage oligomerization was needed. This method needed to be rapid, and we hoped it 
would be applicable to complex solutions like lysates so as to bypass time- and resource-
intensive protein purification, and we needed it to be readily expandable to high throughput 
so that we could screen multiple in vitro conditions such as those for conjugation of SPECT 
labels or for the generation of nanoparticles. We also wanted a technique that could work in 
live cells so that we could understand the role of protein nanocage assembly on cell or virus 
biology or for the screening of protein libraries.  
Chapter 4 describes the development of a bipartite strategy to design, across 
oligomerization dependent protein-protein interfaces, binding sites on Bfr for the fluorescent 
imagining reagent FlAsH.  Control experiments eventually demonstrated that FlAsH binding 
was not specific for the nanocage oligomerization state. It is possible the in vitro conditions 
used could be optimized in the future; the experience that was gained by working with this 
strategy in Bfr was ported to Dps with the hope that the mini-ferritin would be more amenable 
to the technique.  
In Chapter 5 we demonstrated that the mini-ferritin Dps worked exactly as designed 
and we were able to show that the FlAsH fluorphore and bipartite tetracysteine display 
technology could be applied to large nanocage proteins to create a direct assay that is specific 
for the nanocage oligomerization state. The method was readily expanded to an in vitro, 
medium throughput assay to screen potential conditions for gold nanoparticle generation. In 
the future, this data and similar experiments could be used to overcome challenges in 
materials applications related to those described in the first half of Chapter 2. It is also thought 
that this in vitro technique could be developed to identify assembly intermediates and to 
possibly characterise the kinetics of their formation and consumption, thus shedding light on 





 Chapter 6 follows directly on the strong success of the research in Chapter 5. We 
realised that if we could port the FlAsH assay into living bacteria we could perform high 
throughput screens of protein libraries using cell sorting to discover proteins with enhanced 
nanocage forming properties. Using microscopy and flow cytometry, we demonstrated that an 
in vivo assay was possible. As a proof of principle library screen we randomised the protein-
protein interface of a Dps mutant that was crippled in its ability to assemble into a nanocage. 
After four rounds of screening with cell sorting, we isolated library members with recovered 
nanocage formation emphasizing the success of the strategy. Like any enabling technology, the 
methods described in Chapters 5 and 6 could go in many future directions. Optimised library 
generation conditions are clearly required, but the technique itself could be used to further 
optimise bipartite FlAsH binding site linkers, with further expansion into other nanocages. 
Along with applying this approach to other protein nanocages, we are also interested in 
screening for function; perhaps conditional assembly could be achieved by developing a 
“chemical inducers of oligomerization” strategy using small molecules that are 
photoisomerisable. Other interfaces of the Dps protein could also be screened to enhance 
stability and interface packing to overcome the crippled assembly mutations. 
 Taken together, the research projects presented in this thesis have explored the 
fundamentals of protein nanocage assembly, have made inroads into protein nanocage-based 
nanomaterials applications, and have developed an enabling technology which should support 
both fundamental and application based protein nanocage research. The work presented here 
has added to scientific understanding of this ubiquitous class of proteins and will help protein 
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Appendix 2.1 – Amino acid (single letter code) sequences for the wild type monomers used in 
Chapter 2, DNA binding protein from starved cells (Dps)1, Horse spleen light chain ferritin 
(HsFn)2 and Bacterioferritin (Bfr)3. 
 
 
Appendix 2.2 - SDS-PAGE gel (15%) analysis for (left) Dps and (right) Bfr during purification. 
(both gels) Lane 1: Protein standard ladder (NEB), Lane 2: insoluble fraction, lane 3: soluble 
fraction, lane 4: wash from first histrap, lane 5: elution from first histrap. (left gel) lane 6: SEC 
after Ek digestion and second histrap. (right gel) Lane 6: elution from second histrap after Ek 





Appendix 2.3 - Circular Dichroism spectra demonstrating the effect of heating on the fold of 
(left) Dps and (right) Bfr. Black:  CD signal before heating denaturation.  Red: CD signal after 
cooling post heating denaturation. Protein set to 0.2 mg/ml in phosphate buffer (50 mM 
Na2HPO4, 50 mM NaCl, pH 7) performed on JASCO J-810 spectropolarimeter from 250 nm to 
200 nm with a path length of 0.5 mm.  
 
 
Appendix 2.4 - Thermal melting plots of wild type Dps and Bfr at 222 nm in CD thermal melts 
were performed using 0.2 mg/ml protein in phosphate buffer, 50 mM Na2HPO4, 50 mM NaCl, 
pH 7 in a range of 4 to 100 °C with a path length of 0.5 mm on a JASCO J-810 
spectropolarimeter from 250 nm to 200 nm. Data fitted to a two state unfolding (m1+(m2-
m1)/(1+(m0/m3)^m4)equation4, 5, 6 which calculated the melting temperature of Dps – 68.2 0C 
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             Reaction buffer - Phosphate pH 7 Reaction Buffer - Tris pH 7.8 Reaction Buffer - dH₂O 
    Buffer for NaBH₄ Buffer for NaBH₄ Buffer for NaBH₄ 
    Na₂HPO₄ Tris dH₂O Na₂HPO₄ Tris dH₂O Na₂HPO₄ Tris dH₂O 
Buffer Na₂HPO₄ Purple Purple Purple Purple Purple Purple Purple Purple Purple 
for Tris Purple Purple Purple Purple Red Red Purple Red Red 
HAuCl₄ dH₂O Purple Purple Purple Purple Red Red Purple Purple Purple 
0.001M NaBH4 
             Reaction buffer - Phosphate pH 7 Reaction Buffer - Tris pH 7.8 Reaction Buffer - dH₂O 
    Buffer for NaBH₄ Buffer for NaBH₄ Buffer for NaBH₄ 
    Na₂HPO₄ Tris dH₂O Na₂HPO₄ Tris dH₂O Na₂HPO₄ Tris dH₂O 
Buffer Na₂HPO₄ Purple Purple Purple Purple Purple Purple Purple Purple Purple 
for Tris Yellow Yellow Yellow Red Red Red Red Red Red 
HAuCl₄ dH₂O Purple Purple Purple Purple Red Red Purple Purple Purple 
Appendix 2.5 – Colourmetric screen to evaluate the ability of NaBH4 at different concentrations to reduce gold in different buffering solutions by 
observing colour change with red/purple being seen as NaBH4 maintaining its ability to reduce gold. Reaction buffer is 1 ml of solution either 
Phosphate buffer (50 mM Na₂HPO₄, pH 7), Tris buffer (50 mM Tris.HCl, pH 7.8) or unbuffered in water, to which 20 µl of 0.1 M HAuCl4 in either a 
solution of Tris, phosphate or water, followed by 20 µl of 0.1 M NaBH4 also in either a solution of Tris, phosphate or water and left to incubate at 





             Reaction buffer - Phosphate pH 7 Reaction Buffer - Tris pH 7.8 Reaction Buffer - dH₂O 
    Buffer for NaCNBH₃ Buffer for NaCNBH₃ Buffer for NaCNBH₃ 
    Na₂HPO₄ Tris dH₂O Na₂HPO₄ Tris dH₂O Na₂HPO₄ Tris dH₂O 
Buffer Na₂HPO₄ Purple Purple Purple Purple Purple Purple Purple Purple Purple 
for Tris Purple Purple Purple Purple Purple Purple Purple Purple Purple 
HAuCl₄ dH₂O Purple Purple Purple Purple Purple Purple Purple Purple Purple 
0.01M NaCNBH3 
             Reaction buffer - Phosphate pH 7 Reaction Buffer - Tris pH 7.8 Reaction Buffer - dH₂O 
    Buffer for NaCNBH₃ Buffer for NaCNBH₃ Buffer for NaCNBH₃ 
    Na₂HPO₄ Tris dH₂O Na₂HPO₄ Tris dH₂O Na₂HPO₄ Tris dH₂O 
Buffer Na₂HPO₄ No change Purple Purple No change Purple Purple No change Purple Purple 
for Tris Yellow Purple Purple Yellow Purple Purple Yellow Purple Red 
HAuCl₄ dH₂O No change Purple Purple No change Purple Purple No change Purple Red 
0.001M NaCNBH3 
             Reaction buffer - Phosphate pH 7 Reaction Buffer - Tris pH 7.8 Reaction Buffer - dH₂O 
    Buffer for NaCNBH₃ Buffer for NaCNBH₃ Buffer for NaCNBH₃ 
    Na₂HPO₄ Tris dH₂O Na₂HPO₄ Tris dH₂O Na₂HPO₄ Tris dH₂O 
Buffer Na₂HPO₄ No change No change No change No change No change Purple No change No change Purple 
for Tris Yellow Yellow Yellow Yellow Yellow Purple Yellow Yellow Red 
HAuCl₄ dH₂O No change No change No change No change No change Purple No change No change Purple 
Appendix 2.6 - Screen to evaluate the ability of NaCNBH3 at different concentrations to reduce gold in different buffering solutions by observing 
colour change with red/purple being seen as NaCNBH3 maintaining its ability to reduce gold. Reaction buffer is 1 ml of solution either Phosphate 
buffer (50 mM Na₂HPO₄, pH 7), Tris buffer (50 mM Tris.HCl, pH 7.8) or unbuffered in water, to which 20 µl of 0.1 M HAuCl4 in either a solution of Tris, 
phosphate or water, followed by 20 µl of 0.1 M NaCNBH3 also in either a solution of Tris, phosphate or water and left to incubate at room 






































        
From 
paper 22.6 0.1 H₂O 20 0.1 H₂O 10 0.1 H₂O 30 0.1 H₂O   
1 1 
1 22.6 0.1 H₂O 20 0.1 H₂O 10 0.1 H₂O 30 0.1 H₂O Incubation at 4 °C 1 1 
2 22.6 0.1 H₂O 20 0.1 H₂O 10 0.1 H₂O 30 0.1 H₂O Addition of  0.1% Tween20 1 1 
3 22.6 0.1 H₂O 20 0.01 H₂O 10 0.1 H₂O 30 0.1 H₂O   1 1 
4 22.6 0.1 H₂O 20 0.001 H₂O 10 0.1 H₂O 30 0.1 H₂O   1 1 
5 50 0.05 H₂O 20 0.1 H₂O 10 0.1 H₂O 30 0.1 H₂O   1 1 
6 22.6 0.1 Tris 20 0.1 H₂O 10 0.1 Tris 30 0.1 H₂O   1 2 
7 50 0.05 Tris 20 0.1 H₂O 20 0.05 Tris 30 0.1 H₂O   1 2 
8 22.6 0.1 Tris     
 
    
 
    
 
Examined after 3 hours 2 2 
9 50 0.05 Tris     
 
    
 
    
 
Examined after 3 hours 3 3 
10     
 
20 0.1 Tris     
 
    
 
Examined after 3 hours 1 2 
11     
 
20 0.01 Tris     
 
    
 













    
    
12     
 
20 0.1 Tris     
 
    
 
Examined after 3 hours 3 3 
13     
 
20 0.01 Tris     
 
    
 
Examined after 3 hours 3 3 
14     
 
100 0.1 Tris     
 
    
 
Examined after 3 hours 3 3 
15       200 0.1 Tris     
 
    
 
Examined after 3 hours 3 3 
16 20 0.1 Tris 20 0.1 Tris 10 0.1 Tris 30 0.1 H₂O   2 2 
17 5x20 0.05 Tris 20 0.1 Tris 5x10 0.05 Tris 30 0.1 H₂O   3  3  
18 100 0.05 Tris 20 0.1 Tris 100 0.05 Tris 30 0.1 H₂O   3  3  
19 20 0.1 Tris 100 0.1 Tris 10 0.1 Tris 30 0.1 H₂O   2 3 




21 100 0.05 Tris 100 0.1 Tris 100 0.05 Tris 30 0.1 H₂O   3  3  
22 5x20 0.05 Tris 100 0.1 Tris 10 0.1 Tris 50 0.1 Tris   4 # 3 # 
23 5x40 0.05 Tris 100 0.1 Tris 10 0.1 Tris 50 0.1 Tris   4 # 3 # 
24 100 0.05 Tris 100 0.1 Tris 10 0.1 Tris 50 0.1 Tris   4 # 3 # 
25 5x20 0.05 Tris 100 0.1 Tris 100 0.05 Tris 50 0.1 Tris   4 # 4 # 
26 5x40 0.05 Tris 100 0.1 Tris 100 0.05 Tris 50 0.1 Tris   4 # 4 # 
27 100 0.05 Tris 100 0.1 Tris 100 0.05 Tris 50 0.1 Tris   4 # 4 # 
 
 
Appendix 2.7 – Summary of the optimisation conditions employed for the genesis of gold nanoparticles inside of the ferritins Dps and Bfr. This table 
lists the volume added, concentration and buffering solution either Tris (50 mM Tris.HCl, pH 7.8) or unbuffered in water, of the first gold addition, the 
first reducing agent, the second gold addition and second reducing agent. The results of each trial are recorded by number. 1 – Condition lead to total 
aggregation of the protein. 2 – Condition lead to almost complete protein aggregation but with a much longer elution UV 280 nm signal with low 
intensity but with no clear nanocage peak. 3 – Condition lead to slight aggregation, with a longer elution UV 280 nm signal with higher intensity but 
with no clear nanocage peak. 4 – Condition lead to the presence of a small protein aggregate peak with a longer UV 280 nm elution signal of high 
intensity but with a well-defined nanocage peak. # - Indicates the presence of a SPR peak with a defined peak corresponding to the elution volume of 







Appendix 2.8 – Radioactivity from serial dilutions of the standard radiolabelled conjugated 
HsFn sample containing 0.1 mg of protein, 25 μl of 111In with 193 Mbq of activity which was 
diluted to 100 μl with saline before undergoing serial dilutions. Used as a comparison to 





























Appendix for Chapter 3 
 
 
Primer name Primer sequences (5'-3') 
Dps+E F GACGACGACAAGATGAGCACCGCAAAACTGGTG 




Appendix 3.1 – Primer used to transfer the gene for the protein Dps+E from pET-32b into pET-




Appendix 3.2 - Amino acid (one letter code) sequences for the hybrid ferritin Dps+E monomers 




Appendix 3.3 - SDS-PAGE gel (15%) analysis for the purification of Dps+E. Lane 1: Protein 
standard ladder (NEB), Lane 2: soluble fraction, lane 3: insoluble fraction, lane 4: wash from 









Dps+E 22460 22493.4 33.4 
 






Appendix 3.4 – Maldi-TOF mass spectrometry analysis of the purified protein Dps+E. Expected 
mass is minus the N-terminal methionine. 
 
 
Appendix 3.5 – Transmission electron microscopy micrographs to show that Dps+E can form a 
nanocage, using 1% uranyl acetate as a negative stain. Images made using ImageJ7. 
 
 
Appendix 3.6 - Size exclusion chromatogram of purified Dps+E. Chromatogram normalised to 
its highest intensity and the average of three runs (0.5 ml injection of 1 mg/ml protein 
(followed at 280 nm), using running buffer, 50 mM Na2HPO4, 50 mM NaCl, pH 7 at a flow rate 
of 0.5 ml/min. 
       
1   5% 10% 15% 20% 25% 
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PEG 6000           
 
All cells contain 0.1 M Tris pH 8.6 
    
       
  
PEG 400 
    
2   5% 10% 15% 20% 25% 
 
0.2 M Lithium sulfate           
 
0.2 M Magnesium chloride           
 
0.2 M Tri Sodium citrate           
 
All cells contain 0.1 M Tris pH 8.6  
    
       
  
PEG 3350 
    
3   5% 10% 15% 20% 25% 
 
0.2 M Lithium sulfate           
 
0.2 M Magnesium chloride           
 
0.2 M Tri Sodium citrate           
 
All cells contain 0.1 M Tris pH 8.6  
    
       
  
PEG 6000 
    
4   5% 10% 15% 20% 25% 
 
0.2 M Lithium sulfate           
 
0.2 M Magnesium chloride           
 
0.2 M Tri Sodium citrate           
 
All cells contain 0.1 M Tris pH 8.6  
    
       
  
PEG 400 
    
5   30% 35% 40% 45% 50% 
 
0.2 M Lithium sulfate           
 
0.2 M Magnesium chloride           
 
0.2 M Tri Sodium citrate           
 
All cells contain 0.1 M Tris pH 8.6  
    
       
  
PEG 3350 
    
6   12% 14% 16% 18% 20% 
 
0.1 M Tris pH 8.4           
 
0.1 M Tris pH 8.6           
 
0.1 M Tris pH 8.8           
 
All cells contain 0.2 M Magnesium chloride 
   
       
       
7             
 

























0.1 M sodium acetate pH 4.6 
20% PEG 
400 25% PEG 400 
30% PEG 






       
  
PEG 6000 
    
8   12% 14% 16% 18% 20% 
 
0.1 M Tris pH 8.2           
 
0.1 M Tris pH 8.6           
 
0.1 M Tris pH 8.8           
 
All cells contain 0.2 M Magnesium chloride 
   
       
  
PEG 6000 
    
9   12% 14% 16% 18% 20% 
 
0.1 M Tris pH 8.2           
 
0.1 M Tris pH 8.6           
 
0.1 M Tris pH 8.8           
 
All cells contain 0.2 M Lithium sulfate 





    
  
PEG 3350 
    
10   12% 14% 16% 18% 20% 
 
0.1 M Magnesium formate           
 
0.2 M Magnesium formate           
 
0.3 M Magnesium formate           
 
All cells contain 0.1 M Tris pH 8.6 
     
       
  
PEG 1000 
    
11   16% 18% 20% 22% 24% 
 
0.1 M Sodium acetate trihydrate pH 4           
 
0.1 M Sodium acetate trihydrate pH 4.2           
 
0.1 M Sodium acetate trihydrate pH 4.4           
 
All cells contain 0.2 M Lithium sulfate 
    
       
  
PEG 3350 
    
12   14% 15% 16% 17% 18% 
 
0.1 M Magnesium chloride           
 
0.2 M Magnesium chloride           
 
0.3 M Magnesium chloride           
 
All cells contain 0.1 M Tris pH 8.6 
    
       
  
PEG 3350 
    
13   14% 15% 16% 17% 18% 
 
0.1 M Tris pH 8           
 
0.1 M Tris pH 8.6           
 
0.1 M Tris pH 9           
 
All cells contain 0.2 M Magnesium chloride 
   






    








14% PEG 3350           
 
15% PEG 3350           
 
16% PEG 3350           
 
All cells contain 0.1 M Tris pH 8.6 
    
       
       












14% PEG 3350           
 
15% PEG 3350           
 
16% PEG 3350           
       




    
16   12% 12.5% 13% 13.5% 14% 
 
0.3 M Magnesium chloride           
 
0.4 M Magnesium chloride           
 
0.5 M Magnesium chloride           
 
All cells contain 0.1 M Tris pH 8.6 
    
       
  
PEG 400 
    
17   20% 21% 22% 23% 24% 
 
0.1 M Sodium acetate trihydrate pH 4           
 
0.1 M Sodium acetate trihydrate pH 4.6           
 
0.1 M Sodium citrate tribasic dihydrate pH 5           
       
       
  
PEG 3350 
    
18   16% 18% 20% 22% 24% 
 
0.1 M Tri sodium citrate           
 
0.2 M Tri sodium citrate           
 
0.3 M Tri sodium citrate           
 
All cells contain 0.1 M Tris pH 8.6 
    
       
  
PEG 8000 
    
19   8% 9% 10% 11% 12% 
 
0.1 M Calcium acetate           
 
0.2 M Calcium acetate           
 
0.3 M Calcium acetate           
 
All cells contain 0.1 M HEPES pH 7.4 
    






    
20   17% 18% 19% 20% 21% 
 
0.1 M Sodium citrate tribasic dihydrate pH 5           
 
0.1 M Sodium citrate tribasic dihydrate pH 5.6           
 
0.1 M Sodium cacodylate trihydrate pH 6           
       
       
  
PEG 3350 
    
6   18% 19% 20% 21% 22% 
 
0.3 M Trisodium acetate           
 
0.2 M Trisodium acetate           
 
0.3 M Trisodium acetate           
 
All cells contain 0.1 M Tris pH 8.6 
    
       
  
PEG 1000 
    
7   pH 3.6 pH 4 pH 4.4 pH 4.8 pH 5.2 
 
18% PEG 1000           
 
20% PEG 1000           
 
22% PEG 1000           
 
  
     
       
  
PEG 1000 
    
21   14% 16% 18% 20% 22% 
 
0.2 M Lithium sulfate           
 
0.3 M Lithium sulfate           
 
0.4 M Lithium sulfate           
 
All cells contain 0.1 M Sodium acetate trihydrate pH 4.2 
    
       
  
PEG 1000 
    
22   16% 17% 18% 19% 20% 
 
0.1 M Lithium sulfate           
 
0.15 M Lithium sulfate           
 
0.2 M Lithium sulfate           
 
All cells contain 0.1 M Sodium acetate trihydrate pH 4 
   
       
  
PEG 1000 
    
23   16% 17% 18% 19% 20% 
 
0.1 M Lithium sulfate           
 
0.15 M Lithium sulfate           
 
0.2 M Lithium sulfate           
 
All cells contain 0.1 M Sodium acetate trihydrate pH 4.8 
    
Appendix 3.7 – Hand-made 15 well plates for optimisation of conditions to crystallise the 





















13 N 0.123 66 L 0.254 124 R 0.044 
14 L 0.215 67 D 0.481 125 Y 0.116 
15 L 0.125 68 G 0.498 126 A 0.106 
16 Y 0.245 69 F 0.296 127 I 0.140 
17 T 0.139 70 R 0.360 128 V 0.055 
18 R 0.319 71 T 0.328 129 A 0.134 
19 N 0.240 72 A 0.356 130 N 0.164 
20 D 0.229 73 L 0.243 131 D 0.121 
21 V 0.146 74 I 0.177 132 V 0.080 
22 S 0.267 75 D 0.275 133 R 0.110 
23 D 0.251 76 H 0.213 134 K 0.205 
24 S 0.167 77 L 0.165 135 A 0.152 
25 E 0.223 78 D 0.155 136 I 0.127 
26 K 0.186 79 T 0.182 137 G 0.386 
27 K 0.216 80 M 0.211 138 E 0.491 
28 A 0.173 81 A 0.363 139 A 0.208 
29 T 0.138 82 E 0.337 140 K 0.156 
30 V 0.116 83 R 0.206 141 D 0.252 
31 E 0.172 84 A 0.141 142 D 0.197 
32 L 0.110 85 V 0.178 143 D 0.069 
33 L 0.086 86 Q 0.180 144 T 0.151 
34 N 0.152 87 L 0.133 145 A 0.118 
35 R 0.135 88 G 0.055 146 D 0.113 
36 Q 0.151 89 G 0.088 147 I 0.125 
37 V 0.171 90 V 0.112 148 L 0.088 
38 I 0.118 91 A 0.094 149 T 0.156 
39 Q 0.080 92 L 0.079 150 A 0.116 
40 F 0.096 93 G 0.159 151 A 0.096 
41 I 0.112 94 T 0.189 152 S 0.165 
42 D 0.070 95 T 0.164 153 R 0.147 
43 L 0.109 96 Q 0.248 154 D 0.140 
44 S 0.070 97 V 0.200 155 L 0.198 
45 L 0.061 98 I 0.180 156 D 0.083 
46 I 0.079 99 N 0.083 157 K 0.078 
47 T 0.130 100 S 0.376 158 F 0.101 
48 K 0.232 101 K 0.164 159 L 0.127 
49 Q 0.101 102 T 0.147 160 W 0.058 




51 H 0.471 104 L 0.164 162 I 0.072 
52 W 0.150 105 K 0.234 163 E 0.079 
53 N 0.108 106 S 0.140 164 C 0.193 
54 M 0.194 107 Y 0.075 165 N 0.112 
55 R 0.132 108 P 0.128 
 
    
56 G 0.135 109 L 0.042 
 
    
57 A 0.169 110 D 0.136 
 
    
58 N 0.067 111 I 0.137 
 
    
59 F 0.066 112 H 0.028 
 
    
60 I 0.089 113 N 0.115 
 
    
61 A 0.149 114 V 0.128 
 
    
62 V 0.096 115 Q 0.116 
 
    
63 H 0.173 116 D 0.153 
 
    
64 E 0.122 122 A 0.080 
 
    
65 M 0.093 123 D 0.053 
 
    
                  
 
Figure 3.8 – RMSD calculations from a comparison of all the residues between the wild type 
Dps protein (PDB:1DPS1) and the obtained Dps+E crystal structure. RMSD calculation made 















Appendix for Chapter 4 
 
Table 1 
Primer name Primer sequences (5'-3') 
BfrWT F CATCTACAGCATATGAAAGGTGATACCAAAGTGATCAAC 
BfrWT R GAGGAGAACGGTTAACCTTCTTCACGGATCTGTGCCTGCAG 
BfrCC-N-term F CATCTACAGCATATGTGCTGCAAAGGTGATACCAAAGTGATCAAC 
BfrCCPGCC-N-term F CATCTACAGCATATGTGTTGTCCGGGCTGTTGTAAAGGTGATACCAAAGTGATCAAC 
 
Table 2 
Primer name Primer sequences (5'-3') 
BfrCC-C-term F CAGATCCGTGAAGAAGGTTGCTGCTGACTTCTCCTCAACCATGGCG     
BfrCC-C-term R CGCCATGGTTGAGGAGAAGTCAGCAGCAACCTTCTTCACGGATCTG 
BfrCCGPCC-C-term F CCGTGAAGAAGGTTGCTGCGGCCCGTGCTGCTAACATGGCGATATCGG      
BfrCCGPCC-C-term R CCGATATCGCCATGTTAGCAGCACGGGCCGCAGCAACCTTCTTCACGG 
BfrExt-C F CACAGATCCGTGAAGAAGGTTGTTGACGGGCTTCTCCTCAACCATGGCG 
BfrExt-C R CGCCATGGTTGAGGAGAAGCCCGTCAACAACCTTCTTCACGGATCTGTG 
BfrExt-G-C F CACAGATCCGTGAAGAAGGTGGTTGTTGACTTCTCCTCAACCATGGC 
BfrExt-G-C R GCCATGGTTGAGGAGAAGTCAACAACCACCTTCTTCACGGATCTGTG 
BfrN148C F CTGATCCAGAAAATGGGTCTGCAGTGCTACCTGCAGGCACAGATCCGTGAAG 
BfrN148C R CTTCACGGATCTGTGCCTGCAGGTAGCACTGCAGACCCATTTTCTGGATCAG 
BfrM147A,N148C F CTGATCCAGAAAATGGGTCTGGCCTGCTACCTGCAGGCACAGATCCGTGAAG 
BfrM147A,N148C R CTTCACGGATCTGTGCCTGCAGGTAGCAGGCCAGACCCATTTTCTGGATCAG 
BfrQ151C F GGGTCTGCAGAACTACCTGTGCGCACAGATCCGTGAAGAAGG 
BfrQ151C R GGGTCTGCAGAACTACCTGTGCGCACAGATCCGTGAAGAAGG 
BfrE157C F CTGCAGGCACAGATCCGTGAATGTGGTTGAACCGGGCTTCTCCTCAACC 
BfrE157C R GGTTGAGGAGAAGCCCGGTTCAACCACATTCACGGATCTGTGCCTGCAG 
 
Table 3 
Primer name Primer sequences (5'-3') 
BfrN23F F  AACGAACTGGTGGCAATCTTCCAGTACTTCCTGCATGCA 
BfrN23F R  TGCATGCAGGAAGTACTGGAAGATTGCCACCAGTTCGTT 
BfrD118W F  GTGCATGATTACGTGAGCCGTTTCATGATGATCGAAATCCTGCGT 
BfrD118W R  ACGCAGGATTTCGATCATCATGAAACGGCTCACGTAATCATGCAC 
 
Table 4 
Primer name Primer sequences (5'-3') 
BfrWT LIC F  GACGACGACAAGATGAAAGGTGATACCAAAGTGATCAAC 
BfrWT LIC R GAGGAGAACGGTTAACCTTCTTCACGGATCTGTGCCTGCAG 
BfrCCPGCC-N-term LIC F GACGACGACAAGATGTGTTGTCCGGGCTGTTGTAAAGGTGATACCAAAGTGATCAAC 
BfrCCPGCC-C-term LIC R  GAGAAGCCCGGTTAGCAGCACGGGCCGCAGCACCATTCTTC 
BfrCC-C-term LIC F  GACGACGACAAGATGTGCTGCAAAGGTGATACCAAAGTGATCAAC  





Appendix 4.1 - Primers used for the construction of all mutants and controls used in Chapter 4 
for Bfr. Table – Primers used to transfer the wild type Bfr gene from pET-32b to pET-22b and 
extend the N-terminus. Table 2 – Primers used to construct all pET-22b C-terminus designs and 
tetrapartite designs. Table 3 – Primers needed to introduce the nanocage stabilising mutations 
N23F and D118F. Table 4 – Primers needed to transfer successful bipartite designs and control 
from pET-22b to pEt-32b. All primers were sourced from Suprenom, Singapore. F - forward 
primer, R – reverse primer. 
 
Appendix 4.2 - SDS-PAGE (15%) of lysate samples for each Bfr bipartite designs diluted to 1 
mg/ml total protein concentration for comparison of expression levels. Lane 1: BfrCC-N-term, 
lane 2: BfrCCPGCC-N-term, lane 3: BfrCCPGCC-C-term, lane 4: BfrCC-C-term, lane 5: BfrCC-
N/C-term, lane 6: BfrWT, lane 7: BfrCC-C-termN23f, lane 8: BfrCC-N/C-termN23F, lane 9: 
BfrCC-C-termD118F, and lane 10: BfrCC-N/C-termD118F. Each gel (top and bottom) are from 





Appendix 4.3 - SDS-PAGE (15%) of lysate samples for each Bfr tetrapartite designs diluted to 1 
mg/ml total protein concentration for comparison of expression levels. Lane 1: BfrN148C, lane 
2: BfrM147A,N148C, lane 3: BfrQ151C: lane4: BfrE157C, lane 5: BfrExt-C, and lane 6: BfrExt-




Appendix 4.4 - SDS-PAGE (15%) of lysate samples for each stabilised Bfr tetrapartite designs 
diluted to 1 mg/ml total protein concentration for comparison of expression levels. Lane 1: 
BfrQ151CN23F, lane 2: BfrQ151CD118F, lane 3: BfrE157CN23F, and lane 4: BfrE157CD118F. 















Appendix 4.5 - SDS-PAGE (15%) analysis of the expression and purification of Bfr designs and 
controls used in Chapter 4. Lane 1: protein ladder 10KDa-250KDa; Lane 2: post induction, 
soluble fraction; Lane 3: post induction insoluble fraction; Lane 4: wash through from first 
Histrap; Lane 5: elution from first Histrap; Lane 6: post Enteriokinase digestion, second Histrap 
elution; Lane7: post Enteriokinase digestion, second Histrap wash; Lane 8: fraction after SEC, 
cage peak; Lane 9: fraction after SEC, dimer peak. 
 
 
Appendix 4.6 - Circular Dichroism spectra demonstrating that the wild type Bfr protein and the 
most successful design found in Chapter 4, BfrCC-C-term are folded.  Black: CD signal. Protein 
set to 0.2 mg/ml in phosphate buffer (50 mM Na2HPO4, 50 mM NaCl, pH 7) performed on 





Appendix 4.7 - Thermal melting plots of the Bfr wild type (BfrWT, Red), the purified most 
interesting bipartite designs (BfrCC-C-term, black and BfrCC-N/C-term, blue) monitored at 222 
nm with CD. Thermal melts were performed using 0.2 mg/ml protein in phosphate buffer, 50 
mM Na2HPO4, 50 mM NaCl, pH 7 in a range of 4 to 100 °C with a path length of 0.5 mm on a 
JASCO J-810 spectropolarimeter from 250 nm to 200 nm. Data fitted to a two state unfolding 
(m1+(m2-m1)/(1+(m0/m3)^m4)equation4, 5, 6 which calculated the melting temperature of 











































































Appendix 4.8 – Transmission electron microscopy micrographs to show the self-assembly 
ability of all the controls and designs used in Chapter 4, using 1% uranyl acetate as a negative 
stain. Images made using ImageJ7. 
 
Protein Measured mass (Da) Expected Mass (Da) Difference (Da) 
BfrWT 18493.6 18495.0 1.4 
BfrCCPGCC-N-term 19056.3 19061.8 5.5 
BfrCCPGCC-C-term 19055.6 19061.8 6.2 
BfrCC-C-term  18706.5 18701.3 5.2 
BfrCC-N/C-term 18902.1 18907.6 5.5 
BfrCC-C-termN23F  18741.2 18734.4 6.8 
BfrCC-C-termD118F  18726.8 18733.4 6.6 
BfrCCPGCC-C-term N23F 19058.0 19094.6 36.6 
BfrCCPGCC-C-term D118F 19072.3 19093.6 21.3 
 
Appendix 4.9 – Electrospray mass spectrometry analysis of all the Bfr controls and designs 
used in Chapter 4 that were purified, using 1% formic acid. 
 
Appendix 4.10 – Size exclusion chromatogram of purified Bfr inaccessible binding site 
nanocage stabilised designs BfrCCPGCC-C-termN23f and BfrCCPGCC-C-termD118F. 
Chromatogram normalised to their highest intensities and are an average of three runs each 
(0.5 ml injection of 0.5 mg/ml protein (followed at 280 nm), using running buffer, 100 mM 






Appendix 4.11 - Fluorescence analysis to detect Bfr assembly through binding site 
inaccessibility while varying the concentration of protein and denaturant but all with a 1:1 
molar ratio of protein to fluorophore. a, b and c), 0.01 mg/ml protein concentration. d, e and 
f), 0.001 mg/ml protein concentration. a and d) Purified proteins only (light grey), b and e)  
purified proteins with 3 M Gu·HCl denaturant (grey) c and f) Purified proteins with 6 M Gu·HCl 
denaturant (Dark grey). All designs in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM 
EDTA, pH 7.8) with, 3.5 mM TCEP, 1 mM EDT, 1 mM 2-ME and varying concentrations of FlAsH-





Appendix for Chapter 5 
 
Table 1 
Primer name Primer sequence (5'-3')       
Dps p22 F GGA ACT CAT ATG AGC ACC GCA AAA CTG GTG 
Dps p22 R GGT ACT CTC GAT TTA TTC GAT GTT GCA TTC G 
  
Table 2 
Primer name Primer sequence (5'-3')         
DpsCC F GAA TGC AAC ATC GAA TGC TGC TGA TTC TCC TCA ACC ATG GCG ATA TC 
DpsCC R GAT ATC GCC ATG GTT GAG GAG AAT CAG CAG CAT TCG ATG TTG CAT TC 
DpsGCC F GAA TGC AAC ATC GAA GGA TGC TGC TGA TCC TCA ACC ATG GCG ATA TC 
DpsGCC R GAT ATC GCC ATG GTT GAG GAT CAG CAG CAT CCT TCG ATG TTG CAT TC 
DpsGGCC GAA TGC AAC ATC GAA GGA GGT TGC TGC TGA TCA ACC ATG GCG ATA TC 
DpsGGCC GAT ATC GCC ATG GTT GAT CAG CAG CAA CCT CCT TCG ATG TTG CAT TC 
DpsGGGCC GAA TGC AAC ATC GAA GGC GGT GGA TGC TGC TGA ACC ATG GCG ATA TC 
DpsGGGCC R GAT ATC GCC ATG GTT CAG CAG CAT CCA CCT CCT TCG ATG TTG CAT TC 
DpsPAGCC F GAA TGC AAC ATC GAA CCA GCG GGA TGC TGC TGA ACC ATG GCG ATA TC 
DpsPAGCC R GAT ATC GCC ATG GTT CAG CAA CAT CCC GCT GGT TCG ATG TTG CAT TC 
DpsCCPGCC F GAA TGC AAC ATC GAA TGC TGC CCA GGT TGC TGC TAA ATG GCG ATA TC 
DpsCCPGCC R GAT ATC GCC ATT TAG CAG CAA CCT GGG CAG CAT TCG ATG TTG CAT TC 
 
Table 3 
Primer name Primer sequence (5'-3')         
DpsR18C,N19C F CAA CCA ACC TGC TGT ACA CCT GCT GCG ATG TGA GCG ATA GCG AAA AAA AAG 
DpsR18C,N19C R CTT TTT TTT CGC TAT CGC TCA CAT CGC AGC AGG TGT ACA GCA GGT TGG TTG 
DpsN19C,D20C F CCA ACC TGC TGT ACA CCC GTT GCT GCG TGA GCG ATA GCG AAA AAA AAG C 
DpsN19C,D20C R GCT TTT TTT TCG CTA TCG CTC ACG CAG CAA CGG GTG TAC AGC AGG TTG G 
DpsR18C,D20C F CAA CCA ACC TGC TGT ACA CCT GCA ACT GCG TGA GCG ATA GCG AAA AAA AAG 
DpsR18C,D20C R CTT TTT TTT CGC TAT CGC TCA CGC AGT TGC AGG TGT ACA GCA GGT TGG TTG 
DpsD123C,A126C F GAT CAT CTG AAA GAA CTG GCA TGC CGT TAC TGC ATC GTG GCA AAC GAT GTG CG 
DpsD123C,A126C R CGC ACA TCG TTT GCC ACG ATG CAG TAA CGG CAT GCC AGT TCT TTC AGA TGA TC 
DpsA126C,N130C F GAA CTG GCA GAT CGT TAC TGC ATC GTG GCA TGC GAT GTG CGT AAA GCA ATC GG 





Primer name Primer sequence (5'-3')       
DpsGGGCC p32 R GAG GAG AAG CCC GGT CAG CAG CAT CCA CCT CCT TC 
 DpsPAGCC p32 R GAG GAG AAG CCC GGT CAG CAA CAT CCC GCT G 





Dps F GAC GAC GAC AAG ATG AGC ACC GCA AAA CTG GTG 
  
Appendix 5.1 - Primers used for the construction of all designs and controls of Dps used in 
Chapter 5. Table 1 – Primers used to transfer the wild type Dps gene from pET-32b to pET-22b. 
Table 2 – Primers used to create all bipartite Dps designs. Table 3 – Primers used to create all 
geometrically correct Dps designs. Table 4 – Primers used to transfer the successful Dps 
bipartite designs from pET-22b to pET-32b for purification. Primers sourced from Supranom, 




Appendix 5.2 – Three fold axis of symmetry of Dps (PDB:1DPS1) highlighting native cysteine 
residues in the structure (red). While there is only one per-structure and near the C-terminus, 








Appendix 5.3 – SDS-PAGE (15%) of lysate samples for each Dps design diluted to 1 mg/ml total 







Appendix 5.4 – SDS-PAGE gel (15%) for each of the purified proteins explored in Chapter 5. 
Lane 1: Protein standard ladder (NEB), Lane 2: Soluble fraction, lane 3: insoluble fraction, lane 
4: wash from first histrap, lane 5: elution from first histrap, lane 6: elution from second histrap 




















Appendix 5.5 – Circular Dichroism spectra demonstrating the effect of heating on the fold of 
the Dps controls and bipartite designs purified in Chapter 5. Black:  CD signal before heating 
denaturation.  Red: CD signal after cooling post heating denaturation. The purified proteins (0.2 
mg/ml) were inspected in FlAsH buffer (100 mM Tris, 100 mM NaCl, 1 mM EDTA, pH 7.8). This 
experiment was performed on an Applied Photophysics LTD Chirascan spectrometer in a range 


































































































































Appendix 5.6 – Thermal melting plots of the Dps controls and bipartite designs purified in 
Chapter 5 at 222 nm in CD. Thermal melts were performed on all purified proteins (0.2 mg/ml 
in FlAsH buffer, 100 mM Tris, 100 mM NaCl, 1 mM EDTA, pH 7.8) in a range of 4 to 85 °C with a 
path length of 0.5 mm on an Applied Photophysics LTD Chirascan spectrometer from 250 nm 
to 200 nm. Data fitted to a two state unfolding (m1+(m2-m1)/(1+(m0/m3)^m4)equation4, 5, 6 




Design Tm average (°C) 
  
DpsCCPGCC 70.35 ± 1.42 
DpsGGGCC 61.87 ± 0.13 
DpsPAGCC 58.84 ± 0.40 






Appendix 5.7 – Melting temperature averages from the data seen in Appendix 5.6. S.D from 
three heating denaturation’s from each protein. 
 
Protein Measured mass (Da) Expected mass (Da) Difference (Da) 
DpsCCPGCC 19273.0 19278.0 5.0 
DpsGGGCC 19100.3 19088.8 -11.5 
DpsPAGCC 19154.0 19142.8 -11.2 
Dps 18710.2 18711.3 1.1 
  
Appendix 5.8 – Electrospray mass spectrometry analysis of all the Dps controls and designs 







Appendix 5.9 – CD signal from the Dps bipartite design DpsPAGCC during denaturation with 
Gu·HCl. The purified proteins (0.2 mg/ml) were inspected in FlAsH buffer (100 mM Tris, 100 
mM NaCl, 1 mM EDTA, pH 7.8). This experiment was performed on an Applied Photophysics 
LTD Chirascan spectrometer in a range of 200 nm to 260 nm with a path length of 0.5 mm. The 













































































Appendix 5.10 – Transmission electron microscopy micrographs to show the self-assembly 
ability of all the controls and designs used in Chapter 5, using 1% uranyl acetate as a negative 











Name   5’-3’ sequence 
DpsPAGCC (R83A) F CTG GAT ACC ATG GCA GAA GCA GCA GTG CAG CTG GGT GGT 
DpsPAGCC (R83A) R ACC ACC CAG CTG CAC TGC TGC TTC TGC CAT GGT ATC CAG 
DpsPAGCC (R133A) F TCG TGG CAA ACG ATG TGG CAA AAG CAA TCG GTG AAG C 
DpsPAGCC (R133A) R GCT TCA CCG ATT GCT TTT GCC ACA TCG TTT GCC ACG A 
  
  
DpsPAGCC (R83D) F CTG GAT ACC ATG GCA GAA GAC GCA GTG CAG CTG GGT GGT 
DpsPAGCC (R83D) R ACC ACC CAG CTG CAC TGC GTC TTC TGC CAT GGT ATC CAG 
DpsPAGCC (R133D) F TCG TGG CAA ACG ATG TGG ACA AAG CAA TCG GTG AAG C 
DpsPAGCC (R133D) R GCT TCA CCG ATT GCT TTG TCC ACA TCG TTT GCC ACG A 
  
  
DpsPAGCC (R83W) F CTG GAT ACC ATG GCA GAA TGG GCA GTG CAG CTG GGT GGT 
DpsPAGCC (R83W) R ACC ACC CAG CTG CAC TGC CCA TTC TGC CAT GGT ATC CAG 
DpsPAGCC (R133W) F TCG TGG CAA ACG ATG TGT GGA AAG CAA TCG GTG AAG C 







  5’-3’ sequence  
   
TM (°C) 
Dps(AA)PAGCC 19, 20, 21, F TAC ACC CGT NNS NNS NNS AGC GAT AG   64 
Dps(AA)PAGCC 86, 87, F CAG CAG TGN NSN NSG GTG GTG T   64 
Dps(AA)PAGCC 130, F ATC GTG GCA NNS GAT GTG GCA AAA G   63 
Dps(AA)PAGCC 141, 142, 143, F GTG AAG CAA AAN NSN NSN NSA CCG CAG AT 64 
Dps(AA)PAGCC 152, 153, 156, F CAG CAN NSN NSG ATC TGN NSA AAT TCC T 63 
DpsPAGCC R 
 
GCA ACA TCC CGC TGG TTC GAT GTT   63 






   
Name 5’-3’ sequence           
Dps LIC F GAC GAC GAC AAG ATG AGC ACC GCA AAA CTG GTG 
DpsCCPGCC LIC R GAG GAG AAG CCC GGT TAG CAG CAA CCT GGG CAG 
Dps PAGCC LIC R GAG GAG AAG CCC GGT CAG CAA CAT CCC GCT G 
 DpsWT LIC R GAG GAG AAG CCC GGT TAT TCG ATG TTG CAT TCG 
 
  






Primer sequence (5’-3’) 
TM 
(°C) 
Dps(AA)PAGCC 19, 20, 21, F 
CCT GCT GTA CAC CCG TNN SNN SNN SAG CGA TAG CGA AAA 
AAA AG 66 
Dps(AA)PAGCC 86, 87, F AGA AGC AGC AGT GNN SNN SGG TGG TGT GGC ACT 71 
Dps(AA)PAGCC 130, F 
ATC GTT ACG CAA TCG TGG CAN NSG ATG TGG CAA AAG CAA 
TC 67 
Dps(AA)PAGCC 141, 142, 143, F 
ATC GGT GAA GCA AAA NNS NNS NNS ACC GCA GAT ATC CTG 
ACC G 66 
Dps(AA)PAGCC 152, 153, 156, F 
GAT ATC CTG ACC GCA GCA NNS NNS GAT CTG NNS AAA TTC 
CTG TG 67 
DpsPAGCC R TCA GCA ACA TCC CGC TGG TTC GAT GTT GCA TTC GAT GAA 68 
 
Appendix 6.1 – Primers used in the investigation undertaken in Chapter 6. Table 1 – Primers 
used to transfer the Dps genes from Chapter 5 that were in pET-32b to pET-46. Table 2 – 
Primers used to introduce the nanocage crippling mutations into the Dps positions R83 and 
R133. Table 3 – Short primers used in the creation of a TPCR library. Table 4 – Long primers 
used in the creation the TPCR library. Primer sourced from Eurofins, Germany. F – Forward 









Appendix 6.2 – SDS-PAGE gel (15%) for each of the purified proteins explored in Chapter 6. 
Lane 1: Protein standard ladder (NEB), Lane 2: Soluble fraction, lane 3: insoluble fraction, lane 
4: wash from histrap, lane 5: elution from histrap, lane 6: SEC. 
Protein Measured mass (Da) Expected Mass (Da) Difference (Da) 
DpsWT 20710.9 20422.3 -288.5 
DpsPAGCC 20710.8 20853.9 143.1 
Dps(AA)PAGCC 20540.7 20681.6 140.9 
DpsCCPGCC 20833.4 21214.3 380.9 
Dps(AA)PAGCC Q86V,L87F, N130F 20824.5 20719.7 -104.8 
Dps(AA)PAGCC Q86R, L87G, N130Stop 16994.7 16208.8 -785.9 
Dps(AA)PAGCC N130Y 20828.4 20730.7 -97.7 
Dps(AA)PAGCC N130L, D1414D, D142W, 
D143G 20540.7 20695.8 155.1 
Dps(DD)PAGCC 20650.0 20769.6 119.6 
Dps(WW)PAGCC 20798.0 20911.8 113.8 
    
 
Appendix 6.3 – Maldi-TOF mass spectrometry analysis of the purified proteins explored in 










































































Appendix 6.4 – Transmission electron microscopy micrographs to show the self-assembly 
ability of all the controls and designs used in Chapter 6, using 1% uranyl acetate as a negative 





Appendix 6.5 – Analysis of the interaction network at the three-fold Dps like symmetry axis of 
a crystal structure (PDB:1DPS1) around the residues R82 and R133. Blue box represents an 
interaction between those amino acids. Analysis performed using the Contact map analysis 












Appendix 6.6 – 1% agarose gels to analyse the success of the PCR reaction to create the TPCR 




kb ladder. All wells loaded with 10 µl of PCR product solution after mixing with 6 x loading dye. 
Red dashed box highlights the position of the expected amplified plasmid band. 
 
    
Amount of primer 
(ng) 
    
      













1 Long 40 40 40 40 40 40 20 2 1 
2 Long 80 80 80 80 80 80 20 2 1 
3 Long 20 20 20 20 20 20 20 2 1 
4 Long 40 40 40 40 40 40 20 2 2 
5 Long 80 80 80 80 80 80 20 2 2 
6 Long 20 20 20 20 20 20 20 2 2 
7 Long 40 40 40 40 40 40 20 2 3 
8 Long 80 80 80 80 80 80 20 2 3 
9 Long 20 20 20 20 20 20 20 2 3 
10 Long 40 40 40 40 40 40 20 2 4 
11 Long 80 80 80 80 80 80 20 2 4 
12 Long 20 20 20 20 20 20 20 2 4 
 
                  
 13 Short 10 10 10 10 10 10 20 2 1 
14 Short 20 20 20 20 20 20 20 2 1 
15 Short 40 40 40 40 40 40 20 2 1 
16 Short 10 10 10 10 10 10 20 2 3 
17 Short 20 20 20 20 20 20 20 2 3 
18 Short 40 40 40 40 40 40 20 2 3 
19 Long 10 10 10 10 10 10 20 2 3 
20 Long 20 20 20 20 20 20 20 2 3 
21 Long 40 40 40 40 40 40 20 2 3 
22 Short 10 10 10 10 10 10 20 2 4 
23 Short 20 20 20 20 20 20 20 2 4 
24 Short 40 40 40 40 40 40 20 2 4 
25 Long 10 10 10 10 10 10 20 2 4 
26 Long 20 20 20 20 20 20 20 2 4 
27 Long 40 40 40 40 40 40 20 2 4 
 
                  
 28 Long 5 5 5 5 5 5 20 0 3 
29 Long 10 10 10 10 10 10 20 0 3 
30 Long 15 15 15 15 15 15 20 0 3 
31 Long 5 5 5 5 5 5 20 1 3 
32 Long 10 10 10 10 10 10 20 1 3 
33 Long 15 15 15 15 15 15 20 1 3 
34 Long 5 5 5 5 5 5 20 2 3 
35 Long 10 10 10 10 10 10 20 2 3 




37 Long 5 5 5 5 5 5 20 0 4 
38 Long 10 10 10 10 10 10 20 0 4 
39 Long 15 15 15 15 15 15 20 0 4 
40 Long 5 5 5 5 5 5 20 1 4 
41 Long 10 10 10 10 10 10 20 1 4 
42 Long 15 15 15 15 15 15 20 1 4 
43 Long 5 5 5 5 5 5 20 2 4 
44 Long 10 10 10 10 10 10 20 2 4 
45 Long 15 15 15 15 15 15 20 2 4 
 
                  
 46 Long 5 5 5 5 5 5 10 0 3 
47 Long 10 10 10 10 10 10 10 0 3 
48 Long 15 15 15 15 15 15 10 0 3 
49 Long 5 5 5 5 5 5 10 1 3 
50 Long 10 10 10 10 10 10 10 1 3 
51 Long 15 15 15 15 15 15 10 1 3 
52 Long 5 5 5 5 5 5 10 2 3 
53 Long 10 10 10 10 10 10 10 2 3 
54 Long 15 15 15 15 15 15 10 2 3 
55 Long 5 5 5 5 5 5 10 0 4 
56 Long 10 10 10 10 10 10 10 0 4 
57 Long 15 15 15 15 15 15 10 0 4 
58 Long 5 5 5 5 5 5 10 1 4 
59 Long 10 10 10 10 10 10 10 1 4 
60 Long 15 15 15 15 15 15 10 1 4 
61 Long 5 5 5 5 5 5 10 2 4 
62 Long 10 10 10 10 10 10 10 2 4 
63 Long 15 15 15 15 15 15 10 2 4 
 
                  
 64 Long 0 0 0 0 0 0 20 2 4 
65 Long 2 2 2 2 2 2 20 2 4 
66 Long 4 4 4 4 4 4 20 2 4 
67 Long 6 6 6 6 6 6 20 2 4 
68 Long 8 8 8 8 8 8 20 2 4 
69 Long 10 10 10 10 10 10 20 2 4 
 
                  
 70 Long 10 6 6 6 10 6 20 2 4 
71 Mix Short 6 Long 6 Long 6 Long 6 Short 6 Long 6 20 2 4 
72 Long 6 6 6 6 6 6 20 2 4 
73 Short 6 6 6 6 6 6 20 2 4 
 
                  
  
Program 1 - The PCR reaction contained a total volume of 50 µl including, Pfu reaction buffer 
(Promega, 5 µl of 10), dNTP mix (Promega, 2 µl of a solution containing dATP, dTTP, dGTP, and 




Pfu polymerase (Promega, 1 µl of 3 U/µl) and deionised H2O (to a total of 50 µl) which was 
subjected to an initial melting step (95 °C for 5 min) followed by 20 cycles of amplification (95 
°C for 30 s, 56 °C for 1 min, raising 0.3 °C every cycle and 72 °C for 6 min) followed by 20 more 
cycles of amplification (95 °C for 30 s, 64 °C for 1 min, raising 0.3 °C every cycle and 72 °C for 6 
min) finishing with 72 °C for 10 min.  
Program 2 - The PCR reaction contained a total volume of 50 µl including, Pfu reaction buffer 
(Promega, 5 µl of 10), dNTP mix (Promega, 2 µl of a solution containing dATP, dTTP, dGTP, and 
dCTP at 2 mM each), and primers, template and DMSO concentrations as stated above and, 
Pfu polymerase (Promega, 1 µl of 3 U/µl) and deionised H2O (to a total of 50 µl) which was 
subjected to an initial melting step (95 °C for 5 min) followed by 10 cycles of amplification (95 
°C for 30 s, 56 °C for 1 min and 72 °C for 6 min) with 10 more cycles of amplification (95 °C for 
30 s, 58 °C for 1 min and 72 °C for 6 min) with 10 more cycles of amplification (95 °C for 30 s, 
64 °C for 1 min and 72 °C for 6 min) with 10 more cycles of amplification (95 °C for 30 s, 66 °C 
for 1 min and 72 °C for 6 min) followed with 72 °C for 10 min.  
Program 3 - The PCR reaction contained a total volume of 50 µl including, Pfu reaction buffer 
(Promega, 5 µl of 10), dNTP mix (Promega, 2 µl of a solution containing dATP, dTTP, dGTP, and 
dCTP at 2 mM each), and primers, template and DMSO concentrations as stated above and, 
Pfu polymerase (Promega, 1 µl of 3 U/µl) and deionised H2O (to a total of 50 µl) which was 
subjected to an initial melting step (95 °C for 5 min) followed by 10 cycles of amplification (95 
°C for 30 s, 58 °C for 1 min and 72 °C for 6 min) with 10 more cycles of amplification (95 °C for 
30 s, 60 °C for 1 min and 72 °C for 6 min) with 10 more cycles of amplification (95 °C for 30 s, 
66 °C for 1 min and 72 °C for 6 min) with 10 more cycles of amplification (95 °C for 30 s, 68 °C 
for 1 min and 72 °C for 6 min) followed with 72 °C for 10 min. 
Program 4 (see methods and materials Chapter 6)- The PCR reaction contained a total volume 
of 50 µl including, Pfu reaction buffer (Promega, 5 µl of 10), dNTP mix (Promega, 2 µl of a 
solution containing dATP, dTTP, dGTP, and dCTP at 2 mM each), and primers, template and 
DMSO concentrations as stated above and, Pfu polymerase (Promega, 1 µl of 3 U/µl) and 
deionised H2O (to a total of 50 µl) which was subjected to an initial melting step (95 °C for 5 
min) followed by 40 cycles of amplification (95 °C for 30 s, 58 °C for 1 min, raising 0.3 °C every 
cycle and 72 °C for 6 min) followed by 72 °C for 10 min.  
Appendix 6.7 – Summary of the conditions assayed to create the TPCR library for Chapter 6. 
Table highlights the sample name, which corresponds to the gel lane in Appendix 6.6, the 
primer set that was used either long or short (see Appendix 6.1) the concentration of each 






Appendix 6.8 – Circular Dichroism spectra demonstrating the effect of heating on the fold of 
the Dps controls and bipartite designs purified in Chapter 6. Black:  CD signal before heating 
denaturation.  Red: CD signal after cooling post heating denaturation. The purified proteins 
(0.2 mg/ml) were inspected in FlAsH buffer (100 mM Tris, 100 mM NaCl, 1 mM EDTA, pH 7.8). 
This experiment was performed on an Applied Photophysics LTD Chirascan spectrometer in a 





Appendix 6.9 – Thermal melting plots of the Dps controls and designs purified in Chapter 6 at 
222 nm in CD. Thermal melts were performed on all purified proteins (0.2 mg/ml in FlAsH 
buffer, 100 mM Tris, 100 mM NaCl, 1 mM EDTA, pH 7.8) in a range of 4 to 85 °C with a path 






Sequence Appendix  
 Comparison of the sequencing results with expected sequence. Sequencing result 
shown on the top line, aligned with the expected sequence on the bottom. Yellow indicates 
extension or codon mutation. Protein design and vector used is indicated in each sequence 
alignment title. 
Sequence Appendix 2 - Sequence alignment for all mutants used in nanoparticle formation in 
chapter 2. ‘Query’, obtained from sequence results from Supranom, Singapore, aligned against 
expected sequences ‘Subject’. Aligned using Blast10. 
 
Wild type proteins in pET-32b 
DpsWT in pET-32b 
Query  9    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  68 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  69   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  128 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  129  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  188 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  189  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  248 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  249  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  308 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  309  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  368 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  369  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  428 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  429  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  488 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  489  TTCATCGAATGCAACATCGAATAA  512 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA  504 
 
BfrWT in pET-32b 
Query  543   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  602 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  603   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  662 




Sbjct  61    GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  663   AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  722 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  723   CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  782 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  783   GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  842 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  843   CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  902 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  903   ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  962 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  963   ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGA  1019 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 






Sequence Appendix 3 - Sequence alignment for the Dps+E mutant used in chapter 3. E-helix 
highlighted in grey. ‘Query’, obtained from sequence results from Supranom, Singapore, 
aligned against expected sequences ‘Subject’. Aligned using Blast10. 
Dps+E in pET-46 plasmid 
Query  61   ATGGCACATCACCACCACCATCACGTGGATGACGACGACAAGATGAGCACCGCAAAACTG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGGCACATCACCACCACCATCACGTGGATGACGACGACAAGATGAGCACCGCAAAACTG  60 
 
Query  121  GTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGATGTGAGCGATAGCGaaaaa  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGATGTGAGCGATAGCGAAAAA  120 
 
Query  181  aaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTCATCGATCTGAGCCTGATC  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTCATCGATCTGAGCCTGATC  180 
 
Query  241  ACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATCGCAGTGCATGAAATGCTG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  ACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATCGCAGTGCATGAAATGCTG  240 
 
Query  301  GATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATGGCAGAACGTGCAGTGCAG  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATGGCAGAACGTGCAGTGCAG  300 
 
Query  361  CTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGCAAAACCCCGCTGAAAAGC  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGCAAAACCCCGCTGAAAAGC  360 
 
Query  421  TACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAACTGGCAGATCGTTACGCA  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  TACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAACTGGCAGATCGTTACGCA  420 
 
Query  481  ATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAAGATGATGATACCGCAGAT  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAAGATGATGATACCGCAGAT  480 
 
Query  541  ATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGGTTCATCGAATGCAACCTG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  ATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGGTTCATCGAATGCAACCTG  540 
 
Query  601  GATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGT  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541  GATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGT  600 
 
Query  661  TGA  663 
            ||| 





Sequence Appendix 4 - Sequence alignment for all Bfr mutants used in chapter 4. Grey 
indicates the added or mutated codons. ‘Query’, obtained from sequence results from 
Supranom, Singapore, aligned against expected sequences ‘Subject’. Aligned using Blast10. 
Designs and controls in pET-22b for lysate analysis 
BfrWT 
Query  52   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  111 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  112  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  171 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  172  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  231 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  232  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  291 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  292  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  351 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  352  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  411 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  412  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  471 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  472  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTAA  528 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTAA  477 
 
BfrCC-N-term 
Query  50   ATGTGTTGCAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAA  109 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGTGTTGCAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAA  60 
 
Query  110  CTGGTGGCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAA  169 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   CTGGTGGCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAA  120 
 
Query  170  CGTCTGAACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTAC  229 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  CGTCTGAACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTAC  180 
 
Query  230  ATCGAACGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAAC  289 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  ATCGAACGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAAC  240 
 
Query  290  ATCGGTGAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCA  349 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  ATCGGTGAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCA  300 
 




            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAAACCTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGAT  360 
 
Query  410  ATGATGATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTG  469 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATGATGATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTG  420 
 
Query  470  GATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGT  529 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGT  480 
 
Query  530  TAA  533 
            ||| 
Sbjct  481  TAA  484 
 
BfrCCPGCC-N-term 
Query  49   ATGTGTTGTCCGGGCTGTTGTAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTG  108 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGTGTTGTCCGGGCTGTTGTAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTG  60 
 
Query  109  CTGGGTAACGAACTGGTGGCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAAC  168 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   CTGGGTAACGAACTGGTGGCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAAC  120 
 
Query  169  TGGGGTCTGAAACGTCTGAACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACAT  228 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  TGGGGTCTGAAACGTCTGAACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACAT  180 
 
Query  229  GCAGATCGTTACATCGAACGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTG  288 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGATCGTTACATCGAACGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTG  240 
 
Query  289  GGTAAACTGAACATCGGTGAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAA  348 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GGTAAACTGAACATCGGTGAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAA  300 
 
Query  349  CTGGATGGTGCAAAAAACCTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTAC  408 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGGATGGTGCAAAAAACCTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTAC  360 
 
Query  409  GTGAGCCGTGATATGATGATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTG  468 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  GTGAGCCGTGATATGATGATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTG  420 
 
Query  469  GAAACCGAACTGGATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATC  528 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GAAACCGAACTGGATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATC  480 
 
Query  529  CGTGAAGAAGGTTAA  543 
            ||||||||||||||| 
Sbjct  481  CGTGAAGAAGGTTAA  495 
 
BfrCC-C-term 
Query  51   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  110 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  111  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  170 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  171  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  230 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  231  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  290 




Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  291  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  350 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  351  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  410 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  411  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  470 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  471  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  530 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  480 
 
Query  531  TGA  534 
            ||| 
Sbjct  481  TGA  484 
 
BfrCC-N/C-term 
Query  48   ATGTGTTGCAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAA  107 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGTGTTGCAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAA  60 
 
Query  108  CTGGTGGCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAA  167 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   CTGGTGGCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAA  120 
 
Query  168  CGTCTGAACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTAC  227 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  CGTCTGAACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTAC  180 
 
Query  228  ATCGAACGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAAC  287 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  ATCGAACGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAAC  240 
 
Query  288  ATCGGTGAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCA  347 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  ATCGGTGAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCA  300 
 
Query  348  AAAAACCTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGAT  407 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAAACCTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGAT  360 
 
Query  408  ATGATGATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTG  467 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATGATGATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTG  420 
 
Query  468  GATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGT  527 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGT  480 
 
Query  528  TGCTGCTGA  536 
            ||||||||| 
Sbjct  481  TGCTGCTGA  489 
 
BfrCCGPCC-C-term 
Query  46   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  105 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  106  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  165 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  166  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  225 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  226  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  285 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  286  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  345 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  346  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  405 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  406  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  465 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  466  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  525 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  480 
 
Query  526  GGCCCGTGCTGCTGA  540 
            ||||||||||||||| 
Sbjct  481  GGCCCGTGCTGCTGA  495 
 
BfrExt-C 
Query  59   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  118 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  119  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  178 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  179  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  238 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  239  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  298 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  299  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  358 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  359  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  418 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  419  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  478 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  479  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGTTGA  537 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGTTGA  480 
 
BfrExt-G-C 
Query  48   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  107 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  108  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  167 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  168  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  227 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  228  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  287 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  288  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  347 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  348  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  407 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  408  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  467 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  468  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTGGTTGT  527 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTGGTTGT  480 
 
Query  528  TGA  531 
            ||| 
Sbjct  481  TGA  484 
 
BfrN148C 
Query  52   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  111 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  112  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  171 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  172  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  231 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  232  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  291 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  292  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  351 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  352  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  411 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  412  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  471 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  472  ATCCAGAAAATGGGTCTGCAGTGCTACCTGCAGGCACAGATCCGTGAAGAAGGTTAA  528 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGTGCTACCTGCAGGCACAGATCCGTGAAGAAGGTTAA  477 
 
BfrM147A,N148C 




            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  109  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  168 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  169  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  228 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  229  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  288 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  289  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  348 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  349  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  408 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  409  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  468 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  469  ATCCAGAAAATGGGTCTGGCTTGCTACCTGCAGGCACAGATCCGTGAAGAAGGTTAA  525 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGGCTTGCTACCTGCAGGCACAGATCCGTGAAGAAGGTTAA  477 
 
BFRQ151C 
Query  63   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  122 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  123  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  182 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  183  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  242 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  243  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  302 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  303  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  362 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  363  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  422 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  423  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  482 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  483  ATCCAGAAAATGGGTCTGCAGAACTACCTGTGCGCACAGATCCGTGAAGAAGGTTAA  539 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGTGCGCACAGATCCGTGAAGAAGGTTAA  477 
 
BfrE157C 
Query  59   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  118 




Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  119  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  178 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  179  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  238 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  239  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  298 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  299  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  358 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  359  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  418 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  419  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  478 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  479  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAATGTGGTTAA  535 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAATGTGGTTAA  477 
 
BfrCC-C-termN23F 
Query  64   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  123 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  124  GCAATCTTCCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  183 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCTTCCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  184  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  243 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  244  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  303 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  304  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  363 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  364  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  423 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  424  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  483 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  484  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  543 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  480 
 
Query  544  TGA  547 
            ||| 






Query  63   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  122 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  123  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  182 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  183  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  242 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  243  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  302 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  303  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  362 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  363  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTTTCATGATG  422 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTTTCATGATG  360 
 
Query  423  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  482 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  483  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  542 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  480 
 
Query  543  TGA  546 
            ||| 
Sbjct  481  TGA  484 
 
BFRQ151C,N23F 
Query  53   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  112 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  113  GCAATCTTCCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  172 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCTTCCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  173  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  232 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  233  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  292 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  293  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  352 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  353  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  412 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  413  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  472 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 




            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGTGCGCACAGATCCGTGAAGAAGGTTGA  477 
 
BFRQ151C,D118F 
Query  48   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  107 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  108  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  167 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  168  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  227 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  228  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  287 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  288  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  347 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  348  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTTTCATGATG  407 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTTTCATGATG  360 
 
Query  408  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  467 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  468  ATCCAGAAAATGGGTCTGCAGAACTACCTGTGCGCACAGATCCGTGAAGAAGGTTGA  524 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGTGCGCACAGATCCGTGAAGAAGGTTGA  477 
 
BfrE157C,N23F 
Query  51   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  110 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  111  GCAATCTTCCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  170 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCTTCCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  171  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  230 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  231  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  290 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  291  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  350 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  351  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  410 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  411  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  470 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  471  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAATGTGGTTGA  527 




Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAATGTGGTTGA  477 
 
BfrE157C,D118F 
Query  49   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  108 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  109  GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  168 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  169  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  228 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  229  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  288 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  289  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  348 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  349  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTTTCATGATG  408 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTTTCATGATG  360 
 
Query  409  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  468 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  469  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAATGTGGTTGA  525 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAATGTGGTTGA  477 
 
Designs and controls in pET-32b to allow for protein purification 
BfrWT  
Query  543   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  602 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  603   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  662 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  663   AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  722 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  723   CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  782 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  783   GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  842 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  843   CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  902 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  903   ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  962 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 




             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGA  477 
 
BfrCC-C-term 
Query  535   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  594 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  595   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  654 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  655   AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  714 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  715   CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  774 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  775   GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  834 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  835   CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  894 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  895   ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  954 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  955   ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  
1014 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  480 
Query  1015  TAA  1028 
             ||| 
Sbjct  481   TAA  484 
 
BfrCC-N/C-term 
Query  537   ATGTGCTGCAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAA  596 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGTGCTGCAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAA  60 
 
Query  597   CTGGTGGCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAA  656 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    CTGGTGGCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAA  120 
 
Query  657   CGTCTGAACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTAC  716 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   CGTCTGAACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTAC  180 
 
Query  717   ATCGAACGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAAC  776 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   ATCGAACGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAAC  240 
 
Query  777   ATCGGTGAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCA  836 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   ATCGGTGAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCA  300 
 
Query  837   AAAAACCTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGAT  896 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   AAAAACCTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGAT  360 
 




             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   ATGATGATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTG  420 
 
Query  957   GATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGT  
1016 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   GATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGT  480 
 
Query  1017  TGCTGCTAA  1025 
             ||||||||| 
Sbjct  481   TGCTGCTAA  489 
 
BfrCCPGCC-N-term 
Query  527   ATGTGTTGTCCGGGCTGTTGTAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTG  586 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGTGTTGTCCGGGCTGTTGTAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTG  60 
 
Query  587   CTGGGTAACGAACTGGTGGCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAAC  646 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    CTGGGTAACGAACTGGTGGCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAAC  120 
 
Query  647   TGGGGTCTGAAACGTCTGAACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACAT  706 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   TGGGGTCTGAAACGTCTGAACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACAT  180 
 
Query  707   GCAGATCGTTACATCGAACGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTG  766 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   GCAGATCGTTACATCGAACGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTG  240 
 
Query  767   GGTAAACTGAACATCGGTGAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAA  826 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   GGTAAACTGAACATCGGTGAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAA  300 
 
Query  827   CTGGATGGTGCAAAAAACCTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTAC  886 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   CTGGATGGTGCAAAAAACCTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTAC  360 
 
Query  887   GTGAGCCGTGATATGATGATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTG  946 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   GTGAGCCGTGATATGATGATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTG  420 
 
Query  947   GAAACCGAACTGGATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATC  
1006 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   GAAACCGAACTGGATCTGATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATC  480 
 
Query  1007  CGTGAAGAAGGTTAA  1021 
             ||||||||||||||| 
Sbjct  481   CGTGAAGAAGGTTAA  495 
 
BfrCCGPCC-C-term  
Query  528   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  587 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  588   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  647 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  648   AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  707 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  708   CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  767 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  768   GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  827 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  828   CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  887 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  888   ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  947 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  948   ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  
1007 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  480 
 
Query  1008  GGCCCGTGCTGCTAA  1022 
             ||||||||||||||| 
Sbjct  481   GGCCCGTGCTGCTAA  495 
 
BfrCC-C-term,N23F 
Query  42   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  101 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  102  GCAATCTTCCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  161 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCTTCCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  162  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  221 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  222  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  281 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  282  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  341 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  342  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  401 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  402  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  461 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  462  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  521 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  480 
 
Query  522  TGA  524 
            ||| 
Sbjct  481  TGA  483 
BfrCC-C-term,D118F 
Query  26   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  85 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  86   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  145 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  146  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  205 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  206  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  265 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  266  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  325 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  326  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTTTCATGATG  385 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTTTCATGATG  360 
 
Query  386  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  445 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  446  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  505 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  480 
 
Query  506  TGA  508 
            ||| 
Sbjct  481  TGA  483 
BfrCCGPCC-C-term,N23F 
Query  30   ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  89 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  90   GCAATCTTCCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  149 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCTTCCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  150  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  209 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  210  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  269 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  270  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  329 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  330  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  389 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTGATATGATG  360 
 
Query  390  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  449 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  450  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  509 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  480 
 
Query  510  GGCCCGTGCTGCTGA  524 
            ||||||||||||||| 
Sbjct  481  GGCCCGTGCTGCTGA  495 
BfrCCGPCC-C-term,D118F 




            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAAAGGTGATACCAAAGTGATCAACTACCTGAACAAACTGCTGGGTAACGAACTGGTG  60 
 
Query  87   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  146 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GCAATCAACCAGTACTTCCTGCATGCACGTATGTTCAAAAACTGGGGTCTGAAACGTCTG  120 
 
Query  147  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  206 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AACGATGTGGAATACCATGAAAGCATCGATGAAATGAAACATGCAGATCGTTACATCGAA  180 
 
Query  207  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  266 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CGTATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGTAAACTGAACATCGGT  240 
 
Query  267  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  326 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GAAGATGTGGAAGAAATGCTGCGTAGCGATCTGGCACTGGAACTGGATGGTGCAAAAAAC  300 
 
Query  327  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTTTCATGATG  386 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CTGCGTGAAGCAATCGGTTACGCAGATAGCGTGCATGATTACGTGAGCCGTTTCATGATG  360 
 
Query  387  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  446 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  ATCGAAATCCTGCGTGATGAAGAAGGTCATATCGATTGGCTGGAAACCGAACTGGATCTG  420 
 
Query  447  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  506 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  ATCCAGAAAATGGGTCTGCAGAACTACCTGCAGGCACAGATCCGTGAAGAAGGTTGCTGC  480 
 
Query  507  GGCCCGTGCTGCTGA  521 
            ||||||||||||||| 
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Eurofins, Germany, aligned against expected sequences ‘Subject’. Aligned using Blast10. 
Designs and controls in pET-22b for lysate analysis 
 
DpsR18C,N19C,A126C,N130C 
Query  51   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCTGCTGCGAT  110 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCTGCTGCGAT  60 
 
Query  111  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  170 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  171  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  230 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  231  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  290 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  291  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  350 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  351  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  410 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  411  CTGGCAGATCGTTACTGCATCGTGGCATGCGATGTGCGTAAAGCAATCGGTGAAGCAAAA  470 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACTGCATCGTGGCATGCGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  471  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  530 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  531  TTCATCGAATGCAACATCGAATAA  554 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA  504 
 
DpsR18C,N19C,D123C,A126C 
Query  62   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCTGCTGCGAT  121 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCTGCTGCGAT  60 
 
Query  122  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  181 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  182  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  241 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  242  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  301 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  302  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  361 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 




            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  422  CTGGCATGCCGTTACTGCATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  481 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCATGCCGTTACTGCATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  482  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  541 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  542  TTCATCGAATGCAACATCGAATAA  565 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA  504 
 
DpsN19C,D20C,D123C,A126C 
Query  60   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTTGCTGC  119 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTTGCTGC  60 
 
Query  120  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  179 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  180  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  239 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  240  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  299 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  300  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  359 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  360  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  419 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  420  CTGGCATGCCGTTACTGCATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  479 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCATGCCGTTACTGCATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  480  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  539 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  540  TTCATCGAATGCAACATCGAATAA  563 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA 504 
 
DpsN19C,D20C,A126C,N130C 
Query  59   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTTGCTGC  118 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTTGCTGC  60 
 
Query  119  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  178 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  179  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  238 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  239  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  298 




Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  299  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  358 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  359  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  418 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  419  CTGGCAGATCGTTACTGCATCGTGGCATGCGATGTGCGTAAAGCAATCGGTGAAGCAAAA  478 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACTGCATCGTGGCATGCGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  479  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  538 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  539  TTCATCGAATGCAACATCGAATAA  562 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA  504 
 
DpsR18C,D20C,D123C,A126C,N130C 
Query  60   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCTGCAACTGC  119 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCTGCAACTGC  60 
 
Query  120  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  179 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  180  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  239 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  240  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  299 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  300  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  359 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  360  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  419 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  420  CTGGCATGCCGTTACTGCATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  479 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCATGCCGTTACTGCATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  480  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  539 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  540  TTCATCGAATGCAACATCGAATAA  563 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA  504 
 
DpsR18C,D20C,A126C,N130C 
Query  57   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCTGCAACTGC  116 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCTGCAACTGC  60 
 
Query  117  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  176 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  177  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  236 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  237  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  296 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  297  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  356 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  357  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  416 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  417  CTGGCAGATCGTTACTGCATCGTGGCATGCGATGTGCGTAAAGCAATCGGTGAAGCAAAA  476 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACTGCATCGTGGCATGCGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  477  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  536 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  537  TTCATCGAATGCAACATCGAATAA  560 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA  504 
 
DpsWT  
Query  50   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  109 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  110  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  169 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  170  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  229 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  230  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  289 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  290  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  349 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  350  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  409 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  410  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  469 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  470  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  529 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  530  TTCATCGAATGCAACATCGAATAA  553 
            |||||||||||||||||||||||| 







Query  41   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  100 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  101  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  160 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  161  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  220 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  221  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  280 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  281  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  340 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  341  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  400 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  401  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  460 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  461  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  520 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  521  TTCATCGAATGCAACATCGAATGCTGCCCAGGTTGCTGCTAA  562 
            |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATGCTGCCCAGGTTGCTGCTAA  522 
 
DpsCC  
Query  30   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  89 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  90   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  149 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  150  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  209 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  210  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  269 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  270  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  329 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  330  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  389 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  390  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  449 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 




            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  510  TTCATCGAATGCAACATCGAATGCTGCTGA  539 
            |||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATGCTGCTGA  510 
 
DpsGCC  
Query  14   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  73 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  74   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  133 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  134  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  193 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  194  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  253 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  254  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  313 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  314  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  373 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  374  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  433 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  434  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  493 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  494  TTCATCGAATGCAACATCGAAGGATGCTGCTGA  526 
            ||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAAGGATGCTGCTGA  513 
 
DpsGGCC  
Query  40   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  99 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  100  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  159 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  160  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  219 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  220  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  279 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  280  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  339 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  340  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  399 




Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  400  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  459 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  460  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  519 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  520  TTCATCGAATGCAACATCGAAGGAGGTTGCTGCTGA  555 
            |||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAAGGAGGTTGCTGCTGA  516 
 
DpsGGGCC  
Query  37   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  96 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  97   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  156 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  157  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  216 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  217  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  276 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  277  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  336 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  337  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  396 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  397  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  456 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  457  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  516 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  517  TTCATCGAATGCAACATCGAAGGAGGTGGATGCTGCTGA  555 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAAGGAGGTGGATGCTGCTGA  519 
 
DpsPAGCC  
Query  39   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  98 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  99   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  158 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  159  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  218 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  219  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  278 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  279  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  338 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  339  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  398 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  399  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  458 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  459  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  518 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  519  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  557 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  519 
 
Designs and controls in pET-32b to allow for protein purification 
 
DpsWT 
Query  9    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  68 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  69   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  128 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  129  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  188 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  189  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  248 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  249  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  308 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  309  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  368 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  369  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  428 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  429  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  488 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  489  TTCATCGAATGCAACATCGAATAA  512 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA  504 
 
DpsCCPGCC 
Query  9    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  68 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 




            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  129  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  188 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  189  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  248 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  249  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  308 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  309  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  368 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  369  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  428 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  429  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  488 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  489  TTCATCGAATGCAACATCGAATGCTGCCCAGGTTGCTGCTAA  530 
            |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATGCTGCCCAGGTTGCTGCTAA  522 
 
DpsGGGCC 
Query  9    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  68 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  69   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  128 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  129  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  188 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  189  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  248 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  249  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  308 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  309  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  368 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  369  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  428 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  429  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  488 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  489  TTCATCGAATGCAACATCGAAGGAGGTGGATGCTGCTGA  527 
            ||||||||||||||||||||||||||||||||||||||| 







Query  11   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  70 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  71   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  130 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  131  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  190 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  191  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  250 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  251  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  310 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  311  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  370 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  371  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  430 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  431  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  490 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  491  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  529 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  519 
 
DpsR18C,N19C,D123C,A126C 
Query  534   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCTGCTGCGAT  593 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCTGCTGCGAT  60 
 
Query  594   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  653 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  654   ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  713 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  714   GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  773 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  774   GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  833 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  834   AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  893 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  894   CTGGCATGCCGTTACTGCATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  953 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  954   GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  
1013 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  1014  TTCATCGAATGCAACATCGAATAA  1037 
             |||||||||||||||||||||||| 






Sequence Appendix 6 - Sequence alignment for all Dps mutants used in chapter 6. Grey 
indicates the added or mutated codons. ‘Query’, obtained from sequence results from 
Eurofins, Germany, aligned against expected sequences ‘Subject’. Aligned using Blast10. 
Designs and controls in pET-46 for both in vitro and in vivo analysis 
 
DpsCCPGCC 
Query  85   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  144 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  145  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  204 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  205  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  264 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  265  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  324 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  325  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  384 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  385  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  444 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  445  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  504 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  505  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  564 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  565  TTCATCGAATGCAACATCGAATGCTGCCCAGGTTGCTGCTAA  606 
            |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATGCTGCCCAGGTTGCTGCTAA  522 
DpsPAGCC    
Query  84   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  143 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  144  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  203 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  204  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  263 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  264  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  323 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  324  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  383 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 




            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  444  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  503 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  504  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  563 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  564  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  602 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  519 
DpsWT 
Query  79   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  138 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  139  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  198 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  199  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  258 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  259  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  318 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  319  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  378 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  379  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  438 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  439  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  498 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  499  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  558 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  559  TTCATCGAATGCAACATCGAATAA  582 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA  504 
Dps(AA)PAGCC 
Query  100  ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  159 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  160  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  219 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  220  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  279 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  280  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  339 




Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  340  GCAGAAGCAGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  399 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAAGCAGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  400  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  459 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  460  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGGCAAAAGCAATCGGTGAAGCAAAA  519 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGGCAAAAGCAATCGGTGAAGCAAAA  420 
 
Query  520  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  579 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  580  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  618 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  519 
Dps(DD)PAGCC 
Query  110  ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  169 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  170  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  229 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  230  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  289 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  290  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  349 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  350  GCAGAAGACGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  409 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAAGACGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  410  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  469 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  470  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGGACAAAGCAATCGGTGAAGCAAAA  529 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGGACAAAGCAATCGGTGAAGCAAAA  420 
 
Query  530  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  589 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  590  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  628 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  519 
Dps(WW)PAGCC 
Query  70   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  129 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  130  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  189 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  190  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  249 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  250  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  309 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  310  GCAGAATGGGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  369 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAATGGGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  370  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  429 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  430  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGTGGAAAGCAATCGGTGAAGCAAAA  489 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGTGGAAAGCAATCGGTGAAGCAAAA  420 
 
Query  490  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  549 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  550  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  588 
            ||||||||||||||||||||||||||||||||||||||| 




Query  99   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  158 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  159  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  218 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  219  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  278 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  279  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  338 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  339  GCAGAAGCAGCAGTGGTCTTCGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  398 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAAGCAGCAGTGGTCTTCGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  399  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  458 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  459  CTGGCAGATCGTTACGCAATCGTGGCATTCGATGTGGCAAAAGCAATCGGTGAAGCAAAA  518 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCATTCGATGTGGCAAAAGCAATCGGTGAAGCAAAA  420 
 
Query  519  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  578 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  579  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  617 
            ||||||||||||||||||||||||||||||||||||||| 





Query  94   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  153 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  154  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  213 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  214  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  273 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  274  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  333 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  334  GCAGAAGCAGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  393 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAAGCAGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  394  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  453 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  454  CTGGCAGATCGTTACGCAATCGTGGCATACGATGTGGCAAAAGCAATCGGTGAAGCAAAA  513 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCATACGATGTGGCAAAAGCAATCGGTGAAGCAAAA  420 
 
Query  514  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  573 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  574  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  612 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  519 
Dps(AA)PAGCC N130L,D141D,D142W,D143G 
Query  111  ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  170 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  171  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  230 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  231  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  290 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  291  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  350 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  351  GCAGAAGCAGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  410 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAAGCAGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  411  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  470 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  471  CTGGCAGATCGTTACGCAATCGTGGCACTCGATGTGGCAAAAGCAATCGGTGAAGCAAAA  530 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCACTCGATGTGGCAAAAGCAATCGGTGAAGCAAAA  420 
 
Query  531  GACTGGGGCACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  590 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  591  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  629 
            ||||||||||||||||||||||||||||||||||||||| 
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Detection of Protein Cage Assembly through Probing with 
BisArsenic Fluorophores. 
Thomas A. Cornell and Brendan P. Orner 
 
Summary 
We describe a method for the detection of specific protein-protein interactions in protein 
cages through the exploitation of designed binding sites for bisarsinic fluorescent 
probes.  These sites are engineered to be protein-protein interface specific. We have 
adapted this method to ferritins, however it could conceivably be applied to other 
protein cages.  It is thought that this technique could be utilised in the thermodynamic 
and kinetic characterisation of cage assembly mechanisms and in the high throughput 
screening of protein cage libraries for the discovery of proteins with new assembly 
properties or of optimised conditions for assembly. 
Keywords – FlAsH-EDT2, Protein-protein interactions, Fluorescence detection, 
Oligomerization state, Ferritin.  
Running head – Fluorescence assay to detect protein cage formation. 
1. Introduction 
Nanocage proteins play key roles across many biological systems. They perform wide-
ranging functions, such as metabolite synthesis (1), protein folding assistance (2), viral 
genome protection and delivery (3), and ion and metabolite storage and sequestration 




assembly controlled, structures (5). Many of the techniques employed to study the 
formation of these unique architectures are often indirect and provide only low 
structural and temporal resolution.   
Because of their unique hollow nanostructure, protein cages are attractive for a wide 
range of non-natural applications. For example, they have been employed as vehicles 
capable of controlled drug delivery and as size-constrained synthetic reaction vessels for 
mineralised materials (6, 7). To develop such systems with greater utility, proteins with 
properties tailored to each specific application are required. However, the rational 
design of protein cages with bespoke properties, faces the dual challenges of 
engineering both protein folding and protein-protein interactions.  While advancing (6, 
8, 9),  these both are far from solved problems. Thus, it is envisioned that high 
throughput techniques to discover protein cages with novel properties would not only be 
helpful but are necessary. 
The complex and often highly symmetric structures of many protein cages are stitched 
together by protein-protein interactions between their protein building blocks. 
Understanding the fundamentals controlling the assembly could help scientists to utilise 
better and to engineer protein cages in the future. Research to dissect the role of the 
individual protein-protein interactions and their components can be slow and tedious, 
utilising often limited and indirect techniques, such as alanine scanning via site directed 
mutagenesis, followed by size exclusion chromatography (SEC) and transmission 
electron microscopy (TEM) for characterisation of each of the mutants individually (10, 
11, 12, 13, 14, 15).  While these strategies have provided much insight, a more rapid 
method could enhance the field by acquiring this information more swiftly.  
Furthermore, a technique that more directly assesses specific protein-protein 




A growing number of methods, such as Förster resonance energy transfer (FRET),split 
green fluorescent proteins (GFP) and split luciferase enzymes (16, 17, 18, 19), have 
been employed to study the assembly of two protein binding partners. Such techniques 
often require very large protein fusions (20), antibodies (21), or post-translational 
modifications (22, 23) and are often limited to two binding partners.  
Recently bisarsenic fluorescent reagents, such as FlAsH and ReAsH, have been 
developed as protein probes.  These reagents become fluorescent when bound to a 
protein with four cysteine residues displayed in a specific geometric relationship (24).  
The reagents provide a smaller labelling tag than GFP fusions and thus allow the 
probing of proteins in a more native state within cells (25). Moreover, by splitting the 
tetra cysteine peptide tag into two cysteine pairs that straddle a protein-protein interface, 
it is possible to design binding sites for these reagents that are dependent upon the 
formation of specific protein-protein interactions (26, 27). While this method was 
originally shown to work for short peptide chains, more recently it has been used to 
establish structurally detailed insight into the conformationally driven transduction of 
binding information in the trans-membrane helix of EGFR (28).  
We have recently expanded this technique to interrogate the self-assembly of a large 
multimeric ferritin protein cage (see Figure 1) (29).  In our study, the ferritin protein, 
DNA-binding protein from starved cells (Dps), was engineered with a C-terminal 
bipartite cysteine pair. The C-termini of Dps monomers converge when this protein 
assembles into a tetrahedrally symmetric cage but diverge in the presumed two-fold 
symmetric dimer intermediate of the assembly process. The convergent cysteines create 
a binding site for the bisarsenic fluorescent reagent, resulting in a cage-dependent 
signal. We have demonstrated that this technique works in bacterial lysates thus 




increasing throughput. This flexible strategy could be used to establish the assembly 
dynamics of protein cages in vitro or in cells.  In a high throughput format, it also has 
potential for the discovery of mutant protein cages with enhanced properties or for 
screening conditions for cage stability and assembly.  The following chapter describes a 
method for the application of this technique. 
[INSERT FIGURE 1 HERE] 
2. Materials    
2.1. Protein design and preparation 
1. PDB coordinates for the protein cage. 
2. Inducible expression plasmid containing gene encoding the protein cage and 
carrying antibiotic resistance. 
3. Primers for site directed mutagenesis or extension PCR. 
4. Expression host cell line such as Rosetta (BL21) E. coli (Novagen). 
5. Luria Broth (LB): 10 g Tryptone plus (Sigma), 5 g Yeast extract (Sigma), 10 g 
NaCl (Sigma), 1 L water. Autoclave.  
6. Antibiotics for inoculation (such as Carbenicillin, 50 mg/mL) and reagent to 
activate expression (such as IPTG, 0.5 mM final concentration). 
7. FlAsH buffer: 100 mM Tris.HCl (Sigma), 100 mM NaCl (Sigma), 1 mM EDTA 
(Sigma), pH 7.8.  Degas. 
2.2. FlAsH analysis 




2. Additives for signal and specificity optimisation: 1, 2-Ethanedithiol (EDT): 1 
mM (Sigma), 2-Mercaptoethanol (2-ME): 1 mM (Sigma), Tris(2-
carboxyethyl)phosphine (TCEP): 3.5 mM (Sigma). Make all stocks in FlAsH 
buffer immediately before use.   
3. Guanidine-HCl (Sigma): 8 M in FlAsH buffer. 
4. Steady state fluorimeter or fluorescent plate reader. 
3. Methods 
The following procedure should be used as a guide to help utilise the fluorescent 
reagent FlAsH-EDT2 to detect specific protein-protein interactions in protein cages. 
Because these interactions arise only when the cages assemble into higher order 
oligomerization states, this strategy is based on designing FlAsH binding sites at the 
protein-protein interfaces that appear when the cage forms. The binding sites are 
generated when bipartite cysteine pairs engineered into the monomers become proximal 
upon cage assembly. Once the binding sites emerge, in vitro or in vivo detection of 
oligomerization is possible by observing fluorescence. 
3.1. Designing binding sites dependent upon cage assembly 
1. Design FlAsH binding sites guided by the inspection of a protein data bank 
(PDB) structure.  Position two pairs of cysteines across an interface that ideally 
only forms in the highest order cage structure and does not appear in any 
assembly intermediate (unless the identification of such an intermediate is the 
goal of the study), (see Note 1, 2, 3, 4, 5, and see Figure 2).  




2. Design a positive control protein by fusing a peptide sequence containing 
CCPGCC (there are several optimised versions) (30) onto a monomer.  This is 
most easily done as an extension to one of the termini (see Note 6).  
3.2. Protein preparation 
1. Use standard extension or site directed mutagenesis cloning techniques to 
introduce mutations required to generate the designed proteins (see Note 7, 8). 
2. Express the designed proteins by first transferring constructed plasmids into an 
expression host (for example Rosetta, E. coli expression cells) and induce 
protein expression (such as by growing in inoculated LB until an O.D600 of 0.6 
followed by the addition of IPTG), (see Note 9). 
3. Isolate cell pellet by centrifugation, disrupt cells (for example by sonication), 
clarify by centrifugation to obtain the soluble proteins (see Note 10). 
4. If choosing to assay the proteins in purified form, as opposed to in lysates, 
isolate and characterise the proteins with size exclusion chromatography (SEC) 
(see Note 11, 12, 13, 14) to confirm assembly.  
3.4. Sample preparation and fluorescence analysis 
Initial screening in lysate samples can be used to rapidly guide the design 
process. Samples can either be screened in a high throughput plate format, 
which speeds up data collection and mitigates the running of replicate 
experiments, or in cuvettes with a fluorimeter (See Note 15). Experiments 
should be designed to include a positive control protein, which not only can help 
establish that the dye is working as expected, but also can provide a detection 




sensitivity of the fluorimeter. A negative control, typically a wild-type protein 
with no additional cysteines, should also be included. This control determines 
the level of the background fluorescence due to non-selective binding to the 
protein. A no-protein control should also be used to establish further sources of 
background from the FlAsH itself. 
1. Dilute the lysate sample to the required total protein concentration (0.1 mg/ml, 
BCA, Merck) with FlAsH buffer and add EDT, 2-ME and TCEP solutions and 
incubate for two hours at room temperature (see Note 16, 17, 18 and see Figure 
3). 
[INSERT FIGURE 3 HERE] 
2. Add FlAsH-EDT2 solution and incubate for an additional two hours at room 
temperature away from light (see Note 19 and 20). 
3. Read each sample in a fluorimeter or plate reader. Multiple replicates are 
suggested (see Note 21). 
3.5. Denatured protein fluorescence analysis 
A useful control for multimeric proteins is to assay the designs, but in the presence 
of a denaturant such as 6 M Guanidine-HCl. At high enough concentrations of the 
denaturant, the proteins should unfold and all quaternary structure will be lost.  This 
will destroy the designed FlAsH binding sites, resulting in the loss of any 
fluorescent signal observed in assembly promoting conditions.  This should confirm 
that the signal is indeed oligomerization independent especially if the positive 




1. For protein denaturation experiments, dilute the sample to the required protein 
concentration with 8 M Guanidine-HCl in FlAsH buffer, until a final 
concentration of 6 M Guanidine-HCl is achieved. Incubate for two hours at 
room temperature. 
2. Add EDT, 2-ME and TCEP solutions and incubate for a further two hours at 
room temperature (see above). 
3. Add FlAsH-EDT2 and incubate for 2 more hours, away from light at room 
temperature. Run each sample in a fluorimeter and compare to non-denatured 
samples (see Note 22). 
4. Notes 
1. For large multimeric nanostructures, look for interfaces that form only when the 
highest oligomerization state is achieved. By directing the design towards highly 
symmetric interfaces on protein nanostructures, it is possible to increase the 
number of binding sites per structure allowing for detection at lower protein 
concentrations.  
2. The two-fold symmetry dimer is presumed to be an assembly intermediate in 
most mini-and maxi-ferritin cages.  The protein-protein interface of this dimer is 
avoided for binding site engineering as it would exist regardless of the formation 
of higher order cage structures.   
3. Termini that converge at interfaces make for ‘quick and easy’ locations for the 
addition of cysteine pairs, however by using this strategy, the potential for an 
optimal geometry may be unachievable, and may require flexible termini. 




to form an appropriate FlAsH binding site, others may require screening a range 
of linkers in order to optimise FlAsH binding (see Figure 2).  
4. Binding site designs that employ a more structurally complex strategy than 
simply attaching cysteines to termini may initially be thought to be preferred.  
However, care must be taken when swapping one amino acid for a cysteine as 
this could lead to a) protein misfolding due to undesired disulphide bond 
formation or b) the removal of key hot-spots residues essential for stabilising 
protein-protein interactions.  It is reasonable to pursue both strategies in parallel.  
5. Take note of all native cysteines in the structure. Any that are too close to the 
FlAsH binding site might need to be mutated out; on the other hand it could be 
imagined that some native cysteines could be included in the engineered binding 
site.  
6. This can be a more useful control than simply using the synthesized small 
peptide, because this protein can also be employed as a control for 
oligomerization/denaturation studies to determine how assembly-dependent the 
designed interfacial binding site is.  
7. If the protein cage monomers can be expressed in a soluble form and assemble 
without extraordinary measures, then it is possible that the fluorescence assay 
can be implemented directly in the clarified lysate avoiding arduous purification 
and thereby increasing the throughput of designs or conditions that can be 
screened.  
8. Expressing the protein cage with purification tags, while easing purification, 




blocking by the affinity label.  Therefore, it is recommended to use purification 
strategies that involve either a very small tag (like His6) or proteolytic removal 
of the tag.  The small tag approach, although requiring controlled 
characterisation to ensure native assembly, may prove most flexible in that the 
same protein construct could be used for screening in homogeneously purified 
proteins, in lysates, and in living cells. This should be taken into account while 
designing the cloning strategy.   
9. The ideal conditions for the expression of proteins varies depending on the 
nature of the protein. Care must be taken with protein cages that have been 
observed to exist as multiple, metastable oligomerization states. Extensive 
characterisation of the protein after expression should be performed to ensure 
that the desired oligomerization is achieved especially when establishing 
benchmarks in new systems.  
10. Re-suspending the cell pellet in FlAsH buffer can save some steps and loss of 
protein especially if the screening will be undertaken with lysates. The addition 
of EDTA to the buffer can be helpful not only for maintaining ion concentration, 
but can also stop some protease activity in the lysate samples (see Note 12). 
11. SEC provides information about what oligomerization states exist in each 
sample and their ratios with respect to each other.  Thus, this technique can be 
used to ensure that the expression method has produced the expected 
oligomerization states of the protein cage. Extended purification methodologies, 
especially ones including digestion of purification tags can alter previously 
observed oligomerization state ratios, and re-characterisation is essential after 




characterisation should be performed with purified proteins for the top hits.   
Moreover, SEC should prove to be a powerful characterisation tool in systems 
that form multiple oligomerization states of which the FlAsH binding sites were 
designed to probe one specifically.  The FlAsH technique can be used in concert 
with SEC to determine which states are FlAsH-active. (29) 
12. Purifying the protein into FlAsH buffer speeds up assaying as no buffer 
exchange is needed. Buffer exchange can cause protein aggregation or increase 
protease activity in a highly concentrated sample.  Changing the concentration 
of the sample can also have an effect on the oligomerization state observed. 
Creating the simplest route from expression to screening is key to having the 
most reproducible results. 
13. Storing lysate samples at 4 °C is recommended, however, temperature can 
possibly affect the oligomerization state ratio of the nanocage. Consistency 
between how all the samples are treated is important to maintain reproducibility. 
14. Protein aggregation resulting in false positives can be the biggest problem at this 
step. The likelihood of this happening is increased if the design involves 
mutating residues in the more highly structured regions of the protein such as on 
a β-sheet.  
15. Keep note of the sensitivity of the machine as different fluorimeters will provide 
different absolute readings; comparisons can be made by normalisation to 
controls. If filters are being used, ensure that they are the closest to the required 




16. Protein concentration analysis for lysate samples is a measure of all the proteins 
in the sample. While it can be difficult to estimate how much of the sample is 
the protein of interest, steps such as PAGE gels and ensuring that the samples 
are treated identically from the protein production stage should lead to similar 
concentrations of the protein of interest. If multiple designs are to be compared, 
then additional control experiments should be conducted to ensure that each 
protein is expressed at a similar level. 
17. In less stable nanocage systems, the oligomerization state may be altered if the 
sample is diluted from a stock concentration for the experiment. This also 
requires a control experiment. 
18. The additives used in FlAsH fluorescence experiments can vary.  TCEP is a 
commonly employed additive at concentrations ranging from 1 – 10 mM.  It 
helps to maintain a reduced redox state. EDT is used to ensure that any FlAsH 
unbound to protein produces a low background. Commonly used concentrations 
range from 1 – 5 mM, however high concentrations have been shown to increase 
stringency and even inhibit FlAsH binding completely (24).  2-ME is used less 
often but it is suggested to not only help maintain the redox state but to increase 
the binding kinetics so that the FlAsH binding process can more readily reach 
equilibrium. Concentrations of 1 mM have typically been used. Optimisation for 
different systems is advised (27, 29).  (see Figure 3) 
19. The amount of FlAsH dye to use can depend on the experiment and the 
sensitively of the fluorimeter. To quickly screen binding site designs with a 
yes/no output, a small amount of dye can be used (nM to µM range). For more 




binding sites will have an effect on how much FlAsH-EDT2 is added so as to 
maintain saturated stoichiometric ratios.  
20. A standard incubation time between additions is 2 hours, however this can vary 
if the binding kinetics of the specific system are atypical. 
21. Fluorescence experiments for purified proteins are the same as the above 
procedure, except that the amount of FlAsH-EDT2 dye used might be altered to 
maintain saturated stoichiometry. Purified proteins provide much higher 
confidence that any observed fluorescence is coming from the designed binding 
site than in lysate experiments, but this can be countered by the decreased 
throughput due to the time required for purification. 
22. The time required to fully denature the protein may also require optimisation. A 
positive control is especially useful here as often a small decrease in signal is 
observed in the presence of large amounts of Guanidine-HCl and this should be 
taken into account. 
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Figure captions 
Fig. 1. Conceptual evolution of FlAsH binding site design. (A) Structure and schematic 
of FlAsH-EDT2.  (B) Initial presentation of four cysteines on one face of an α-helix.  
(C) Optimized hairpin peptide. (D) Bipartite cysteine display with the two cysteine pairs 
placed proximately on each of the termini of the same protein.  (E) Bipartite cysteine 
display with cysteine pairs straddling a protein-protein interface between interacting 
proteins. (F) Strategy to detect self-assembly of nanocage structures. 
Fig. 2. Effect of the length and conformation of the sequence linking the nanocage 
protein Dps C-terminus to a bipartite pair.  (Fluorescence is normalised to a positive 
control, G = glycine, A = alanine and P = proline), (1 μM FlAsH-EDT2, 1 mM EDT, 1 
mM 2-ME, 3.5 mM TCEP, 0.1 mg/ml final protein concentration). Results shown are 
from 6 replicates of lysate samples with over expressed proteins of interest. Error bars 




Fig. 3. Relationship between additives and the observed fluorescence intensity on a 
E.coli Bacterioferritin (Bfr) FerritinCCPGCC positive control (1 μM FlAsH-EDT2, 1 
mM EDT, 1 mM 2-ME, 3.5 mM TCEP, 0.1 mg/ml final protein concentration). Results 
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ABSTRACT: Proteins that form cage-like structures have been of much recent cross-disciplinary interest due to their application 
to bioconjugate and materials chemistry, their biological functions spanning multiple essential cellular processes, and their 
complex structure, often defined by highly symmetric protein-protein interactions.  Thus, establishing the fundamentals of their 
formation, through detecting and quantifying important protein-protein interactions, could be crucial to understanding 
essential cellular machinery, and for further development of protein-based technologies. Herein we describe a method to 
monitor the assembly of protein cages by detecting specific, oligomerization state dependent, protein-protein interactions. Our 
strategy relies on engineering protein monomers to include cysteine pairs that are presented proximally if the cage state 
assembles. These assembled pairs of cysteines act as binding sites for the fluorescent reagent FlAsH which, once bound, provides 
a readout for successful oligomerization.  As a proof of principle, we applied this technique to the iron storage protein, DNA-
binding protein from starved cells (Dps) from E.coli. Several linker lengths and conformations for the presentation of the 
cysteine pairs were screened to optimize the engineered binding sites. We confirmed that our designs were successful in both 
lysates and with purified proteins, and that FlAsH binding was dependent upon cage assembly.  Following successful 
characterization of the assay, its throughput was expanded. A two-dimension matrix of pH and denaturing buffer conditions was 
screened to optimize nanocage stability. We intend to use this method for the high throughput screening of protein cage 
libraries and of conditions for the generation of inorganic nanoparticles within the cavity of these and other cage proteins.   
Introduction 
Large, hollow, and often symmetric, cage-like protein 
assemblies, like ferritin nanocages and virus capsids, provide 
impetus for investigations into protein folding, protein-
protein interactions and self-assembly, all of which underpin 
protein quaternary structure.1,2,3 On a biofunctional level, 
similar protein nanostructures are involved in sequestering 
metals,4 creating size-specific pockets of a hydrophobic 
environment to assist in protein folding,3 catalyzing the 
generation of metabolites,5 as well as delivering and 
protecting viral genomes.6  Along with having fundamental 
importance, protein cages have been the focus of much 
applied research. To date, protein cages have been used as 
size constraining reaction vessels for the construction of 
inorganic materials, and for several potential bio-medically 
relevant applications such as drug and siRNA delivery.7, 8, 9, 10, 
11, 12, 13     
Many high resolution protein cage structures are available. 14, 
15 These structures have paved the way for rational 
engineering and design, a pursuit that is important for 
enhancing the properties of protein cages to match those 
required for further applications.  One successful design 
strategy, applied in different ways, has been to enhance the 
protein-protein interactions between monomers. 16, 17, 18, 19  
However, this type of research can be protracted due to the 
necessity of iteratively purifying each mutant followed by 
extensive biophysical characterization with techniques that 
are often not directly related to cage formation.2, 20  
Ferritins are ubiquitous protein cages whose structure has 
been extensively studied due to its relatively straightforward 
folding and assembly. They store cellular iron through 
mineralization inside their hollow cavity. E.coli DNA-binding 
protein from starved cells (Dps), a mini-ferritin, has a 9 nm 
outer diameter and assembles from twelve identical 
monomers.21, 22, 23, 24, 25, 26  Each monomer folds into a four 
helix bundle with an additional helix along the loop between 
the second and third helix of the bundle (the “BC helix”). 17, 27  
During ferritin self-assembly, monomers rarely persist and 
for most ferritins, a 2-fold symmetric dimer is believed to be 
the most prevalent intermediate.  This dimer is thought to be 
the fundamental building block for cage formation.21 In Dps, 
these intermediates are most likely anti-parallel dimers. A 
consequence of this is that the termini of each monomer 
projects away from those of the other monomer; only with 
increased oligomerization to the fully formed cage state do 
the termini converge. (Figure 2A) Although ferritins have 
been pursued extensively for applications in material 
science,10 only minimal work has been performed to optimize 




Unfortunately, there are few methods for determining the 
oligomerization states of the cages other than expressing, 
purifying and assaying each protein followed by mostly low 
throughput biophysical techniques, such as size exclusion 
chromatography (SEC), dynamic light scattering (DLS) and 
transmission electron microscopy (TEM).2, 16-17, 20, 28 Creating a 
system that can rapidly identify specific oligomerization 
states in vivo or in cell lysates, would greatly advance 
research on protein nanocages and protein self-assembly in 
general.  
An ideal method would be one that could distinguish specific 
protein-protein interactions during the assembly process. A 
direct oligomerization assay employing a biarsinical 
fluorescent reagent,29, 30 of which FlAsH and ReAsH are the 
most common, is one possibility. These reagents, which have 
been used as an alternative to GFP variants for protein 
labeling, 31, 32, 33, 34 exploit the affinity of their arsenic atoms 
for sulfur atoms in a protein.  The reagents bind selectively to 
proteins with four appropriately presented cysteines (SI 
Figure S1).  This binding results in  fluorescence most likely 
due to a change in rotational properties about the carbon-
arsenic bond.35, 36 Originally, it was suggested that FlAsH 
ideally interacts with cysteines displayed on a single face of 
an alpha helix, but later it was shown that the sequence 
CCPGCC provides an ideal FlAsH binding site.  
 
Figure 1 – Fluorescence (green) from the reagent, FlAsH, is 
assembly state dependent only in the bipartite design 
because of the need to have two sets of cysteine pairs (red) to 
form a binding site.  The positive control provides a binding 
site that is neither folding, nor oligomerization dependent 
whereas the negative control provides no FlAsH binding.  
This is the basis of our strategy to directly monitor protein 
cage formation. 
Recently, it has been shown that the four cysteines in the 
FlAsH binding motif can be split into two ‘bipartite’ cysteine 
pairs. If the two pairs are positioned apart from each other in 
the polypeptide sequence, FlAsH can be used to detect when 
they become proximal during protein folding.  Similarly, the 
two pairs can be placed on two separate polypeptides, and 
FlAsH can be used to monitor the formation of a protein-
protein interaction if the cysteines are positioned 
appropriately across the interface.35, 37, 38, Recently this 
strategy was used to elucidate conformationally transduced 
signals through the cellular membrane and to provide an 
explanation for the divergent signaling outcomes of an EGF 
receptor that dimerizes through coiled-coil motifs.39  
The first step in developing the biarsinical reagents into 
probes for protein cage assembly is to design binding sites 
that only appear upon cage formation.  This goal is made 
more challenging by the fact that the monomers of protein 
cages, such as Dps, use multiple interfaces for cage formation 
and various states could be intermediates along the 
oligomerization pathway. Thus, a design with ultimate utility 
would be robust enough to distinguish between these 
oligomerization states.  One possible solution therefore 
would be to design ferritin binding sites that exploit the 
divergence of monomer termini in the antiparallel dimer 
intermediate (see above).  In the cage form, these termini 
converge. Thus, terminally appended cysteines would 
provide a sulfur rich area for a FlAsH binding site that only 
forms upon cage assembly and not in a dimer intermediate. 
One must also consider the location of native cysteine 
residues. Dps has a single cysteine close to the C-terminus of 
the monomer (SI Figure S2). While this will not impede this 
investigation, consideration must be taken when utilizing 
this approach for other proteins.   
In our design, we placed cysteine pairs at the Dps C-
terminus. (Figure 1)  A series of mutants were generated to 
optimize the binding site; these mutants differ in how the 
two cysteines are displayed by the monomer either based on 
linker length (DpsCC, DpsGCC, DpsGGCC, DpsGGGCC) or 
conformation (DpsPAGCC). (Figure 2a) Extending the C-
terminus to display the peptide sequence CCPGCC which 
includes all four cysteines of an ideal binding site on a single 
monomer (see above) resulted in the positive control 
(DpsCCPGCC) which would require neither folding nor 
assembly to generate a FlAsH signal.  We used wild type Dps, 
which has no additional cysteines, as a negative control 
(Dps). 
Results and Discussion 
An oligomerization state assay with the most utility would be 
able to evaluate multiple samples rapidly.  Therefore, instead 
of initially working with purified proteins, we used cellular 
lysates.  This decision increased our throughput, allowing the 
screening of more potential designs.  In addition, the uses of 
complex solutions allowed us to optimize for selectivity. In 
these conditions, (Figure 2b) the positive control, 
DpsCCPGCC, generated robust fluorescence with added 
FlAsH, and the negative control (Dps) gave nearly 
undetectable signal.  Of the bipartite designs, DpsCC and 
DpsGCC had a very weak response whereas DpsGGCC, 
DpsGGGCC, and DpsPAGCC gave fluorescence that was 
between 15 and 35% of the positive control suggesting that a 
longer linker is ideal and one that is more rigid may be 
optimal. Observing signal in lysate samples shows this 




Figure 2 – (a) Dps crystal structure (PDB: 1DPS) emphasizing a dimer subunit and divergent presentation of the C-termini along 
with schematics representing proteins used in this study.  The negative control (Dps) has no appended C-terminal cysteines 
whereas the monomer of the positive control (DpsCCPGCC) displays a full binding site.  The other proteins present a pair of 
cysteines with a variety of flexible and constrained linkers. Cysteine (red), glycine (light grey), alanine (dark grey), proline 
(black) (b) FlAsH fluorescence, normalized to controls, for the proteins overexpressed as cell lysates diluted to the same total 
protein concentration (0.1 mg/ml). (c) Percent fluorescence loss for the proteins in lysates in denaturing conditions. (d) FlAsH 
fluorescence, normalized to controls, for the proteins overexpressed and purified, diluted to the same protein concentration (0.1 
mg/ml) (e) Percent fluorescence loss for the purified proteins in denaturing conditions. The lysate and purified protein data are 
from six and eight replicates respectively.  Error bars are S.D. * Two-tailed P-values = 0.4804. ** Two-tailed P-values = 0.020050. 
*** Two-tailed P-values = 0.0001.   
presence of many ions, organic molecules and proteins. 
While lysates are still not as complex as intact cells, this 
report shows positive movement towards that direction. This 
investigation uses set concentrations of 1, 2 ethanedithiol 
(EDT), 2-mercaptoethanol (2-ME),  tris(2-
carboxyethyl)phosphine (TCEP) and 
ethylenediaminetetraacetic acid (EDTA) and while TCEP has 
been shown to be necessary to ensure that there are no 
disulfide bonds, the methodology for EDT and 2-ME is less 
clear with the latter only been used sparingly. 29 The EDT 
ligand is needed to keep unbound FlAsH non-fluorescent, 
however its concentration is often modified in line with the 
system being used.30, 37, 38 Moreover EDTA which is 
commonly used could be doubly benefiting to lysate 
experiments by removing the extra ions seen. All of these 
additives would require further optimization if a high 
through put screen was to be attempted.    
To confirm that the FlAsH binding is indeed dependent on 
cage formation, we subjected the lysates to similar 
experiments but in denaturing conditions. (Figure 2c)  As 
expected the negative control, Dps, exhibited no change in 
fluorescence upon denaturation.  The positive control, 
DpsCCPGCC, was also expected to have no change, 
however, it did generate a small, but significant loss which 
may be attributed to restricted access to the tetracysteine tag 




equilibration times could enhance the assay.  As expected, the  
Figure 3 – Size exclusion chromatograms monitored at absorbance of 280 nm (protein) and fluorescence at 535 nm (bound 
FlAsH) to determine if the assay is selective for the cage oligomerization state. (a-d) Purified proteins (0.5 ml injection of 1 
mg/ml). (e, f) Lysate solutions with overexpressed designed protein (0.5 ml injection of 1 mg/ml total protein). All absorbance 
and fluorescence signals are normalized to the positive control. Results for both the UV and fluorescence traces are averages of 
three runs. 
bipartite designs displayed a large loss in fluorescence upon 
denaturation with DpsGGGCC and DpsPAGCC exhibiting 
nearly a 100% loss in signal with added denaturant. To verify 
these results, the leading proteins were expressed, purified 
(SI Figure S11 for sequencing data) and fully characterized (SI 
Figure S4-8 and SI Table S4 for gels and mass spec, SEC, 
TEM, CD) and were subjected to the binding experiment and 
subsequent denaturation. (Figures 2d and 2e)  Again, the 
controls behaved as expected with the exception of the 
positive control that, again, lost a small amount of signal 
upon denaturation.   
The bipartite designs, DpsGGGCC and DpsPAGCC, 
displayed strong, oligomerization dependent binding of 
FlAsH with the latter generating ~50% of control.  While the 
stoichiometry between dye and protein is unclear in the 
lysate samples, as our set protein concentrations are a 
measure of all soluble proteins, it is clear in the purified 
experiments that the sum of proteins and therefore binding 
sites, far outnumber the amount of dye. While this could be 
of concern in a quantitative screen, this does not detract 
away from this investigation to discover binding sites that 
work across complex ferritin interfaces.  
 The steady state fluorescence experiments, coupled with 
denaturation, strongly demonstrate that we have successfully 
designed FlAsH binding sites that are oligomerization 
dependent. While those experiments, combined with the 
geometrical placement of the binding sites, suggested that 
this dependence is specific to the cage state over the dimer 
state, it needed to be confirmed directly. We have previously 
shown that some ferritins can exist in solution as mixtures of 
cage and dimer through the use of SEC.28 Therefore we 
employed SEC, combining protein absorbance (280 nm) with 
FlAsH fluorescence (535 nm). If the binding sites were 
successfully designed to appear during the formation of 
specific protein-protein interactions, fluorescent peaks 
should correspond to only certain oligomerization forms. 
(Figure 3)  The negative control, Dps, which is a wild type 
protein we have worked with extensively, generates a single 
peak from the cage and no detectable dimer when monitored 
at 280 nm. (Figure 3b) Also as expected, no peak is observed 
in the FlAsH channel.  For the positive control, 
DpsCCPGCC, a cage and a small dimer peak at 280 nm are 
observed, and the fluorescence elutes with both, again as 
expected, indicating no preference for oligomerization state. 




DpsPAGCC and DpsGGGCC, both show a cage and a dimer 
peak at 280 nm however, the fluorescence only elutes with 
the cage, suggesting that the designed binding sites are 
forming only upon cage formation and that this assay can 
distinguish between oligomerization states. (Figures 3c and 
3d)  It should be noted that DpsPAGCC did aggregate 
slightly.  The fact that the aggregate peak also had no 
fluorescence further demonstrates the robustness of this 
approach.  As a further test of specificity, the same technique 
was used to assess clarified lysates for DpsPAGCC and 
DpsGGGCC. (Figures 3e and 3f) Again, fluorescence elutes at 
a volume consistent with the cage state.  Taken together 
these data strongly suggest that not only are the designed 
binding sites forming upon oligomerization, they form only 
upon cage formation.  
An additional goal of this technique is not only to develop a 
direct screen for specific oligomerization states of protein 
cages, but also to expand the throughput of this 
characterization.  Therefore it was modified to a 96-well 
plate format.  As a proof of principle, but also as a means to 
optimize our work with these proteins (see above), we 
sought to discover conditions of highest stability.  First we 
expanded our denaturation experiment described in Figure 1 
to screen a variety of denaturant concentrations.  (Figure 4a)  
As expected, and consistent with our previous data, the 
positive control, DpsCCPGCC, generated high signal at all 
conditions, demonstrating that FlAsH binding is not 
oligomerization dependent.  The negative control, Dps, 
generates no signal across all conditions.  However, a protein 
with the designed bipartite binding site, DpsPAGCC, loses 
its ability to bind FlAsH near 1.4M denaturant. (SI Figure S10)  
 Figure 4 – Medium throughput screen of buffer conditions 
favoring cage oligomerization state. Fluorescence intensity is 
greyscaled so that black is most intense and white is least. (a) 
Normalized fluorescence intensity of DpsCCPGCC, 
DpsPAGCC and Dps as a function of GuHCl concentration 
at pH 7.8. Values are the average of at least six replicates.  
S.D. is included in Supporting Information (SI Figure S10) (b) 
Normalized fluorescence intensity for DpsPAGCC as a 
function of both pH and GuHCl. Values are averages of three 
replicates.  S.D. is included in Supporting Information (SI 
Figure S9) 
Further expanding our enquiry into ideal conditions for Dps 
stability, we screened both denaturant and pH concurrently. 
(Figure 4b and SI Figure S9)  It should be noted that, 
consistent with most of the literature,35,37 we usually preform 
our experiments with Dps at pH 7.8.  Thus, it was somewhat 
surprising to discover that the protein is most stable below 
pH 7.0. These experiments would have been less possible in 
lower throughput screens as they would have taken longer 
and expended a large amount of reagents.  This not only 
emphasizes the strength of this approach in that its 
throughput can be expanded, but this increased throughput 
can lead to useful experiments (with potentially unexpected 
results) that may not have been run due to the exigent 
nature of traditional techniques. 
Conclusion 
Protein cages have the potential for applications in fields as 
wide spanning as drug delivery, catalysis, and nanomaterials.  
Moreover, they can act as model systems to study 
biologically ubiquitous protein-protein interactions, self-
assembly and quaternary structure all of which are at the 
cutting edge of pharmaceutical interest.  However, for 
protein cages to reach their full potential, tools to assess 
directly their solution assembly properties in higher 
throughput are necessary. By engineering FlAsH binding 
sites and protein-protein interfaces that only form in the 
cage oligomerization state and not in the presumed dimer 
intermediate, we designed a system to directly detect 
assembly in cellular lysates of the miniferritin E.coli Dps.  We 
have shown that indeed this system is oligomerization 
dependent and is specific for the cage and not the dimer.  In 
addition, we demonstrated the scalability of this system by 
performing a two dimensional, medium throughput screen 
to determine conditions that favor the cage state.   We are 
currently expanding this technique to other ferritins in the 
form of protein libraries screened in whole bacteria for the 
purpose of discovering “switchable” protein cages and those 
with bespoke properties for specific applications like 
nanoparticle formation while optimizing the designs based 
on ideal binding sites. 38 In addition, we are intending to use 
this technique to target specific oligomerization states in 
order to monitor their formation along the self-assembly 
pathway.  We believe that this strategy can be easily ported 
to other protein cages and self-assembling protein systems in 
order to optimize their properties and to understand their 
formation.  
Methods and Materials 
FlAsH Binding in Lysates. The pET-22b expression vectors 
containing Dps design variants (SI Methods and materials S1 
for cloning information) were transformed into Rosetta E.coli 
cells (Novagen) and plated on LB agar plates (50 μl/ml of 
carbenicillin and 34 μl/ml chloramphenicol). Selected 




carbenicillin, 37 0C, overnight) as a pre-culture which was 
then added to LB (100 ml) and grown (37 °C) until an O.D600 
of 0.6. Protein expression was then induced by the addition 
of IPTG (50 µl of a 1 M stock) and the culture was further 
incubated (3 h, 30 0C). The cells were isolated by 
centrifugation (4,000 rpm, 15 min at 4 0C). The cell pellet was 
resuspended in FlAsH buffer (100 mM Tris.HCl, 100 mM 
NaCl, 1 mM EDTA, pH 7.8) and sonicated (Misonix, 
Ultrasonic cell disruptor, pulsed 5 s on 5 s off for 5 min). The 
protein solution was clarified by centrifugation (15,000 rpm, 
45 min, 4 0C) and then filtered (Sartorius, 0.2 μm).  
The protein concentration was determined (BCA, Novagen) 
and the cell lysate was diluted to 1 mg/ml with FlAsH buffer.  
To insure that all the 1 mg/ml samples had similar amounts 
of the desired protein, each was analyzed by SDS PAGE (SI 
Figure S3). Each fluorescence experiment contained protein 
lysate (200 μl, 0.1 mg/ml) in FlAsH buffer,  TCEP (Sigma, 
final concentration of 3.5 mM), EDT (Sigma, final 
concentration of 1 mM) and 2-ME (Sigma, final 
concentration of 1 mM) were added and the solution was 
incubated (room temperature, 2 h) followed by the addition 
of FlAsH-EDT2 (Invitrogen, final concentration of 0.1 μM) 
followed by a further incubation (room temperature, 2 h) in 
the dark. Each lysate sample was tested in a black Corning 96 
well plate in a PerkinElmer Envision 2101 multilabel plate 
reader, with each design being expressed three times and 
each expression being tested in 6 different wells and re read 
twice (Ex filter 485 nm bandwidth 14 nm, Em filter 535 nm 
bandwidth 25 nm). For the denatured experiments, the above 
was repeated but with the extra addition of 6 M guanidine 
and incubated for 2 hours prior to the addition of TCEP, EDT 
and 2-ME, with protein concentration remaining the same as 
in previous un-denatured experiments. 
FlAsH Binding with Purified Proteins. The pET-32b 
vectors containing the Dps variants (SI Methods and 
materials S2 for cloning information) were transformed into 
Rosetta E.coli cells (Novagen) and plated on LB agar plates 
(50 μl/ml of carbenicillin and 34 μl/ml of chloramphenicol). 
Selected colonies were then grown in LB (5 ml, 37 0C, 
overnight) as a pre-culture which was added to LB (500 ml) 
and grown (37 0C) until an O.D600 of 0.6. Protein expression 
was then induced by the addition of IPTG (250 µl of a 1 M 
stock) and the cultures were further incubated (3 h, 30 0C). 
The cells were isolated by centrifugation (4,000 rpm, 20 min, 
4 0C). The cell pellet was resuspended in lysis buffer (50 mM 
NaH2PO4, 300 mM NaCl, 40 mM Imidazole, 1 mM EDTA, pH 
8). Cellytic (10x, Sigma) was added and the solution was 
incubated (20 min, on ice) and then sonicated (Misonix, 
ultrasonic cell distruptor, pulsed 5 s on, 5 s off for 5 min). 
The protein solution was clarified by centrifugation (15,000 
rpm, 45 min at 4 0C) and then filtered (Sartorius, 0.2 μm). 
The protein was purified via affinity purification (GE, Histrap 
FF, 5 ml, (wash buffer-40 mM Imidazole, 50 mM NaH2PO4, 
300 mM NaCl, pH 7.4), (elution buffer-500 mM Imidazole, 50 
mM NaH2PO4, 300 mM NaCl, pH 7.4)). Enterokinase 
digestion (NEB 2 μg/ml) was performed to cleave off the 
peptide tag from the protein of interest followed by a second 
Histrap (GE, Histrap HP, 5 ml, (wash buffer-50 mM 
NaH2PO4, 300 mM NaCl, pH 7.4), (elution buffer-500 mM 
Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4)) to 
remove the tag from solution. The protein solution was 
further purified by size exclusion chromatography (GE 
Hiload 16/60 Superdex, running buffer-50 mM NaH2PO4). 
Each protein was then placed into FlAsH buffer via 
ultrafiltration (Millipore).  
Each purified protein was tested by incubating the protein 
(200 μl of 0.1 mg/ml) in FlAsH buffer with TCEP (Sigma, final 
concentration of 3.5 mM), EDT (Sigma, final concentration of 
1 mM) and 2-ME (Sigma, final concentration of 1 mM) and 
left to incubate (2 h, room temperature) followed by the 
addition of FlAsH-EDT2 (Invitrogen, final concentration of 0. 
1 μM, 2 h, room temperature). Each sample was prepared 
directly into a black Corning 96 well plate which was tested 
in a PerkinElmer Envision 2101 multilabel plate reader (Ex 
filter 485 nm bandwidth 14 nm, Em filter 535 nm bandwidth 
25 nm). Each pure protein was tested six times and reread 
three times. For the denaturant experiment, each protein was 
tested as described above but with the addition of 6 M 
guanidine, while keeping the protein concentration the same 
and was incubated for 2 hours prior to the addition of TCEP, 
2-ME, and EDT.  
Analytical Size Exclusion Chromatography (SEC). The 
samples (0.5 ml of 1 mg/ml) in FlAsH buffer (100 mM Tris-
HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8) were injected onto 
the column (GE Superdex 200 10/300 GL) at 0.5 ml/min with 
each protein repeated 3 times.   The column was calibrated 
using six proteins as standards (GE Biosystems Calibration 
Kit). (See SI Figure S7.) 
For fluorescent monitoring, samples were prepared by 
adding to pure protein (0.5 ml of 1 mg/ml) in FlAsH buffer, 
TCEP (Sigma, final concentration of 3.5 mM), EDT (Sigma, 
final concentration of 1 mM) and 2-ME (Sigma, final 
concentration of 1 mM) and incubated (2 h, room 
temperature). FlAsH-EDT2 dye was added and incubated in 
the dark (Invitrogen, final concentration of 0.4 μM, 2 h, room 
temperature). This sample was desalted (GE, HiTrap 5 ml 
Desalting column) before injection onto a SEC column (GE 
Superdex 200 10/300 GL). Samples were taken every 200 μl 
during the elution and placed into a black Corning 96 well 
plate. This plate was tested in a PerkinElmer Envision 2101 
multilabel plate reader (Ex filter 485 nm bandwidth 14 nm, 
Em filter 535 nm bandwidth 25 nm). Each purified protein 
was tested three times with each plate reread three times.  
Transmission Electron Microscopy (TEM). TEM was 
performed on a FEI, Tecnai G2 20, electron microscope set at 
200 KeV. Proteins were immobilized on Formvar/carbon 
coated 3.05 mm copper grids (TAAB) and negatively stained 
with 1 % Uranyl acetate. 7 Micrographs were analyzed using 
ImageJ. 41 (See SI FigureS8.) 
Circular Dichroism Spectroscopy (CD). The purified 
proteins were used in FlAsH buffer (100 mM Tris, 100 mM 
NaCl, 1 mM EDTA, pH 7.8). This experiment was performed 
on a Applied Photophysics LTD Chirascan spectrometer in a 
range of 200 nm to 260 nm with a protein concentration of 
0.2 mg/ml with a path length of 0.5 mm. Thermal melts were 
performed on all purified proteins (0.2 mg/ml in FlAsH 
buffer) in a range of 4 to 85 degrees Celsius. 42, 43 (See SI 




Electrospray Mass Spectrometry. Purified proteins were 
desalted (GE, Hitrap 5ml Desalting column) and analyzed on 
a Bruker MaXis mass spectrometer after the addition of 1 % 
Formic acid.(See SI Table S5.) 
pH Vs GuHCl measurement. Each purified protein was 
analyzed by incubating the protein (200 μl of 0.1 mg/ml) in a 
buffer at the relevant pH (pH 6-7, 100 mM Citrate-phopshate. 
pH 7.5-8.5 100 mM Tris.HCl) and with the correct 
concentration of GuHCl, with TCEP (Sigma, final 
concentration of 3.5 mM), EDT (Sigma, final concentration of 
1 mM) and 2-ME (Sigma, final concentration of 1 mM) and 
incubated (2 h, room temperature) followed by the addition 
of FlAsH-EDT2 (Invitrogen, final concentration of 0. 1 μM, 2 
h, room temperature). Each sample was prepared directly in 
a black Corning 96 well plate which was scanned in a 
PerkinElmer Envision 2101 multilabel plate reader (Ex filter 
485 nm bandwidth 14 nm, Em filter 535 nm bandwidth 25 
nm). Each protein was prepared three times separately and 
each was reread three times.44 
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Table S1. Primers used for the construction of WTDps to be screened in lysates. Primers 
sourced from Supranom, Singapore. 
 
Primer name Primer sequence (5'-3')           
Dps p22 F GGA ACT CAT ATG AGC ACC GCA AAA CTG GTG 
   Dps p22 R GGT ACT CTC GAT TTA TTC GAT GTT GCA TTC G 
    
Table S2. Primers used for the construction of all designs to be used in lysates constructed via 
site directed mutagenesis. Primers sourced from Supranom, Singapore. 
 
Primer name Primer sequence (5'-3')         
  
DpsCC F GAA TGC AAC ATC GAA TGC TGC TGA TTC TCC TCA ACC ATG GCG ATA TC 
DpsCC R GAT ATC GCC ATG GTT GAG GAG AAT CAG CAG CAT TCG ATG TTG CAT TC 
DpsGCC F GAA TGC AAC ATC GAA GGA TGC TGC TGA TCC TCA ACC ATG GCG ATA TC 
DpsGCC R GAT ATC GCC ATG GTT GAG GAT CAG CAG CAT CCT TCG ATG TTG CAT TC 
DpsGGCC GAA TGC AAC ATC GAA GGA GGT TGC TGC TGA TCA ACC ATG GCG ATA TC 
DpsGGCC GAT ATC GCC ATG GTT GAT CAG CAG CAA CCT CCT TCG ATG TTG CAT TC 
DpsGGGCC GAA TGC AAC ATC GAA GGC GGT GGA TGC TGC TGA ACC ATG GCG ATA TC 
DpsGGGCC R GAT ATC GCC ATG GTT CAG CAG CAT CCA CCT CCT TCG ATG TTG CAT TC 
DpsPAGCC F GAA TGC AAC ATC GAA CCA GCG GGA TGC TGC TGA ACC ATG GCG ATA TC 
DpsPAGCC R GAT ATC GCC ATG GTT CAG CAA CAT CCC GCT GGT TCG ATG TTG CAT TC 
DpsCCPGCC F CAT CGA ACC AGC GGG ATG CTG CCC AGG TTG CTG CTA AAT GGC GAT ATC 
DpsCCPGCC R GAT ATC GCC ATT TAG CAG CAA CCT GGG CAG CAT CCC GCT GGT TCG ATG 
 
Table S3. Primers used for the transfer of successful designs into pET-32b (for the production 
of purified proteins). Primers sourced from Integrated DNA technologies. 
 
  
Primer name Primer sequence (5'-3')           
DpsGGGCC p32 R GAG GAG AAG CCC GGT CAG CAG CAT CCA CCT CCT TC 
 DpsPAGCC p32 R GAG GAG AAG CCC GGT CAG CAA CAT CCC GCT G 
  DpsCCPGCC p32 R GAG GAG AAG CCC GGT TAG CAG CAA CCT GGG CAG 








Methods and materials S1 - Cloning of DpsCCPGCC, DpsCC, DpsGCC, DpsGGCC, DpsGGGCC, 
DpsPAGCC and Dps for Screening in Protein Lysates. The WT Dps gene was amplified with 
primers providing restriction sites.  The PCR reaction (50 µl total volume) was a solution of 
reaction buffer (Fermentas, 5 μl of 10xPfu buffer), dNTP mix (Fermentas, 2 μl of a solution 
containing dATP, dTTP, dGTP, and dCTP 2 mM each), forward and reverse primers (400 ng each, 
Suprenom, Singapore), template (100 ng) and Pfu polymerase (Fermentas, 2 μl of 2.5 U/μl) 
which was subjected to an initial melting step at 95 0C for 30 s, followed by 30 cycles of 
amplification (95 0C for 30 s, 55 0C for 45 s and 72 0C for 1 min) followed by 72 0C for 7 min. The 
resulting PCR product was isolated by gel purification (Promega). The PCR product (300 ng) was 
digested (Tango buffer, Fermentas, 10 μl of 2x buffer), Nde1 (Fermentas, 1.5 μl of 20 U/μl), 
Xho1 (Fermentas, 1.5 μl of 20 U/μl), 50 μl total volume, 37 0C, 3 hours). The plasmid pET-22b 
(Novagen) was treated in the same way, followed by ligation of the insert with T4 ligase buffer 
(Fermentas, 2 µl, 10x buffer), digested insert (30 ng), digested plasmid (80 ng), T4 ligase 
(Fermentas, 0.2 µL of 20 U/µl), 20 μl total volume (37 0C, 2 hours). The constructs (2 μl) were 
transformed (Novablue, Novagen) and the resulting colonies were assessed by colony  PCR, a 
solution of Gotaq buffer (Promega, 5 μl of 5x), dNTP mix (Promega, 2 μl of a solution containing 
dATP, dTTP, dGTP, and dCTP at 2 mM each), T7 promoter and terminator primers (150 ng each, 
Eurofins MWG), Gotaq DNA polymerase (Fermentas, 0.25 μl of 5 U/μl), colony suspension (10 
μl of a 50 μl total colony suspension in deionised water) and deionised water (5 μl), was 
subjected to an initial melting step (95 0C for 10 min) followed by 30 cycles of amplification, 
((95 0C for 30 s, 59 0C for 30 s and 72 0C for 30 s) followed by 72 0C for 7 min). Clones 
demonstrating a PCR product of the predicted size were subjected to miniprep (Invitrogen) and 
the resulting purified plasmids were sequenced (SI Figure S11 for sequencing results and SI 




Using the newly constructed Dps in pET-22b as a template, site directed mutagenesis was 
performed to create all other designs (Quikchange, Stratagene) by introducing mutations at the 
C-terminus. The reaction mixture containing Pfu buffer (Promega, 2 μl of 10x), dNTP mix 
(Promega, 2 μl of a solution containing dATP, dTTP, dGTP, and dCTP at 2 mM each), forward and 
reverse primers (125 ng each, Suprenom, Singapore), the dsDNA template (Dps pET-22b, 100 
ng) and Pfu  polymerase (Promega, 1 μl of 3 U/μl) in a total volume of 25 μl was subjected to 
melting (95 0C for 5 min), followed by 20 cycles of amplification (95 0C for 1 min, 55 0C for 1 min 
and 68 0C for 6 min) followed by 70 0C for 10 min. The reaction was then digested with Dpn1 
(NEB buffer 4 (1 μl of 10x), amplification product (5 μl), deionized water (3.5 μl), Dpn1 (NEB, 0.7 
μl of 10 U/μl), 370C, 2h). The resulting solution was transformed (XL-1 blue, Novagen) and the 
subsequent colonies subjected to miniprep (Promega, Wizard plus SV) and sequenced (SI 
Figure S11 for sequencing results and SI Table S2 for primers). 
 
Methods and materials S2 - Cloning of all Designs for Screening as Purified Proteins. In order 
to express the proteins for isolation and purification, the genes were placed into a vector that 
provided affinity tags. The constructs were amplified from the mutated pET-22b plasmid with 
primers providing ligation independent cloning (LIC) sites. The PCR  solution Pfu reaction buffer 
(Promega, 5 μl of 10x), dNTP mix (Fermentas, 2 μl of a solution containing dATP, dTTP, dGTP, 
and dCTP at 2 mM each), forward and reverse primers (400 ng each, Integrated DNA 
technologies), the template (100 ng) and Pfu polymerase (Promega, 2 μl of 2.5 U/μl) in 50 μl 
total volume was subjected to an initial melting step (95 0C for 30 s), followed by 30 cycles of 
amplification(95 0C for 30 s, 55 0C for 45 s and 72 0C for 1 min) followed by 72 0C for 7 min. The 
resulting PCR product was isolated by gel purification (Qiagen).The PCR product was then 
treated with T4 polymerase in order to create the required complementary overhangs (NEB 
buffer 2, 2 μl of 10x buffer), dATP (NEB, 2 μl of 25 mM), DTT (Sigma, 1 μl of 100 mM), BSA (NEB, 




total volume of 20 μl, 30 min,  22 0C ). The vector, pET-32b (Novagen) was treated in the same 
way. The insert was annealed to open plasmid (1 μl of the T4 Pol product, 0.5 μl of plasmid 
solution (50 ng/µl) by incubating (room temperature, 30 min) followed by a second incubation 
(room temperature, 30 min) with an addition of EDTA (1 μl of 100 mM). The constructs (2.5 μl) 
were transformed (XL-1 Blue, Novagen) and the resulting colonies were assessed by colony 
PCR. A solution of Gotaq reaction buffer (5 μl of 5x), dNTP mix (Promega, 2 μl of a solution 
containing dATP, dTTP, dGTP, and dCTP at 2 mM each), T7 promoter and terminator primers 
(150 ng each, Eurofins MWG), Gotaq DNA polymerase (Promega, 0.25 μl of 5 U/μl), colony 
suspension (10 μl of a 50 μl total colony suspension in deionised water) and deionised water (5 
μl), was subjected to an initial melting step (95 0C for 10 min) followed by amplification 30 
cycles (95 0C for 30 s, 59 0C for 30 s and 72 0C for 30 s followed by 72 0C for 7 min). Clones 
demonstrating a PCR product of the predicted size were subjected to miniprep (Promega) and 
the resulting purified plasmid was sequenced (SI Figure S11 for sequence results and Table S3 







Figure S1 – FlAsH-EDT2 (left) quenched and non-fluorescent. Once EDT is exchanged with a tetracysteine 






Figure S2 – Three fold axis of symmetry of Dps (PDB:1DPS) highlighting native cysteine residues in the 
structure (red). While there is only one per-structure and near the C-terminus, their distance apart is 23.33 Å 








Figure S3 – SDS-PAGE (15 %) of lysate samples for each Dps design diluted to 1 mg/ml total protein 






Figure S4 – SDS-PAGE gel (15 %) for each of the purified proteins. Lane 1: Protein standard 
ladder (NEB), Lane 2: Soluble fraction, lane 3: insoluble fraction, lane 4: wash from first 
histrap, lane 5: elution from first histrap, lane 6: elution from second histrap after EK 





















Figure S5 – Circular Dichroism spectra demonstrating the effect of heating on the fold of each 






























































































































Figure S6 – Thermal melting plots of Dps designs and controls monitored at 222 nm in CD.  Dotted lines 




Table S4 – Melting temperature of all repeats from thermal denaturation. S.D from three replicates. 
 
Design Tm average (⁰C) 
  
DpsCCPGCC 70.35 ± 1.42 
DpsGGGCC 61.87 ± 0.13 
DpsPAGCC 58.84 ± 0.40 












Table S5 – Electrospray mass spectrometry from purified protein samples. 
 
Protein Measured mass (Da) Expected mass (Da) Difference (Da) 
DpsCCPGCC 19273.0 19278.0 5.0 
DpsGGGCC 19100.3 19088.8 -11.5 
DpsPAGCC 19154.0 19142.8 -11.2 
Dps 18710.2 18711.3 1.1 
  
 









































Figure S7. Analytical size exclusion chromatography data for all purified Dps designs and 
controls. Each was repeated three times using a 0.5 ml injection of 1 mg/ml protein in a GE 































































































































Figure S8 – TEM micrographs for characterization of DpsGGGCC, DpsPAGCC, DpsCCPGCC and 








Figure S9 –Raw data for pH vs GuHCl (See Figure 4b). Showing the effect on the stability of 
DpsPAGCC at different pH’s by monitoring the fluorescence. Data normalized using the 




















































































































Figure S10 – Monitoring fluorescence loss during protein unfolding for DpsPAGCC at pH 7.8. (See Figure 4a) 
Data normalized using the controls DpsCCPGCC and Dps by taking the average reading as 100 and zero 






























Concentration of Gu.HCl (M)











Dps in pET-22b 
Query  50   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  109 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  110  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  169 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  170  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  229 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  230  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  289 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  290  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  349 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  350  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  409 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  410  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  469 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  470  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  529 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  530  TTCATCGAATGCAACATCGAATAA  553 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA  504 
 
 
DpsCCPGCC in pET-22b 
Query  41   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  100 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  101  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  160 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  161  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  220 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  221  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  280 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  281  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  340 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  341  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  400 




Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  401  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  460 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  461  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  520 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  521  TTCATCGAATGCAACATCGAATGCTGCCCAGGTTGCTGCTAA  562 
            |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATGCTGCCCAGGTTGCTGCTAA  522 
 
 
DpsCC in pET-22b 
Query  30   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  89 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  90   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  149 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  150  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  209 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  210  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  269 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  270  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  329 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  330  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  389 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  390  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  449 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  450  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  509 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  510  TTCATCGAATGCAACATCGAATGCTGCTGA  539 
            |||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATGCTGCTGA  510 
 
 
DpsGCC in pET-22b 
Query  14   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  73 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  74   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  133 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  134  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  193 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 




            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  254  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  313 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  314  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  373 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  374  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  433 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  434  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  493 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  494  TTCATCGAATGCAACATCGAAGGATGCTGCTGA  526 
            ||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAAGGATGCTGCTGA  513 
 
 
DpsGGCC in pET-22b 
Query  40   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  99 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  100  GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  159 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  160  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  219 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  220  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  279 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  280  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  339 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  340  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  399 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  400  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  459 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  460  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  519 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  520  TTCATCGAATGCAACATCGAAGGAGGTTGCTGCTGA  555 
            |||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAAGGAGGTTGCTGCTGA  516 
 
 
DpsGGGCC in pET-22b 
Query  37   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  96 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  97   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  156 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  157  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  216 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  217  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  276 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  277  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  336 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  337  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  396 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  397  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  456 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  457  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  516 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  517  TTCATCGAATGCAACATCGAAGGAGGTGGATGCTGCTGA  555 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAAGGAGGTGGATGCTGCTGA  519 
 
 
DpsPAGCC in pET-22b 
Query  39   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  98 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  99   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  158 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  159  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  218 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  219  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  278 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  279  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  338 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  339  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  398 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  399  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  458 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  459  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  518 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 




            ||||||||||||||||||||||||||||||||||||||| 




Dps in pET-32b 
Query  9    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  68 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  69   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  128 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  129  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  188 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  189  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  248 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  249  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  308 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  309  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  368 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  369  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  428 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  429  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  488 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  489  TTCATCGAATGCAACATCGAATAA  512 
            |||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATAA  504 
 
DpsCCPGCC in pET-32b 
Query  9    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  68 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  69   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  128 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  129  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  188 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  189  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  248 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  249  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  308 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  309  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  368 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  369  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  428 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  429  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  488 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  489  TTCATCGAATGCAACATCGAATGCTGCCCAGGTTGCTGCTAA  530 
            |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAATGCTGCCCAGGTTGCTGCTAA  522 
DpsGGGCC in pET-32b 
Query  9    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  68 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  69   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  128 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  129  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  188 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  189  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  248 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  240 
 
Query  249  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  308 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  309  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  368 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  369  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  428 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  429  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  488 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  489  TTCATCGAATGCAACATCGAAGGAGGTGGATGCTGCTGA  527 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAAGGAGGTGGATGCTGCTGA  519 
 
 
DpsPAGCC in pET-32b 
Query  11   ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  70 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGAGCACCGCAAAACTGGTGAAAAGCAAAGCAACCAACCTGCTGTACACCCGTAACGAT  60 
 
Query  71   GTGAGCGATAGCGaaaaaaaaGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  130 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GTGAGCGATAGCGAAAAAAAAGCAACCGTGGAACTGCTGAACCGTCAGGTGATCCAGTTC  120 
 
Query  131  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  190 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ATCGATCTGAGCCTGATCACCAAACAGGCACATTGGAACATGCGTGGTGCAAACTTCATC  180 
 
Query  191  GCAGTGCATGAAATGCTGGATGGTTTCCGTACCGCACTGATCGATCATCTGGATACCATG  250 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  251  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  310 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GCAGAACGTGCAGTGCAGCTGGGTGGTGTGGCACTGGGTACCACCCAGGTGATCAACAGC  300 
 
Query  311  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  370 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAACCCCGCTGAAAAGCTACCCGCTGGATATCCATAACGTGCAGGATCATCTGAAAGAA  360 
 
Query  371  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  430 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTGGCAGATCGTTACGCAATCGTGGCAAACGATGTGCGTAAAGCAATCGGTGAAGCAAAA  420 
 
Query  431  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  490 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GATGATGATACCGCAGATATCCTGACCGCAGCAAGCCGTGATCTGGATAAATTCCTGTGG  480 
 
Query  491  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  529 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TTCATCGAATGCAACATCGAACCAGCGGGATGTTGCTGA  519 
 
Figure S11. Comparison of the sequencing results with expected sequence. Sequencing result 
shown on the top line, aligned with the expected sequence on the bottom. Yellow indicates 
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